<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0605257344
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TYKERB 250MG F.C. TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LAPATINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        70
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3374.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXO OPERATION" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXO OPERATION
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XE07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Tykerb is used to treat certain types of breast cancer</strong> <em>(HER2-overexpressing)</em> which have spread beyond the original tumour or to other organs (<em>advanced</em> or <em>metastatic</em> breast cancer). It may slow or stop cancer cells from growing, or may kill them.</p><p>&nbsp;</p><p>Tykerb is prescribed to be taken in combination with another anti-cancer medicine.</p><p>&nbsp;</p><p>Tykerb is prescribed in <strong>combination with capecitabine</strong>, for patients who have had treatment for advanced or metastatic breast cancer before. This previous treatment for metastatic breast cancer must have included trastuzumab.</p><p>&nbsp;</p><p>Tykerb is prescribed in <strong>combination with trastuzumab</strong>, for patients who have hormone receptor-negative metastatic breast cancer and have had other treatment for advanced or metastatic breast cancer<strong> </strong>before.</p><p>&nbsp;</p><p>Tykerb is prescribed in <strong>combination with an aromatase inhibitor</strong>, for patients with hormone sensitive metastatic breast cancer (breast cancer that is more likely to grow in the presence of hormones), who are not currently intended for chemotherapy.</p><p>&nbsp;</p><p>Information about these medicines is described in separate patient information leaflets. <strong>Ask your doctor</strong> to give you information about these other medicines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Do not take Tykerb</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to lapatinib or any of the other ingredients of this medicine (listed in Section&nbsp;6).</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Take special care with Tykerb</strong></p><p>&nbsp;</p><p><strong>Your doctor will run tests to check that your heart is working properly</strong> before and during your treatment with Tykerb.</p><p>&nbsp;</p><p><strong>Tell your doctor if you have any heart problems</strong> before you take Tykerb.</p><p>&nbsp;</p><p>Your doctor also needs to know before you take Tykerb:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have lung disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have inflammation of the lung</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any<strong> liver problems</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any<strong> kidney problems</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diarrhoea (see section&nbsp;4).</p><p>&nbsp;</p><p><strong>Your doctor will run tests to check that your liver is working properly</strong> before and during your treatment with Tykerb.</p><p>&nbsp;</p><p><strong>Tell your doctor</strong> if any of these apply to you.</p><p>&nbsp;</p><p><strong>Serious skin reactions</strong></p><p>Serious skin reactions have been seen with Tykerb. Symptoms may include skin rash, blisters and skin peeling.</p><p>&nbsp;</p><p>Tell your doctor as soon as possible if you get any of these symptoms.</p><p>&nbsp;</p><p><strong>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Taking other medicines, herbal or dietary supplements</strong></p><p><strong>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. </strong>This includes herbal medicines and other medicines you bought without a prescription.</p><p>&nbsp;</p><p><strong>It is especially important to tell your doctor</strong> if you are taking, or have recently taken any of the following medicines. Some medicines may affect the way Tykerb works or Tykerb may affect how other medicines work. These medicines include some medicines in the following groups:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&rsquo;s Wort &ndash; a herb extract used to treat <strong>depression</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erythromycin, ketoconazole, itraconazole, posaconazole, voriconazole, rifabutin, rifampicin, telithromycin<strong> &ndash; </strong>medicines<strong> </strong>used to treat <strong>infections</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cyclosporine &ndash; a medicine used to <strong>suppress the immune system</strong> for example after organ transplantations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ritonavir, saquinavir &ndash; medicines used to treat <strong>HIV</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin, carbamazepine &ndash; medicines used to treat <strong>seizures</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cisapride &ndash; a medicine used to treat certain <strong>digestive system</strong> problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pimozide &ndash; a medicine used to treat certain <strong>mental health problems</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; quinidine, digoxin &ndash; medicines used to treat certain <strong>heart problems</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; repaglinide &ndash; a medicine used to treat <strong>diabetes</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; verapamil &ndash; a medicine used to treat <strong>high blood pressure</strong> or <strong>heart problems </strong>(<em>angina</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nefazodone &ndash; a medicine used to treat <strong>depression</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; topotecan, paclitaxel, irinotecan, docetaxel &ndash; medicines used to treat certain types of <strong>cancer</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rosuvastatin &ndash; a medicine used to treat <strong>high cholesterol</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that decrease stomach acidity - used to treat <strong>stomach ulcers</strong> or <strong>indigestion</strong></p><p>&nbsp;</p><p><strong>Tell your doctor </strong>if you are taking, or have recently taken, any of these.</p><p>&nbsp;</p><p>Your doctor will review the medicines you are currently taking to make sure you are not taking something that can&rsquo;t be taken with the Tykerb. Your doctor will advise you whether an alternative is available.</p><p>&nbsp;</p><p><strong>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Taking Tykerb with food and drink</strong></p><p>&nbsp;</p><p><strong>Don&rsquo;t drink grapefruit juice while you are being treated with Tykerb. It can affect the way the medicine works.</strong></p><p>&nbsp;</p><p><strong>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p><strong>The effect of Tykerb during pregnancy is not known. You should not use Tykerb if you are pregnant unless your doctor specifically recommends it.</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are pregnant </strong>or planning to become pregnant, <strong>tell your doctor.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Use a reliable method of contraception</strong> to avoid becoming pregnant while you&rsquo;re taking Tykerb&nbsp;and for 1 week after the last dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you become pregnant</strong> during treatment with Tykerb, <strong>tell your doctor</strong>.</p><p>&nbsp;</p><p>It is not known whether Tykerb passes into breast-milk. Do not breast-feed while taking Tykerb and last for at least 5 days after the dose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are breast-feeding </strong>or planning to breast-feed, <strong>tell your doctor</strong>.</p><p>&nbsp;</p><p><strong>Ask your doctor or pharmacist for advice </strong>before taking Tykerb if you are unsure<strong>.</strong></p><p>&nbsp;</p><p><strong>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>You are responsible to decide if you are able to drive a motor vehicle or perform other tasks that require increased concentration. Because of the possible side effects of Tykerb, your ability to drive or operate machines could be affected. These effects are described in section&nbsp;4, &lsquo;Possible side effects&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take this medicine exactly as your doctor has told you</strong>. Check with your doctor or pharmacist if you&rsquo;re not sure.</p><p>&nbsp;</p><p>Your doctor will decide on the correct dose of Tykerb depending on the type of breast cancer being treated.</p><p>&nbsp;</p><p>If you are prescribed Tykerb in <strong>combination with capecitabine</strong>, the usual dose is <strong>5&nbsp;Tykerb tablets a day</strong>, as a single dose.</p><p>&nbsp;</p><p>If you are prescribed Tykerb in <strong>combination with trastuzumab</strong>, the usual dose is <strong>4 Tykerb tablets a day</strong>, as a single dose.</p><p>&nbsp;</p><p>If you are prescribed Tykerb in <strong>combination with an aromatase inhibitor</strong>, the usual dose is <strong>6&nbsp;Tykerb tablets a day</strong>, as a single dose.</p><p>&nbsp;</p><p>Take the prescribed dose every day for as long as your doctor tells you to.</p><p>&nbsp;</p><p>Your doctor will advise you about the dose of your other anti‑cancer medicine, and how to take it.</p><p>&nbsp;</p><p><strong>Taking your tablets</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Swallow the tablets whole with water</strong>, one after the other, at the same time each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Take Tykerb either at least one hour before or at least one hour after food</strong>. Take Tykerb at the same time in relation to food each day &ndash; for example, you could always take your tablet one hour before breakfast.</p><p>&nbsp;</p><p><strong>While you are taking Tykerb</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depending on the side effects you experience, your doctor may recommend lowering your dose or temporarily stopping your treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will also carry out tests to check your heart and liver function before and during treatment with Tykerb.</p><p>&nbsp;</p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you take more Tykerb than you should</strong></p><p>&nbsp;</p><p>Contact a doctor or pharmacist immediately. If possible, show them the pack.</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you forget to take Tykerb</strong></p><p>&nbsp;</p><p><strong>Don&rsquo;t take a double dose</strong> to make up for a forgotten dose. Just take the next dose at the scheduled time.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>A severe allergic reaction</strong> is a rare side effect (may affect up to 1 in 1000&nbsp;people) and may develop rapidly.</p><p>Symptoms may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash (including itchy, bumpy rash)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual wheezing, or difficulty in breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen eyelids, lips or tongue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pains in muscles or joints</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; collapse or blackout.</p><p>&nbsp;</p><p><strong>Tell your doctor immediately</strong> if you get any of these symptoms. Don&rsquo;t take any more tablets.</p><p>&nbsp;</p><p><strong>Very common side effects</strong> (may affect more than 1 in 10&nbsp;people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea (which may make you dehydrated and lead to more severe complications)</p><p><strong>Tell your doctor immediately at the first sign of diarrhoea (loose stool), as it is important that this is treated right away. Also tell your doctor immediately if your diarrhoea worsens</strong><em>. There is more advice on reducing the risk of diarrhoea at the end of section&nbsp;4.</em></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash, dry skin, itching</p><p><strong>Tell your doctor if you get a skin rash</strong><em>. There is more advice on reducing the risk of skin rash at the end of section&nbsp;4.</em></p><p>&nbsp;</p><p><strong>Other very common side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick (vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness, feeling weak</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore mouth/mouth ulcers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in hands and feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint or back pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a skin reaction on the palms of the hands or soles of the feet (including tingling, numbness, pain, swelling or reddening)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough, shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nose bleed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hot flush</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual hair loss or thinning</p><p>&nbsp;</p><p><strong>Tell your doctor </strong>if any of these side effects get severe or troublesome.</p><p>&nbsp;</p><p><strong>Common side effects</strong> (may affect up to 1 in 10&nbsp;people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an effect on how your heart works</p><p>&nbsp;</p><p>In most cases, the effect on your heart will not have any symptoms. If you do experience symptoms associated with this side effect, these are likely to include an irregular heartbeat and shortness of breath.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver problems, which may cause itching, yellow eyes or skin (<em>jaundice</em>), or dark urine or pain or discomfort in the right upper area of the stomach.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nail disorders &ndash; such as a tender infection and swelling of the cuticles</p><p>&bull; skin fissures (deep cracks on the skin or chapped skin)</p><p>&nbsp;</p><p><strong>Tell your doctor if you get any of these symptoms.</strong></p><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100&nbsp;people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treatment‑induced lung inflammation, which may cause shortness of breath or cough</p><p><strong>Tell your doctor immediately if you get either of these symptoms</strong>.</p><p>&nbsp;</p><p>Other uncommon side effects include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests results that show changes in liver function (usually mild and temporary)</p><p>&nbsp;</p><p><strong>Rare side effects</strong> (may affect up to 1 in 1000&nbsp;people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reactions (<em>see the beginning of section&nbsp;4</em>)</p><p>&nbsp;</p><p><strong>The frequency of some side effects is not known (it cannot be estimated from the available data):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular heart-beat (change in the electrical activity of the heart)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin reaction that might include: rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever or any combination of these</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pulmonary arterial hypertension (increased blood pressure in the arteries (blood vessels) of the lungs)</p><p>&nbsp;</p><p><strong>If you get other side effects</strong></p><p>&nbsp;</p><p><strong>Tell your doctor or pharmacist </strong>if you notice any side effects not listed in this leaflet.</p><p>&nbsp;</p><p><strong>Reducing the risk of diarrhoea and skin rash</strong></p><p>&nbsp;</p><p><strong>Tykerb can cause severe diarrhoea</strong></p><p>&nbsp;</p><p>If you suffer from diarrhoea while taking Tykerb:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drink plenty of fluids (8 to 10 glasses a day), such as water, sports drinks or other clear liquids</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eat low-fat, high protein foods instead of fatty or spicy foods</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eat cooked vegetables instead of raw vegetables and remove the skin from fruits before eating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; avoid milk and milk products (including ice cream)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; avoid herbal supplements (some may cause diarrhoea).</p><p>&nbsp;</p><p><strong>Tell your doctor </strong>if your diarrhoea continues.</p><p>&nbsp;</p><p><strong>Tykerb can cause skin rash</strong></p><p>&nbsp;</p><p>Your doctor will check your skin before and during treatment.</p><p>To care for sensitive skin:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wash with a soap-free cleanser</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; use fragrance free, hypoallergenic beauty products</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; use sunscreen (Sun Protection Factor [SPF] 30 or higher).</p><p>&nbsp;</p><p><strong>Tell your doctor </strong>if you get a skin rash.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the blister or bottle and the carton.</p><p>&nbsp;</p><p>Do not store above 30&ordm;C.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>What Tykerb contains</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance in Tykerb is lapatinib. Each film-coated tablet contains lapatinib ditosylate monohydrate, equivalent to 250&nbsp;mg lapatinib.</p><p>The other ingredients are: microcrystalline cellulose, povidone (K30), sodium starch glycolate (Type A), magnesium stearate, hypromellose, titanium dioxide (E171), macrogol 400, polysorbate 80, iron oxide yellow (E172), iron oxide red (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Tykerb film-coated tablets are oval, biconvex, yellow film-coated, with ‘GS XJG’ marked on one side.
	
	Tykerb is supplied in either blisters packs or bottles:
	
	Blister packs
	Each pack of Tykerb contains 70 or 84 tablets in aluminium foil blisters of 10 or 12 tablets each. Each foil has a perforation down the middle and can be divided into two blisters with 5 or 6 tablets in each, depending on the pack size.
	
	Tykerb is also available in multipacks containing 140 tablets that comprise 2 packs, each containing 70 tablets.
	
	Bottles
	Tykerb is also available in plastic bottles containing 70, 84, 105 or 140 tablets.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved / revised by EMA in 01/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>يُستخدم عقار تايكرب لعلاج أنواع معينة من سرطان الثدي</strong> <em>(فرط تخليق </em><em>HER-2</em><em>)</em> التي انتشرت بمواضع أخرى غير موضع الورم الأصلي أو تلك التي انتشرت في أعضاء أخرى <em>(سرطان الثدي المتقدم</em> أو<em> النقيلي)</em>. قد يبطئ العقار أو يوقف نمو خلايا السرطان أو قد يقضي عليها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم وصف عقار تايكرب؛ ليتم تناوله بمصاحبة دواء آخر مضاد للسرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم وصف عقار تايكرب <strong>بمصاحبة كابيسيتابين</strong>، للمرضى ممن قد تلقوا علاجًا لسرطان الثدي المتقدم أو النقيلي من قبل. لا بد وأن يكون هذا العلاج السابق الخاص بسرطان الثدي النقيلي قد تضمن تراستوزوماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم وصف عقار تايكرب <strong>بمصاحبة تراستوزوماب</strong> للمرضى المصابين بسرطان الثدي النقيلي السلبي لمستقبل الهرمون ممن قد تلقوا علاجًا آخر لسرطان الثدي المتقدم أو النقيلي من قبل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم وصف عقار تايكرب <strong>بمصاحبة أحد مثبطات إنزيم الأروماتيز،</strong> للمرضى المصابين بسرطان الثدي النقيلي ذي الحساسية تجاه الهرمونات (سرطان الثدي المرجح نموه في وجود الهرمونات)، والذين لا توجد حاليًا نية لإخضاعهم للعلاج الكيميائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تكون المعلومات حول هذه الأدوية موضحة في نشرات معلومات منفصلة خاصَّة بالمريض. <strong>اطلب من طبيبك</strong> إعطائك معلومات حول هذه الأدوية الأخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ. موان</strong><strong>ع</strong><strong> استعمال تايكيرب.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه لاباتينيب أو أيٍّ من المكونات الأخرى بهذا الدَّواء (المدرجة بالقسم 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب. الاحتياطات عند استعمال تايكيرب</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سيجري طبيبك اختبارات للتَّحقق من ما إذا كان القلب لديك يعمل بشكل سليم أم لا</strong> قبل وأثناء علاجك بعقار تايكرب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك إذا كنت تعاني من أي مشاكل بالقلب </strong>قبل تناولك لعقار تايكرب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من الضَّروري أيضًا أن يكون طبيبك على دراية بالآتي قبل تناولك لعقار تايكرب:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تعاني من مرض بالرئة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من التهاب رئوي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي <strong>مشاكل بالكبد</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي <strong>مشاكل بالكلى</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من إسهال (انظر قسم: 4).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سيجري طبيبك اختبارات للتَّحقق مما إذا كان الكبد لديك يعمل بشكل سليم أم لا</strong> قبل وأثناء علاجك بعقار تايكرب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك</strong>، إذا انطبق عليك أي مما سبق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التَّفاعلات الجلدية الخطيرة</strong></p><p dir="RTL">لُوحظ حدوث تفاعلات جلدية خطيرة مع تناول عقار تايكرب. قد تتضمن الأعراض طفحًا جلديًّا، بثورًا وتقشر الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك في أسرع وقت ممكن، إذا أصبت بأيٍّ من هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. التداخلات الدوائية من أخذ هذا المستحضر م أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL"><strong>يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى. </strong>يشمل ذلك الأدوية العشبية وغيرها من الأدوية التي قمت بشرائها بدون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>من الهام بشكل خاص أن تخبر طبيبك</strong> إذا كنت تتناول أو تناولت مؤخرًا أيًّا من الأدوية التَّالية. قد تُؤثر بعض الأدوية على طريقة عمل عقار تايكرب أو قد يُؤثر عقار تايكرب على طريقة عمل الأدوية الأخرى. تشمل هذه الأدوية بعض الأدوية الموجودة في المجموعات التَّالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جونز- مستخلص عشبي يُستخدم لعلاج <strong>الاكتئاب</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إريثروميسين، كيتوكونازول، أتراكونازول، پوساکونازول، فوريكونازول، ريفابوتين، ريفامبيسين، تيليثروميسين <strong>&ndash;</strong> أدوية تُستخدم لعلاج <strong>العدوى</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين -أحد الأدوية التي تُستخدم <strong>لكبت الجهاز المناعي</strong>، على سبيل المثال: بعد عمليات زرع الأعضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير، ساكوينافير - أدوية تُستَخدَم لعلاج <strong>فيروس نقص المناعة البشرية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين، كَرْبامازِيبين -أدوية تُستخدم لعلاج <strong>النوبات التَّشنجية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيسابريد &ndash;أحد الأدوية التي تُستخدم لعلاج<strong> </strong>بعض<strong> </strong>مشاكل <strong>الجهاز الهضمي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بيموزيد &ndash;أحد الأدوية التي تُستخدم لعلاج بعض <strong>مشاكل الصحة النفسية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كينيدين، ديجوكسِين &ndash;أدوية تُستخدم لعلاج بعض <strong>مشاكل القلب</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريباجلينيد &ndash;أحد الأدوية التي تستخدم لعلاج <strong>مرض السُّكَّرِي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيراباميل &ndash;أحد الأدوية التي تُستخدم لعلاج <strong>ارتفاع ضغط الدَّم</strong> أو <strong>مشاكل القلب</strong> (<em>الذبحة الصدرية</em>).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نيفازودون &ndash;أحد الأدوية التي تستخدم لعلاج <strong>الاكتئاب</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توبوتيكان، باكليتاكسيل، إرينوتيكان، دوسيتاكسيل &ndash; أدوية تُستخدم لعلاج أنواع معينة من <strong>السرطان.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; روزيوفاستاتين &ndash;أحد الأدوية التي تُستخدم لعلاج <strong>ارتفاع الكوليسترول.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تقلل من حموضة المعدة -تُستخدم لعلاج <strong>قرح المعدة</strong> أو <strong>عسر الهضم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك</strong>، إذا كنت تتناول أو كنت قد تناولت مؤخرًا أيًّا من هذه الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيراجع طبيبك الأدوية التي تتناولها حاليًا؛ للتَّأكد من عدم تناولك لشيء لا يمكن تناوله بمصاحبة عقار تايكرب. سيقوم طبيبك بتقديم المشورة إليك إذا كان هناك أي علاج بديل متوفر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>د. تناول تايكيرب مع الطعام والشراب.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتناول عصير الجريب فروت أثناء خضوعك للعلاج بعقار تايكرب. فقد يُؤثر على طريقة عمل الدَّواء.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ. الحمل والرضاعة </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>یعُد تأثیر عقار تایكرب أثناء الحمل غیر معروف. لا تستخدمي عقار تایكرب إذا كنتِ حاملاً، ما لم یوصِ طبیبكِ بذلك تحدیدًا.<br />&bull; أخبري طبیبكِ، إذا كنتِ حاملاً أو تخططین للحمل.<br />&bull; استخدمي إحدى وسائل منع الحمل الموثوق بھا؛ لتجنب حدوث الحمل أثناء تناولك لعقار تایكرب ولمدة أسبوع بعد آخر جرعة .<br />&bull; أخبري طبیبكِ، إذا أصبحتِ حاملاً أثناء العلاج بعقار تایكرب.<br />من غیر المعروف ما إذا كان عقار تایكرب یمر في حلیب الأم أم لا. لا تمارسي الرضاعة الطبیعیة أثناء تناول عقار تایكرب واستمري لمدة ٥ أیام على الأقل بعد الجرعة.<br />&bull; إذا كنتِ تمارسین الرضاعة الطبیعیةَّ أو تخططین لممارسة الرضاعة الطبیعیةَّ، فأخبري طبیبكِ .<br />استشیري طبیبكِ أو الصیدلي الخاص بكِ قبل تناول عقار تایكرب إذا لم تكوني متأكدة.<br />و. تأثیر تایكیرب على القیادة واستخدام الآلات<br />أنت مسئول عن اتخاذ قرار عما إذا كنت قادرًا على قیادة المركبات أو أداء مھام أخرى تتطلب المزید من التركیز. قد تتأثر قدرتك على القیادة أو تشغیل الآلات بسبب الآثار الجانبیة المُحتملة<br />لعقار تایكرب. ھذه الآثار موضحة في قسم: ٤، &quot;الأعراض الجانبیة &quot;.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تناول دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط.</strong> يُرجى مراجعة طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية التَّناول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيحدد طبيبك الجرعة الصحيحة من عقار تايكرب بناءً على نوع سرطان الثدي الذي يتم علاجه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تم وصف عقار تايكرب لك <strong>بمصاحبة كابيسيتابين</strong>، فتكون الجرعة المعتادة<strong> 5 أقراص من عقار تايكرب في اليوم</strong>، على هيئة جرعة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تم وصف عقار تايكرب لك <strong>بمصاحبة تراستوزوماب</strong>، فتكون الجرعة المعتادة <strong>4 أقراص من عقار تايكرب في اليوم</strong>، على هيئة جرعة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تم وصف عقار تايكرب لك <strong>بمصاحبة أحد مثبطات إنزيم الأروماتيز</strong>، فتكون الجرعة المعتادة <strong>6 أقراص من عقار تايكرب في اليوم</strong>، على هيئة جرعة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول الجرعة الموصوفة كل يوم طالما أخبرك طبيبك بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سو یلبرك طبيبك بنصائح حول جرعة الدَّواء الآخر المضاد للسرطان اللاص بك، وكيفية تناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول الأقراص الخاصة بك</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ابتلع الأقراص كاملة مع الماء</strong>، الواحد تلو الآخر، في الوقت ذاته كل يوم.</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><strong>يجب تناوُل عقار تايكرب إمَّا قبل تناوُل الطعام بساعة واحدة على الأقل أو بعده بساعة واحدة على الأقل.</strong> تناول عقار تايكرب في نفس الوقت المتعلق بتناول الطَّعام كل يوم -على سبيل المثال: يمكنك تناول القرص الخاص بك دائمًا قبل تناول الإفطار بساعة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أثناء تناولك لعقار تايكرب</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بناءً على الآثار الجانبية التي تتعرض لها، قد يوصي طبيبك بخفض جرعتك أو بوقف علاجك مؤقتًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيجري طبيبك أيضًا اختبارات لفحص وظائف القلب والكبد لديك قبل وأثناء تلقيك العلاج بعقار تايكرب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الجرعة الزائدة من عقار تايكيرب</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى الاتصال بالطبيب أو الصيدلي على الفور. إذا أمكن، أرهم العبوة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نسيان تناول جرعة من عقار تايكيرب</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتناول جرعة مضاعفة</strong> لتعويض جرعة أغفلتها. فقط تناول الجرعة التَّالية في الموعد المقرر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات الحساسية الشديدة</strong> هي أحد الآثار<strong> </strong>الجانبية<strong> </strong>النَّادرة (قد تُؤثر في ما يصل إلى 1 من بين كل 1000 شخص) وقد تتطور بسرعة.</p><p dir="RTL">قد تشمل الأعراض الآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفحًا جلديًّا (بما في ذلك: طفح جلدي له نتوءات ومثير للحكة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزيزًا بالصدر غير معتاد أو صعوبة في التَّنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجفون، الشفتين أو اللسان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلامًا في العضلات أو المفاصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبوطًا أو فقدان الوعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك على الفور،</strong> إذا تعرضت للإصابة بأي من هذه الأعراض. لا تتناول المزيد من الأقراص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدًّا</strong> (قد تُؤثر على أكثر من 1 من بين كل 10&nbsp;أشخاص):</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL">إِسْهال (الذي قد يتسبب في إصابتك بالجفاف ويُؤدي إلى حدوث المزيد من المضاعفات الشديدة).</li><li dir="RTL"><strong>أخبر طبيبك على الفور عند ظهور أولى علامات الإسهال (البراز الرخو)؛ حيث إنه من المهم علاج ذلك فورًا. أخبر طبيبك أيضًا على الفور إذا تفاقم الإِسْهال لديك.</strong><em> تتوافر المزيد من النصائح حول الحد من خطر حدوث الإِسْهال في نهاية قسم: 4.</em></li></ul><p dir="RTL">&nbsp;</p><ul><li dir="RTL">طفح جلدي، جفاف الجلد، حكة.</li><li dir="RTL"><strong>أخبر طبيبك إذا أُصبت بطفح جلدي.</strong><em> تتوافر المزيد من النصائح حول الحد من خطر حدوث الطفح الجلدي في نهاية قسم: 4.</em></li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى الشائعة جدًّا</strong></p><p dir="RTL">&nbsp;</p><ul><li dir="RTL">فقدان الشهية.</li><li dir="RTL">الشعور بالإعياء (غثيان).</li><li dir="RTL">إعياء (قيء).</li><li dir="RTL">تعب، شعور بالضعف.</li><li dir="RTL">عسر الهضم.</li></ul><ul><li dir="RTL">إمساك.</li><li dir="RTL">التهاب الفم/ قرح بالفم.</li><li dir="RTL">ألم بالمعدة.</li><li dir="RTL">صعوبة في النوم.</li><li dir="RTL">آلام الظهر.</li><li dir="RTL">ألم باليدين والقدمين.</li><li dir="RTL">ألم بالمفاصل أو بالظهر.</li><li dir="RTL">تفاعل جلدي على راحتي اليدين أو باطن القدمين (بما في ذلك: وخز، تنميل، ألم، تورم أو احمرار).</li><li dir="RTL">سعال، ضيق التنفس.</li><li dir="RTL">صداع.</li><li dir="RTL">نزيف من الأنف.</li><li dir="RTL">هبَّات ساخنة.</li><li dir="RTL">تساقط الشعر أو ترققه بشكل غير معتاد.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك </strong>إذا أصبح أي من هذه الآثار الجانبية شديد أو مزعج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشَّائعة </strong>(قد تُؤثر في ما يصل إلى 1 من بين كل 10&nbsp;أشخاص):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بأحد الآثار التي تُؤثر على كيفية عمل القلب لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في أغلب الحالات، لن يكون لذلك الأثر على قلبك أية أعراض. إذا عانيت بالفعل من أعراض ذات صلة بهذا الأثر الجانبي، فمن المرجح أن تشمل عدم انتظام ضربات القلب وضيق التَّنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالكبد، والتي قد تتسبب في الإصابة بحكة، اصفرار العينين أو الجلد (<em>يرقان</em>)، أو بول داكن اللون أو ألم أو انزعاج بالمنطقة العلوية اليمنى من المعدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بالأظافر -مثل عدوى مسببة للألم وتورم البشرة.</p><p dir="RTL">&bull; شقوق الجلد (شقوق عمیقة على الجلد أو تشقق الجلد)</p><p dir="RTL"><strong>أخبر طبيبك إذا أُصبت بأي من هذه الأعراض.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong> (قد تُؤثر في ما يصل إلى 1 من بين كل 100 شخص):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب رئوي ناجم عن العلاج، والذي قد يتسبب في الإصابة بضيق بالتَّنفس أو سُعال.</p><p dir="RTL"><strong>أخبر طبيبك على الفور،</strong> <strong>إذا تعرضت للإصابة بأي من هذه الأعراض.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تشمل الآثار الجانبية الأخرى غير الشائعة ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج اختبارات الدَّم التي توضح حدوث تغييرات بوظائف الكبد (عادة ما تكون بسيطة ومؤقتة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة</strong> (قد تُؤثر في ما يصل إلى 1 من بين كل 1000 شخص):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية شديدة (انظر بداية قسم: 4)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُعد معدل تكرار بعض الآثار الجانبية غير معروف (لا يمكن تقديره من واقع البيانات المتاحة):</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>عدم انتظام معدل ضربات القلب (تغير في النَّشاط الكهربي للقلب).</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تفاعل جلدي شديد والذي قد يتضمن: طفحًا جلديًّا، احمرار الجلد، ظهور بثور على الشفتين أو العينين أو الفم، تقشُّر الجلد، حُمى أو أي مزيج من هذه الأعراض.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ارتفاع ضغط الدَّم بالشرايين الرئوية (ارتفاع ضغط الدَّم بشرايين (الأوعية الدَّموية) الرئة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا عانيت من آثار جانبية أخرى</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت أية آثار جانبية غير المدرجة في هذه النَّشرة، <strong>يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحد من خطر حدوث الإِسْهال والطفح الجلدي</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يسبب عقار تايكرب إِسْهالًا شديدًا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا عانيت من إِسْهال أثناء تناول عقار تايكرب:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرب الكثير من السوائل (8 إلى 10 أكواب في اليوم)، مثل الماء، المشروبات الرياضية أو السوائل الصافية الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول أطعمة منخفضة الدهون والغنية بالبروتين عوضًا عن الأطعمة الدسمة أو الحارة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول الخضراوات المطهية عوضًا عن الخضراوات النيئة وإزالة القشرة من الفواكه قبل تناولها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب تناول اللبن ومنتجاته (بما في ذلك الآيس كريم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب المكملات العشبية (فبعضها قد يسبب إِسْهالًا).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك </strong>إذا استمر الإِسْهال لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يسبب عقار تايكرب طفحًا جلديًّا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">سيفحص طبيبك جلدك قبل وأثناء العلاج.</p><p dir="RTL">للعناية بالبشرة الحساسة:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اغتسل بغسول خالٍ من الصابون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدم منتجات تجميلية خالية من العطور وضعيفة التأريج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدم واقيًا من الشمس (ذا عامل وقاية من الشمس يبلغ 30 أو أكثر).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك </strong>إذا أُصبت بطفح جلدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي الخاص بك. ويشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة.يمكنك أيضًا الإبلاغ عن الآثار الجانبية بشكل مباشر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على الشريط أو الزجاجة والعبوة الكرتونية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يخزن في درجة حرارة تتعدى 30 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تعد تستخدمها. ستُساعد هذه التَّدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعَّالة بعقار تايكرب هي لاباتينيب. يحتوي كل قرص مُغلَّف على لاباتينيب ديتوسيلات أحادي الهيدرات، بما يُعادل 250 مجم لاباتينيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: سليلوز دقيق التَّبلور، بوفيدون (K30)، جليكولات نشا الصوديوم، (النوع &quot;أ&quot;)، ستيرات الماغنسيوم، هيبروميلوز، ثاني أكسيد التيتانيوم (E171)، ماكروجول 400، بوليسوربات 80، أكسيد الحديد الأصفر (E172)، أكسيد الحديد الأحمر (E172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify; text-indent:50px">أقراص عقار تايكرب المُغلَّفة هي أقراص بيضاوية الشكل، ثنائية التحدُّب، ذات لون أصفر، مغلفة، وموجود على أحد جانبيها العلامة &quot;GS&nbsp;XJG&quot;.</p><p dir="RTL" style="text-align:justify; text-indent:50px">&nbsp;</p><p dir="RTL" style="text-align:justify; text-indent:50px">يتوفر عقار تايكرب إما في عبوات شرائط أو زجاجات:</p><p dir="RTL" style="text-align:justify; text-indent:50px">&nbsp;</p><p dir="RTL" style="text-align:justify; text-indent:50px"><strong>عبوات الشرائط</strong></p><p dir="RTL" style="text-align:justify; text-indent:50px">تحتوي كل عبوة من عقار تايكرب على 70 أو 84 قرصًا في شرائط من رقائق الألومنيوم، بكل شريط 10 أو 12 قرصًا. بكل رقاقة انثقاب بالمنتصف ويمكن تقسيمها إلى شريطين، بكل شريط 5 أو 6 أقراص وذلك بناءً على حجم العبوة.</p><p dir="RTL" style="text-align:justify; text-indent:50px">&nbsp;</p><p dir="RTL" style="text-align:justify; text-indent:50px">يتوافر عقار تايكرب أيضًا في عبوات متعددة تحتوي على 140 قرصًا وتتضمن عبوتين، كل عبوة تحتوي على 70 قرصًا.</p><p dir="RTL" style="text-align:justify; text-indent:50px">&nbsp;</p><p dir="RTL" style="text-align:justify; text-indent:50px"><strong>الزجاجات</strong></p><p dir="RTL" style="text-align:justify; text-indent:50px">يتوافر عقار تايكرب أيضًا في زجاجات من البلاستيك تحتوي على 70 أو 84 أو 105 أو 140 قرصًا.</p><p dir="RTL" style="text-align:justify; text-indent:50px">&nbsp;</p><p dir="RTL" style="text-align:justify; text-indent:50px">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
د‌.	تم اعتماد هذه النَّشرة من قبل منظمة الأدوية الأوروبية في 01/2022

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tykerb 250 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains lapatinib ditosylate monohydrate, equivalent to 250 mg lapatinib.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).
Oval, biconvex, yellow film-coated tablets, with “GS XJG” debossed on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress<br />HER2 (ErbB2);<br /> combination with capecitabine for patients with advanced or metastatic disease with progression<br />following prior therapy, which must have included anthracyclines and taxanes and therapy with<br />trastuzumab in the metastatic setting (see section 5.1).<br /> in combination with trastuzumab for patients with hormone receptor-negative metastatic disease<br />that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy (see<br />section 5.1).<br /> in combination with an aromatase inhibitor for postmenopausal women with hormone receptor<br />positive metastatic disease, not currently intended for chemotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tykerb treatment should only be initiated by a physician experienced in the administration of anti-cancer<br />medicinal products.<br />HER2 (ErbB2) overexpressing tumours are defined by IHC3+, or IHC2+ with gene amplification or gene<br />amplification alone. HER2 status should be determined using accurate and validated methods.<br />Posology<br />Tykerb / capecitabine combination posology<br />The recommended dose of Tykerb is 1250 mg (i.e. five tablets) once daily continuously.<br />The recommended dose of capecitabine is 2000 mg/m2/day taken in 2 doses 12 hours apart on days 1-14<br />in a 21 day cycle (see section 5.1). Capecitabine should be taken with food or within 30 minutes after<br />food. Please refer to the full prescribing information of capecitabine.<br />Tykerb / trastuzumab combination posology<br />The recommended dose of Tykerb is 1000 mg (i.e. four tablets) once daily continuously.<br />The recommended dose of trastuzumab is 4 mg/kg administered as an intravenous (IV) loading dose,<br />followed by 2 mg/kg IV weekly (see section 5.1). Please refer to the full prescribing information of<br />trastuzumab.<br />Tykerb / aromatase inhibitor combination posology<br />The recommended dose of Tykerb is 1500 mg (i.e. six tablets) once daily continuously.<br />Please refer to the full prescribing information of the co-administered aromatase inhibitor for dosing<br />details.<br />Dose delay and dose reduction<br />Cardiac events<br />Tykerb should be discontinued in patients with symptoms associated with decreased left ventricular<br />ejection fraction (LVEF) that are National Cancer Institute Common Terminology Criteria for Adverse<br />Events (NCI CTCAE) grade 3 or greater or if their LVEF drops below the institutions lower limit of<br />normal (see section 4.4). Tykerb may be restarted at a reduced dose (750 mg/day when administered with<br />trastuzumab, 1000 mg/day when administered with capecitabine or 1250 mg/day when administered with<br />an aromatase inhibitor) after a minimum of 2 weeks and if the LVEF recovers to normal and the patient is<br />asymptomatic.<br />Interstitial lung disease / pneumonitis<br />Tykerb should be discontinued in patients who experience pulmonary symptoms which are NCI CTCAE<br />grade 3 or greater (see section 4.4).<br />Diarrhoea<br />Tykerb dosing should be interrupted in patients with diarrhoea which is NCI CTCAE grade 3 or grade 1<br />or 2 with complicating features (moderate to severe abdominal cramping, nausea or vomiting greater than<br />or equal to NCI CTCAE grade 2, decreased performance status, fever, sepsis, neutropenia, frank bleeding<br />or dehydration) (see sections 4.4 and 4.8). Tykerb may be reintroduced at a lower dose (reduced from<br />1000 mg/day to 750 mg/day, from 1250 mg/day to 1000 mg/day or from 1500 mg/day to 1250 mg/day)<br />when diarrhoea resolves to grade 1 or less. Tykerb dosing should be permanently discontinued in patients<br />with diarrhoea which is NCI CTCAE grade 4.<br />Other toxicities<br />Discontinuation or interruption of dosing with Tykerb may be considered when a patient develops<br />toxicity greater than or equal to grade 2 on the NCI CTCAE. Dosing can be restarted, when the toxicity<br />improves to grade 1 or less, at 1000 mg/day when administered with trastuzumab, 1250 mg/day when<br />administered with capecitabine or 1500 mg/day when administered with an aromatase inhibitor. If the<br />toxicity recurs, then Tykerb should be restarted at a lower dose (750 mg/day when administered with<br />trastuzumab, 1000 mg/day when administered with capecitabine or 1250 mg/day when administered with<br />an aromatase inhibitor).<br />Renal impairment<br />No dose adjustment is necessary in patients with mild to moderate renal impairment. Caution is advised in<br />patients with severe renal impairment as there is no experience of Tykerb in this population (see<br />section 5.2).<br />Hepatic impairment<br />Tykerb should be discontinued if changes in liver function are severe and patients should not be retreated<br />(see section 4.4).<br />Administration of Tykerb to patients with moderate to severe hepatic impairment should be undertaken<br />with caution due to increased exposure to the medicinal product. Insufficient data are available in patients<br />with hepatic impairment to provide a dose adjustment recommendation (see section 5.2).<br />Elderly<br />There are limited data on the use of Tykerb / capecitabine and Tykerb / trastuzumab in patients aged<br />&ge; 65 years.<br />In the phase III clinical study of Tykerb in combination with letrozole, of the total number of hormone<br />receptor positive metastatic breast cancer patients (Intent to treat population N= 642), 44 % were<br />&ge; 65 years of age. No overall differences in efficacy and safety of the combination of Tykerb and<br />letrozole were observed between these patients and patients &lt; 65 years of age.<br />Paediatric population<br />The safety and efficacy of Tykerb in children below the age of 18 years have not yet been established. No<br />data are available.<br />Method of administration<br />The daily dose of Tykerb should not be divided. Tykerb should be taken either at least one hour before, or<br />at least one hour after food. To minimise variability in the individual patient, administration of Tykerb<br />should be standardised in relation to food intake, for example always to be taken one hour before a meal<br />(see sections 4.5 and 5.2 for information on absorption).<br />Missed doses should not be replaced and the dosing should resume with the next scheduled daily dose<br />(see section 4.9).<br />Consult the full prescribing information of the co-administered medicinal product for relevant details of<br />their posology including any dose reductions, contraindications and safety information.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Data have shown that Tykerb combined with chemotherapy is less effective than trastuzumab when<br />combined with chemotherapy.<br />Cardiac toxicity<br />Lapatinib has been associated with reports of decreases in LVEF (see section 4.8). Lapatinib has not been<br />evaluated in patients with symptomatic cardiac failure. Caution should be taken if Tykerb is to be<br />administered to patients with conditions that could impair left ventricular function (including coadministration<br />with potentially cardiotoxic medicinal products). Evaluation of cardiac function, including<br />LVEF determination, should be conducted for all patients prior to initiation of treatment with Tykerb to<br />ensure that the patient has a baseline LVEF that is within the institutions normal limits. LVEF should<br />continue to be evaluated during treatment with Tykerb to ensure that LVEF does not decline to an<br />unacceptable level (see section 4.2). In some cases, LVEF decrease may be severe and lead to cardiac<br />failure. Fatal cases have been reported, causality of the deaths is uncertain. In studies across the clinical<br />development programme for lapatinib, cardiac events including LVEF decreases were reported in<br />approximately 1% of patients. Symptomatic LVEF decreases were observed in approximately 0.3% of<br />patients who received lapatinib. However, when lapatinib was administered in combination with<br />trastuzumab in the metastatic setting, the incidence of cardiac events including LVEF decreases was<br />higher (7%) versus the lapatinib alone arm (2%) in the pivotal trial. The cardiac events observed in this<br />study were comparable in nature and severity to those previously seen with lapatinib.<br />A concentration-dependent increase of the QTc interval was demonstrated in a dedicated<br />placebo-controlled crossover study in subjects with advanced solid tumours.<br />Caution should be taken if Tykerb is administered to patients with conditions that could result in<br />prolongation of QTc (including hypokalemia, hypomagnesemia, congenital long QT syndrome), coadministration<br />of other medicinal product known to cause QT prolongation, or conditions that increase<br />the exposure of lapatinib, such as co-administration of strong CYP3A4 inhibitors. Hypokalemia or<br />hypomagnesemia should be corrected prior to treatment. Electrocardiograms with QT measurement<br />should be performed prior to and one to two weeks after the start of Tykerb therapy. When clinically<br />indicated, e.g. after initiation of a concomitant treatment that might affect QT or that may interact with<br />lapatinib, ECG measurement should also be considered.<br />Interstitial lung disease and pneumonitis<br />Lapatinib has been associated with reports of pulmonary toxicity including interstitial lung disease and<br />pneumonitis (see section 4.8). Patients should be monitored for symptoms of pulmonary toxicity<br />(dyspnoea, cough, fever) and treatment discontinued in patients who experience symptoms which are NCI<br />CTCAE grade 3 or greater. Pulmonary toxicity may be severe and lead to respiratory failure. Fatal cases<br />have been reported, causality of the deaths is uncertain.<br />Hepatotoxicity<br />Hepatotoxicity has occurred with Tykerb use and may in rare cases be fatal. The hepatotoxicity may<br />occur days to several months after initiation of treatment. At the initiation of treatment, patients should be<br />advised of the potential for hepatotoxicity. Liver function (transaminases, bilirubin and alkaline<br />phosphatase) should be monitored before the initiation of treatment and monthly thereafter, or as<br />clinically indicated. Tykerb dosing should be discontinued if changes in liver function are severe and<br />patients should not be retreated. Patients who carry the HLA alleles DQA1*02:01 and DRB1*07:01 have<br />increased risk of Tykerb-associated hepatotoxicity. In a large, randomised clinical trial of Tykerb<br />monotherapy (n=1,194), the cumulative frequency of severe liver injury (ALT &gt;5 times the upper limit of<br />normal, NCI CTCAE grade 3) at 1 year of treatment was 2.8% overall. The cumulative frequency in<br />DQA1*02:01 and DRB1*07:01 allele carriers was 10.3% and in non-carriers was 0.5%. Carriage of the<br />HLA risk alleles is common (15 to 25%) in Caucasian, Asian, African and Hispanic populations but<br />lower (1%) in Japanese populations.<br />Caution is warranted if Tykerb is prescribed to patients with moderate or severe hepatic impairment (see<br />sections 4.2 and 5.2).<br />Caution is advised if Tykerb is prescribed to patients with severe renal impairment (see sections 4.2 and<br />5.2).<br />Diarrhoea<br />Diarrhoea, including severe diarrhoea, has been reported with Tykerb treatment (see section 4.8).<br />Diarrhoea can be potentially life-threatening if accompanied by dehydration, renal insufficiency,<br />neutropenia and/or electrolyte imbalances and fatal cases have been reported. Diarrhoea generally occurs<br />early during Tykerb treatment, with almost half of those patients with diarrhoea first experiencing it<br />within 6 days. This usually lasts 4-5 days. Tykerb-induced diarrhoea is usually low-grade, with severe<br />diarrhoea of NCI CTCAE grades 3 and 4 occurring in &lt;10% and &lt;1% of patients, respectively. At the<br />start of therapy, the patients bowel pattern and any other symptoms (e.g. fever, cramping pain, nausea,<br />vomiting, dizziness and thirst) should be determined, to allow identification of changes during treatment<br />and to help identify patients at greater risk of diarrhoea. Patients should be instructed to promptly report<br />any change in bowel patterns. In potentially severe cases of diarrhoea the measuring of neutrophil counts<br />and body temperature should be considered. Proactive management of diarrhoea with anti-diarrhoeal<br />medicinal product is important. Severe cases of diarrhoea may require administration of oral or<br />intravenous electrolytes and fluids, use of antibiotics such as fluoroquinolones (especially if diarrhoea is<br />persistent beyond 24 hours, there is fever, or grade 3 or 4 neutropenia) and interruption or discontinuation<br />of Tykerb therapy (see section 4.2 &ndash; dose delay and dose reduction &ndash;diarrhoea).<br />Serious cutaneous reactions<br />Serious cutaneous reactions have been reported with Tykerb. If erythema multiforme or life-threatening<br />reactions such as Stevens-Johnson syndrome, or toxic epidermal necrolysis (e.g. progressive skin rash<br />often with blisters or mucosal lesions) are suspected, discontinue treatment with Tykerb.<br />Concomitant treatment with inhibitors or inducers of CYP3A4<br />Concomitant treatment with inducers of CYP3A4 should be avoided due to risk of decreased exposure to<br />lapatinib (see section 4.5).<br />Concomitant treatment with strong inhibitors of CYP3A4 should be avoided due to risk of increased<br />exposure to lapatinib (see section 4.5).<br />Grapefruit juice should be avoided during treatment with Tykerb (see section 4.5).<br />Co-administration of Tykerb with orally administered medicinal products with narrow therapeutic<br />windows that are substrates of CYP3A4 and /or CYP2C8 should be avoided (see section 4.5).<br />Concomitant treatment with substances that increase gastric pH should be avoided, as lapatinib solubility<br />and absorption may decrease (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects of other medicinal products on lapatinib<br />Lapatinib is predominantly metabolised by CYP3A (see section 5.2).<br />In healthy volunteers receiving ketoconazole, a strong CYP3A4 inhibitor, at 200 mg twice daily for<br />7 days, systemic exposure to lapatinib (100 mg daily) was increased approximately 3.6&ndash;fold, and half-life<br />increased 1.7&ndash;fold. Co-administration of Tykerb with strong inhibitors of CYP3A4 (e.g. ritonavir,<br />saquinavir, telithromycin, ketoconazole, itraconazole, voriconazole, posaconazole, nefazodone) should be<br />avoided. Co-administration of Tykerb with moderate inhibitors of CYP3A4 should proceed with caution<br />and clinical adverse reactions should be carefully monitored.<br />In healthy volunteers receiving carbamazepine, a CYP3A4 inducer, at 100 mg twice daily for 3 days and<br />200 mg twice daily for 17 days, systemic exposure to lapatinib was decreased approximately 72%. Coadministration<br />of Tykerb with known inducers of CYP3A4 (e.g. rifampicin, rifabutin, carbamazepine,<br />phenytoin or Hypericum perforatum [St John&rsquo;s Wort]) should be avoided.<br />Lapatinib is a substrate for the transport proteins Pgp and BCRP. Inhibitors (ketoconazole, itraconazole,<br />quinidine, verapamil, cyclosporine, erythromycin) and inducers (rifampicin, St John&rsquo;s Wort) of these<br />proteins may alter the exposure and/or distribution of lapatinib (see section 5.2).<br />The solubility of lapatinib is pH-dependent. Concomitant treatment with substances that increase gastric<br />pH should be avoided, as lapatinib solubility and absorption may decrease. Pre-treatment with a proton<br />pump inhibitor (esomeprazole) decreased lapatinib exposure by an average of 27% (range: 6% to 49%).<br />This effect decreases with increasing age from approximately 40 to 60 years.<br />Effects of lapatinib on other medicinal products<br />Lapatinib inhibits CYP3A4 in vitro at clinically relevant concentrations. Co-administration of Tykerb<br />with orally administered midazolam resulted in an approximate 45% increase in the AUC of midazolam.<br />There was no clinically meaningful increase in AUC when midazolam was dosed intravenously. Coadministration<br />of Tykerb with orally administered medicinal products with narrow therapeutic windows<br />that are substrates of CYP3A4 (e.g. cisapride, pimozide and quinidine) should be avoided (see<br />sections 4.4 and 5.2).<br />Lapatinib inhibits CYP2C8 in vitro at clinically relevant concentrations. Co-administration of Tykerb<br />with medicinal products with narrow therapeutic windows that are substrates of CYP2C8 (e.g.<br />repaglinide) should be avoided (see sections 4.4 and 5.2).<br />Co-administration of lapatinib with intravenous paclitaxel increased the exposure of paclitaxel by 23%,<br />due to lapatinib inhibition of CYP2C8 and/or Pgp. An increase in the incidence and severity of diarrhoea<br />and neutropenia has been observed with this combination in clinical studies. Caution is advised if<br />lapatinib is co-administered with paclitaxel.<br />Co-administration of lapatinib with intravenously administered docetaxel did not significantly affect the<br />AUC or Cmax of either active substance. However, the occurrence of docetaxel-induced neutropenia was<br />increased.<br />Co-administration of Tykerb with irinotecan (when administered as part of the FOLFIRI regimen)<br />resulted in an approximate 40% increase in the AUC of SN-38, the active metabolite of irinotecan. The<br />precise mechanism of this interaction is unknown, but it is assumed to be due to inhibition of one or more<br />transport proteins by lapatinib. Adverse reactions should be carefully monitored if Tykerb is coadministered<br />with irinotecan, and a reduction in the dose of irinotecan should be considered.<br />Lapatinib inhibits the transport protein Pgp in vitro at clinically relevant concentrations. Coadministration<br />of lapatinib with orally administered digoxin resulted in an approximate 80% increase in<br />the AUC of digoxin. Caution should be exercised when dosing lapatinib concurrently with medicinal<br />products with narrow therapeutic windows that are substrates of Pgp, and a reduction in the dose of the<br />Pgp substrate should be considered.<br />Lapatinib inhibits the transport proteins BCRP and OATP1B1 in vitro. The clinical relevance of this<br />effect has not been evaluated. It cannot be excluded that lapatinib will affect the pharmacokinetics of<br />substrates of BCRP (e.g. topotecan) and OATP1B1 (e.g. rosuvastatin) (see section 5.2).<br />Concomitant administration of Tykerb with capecitabine, letrozole or trastuzumab did not meaningfully<br />alter the pharmacokinetics of these medicinal products (or the metabolites of capecitabine) or lapatinib.<br />Interactions with food and drink<br />The bioavailability of lapatinib is increased up to about 4 times by food, depending on e.g. the fat content<br />in the meal. Furthermore, depending on type of food the bioavailability is approximately 2-3 times higher<br />when lapatinib is taken 1 hour after food compared with 1 hour before the first meal of the day (see<br />sections 4.2 and 5.2).<br />Grapefruit juice may inhibit CYP3A4 in the gut wall and increase the bioavailability of lapatinib and<br />should therefore be avoided during treatment with Tykerb.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential / Contraception in males and females<br />Women of childbearing potential should be advised to use adequate contraception and avoid becoming pregnant while receiving treatment with Tyverb and for 1 week after the last dose.<br />Based on findings in animal reproduction studies, advise male patients with female partners of reproductive potential to use effective contraception during treatment with TYKERB and for 1 week after the last dose<br />Pregnancy<br />There are no adequate data from the use of Tykerb in pregnant women. Studies in animals have shown<br />reproductive toxicity (see section 5.3). The potential risk for humans is not known.<br />Tykerb should not be used during pregnancy unless clearly necessary.<br />Breast-feeding<br />The safe use of Tykerb during breast-feeding has not been established. It is not known whether lapatinib<br />is excreted in human milk. In rats, growth retardation was observed in pups which were exposed to<br />lapatinib via breast milk. Breast-feeding must be discontinued in women who are receiving therapy with<br />Tykerb. and for at least 5 days after the last dose.<br />Fertility<br />There are no adequate data from the use of Tykerb in women of childbearing potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A detrimental effect on such activities cannot be predicted from the pharmacology of lapatinib. The<br />clinical status of the patient and the adverse event profile of lapatinib should be borne in mind when<br />considering the patient&#39;s ability to perform tasks that require judgement, motor or cognitive skills</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The safety of lapatinib has been evaluated as monotherapy or in combination with other chemotherapies for various cancers in more than 20,000&nbsp;patients, including 198&nbsp;patients who received lapatinib in combination with capecitabine, 149&nbsp;patients who received lapatinib in combination with trastuzumab and 654&nbsp;patients who received lapatinib in combination with letrozole (see section&nbsp;5.1).</p><p>&nbsp;</p><p>The most common adverse reactions (&gt;25%) during therapy with lapatinib were gastrointestinal events (such as diarrhoea, nausea, and vomiting) and rash. Palmar-plantar erythrodysesthesia (PPE) was also common (&gt;25%) when lapatinib was administered in combination with capecitabine. The incidence of PPE was similar in the lapatinib plus capecitabine and capecitabine alone treatment arms. Diarrhoea was the most common adverse reaction resulting in discontinuation of treatment when lapatinib was administered in combination with capecitabine, or with letrozole.</p><p>&nbsp;</p><p>No additional adverse reactions were reported to be associated with lapatinib in combination with trastuzumab. There was an increased incidence of cardiac toxicity, but these events were comparable in nature and severity to those reported from the lapatinib clinical programme (see section&nbsp;4.4 &ndash; cardiac toxicity). These data are based on exposure to this combination in 149&nbsp;patients in the pivotal trial.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The following adverse reactions have been reported to have a causal association with lapatinib alone or lapatinib in combination with capecitabine, trastuzumab or letrozole.</p><p>&nbsp;</p><p>The following convention has been utilised for the classification of frequency: very common ((&sup3;1/10), common (&sup3;1/100 to &lt;1/10), uncommon (&sup3;1/1,000 to &lt;1/100), rare (&sup3;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions including anaphylaxis (see section&nbsp;4.3)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Anorexia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Insomnia*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Decreased left ventricular ejection fraction (see section&nbsp;4.2 - dose reduction &ndash; cardiac events and section&nbsp;4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Ventricular arrhythmias/Torsades de Pointes, electrocardiogram QT prolonged**</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hot flush<sup>&dagger;</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Epistaxis<sup>&dagger;</sup>, cough<sup>&dagger;</sup>, dyspnoea<sup>&dagger;</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Interstitial lung disease/pneumonitis.</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Pulmonary arterial hypertension**.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Diarrhoea, which may lead to dehydration (see section&nbsp;4.2 - dose delay and dose reduction &ndash; other toxicities and section&nbsp;4.4), nausea, vomiting, dyspepsia*, stomatitis*, constipation*, abdominal pain*.</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Constipation<sup>&dagger;</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hyperbilirubinaemia, hepatotoxicity (see section&nbsp;4.4).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Rash (including dermatitis acneiform) (see section&nbsp;4.2 - dose delay and dose reduction &ndash; other toxicities), dry skin*<sup>&dagger;</sup>, palmar-plantar erythrodysaesthesia*, alopecia<sup>&dagger;</sup>, pruritus<sup>&dagger;</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nail disorders including paronychia, skin fissures.</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Serious cutaneous reactions, including Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)**</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pain in extremity*<sup>&dagger;</sup>, back pain*<sup>&dagger;</sup>, arthralgia<sup>&dagger;</sup>.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Fatigue, mucosal inflammation*, asthenia<sup>&dagger;</sup>.</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; These adverse reactions were observed when lapatinib was administered in combination with capecitabine.</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; These adverse reactions were observed when lapatinib was administered in combination with letrozole.</p><p>**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions from spontaneous reports and literature</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><u>Decreased left ventricular ejection fraction and </u><em><u>QT interval prolongation</u></em></p><p>&nbsp;</p><p>Left ventricular ejection fraction (LVEF) decreases have been reported in approximately 1% of patients receiving lapatinib and were asymptomatic in more than 70% of cases. LVEF decreases resolved or improved in more than 70&nbsp;% of cases, in approximately 60&nbsp;% of these on discontinuation of treatment with lapatinib, and in approximately 40&nbsp;% of cases lapatinib was continued. Symptomatic LVEF decreases were observed in approximately 0.3% of patients who received lapatinib monotherapy or in combination with other anti‑cancer medicinal products. Observed adverse reactions included dyspnoea, cardiac failure and palpitations. Overall 58&nbsp;% of these symptomatic patients recovered. LVEF decreases were reported in 2.5&nbsp;% of patients who received lapatinib in combination with capecitabine, as compared to 1.0&nbsp;% with capecitabine alone. LVEF decreases were reported in 3.1&nbsp;% of patients who received lapatinib in combination with letrozole as compared to 1.3&nbsp;% of patients receiving letrozole plus placebo. LVEF decreases were reported in 6.7 % of patients who received lapatinib in combination with trastuzumab, as compared to 2.1&nbsp;% of patients who received lapatinib alone.</p><p>&nbsp;</p><p>A concentration dependent increase in QTcF (maximum mean &Delta;&Delta;QTcF 8.75&nbsp;ms; 90% CI 4.08, 13.42) was observed in a dedicated QT study in patients with advanced solid tumours (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Diarrhoea</u></p><p>&nbsp;</p><p>Diarrhoea occurred in approximately 65&nbsp;% of patients who received lapatinib in combination with capecitabine, in 64&nbsp;% of patients who received lapatinib in combination with letrozole and in 62&nbsp;% of patients who received lapatinib in combination with trastuzumab. Most cases of diarrhoea were grade&nbsp;1 or 2 and did not result in discontinuation of treatment with lapatinib. Diarrhoea responds well to proactive management (see section&nbsp;4.4). However, a few cases of acute renal failure have been reported secondary to severe dehydration due to diarrhoea.</p><p>&nbsp;</p><p><u>Rash</u></p><p>&nbsp;</p><p>Rash occurred in approximately 28&nbsp;% of patients who received lapatinib in combination with capecitabine, in 45&nbsp;% of patients who received lapatinib in combination with letrozole and in 23 % of patients who received lapatinib in combination with trastuzumab. Rash was generally low grade and did not result in discontinuation of treatment with lapatinib. Prescribing physicians are advised to perform a skin examination prior to treatment and regularly during treatment. Patients experiencing skin reactions should be encouraged to avoid exposure to sunlight and apply broad spectrum sunscreens with a Sun Protection Factor (SPF)&nbsp;&sup3;&nbsp;30. If a skin reaction occurs a full body examination should be performed at every visit until one month after resolution. Patients with extensive or persistent skin reactions should be referred to a dermatologist.</p><p>&nbsp;</p><p><u>Hepatotoxicity</u></p><p>&nbsp;</p><p>The risk of lapatinib-induced hepatotoxicity was associated with carriage of the HLA alleles DQA1*02:01 and DRB1*07:01 (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>--<em>To reports any side effect(s): </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia: </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>o Fax: +966112057662</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States: </em></strong></p><p>-- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific antidote for the inhibition of EGFR (ErbB1) and/or HER2 (ErbB2) tyrosine<br />phosphorylation. The maximum oral dose of lapatinib that has been administered in clinical studies is<br />1800 mg once daily.<br />Asymptomatic and symptomatic cases of overdose have been reported in patients being treated with<br />Tykerb. In patients who took up to 5000 mg of lapatinib, symptoms observed include known lapatinib<br />associated events (see section 4.8) and in some cases sore scalp and/or mucosal inflammation. In a single<br />case of a patient who took 9000 mg of Tykerb, sinus tachycardia (with otherwise normal ECG) was also<br />observed.<br />Lapatinib is not significantly renally excreted and is highly bound to plasma proteins, therefore<br />haemodialysis would not be expected to be an effective method to enhance the elimination of lapatinib.<br />Further management should be as clinically indicated or as recommended by the national poisons centre,<br />where available.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agent, other antineoplastic agents, protein kinase inhibitor,<br />ATC code: L01XE07<br />Mechanism of action<br />Lapatinib, a 4-anilinoquinazoline, is an inhibitor of the intracellular tyrosine kinase domains of both<br />EGFR (ErbB1) and of HER2 (ErbB2) receptors (estimated Kiapp values of 3nM and 13nM, respectively)<br />with a slow off-rate from these receptors (half-life greater than or equal to 300 minutes). Lapatinib<br />inhibits ErbB-driven tumour cell growth in vitro and in various animal models.<br />The combination of lapatinib and trastuzumab may offer complementary mechanisms of action as well as<br />possible non-overlapping mechanisms of resistance. The growth inhibitory effects of lapatinib were<br />evaluated in trastuzumab-conditioned cell lines. Lapatinib retained significant activity against HER2-<br />amplified breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in<br />vitro and was synergistic in combination with trastuzumab in these cell lines.<br />Clinical efficacy and safety<br />Combination treatment with Tykerb and capecitabine<br />The efficacy and safety of Tykerb in combination with capecitabine in breast cancer patients with good<br />performance status was evaluated in a randomised, phase III study. Patients eligible for enrolment had<br />HER2-overexpressing, locally advanced or metastatic breast cancer, progressing after prior treatment that<br />included taxanes, anthracyclines and trastuzumab. LVEF was evaluated in all patients (using<br />echocardiogram [Echo] or multi gated acquisition scan [MUGA]) prior to initiation of treatment with<br />Tykerb to ensure baseline LVEF was within the institutions normal limits. In the clinical study LVEF was<br />monitored at approximately eight week intervals during treatment with Tykerb to ensure it did not decline<br />to below the institutions lower limit of normal. The majority of LVEF decreases (greater than 60 % of<br />events) were observed during the first nine weeks of treatment, however limited data was available for<br />long term exposure.<br />Patients were randomised to receive either Tykerb 1250 mg once daily (continuously) plus capecitabine<br />(2000 mg/m2/day on days 1-14 every 21 days), or to receive capecitabine alone (2500 mg/m2/day on<br />days 1-14 every 21 days). The primary endpoint was time to progression (TTP). Assessments were<br />undertaken by the study investigators and by an independent review panel, blinded to treatment. The<br />study was halted based on the results of a pre-specified interim analysis that showed an improvement in<br />TTP for patients receiving Tykerb plus capecitabine. An additional 75 patients were enrolled in the study<br />between the time of the interim analysis and the end of the enrolment. Investigator analysis on data at the<br />end of enrolment is presented in Table 1.<br />Table 1 Time to Progression data from Study EGF100151 (Tykerb / capecitabine)<br />Investigator assessment<br />Tykerb (1,250 mg/day)+<br />capecitabine (2,000 mg/m2/day,<br />days 1-14 q21 days)<br />Capecitabine (2,500 mg/m2/day,<br />days 1-14 q21 days)<br />(N = 198) (N = 201)<br />Number of TTP events 121 126<br />Median TTP, weeks 23.9 18.3<br />Hazard Ratio 0.72<br />(95% CI) (0.56, 0.92)<br />p value 0.008<br />The independent assessment of the data also demonstrated that Tykerb when given in combination with<br />capecitabine significantly increased time to progression (Hazard Ratio 0.57 [95 % CI 0.43, 0.77]<br />p=0.0001) compared to capecitabine alone.<br />Results of an updated analysis of the overall survival data to 28 September 2007 are presented in Table 2.<br />Table 2 Overall survival data from Study EGF100151 (Tykerb / capecitabine)<br />Tykerb (1,250 mg/day)+<br />capecitabine (2,000 mg/m2/day,<br />days 1-14 q21 days)<br />Capecitabine (2,500 mg/m2/day,<br />days 1-14 q21 days)<br />(N = 207) (N = 201)<br />Number of subjects who<br />died<br />148 154<br />Median overall survival,<br />weeks<br />74.0 65.9<br />Hazard Ratio 0.9<br />(95% CI) (0.71, 1.12)<br />p value 0.3<br />On the combination arm, there were 4 (2%) progressions in the central nervous system as compared with<br />the 13 (6%) progressions on the capecitabine alone arm.<br />Data are available on the efficacy and safety of Tykerb in combination with capecitabine relative to<br />trastuzumab in combination with capecitabine. A randomised Phase III study (EGF111438) (N=540)<br />compared the effect of the two regimens on the incidence of CNS as site of first relapse in women with<br />HER2 overexpressing metastatic breast cancer. Patients were randomised to either Tykerb 1250 mg once<br />daily (continuously) plus capecitabine (2000 mg/m2/day on days 1-14 every 21 days), or trastuzumab<br />(loading dose of 8mg/kg followed by 6mg/kg q3 weekly infusions) plus capecitabine (2500mg/m2/day,<br />days 1-14, every 21 days). Randomisation was stratified by prior trastuzumab treatment and number of<br />prior treatments for metastatic disease. The study was halted as the interim analysis (N=475) showed a<br />low incidence of CNS events and, superior efficacy of the trastuzumab plus capecitabine arm in terms of<br />progression-free survival and overall survival (see results of final analysis in Table 3).<br />In the Tykerb plus capecitabine arm 8 patients (3.2%) experienced CNS as site of first progression,<br />compared with 12 patients (4.8%) in the trastuzumab plus capecitabine arm.<br />Lapatinib effect on CNS metastasis<br />Lapatinib has in terms of objective responses demonstrated modest activity in the treatment of established<br />CNS metastases. In the prevention of CNS metastases in the metastatic and early breast cancer settings<br />the observed activity was limited.<br />Table 3 Analyses of Investigator-Assessed Progression-Free Survival and Overall Survival<br />Investigator-Assessed PFS Overall Survival<br />Tykerb (1,250<br />mg/day) +<br />capecitabine<br />(2,000 mg/m2/day,<br />days 1-14 q21<br />days)<br />Trastuzumab<br />(loading dose of<br />8mg/kg followed<br />by 6mg/kg q3<br />weekly infusions)<br />+<br />capecitabine<br />(2,500 mg/m2/day,<br />days 1-14 q21<br />days)<br />Tykerb (1,250<br />mg/day) +<br />capecitabine<br />(2,000 mg/m2/day,<br />days 1-14 q21<br />days)<br />Trastuzumab<br />(loading dose of<br />8mg/kg followed<br />by 6mg/kg q3<br />weekly infusions)<br />+<br />capecitabine<br />(2,500 mg/m2/day,<br />days 1-14 q21<br />days)<br />ITT population<br />N 271 269 271 269<br />Number (%)<br />with Event1<br />160 (59) 134 (50) 70 (26) 58 (22)<br />Kaplan-Meier<br />estimate,<br />months a<br />Median (95%<br />CI)<br />6.6 (5.7, 8.1) 8.0 (6.1, 8.9)<br />22.7 (19.5, -) 27.3 (23.7, -)<br />Stratified<br />Hazard ratio<br />b<br />HR (95% CI) 1.30 (1.04, 1.64) 1.34 (0.95, 1.90)<br />p-value 0.021 0.095<br />Subjects who had received prior trastuzumab*<br />N 167 159 167 159<br />Number (%)<br />with Event1<br />103 (62) 86 (54) 43 (26) 38 (24)<br />Median (95%<br />CI)<br />6.6 (5.7, 8.3) 6.1 (5.7, 8.0)<br />22.7 (20.1,-) 27.3 (22.5, 33.6)<br />HR (95% CI) 1.13 (0.85, 1.50) 1.18 (0.76, 1.83)<br />Subjects who had not received prior trastuzumab*<br />N 104 110 104 110<br />Number (%)<br />with Event1<br />57 (55) 48 (44) 27 (26) 20 (18)<br />Median (95%<br />CI)<br />6.3 (5.6, 8.1) 10.9 (8.3, 15.0)<br />NE2 (14.6, -) NE2 (21.6, -)<br />HR (95% CI) 1.70 (1.15, 2.50) 1.67 (0.94, 2.96)<br />CI = confidence interval<br />a. PFS was defined as the time from randomisation to the earliest date of disease progression or death<br />from any cause, or to the date of censor.<br />b. Pike estimate of the treatment hazard ratio, &lt;1 indicates a lower risk for Tykerb plus capecitabine<br />compared with Trastuzumab plus capecitabine.<br />1. PFS event is Progressed or Died and OS event is Died due to any cause.<br />2. NE=Median was not reached.<br />* Post hoc analysis<br />Combination treatment with Tykerb and trastuzumab<br />The efficacy and safety of lapatinib in combination with trastuzumab in metastatic breast cancer were<br />evaluated in a randomised trial. Eligible patients were women with Stage IV ErbB2 gene amplified (or<br />protein overexpressing) metastatic breast cancer who had been exposed to treatment with anthracyclines<br />and taxanes. In addition, per the protocol, patients were to be reported by the investigators as having<br />progressed on their most recent trastuzumab containing regimen in the metastatic setting. The median<br />number of prior trastuzumab-containing regimens was three. Patients were randomised to receive either<br />oral lapatinib 1,000 mg once daily plus trastuzumab 4 mg/kg administered as an intravenous (IV) loading<br />dose, followed by 2 mg/kg IV weekly (N = 148), or oral lapatinib 1,500 mg once daily (N = 148). Patients<br />who had objective disease progression after receiving at least 4 weeks of treatment with lapatinib<br />monotherapy were eligible to crossover to combination therapy. Of the 148 patients who received<br />monotherapy treatment, 77 (52%) patients elected at the time of disease progression to receive<br />combination treatment.<br />Progression-free survival (PFS) was the primary endpoint of the study with response rate and overall<br />survival (OS) as secondary endpoints. The median age was 51 years and 13% were 65 years or older.<br />Ninety-four percent (94%) were Caucasian. Most patients in both treatment arms had visceral disease<br />(215 [73%] patients overall). In addition, 150 [50%] of patients were hormone receptor negative. A<br />summary of efficacy endpoints and overall survival data is provided in Table 4. Subgroup analysis<br />results based on predefined stratification factor (hormone receptor status) is also shown in Table 5.<br />Table 4 Progression-free survival and overall survival data (Tykerb / trastuzumab)<br />Lapatinib plus<br />trastuzumab<br />(N=148)<br />Lapatinib alone<br />(N=148 )<br />Median PFS1, weeks<br />(95% CI)<br />12.0<br />(8.1, 16.0)<br />8.1<br />(7.6, 9.0)<br />Hazard Ratio (95% CI) 0.73 (0.57, 0.93)<br />P value 0.008<br />Response Rate, %<br />(95% CI)<br />10.3<br />(5.9, 16.4)<br />6.9<br />(3.4, 12.3)<br />Died 105 113<br />Median overall survival1, months<br />(95% CI)<br />14.0<br />(11.9, 17.2)<br />9.5<br />(7.6, 12.0)<br />Hazard Ratio (95% CI) 0.74 (0.57, 0.97)<br />P value 0.026<br />PFS = progression-free survival; CI = confidence interval.<br />1Kaplan-Meier estimates<br />Table 5 Summary of PFS and OS in Studies with Hormone Receptor negative<br />Median PFS Median OS<br />Lap+Tras 15.4 wks (8.4, 16.9) 17.2 mos (13.9, 19.2)<br />Lap 8.2 wks (7.4, 9.3) 8.9 mos (6.7, 11.8)<br />HR (95% CI) 0.73 (0.52, 1.03) 0.62 (0.42, 0.90)<br />Combination treatment with Tykerb and letrozole<br />Tykerb has been studied in combination with letrozole for the treatment of postmenopausal women with<br />hormone receptor-positive (oestrogen receptor [ER] positive and / or progesterone receptor [PgR]<br />positive) advanced or metastatic breast cancer.<br />The Phase III study (EGF30008) was randomised, double-blind, and placebo controlled. The study<br />enrolled patients who had not received prior therapy for their metastatic disease.<br />In the HER2-overexpressing population, only 2 patients were enrolled who had received prior<br />trastuzumab, 2 patients had received prior aromatase inhibitor therapy, and approximately half had<br />received tamoxifen.<br />Patients were randomised to letrozole 2.5 mg once daily plus Tykerb 1500 mg once daily or letrozole with<br />placebo. Randomisation was stratified by sites of disease and by time from discontinuation of prior<br />adjuvant anti-oestrogen therapy. HER2 receptor status was retrospectively determined by central<br />laboratory testing. Of all patients randomised to treatment, 219 patients had tumours overexpressing the<br />HER2 receptor, and this was the pre-specified primary population for the analysis of efficacy. There were<br />952 patients with HER2-negative tumours, and a total of 115 patients whose tumour HER2 status was<br />unconfirmed (no tumour sample, no assay result, or other reason).<br />In patients with HER2-overexpressing MBC, investigator-determined progression-free survival (PFS)<br />was significantly greater with letrozole plus Tykerb compared with letrozole plus placebo. In the HER2-<br />negative population, there was no benefit in PFS when letrozole plus Tykerb was compared with letrozole<br />plus placebo (see Table 6).<br />Table 6 Progression Free Survival data from Study EGF30008 (Tykerb / letrozole)<br />HER2-Overexpressing Population HER2-Negative Population<br />N = 111 N = 108 N = 478 N = 474<br />Tykerb 1500 mg<br />/ day<br />+ Letrozole<br />2.5 mg /day<br />Letrozole<br />2.5 mg /day<br />+ placebo<br />Tykerb 1500 mg<br />/ day<br />+ Letrozole<br />2.5 mg /day<br />Letrozole<br />2.5 mg /day<br />+ placebo<br />Median PFS, weeks<br />(95% CI)<br />35.4<br />(24.1, 39.4)<br />13.0<br />(12.0, 23.7)<br />59.7<br />(48.6, 69.7)<br />58.3<br />(47.9, 62.0)<br />Hazard Ratio 0.71 (0.53, 0.96) 0.90 (0.77, 1.05)<br />P-value 0.019 0.188<br />Objective Response<br />Rate (ORR)<br />27.9% 14.8% 32.6% 31.6%<br />Odds Ratio 0.4 (0.2, 0.9) 0.9 (0.7, 1.3)<br />P-value 0.021 0.26<br />Clinical Benefit Rate<br />(CBR)<br />47.7% 28.7% 58.2% 31.6%<br />Odds Ratio 0.4 (0.2, 0.8) 1.0 (0.7, 1.2)<br />P-value 0.003 0.199<br />CI= confidence interval<br />HER2 overexpression = IHC 3+ and/or FISH positive; HER2 negative = IHC 0, 1+ or 2+ and/or FISH<br />negative<br />Clinical Benefit Rate was defined as complete plus partial response plus stable disease for 6 months.<br />At the time of the final PFS analysis (with median follow-up of 2.64 years), the overall survival data were<br />not mature and there was no significant difference between treatment groups in the HER2-positive<br />population; this had not changed with additional follow-up (&gt;7.5 years median follow-up time; Table 7).<br />Table 7 Overall Survival (OS) results from study EGF30008 (in the HER2-positive population<br />only)<br />Tykerb 1500 mg / day<br />+ Letrozole 2.5 mg<br />/day<br />N=111<br />Letrozole 2.5 mg /day<br />+ placebo<br />N=108<br />Pre-planned OS analysis (conducted at the time of the final PFS analysis, 03 June 2008)<br />Median Follow-up (yrs) 2,64 2,64<br />Deaths (%) 50 (45) 54 (50)<br />Hazard Ratioa (95% CI), p-valueb 0,77 (0,52; 1,14); 0,185<br />Final OS analysis (post-hoc analysis, 07 August 2013)<br />Median Follow-up (yrs) 7,78 7,55<br />Deaths (%) 86 (77) 78 (72)<br />Hazard Ratio (95% CI), p-value 0,97 (0,07; 1,33); 0,848<br />Median values from Kaplan-Meier analysis; HR and p-values from Cox regression models adjusting<br />for important prognostic factors.<br />a. Estimate of the treatment hazard ratio, where &lt;1 indicates a lower risk with letrozole 2.5 mg +<br />lapatinib 1500 mg compared with letrozole 2.5 mg + placebo.<br />b. P-value from Cox regression model, stratifying for site of disease and prior anti-adjuvant therapy<br />at screening.<br />The efficacy and safety of Tykerb in combination with an aromatase inhibitor were further confirmed in<br />another Phase III study (Study EGF114299). Patients enrolled were postmenopausal women who had<br />hormone receptor-positive/ HER2-positive metastatic breast cancer which had progressed after prior<br />trastuzumab-containing chemotherapy regimen and endocrine therapies. The study was primarily<br />designed to evaluate a potential benefit in PFS of dual HER2 blockade (Tykerb + trastuzumab) versus<br />single HER2 blockade (trastuzumab), both in combination with an aromatase inhibitor (AI). The study<br />included a third arm of Tykerb + AI.<br />A total of 355 patients were randomised in a 1:1:1 ratio to Tykerb 1000 mg + trastuzumab (loading dose<br />of 8 mg/kg followed by a maintenance dose of 6 mg/kg IV q3weeks) + AI (N=120), or trastuzumab<br />(loading dose of 8 mg/kg followed by a maintenance dose of 6 mg/kg IV q3weeks) + AI arm (N=117), or<br />Tykerb 1500 mg + AI (N=118).<br />Table 8 Progression Free Survival data from Study EGF114299<br />Tykerb (1500 mg) + AI Trastuzumab (6 mg/kg) + AI<br />N=117 N=118<br />Events, n (%) 74 (63) 75 (64)<br />Median PFS, months<br />(95% CI)<br />8.3<br />(5.8, 11.2)<br />5.7<br />(5.5, 8.4)<br />HR; 95% CI versus<br />trastuzumab + AI<br />0.71 (0.51, 0.98) -<br />P-value 0.0361 -<br />Cardiac electrophysiology<br />The effect of lapatinib on the QT-interval was evaluated in a single-blind, placebo-controlled, single<br />sequence (placebo and active treatment) crossover study in patients with advanced solid tumours<br />(EGF114271) (n=58). During the 4-day treatment period, three doses of matching placebo were<br />administered 12 hours apart in the morning and evening on Day 1 and in the morning on Day 2. This was<br />followed by three doses of lapatinib 2000 mg administered in the same way. Measurements, including<br />electrocardiograms (ECGs) and pharmacokinetic samples, were taken at baseline and at the same time<br />points on Day 2 and Day 4.<br />In the evaluable population (n=37), the maximum mean &Delta;&Delta;QTcF (90% CI) of 8.75 ms (4.08, 13.42) was<br />observed 10 hours after ingestion of the third dose of lapatinib 2000 mg. The &Delta;&Delta;QTcF exceeded the 5 ms<br />threshold and the upper bound 90% CIs exceeded the 10 ms threshold at multiple time points. The results<br />for the pharmacodynamics population (n=52) were consistent with those from the evaluable population<br />(maximum &Delta;&Delta;QTcF (90% CI) of 7.91 ms (4.13, 11.68) observed 10 hours after ingestion of the third dose<br />of lapatinib 2000 mg).<br />There is a positive relationship between lapatinib plasma concentrations and &Delta;&Delta;QTcF. Lapatinib<br />produced a maximum mean concentration of 3920 (3450-4460) ng/ml (geometric mean/95% CI),<br />exceeding the geometric mean Cmax.ss and 95% CI values observed following the approved dosing<br />regimens. An additional increase in peak exposure of lapatinib can be expected when lapatinib is taken<br />repeatedly with food (see sections 4.2 and 5.2) or concomitantly with strong CYP3A4 inhibitors. When<br />lapatinib is taken in combination with strong CYP3A4 inhibitors the QTc interval can be expected to be<br />prolonged by 16.1 ms (12.6-20.3 ms) as demonstrated in a model-based prediction (see section 4.4).<br />Food effects on lapatinib exposure<br />The bioavailability and thereby the plasma concentrations of lapatinib are increased by food, in relation to<br />the content and timing of the meal. Dosing of lapatinib one hour after a meal results in approximately<br />2-3 times higher systemic exposure, compared to dosing one hour before a meal (see sections 4.5 and<br />5.2).<br />The European Medicines Agency has waived the obligation to submit the results of studies with Tykerb<br />in all subsets of the paediatric population in the treatment of breast carcinoma (see section 4.2 for<br />information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />The absolute bioavailability following oral administration of lapatinib is unknown, but it is incomplete<br />and variable (approximately 70% coefficient of variation in AUC). Serum concentrations appear after a<br />median lag time of 0.25 hours (range 0 to 1.5 hours). Peak plasma concentrations (Cmax) of lapatinib are<br />achieved approximately 4 hours after administration. Daily dosing of 1250 mg produces steady state<br />geometric mean (coefficient of variation) Cmax values of 2.43 (76%) &mu;g/ml and AUC values of 36.2 (79%)<br />&mu;g*hr/ml.<br />Systemic exposure to lapatinib is increased when administered with food. Lapatinib AUC values were<br />approximately 3- and 4-fold higher (Cmax approximately 2.5 and 3&ndash;fold higher) when administered with a<br />low fat (5% fat [500 calories]) or with a high fat (50% fat [1,000 calories]) meal, respectively, as<br />compared with administration in the fasted state. Systemic exposure to lapatinib is also affected by the<br />timing of administration in relation to food intake. Relative to dosing 1 hour before a low fat breakfast,<br />mean AUC values were approximately 2- and 3-fold higher when lapatinib was administered 1 hour after<br />a low fat or high fat meal, respectively.<br />Distribution<br />Lapatinib is highly bound (greater than 99%) to albumin and alpha-1 acid glycoprotein. In vitro studies<br />indicate that lapatinib is a substrate for the transporters BCRP (ABCG1) and p-glycoprotein (ABCB1).<br />Lapatinib has also been shown in vitro to inhibit these efflux transporters, as well as the hepatic uptake<br />transporter OATP 1B1, at clinically relevant concentrations (IC50 values were equal to 2.3 &mu;g/ml). The<br />clinical significance of these effects on the pharmacokinetics of other medicinal products or the<br />pharmacological activity of other anti-cancer medicinal products is not known.<br />Biotransformation<br />Lapatinib undergoes extensive metabolism, primarily by CYP3A4 and CYP3A5, with minor<br />contributions from CYP2C19 and CYP2C8 to a variety of oxidated metabolites, none of which account<br />for more than 14% of the dose recovered in the faeces or 10% of lapatinib concentration in plasma.<br />Lapatinib inhibits CYP3A (Ki 0.6 to 2.3 &mu;g/ml) and CYP2C8 (0.3 &mu;g/ml) in vitro at clinically relevant<br />concentrations. Lapatinib did not significantly inhibit the following enzymes in human liver microsomes:<br />CYP1A2, CYP2C9, CYP2C19, and CYP2D6 or UGT enzymes (in vitro IC50 values were greater than or<br />equal to 6.9 &mu;g/ml).<br />Elimination<br />The half-life of lapatinib measured after single doses increases with increasing dose. However, daily<br />dosing of lapatinib results in achievement of steady state within 6 to 7 days, indicating an effective halflife<br />of 24 hours. Lapatinib is predominantly eliminated through metabolism by CYP3A4/5. Biliary<br />excretion may also contribute to the elimination. The primary route of excretion for lapatinib and its<br />metabolites is in faeces. Recovery of unchanged lapatinib in faeces accounts for a median 27% (range 3 to<br />67%) of an oral dose. Less than 2% of the administered oral dose (as lapatinib and metabolites) excreted<br />in urine.<br />Renal impairment<br />Lapatinib pharmacokinetics have not been specifically studied in patients with renal impairment or in<br />patients undergoing haemodialysis. Available data suggest that no dose adjustment is necessary in<br />patients with mild to moderate renal impairment.<br />Hepatic impairment<br />The pharmacokinetics of lapatinib were examined in patients with moderate (n = 8) or severe (n = 4)<br />hepatic impairment (Child-Pugh scores of 7-9, or greater than 9, respectively) and in 8 healthy control<br />patients. Systemic exposure (AUC) to lapatinib after a single oral 100 mg dose increased approximately<br />56% and 85% in patients with moderate and severe hepatic impairment, respectively. Administration of<br />lapatinib in patients with hepatic impairment should be undertaken with caution (see sections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lapatinib was studied in pregnant rats and rabbits given oral doses of 30, 60, and 120 mg/kg/day. There<br />were no teratogenic effects; however, minor anomalies (left-sided umbilical artery, cervical rib and<br />precocious ossification) occurred in rats at &ge;60 mg/kg/day (4 times the expected human clinical<br />exposure). In rabbits, lapatinib was associated with maternal toxicity at 60 and 120 mg/kg/day (8% and<br />23% of the expected human clinical exposure, respectively) and abortions at 120 mg/kg/day. At<br />&ge;60 mg/kg/day there were decreased foetal body weights, and minor skeletal variations. In the rat preand<br />postnatal development study, a decrease in pup survival occurred between birth and postnatal day 21<br />at doses of 60 mg/kg/day or higher (5 times the expected human clinical exposure). The highest no-effect<br />dose for this study was 20 mg/kg/day.<br />In oral carcinogenicity studies with lapatinib, severe skin lesions were seen at the highest doses tested<br />which produced exposures based on AUC up to 2-fold in mice and male rats, and up to 15-fold in female<br />rats, compared to humans given 1250 mg of lapatinib once daily. There was no evidence of<br />carcinogenicity in mice. In rats, the incidence of benign haemangioma of the mesenteric lymph nodes was<br />higher in some groups than in concurrent controls. There was also an increase in renal infarcts and<br />papillary necrosis in female rats at exposures 7 and 10-fold compared to humans given 1250 mg of<br />lapatinib once daily. The relevance of these findings for humans is uncertain.<br />There were no effects on male or female rat gonadal function, mating, or fertility at doses up to<br />120 mg/kg/day (females) and up to 180 mg/kg/day (males) (8 and 3 times the expected human clinical<br />exposure, respectively). The effect on human fertility is unknown.<br />Lapatinib was not clastogenic or mutagenic in a battery of assays including the Chinese hamster<br />chromosome aberration assay, the Ames assay, human lymphocyte chromosome aberration assay and an<br />in vivo rat bone marrow chromosome aberration assay.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core<br />Microcrystalline cellulose<br />Povidone (K30)<br />Sodium starch glycolate (Type A)<br />Magnesium stearate<br />Tablet coating<br />Hypromellose<br />Titanium dioxide (E171)<br />Macrogol 400<br />Polysorbate 80<br />Iron oxide yellow (E172)<br />Iron oxide red (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 Month.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tykerb is supplied in either blister packs or bottles.<br />Blister packs<br />Tykerb / capecitabine combination posology<br />Each pack of Tykerb contains 70 film-coated tablets in foil blisters (polyamide / aluminium / polyvinyl<br />chloride / aluminium) of 10 tablets each. Each foil has a perforation down the middle to allow the blisters<br />to be separated into a daily dose of 5 tablets.<br />Multipacks contain 140 (2 packs of 70) film-coated tablets.<br />Tykerb / aromatase inhibitor combination posology<br />Each pack of Tykerb contains 84 film-coated tablets in foil blisters (polyamide / aluminium / polyvinyl<br />chloride / aluminium) of 12 tablets each. Each foil has a perforation down the middle to allow the blisters<br />to be separated into a daily dose of 6 tablets.<br />Bottles<br />Tykerb is also supplied in high density polyethylene bottles (HDPE) with a child resistant polypropylene<br />closure containing 70, 84, 105 or 140 film-coated tablets.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="data:image/png; base64,iVBORw0KGgoAAAANSUhEUgAABqQAAAiYCAIAAAA&#x2B;NVHkAAAABGdBTUEAALGPC/xhBQAACjFpQ0NQSUNDIFByb2ZpbGUAAEiJnZZ3VFPZFofPvTe9UJIQipTQa2hSAkgNvUiRLioxCRBKwJAAIjZEVHBEUZGmCDIo4ICjQ5GxIoqFAVGx6wQZRNRxcBQblklkrRnfvHnvzZvfH/d&#x2B;a5&#x2B;9z91n733WugCQ/IMFwkxYCYAMoVgU4efFiI2LZ2AHAQzwAANsAOBws7NCFvhGApkCfNiMbJkT&#x2B;Be9ug4g&#x2B;fsq0z&#x2B;MwQD/n5S5WSIxAFCYjOfy&#x2B;NlcGRfJOD1XnCW3T8mYtjRNzjBKziJZgjJWk3PyLFt89pllDznzMoQ8GctzzuJl8OTcJ&#x2B;ONORK&#x2B;jJFgGRfnCPi5Mr4mY4N0SYZAxm/ksRl8TjYAKJLcLuZzU2RsLWOSKDKCLeN5AOBIyV/w0i9YzM8Tyw/FzsxaLhIkp4gZJlxTho2TE4vhz89N54vFzDAON40j4jHYmRlZHOFyAGbP/FkUeW0ZsiI72Dg5ODBtLW2&#x2B;KNR/Xfybkvd2ll6Ef&#x2B;4ZRB/4w/ZXfpkNALCmZbXZ&#x2B;odtaRUAXesBULv9h81gLwCKsr51Dn1xHrp8XlLE4ixnK6vc3FxLAZ9rKS/o7/qfDn9DX3zPUr7d7&#x2B;VhePOTOJJ0MUNeN25meqZExMjO4nD5DOafh/gfB/51HhYR/CS&#x2B;iC&#x2B;URUTLpkwgTJa1W8gTiAWZQoZA&#x2B;J&#x2B;a&#x2B;A/D/qTZuZaJ2vgR0JZYAqUhGkB&#x2B;HgAoKhEgCXtkK9DvfQvGRwP5zYvRmZid&#x2B;8&#x2B;C/n1XuEz&#x2B;yBYkf45jR0QyuBJRzuya/FoCNCAARUAD6kAb6AMTwAS2wBG4AA/gAwJBKIgEcWAx4IIUkAFEIBcUgLWgGJSCrWAnqAZ1oBE0gzZwGHSBY&#x2B;A0OAcugctgBNwBUjAOnoAp8ArMQBCEhcgQFVKHdCBDyByyhViQG&#x2B;QDBUMRUByUCCVDQkgCFUDroFKoHKqG6qFm6FvoKHQaugANQ7egUWgS&#x2B;hV6ByMwCabBWrARbAWzYE84CI6EF8HJ8DI4Hy6Ct8CVcAN8EO6ET8OX4BFYCj&#x2B;BpxGAEBE6ooswERbCRkKReCQJESGrkBKkAmlA2pAepB&#x2B;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&#x2B;jp9DL6Yfp1&#x2B;jtVLVVPVb7qJtU21Suqr9XmqHmo8dVK1NrVRtTeqTPUfdTT1Lepd6nf00BpmGmEa&#x2B;Rq7NE4q/F0Dm2OyxzunJI5h&#x2B;fc1oQ1zTQjNFdo7tMc0JzW0tby08rSqtI6o/VUm67toZ2qvUP7hPakDlXHTUegs0PnpM5jhgrDk5HOqGT0MaZ0NXX9dSW69bqDujN6xnpReoV67Xr39An6LP0k/R36vfpTBjoGIQYFBq0Gtw3xhizDFMNdhv2Gr42MjWKMNhh1GT0yVjMOMM43bjW&#x2B;a0I2cTdZZtJgcs0UY8oyTTPdbXrZDDazN0sxqzEbMofNHcwF5rvNhy3QFk4WQosGixtMEtOTmcNsZY5a0i2DLQstuyyfWRlYxVtts&#x2B;q3&#x2B;mhtb51u3Wh9x4ZiE2hTaNNj86utmS3Xtsb22lzyXN&#x2B;5q&#x2B;d2z31uZ27Ht9tjd9Oeah9iv8G&#x2B;1/6Dg6ODyKHNYdLRwDHRsdbxBovGCmNtZp13Qjt5Oa12Oub01tnBWex82PkXF6ZLmkuLy6N5xvP48xrnjbnquXJc612lbgy3RLe9blJ3XXeOe4P7Aw99D55Hk8eEp6lnqudBz2de1l4irw6v12xn9kr2KW/E28&#x2B;7xHvQh&#x2B;IT5VPtc99XzzfZt9V3ys/eb4XfKX&#x2B;0f5D/Nv8bAVoB3IDmgKlAx8CVgX1BpKAFQdVBD4LNgkXBPSFwSGDI9pC78w3nC&#x2B;d3hYLQgNDtoffCjMOWhX0fjgkPC68JfxhhE1EQ0b&#x2B;AumDJgpYFryK9Issi70SZREmieqMVoxOim6Nfx3jHlMdIY61iV8ZeitOIE8R1x2Pjo&#x2B;Ob4qcX&#x2B;izcuXA8wT6hOOH6IuNFeYsuLNZYnL74&#x2B;BLFJZwlRxLRiTGJLYnvOaGcBs700oCltUunuGzuLu4TngdvB2&#x2B;S78ov508kuSaVJz1Kdk3enjyZ4p5SkfJUwBZUC56n&#x2B;qfWpb5OC03bn/YpPSa9PQOXkZhxVEgRpgn7MrUz8zKHs8yzirOky5yX7Vw2JQoSNWVD2Yuyu8U02c/UgMREsl4ymuOWU5PzJjc690iecp4wb2C52fJNyyfyffO/XoFawV3RW6BbsLZgdKXnyvpV0Kqlq3pX668uWj2&#x2B;xm/NgbWEtWlrfyi0LiwvfLkuZl1PkVbRmqKx9X7rW4sVikXFNza4bKjbiNoo2Di4ae6mqk0fS3glF0utSytK32/mbr74lc1XlV992pK0ZbDMoWzPVsxW4dbr29y3HShXLs8vH9sesr1zB2NHyY6XO5fsvFBhV1G3i7BLsktaGVzZXWVQtbXqfXVK9UiNV017rWbtptrXu3m7r&#x2B;zx2NNWp1VXWvdur2DvzXq/&#x2B;s4Go4aKfZh9OfseNkY39n/N&#x2B;rq5SaOptOnDfuF&#x2B;6YGIA33Njs3NLZotZa1wq6R18mDCwcvfeH/T3cZsq2&#x2B;nt5ceAockhx5/m/jt9cNBh3uPsI60fWf4XW0HtaOkE&#x2B;pc3jnVldIl7Y7rHj4aeLS3x6Wn43vL7/cf0z1Wc1zleNkJwomiE59O5p&#x2B;cPpV16unp5NNjvUt675yJPXOtL7xv8GzQ2fPnfM&#x2B;d6ffsP3ne9fyxC84Xjl5kXey65HCpc8B&#x2B;oOMH&#x2B;x86Bh0GO4cch7ovO13uGZ43fOKK&#x2B;5XTV72vnrsWcO3SyPyR4etR12/eSLghvcm7&#x2B;ehW&#x2B;q3nt3Nuz9xZcxd9t&#x2B;Se0r2K&#x2B;5r3G340/bFd6iA9Puo9OvBgwYM7Y9yxJz9l//R&#x2B;vOgh&#x2B;WHFhM5E8yPbR8cmfScvP174ePxJ1pOZp8U/K/9c&#x2B;8zk2Xe/ePwyMBU7Nf5c9PzTr5tfqL/Y/9LuZe902PT9VxmvZl6XvFF/c&#x2B;At623/u5h3EzO577HvKz&#x2B;Yfuj5GPTx7qeMT59&#x2B;A/eE8/vsbQFrAAAAIGNIUk0AAHomAACAhAAA&#x2B;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&#x2B;f39/fb29uuhwAAf8r&#x2B;rgcAAAB/xPv7&#x2B;8fHx/39/dnZ2ePj49PT0ziOwzDs7&#x2B;8vFouLi4tdDwQAft9ku93uegMAAPCfrNfr5XJ5e3t7cnJyfX09juPPz89isTg&#x2B;Pt5sNuM4Hh4ezmazyWTy9fX18vLy8PBwd3d3eXk5m812vR0A&#x2B;E1iHwAA/E1Wq9U4jjc3N&#x2B;v1ehiG5XL5/Px8cnJydHQ0n8/n8/nBwcG/H3zDMGw2m&#x2B;12O51OJ5PJMAzr9Xo6ne7t7b2&#x2B;vq5Wq6urq/Pz89PT013eAwD8KrEP&#x2B;Ie9Ow2SqzzzRP9/37PlXpWVtag2bWgXQgIJtIBARsYLMggDbjzu8WD39O3b7Yjb0TETPRETc3vC0X1vxETMh5nbcaenuz3d8&#x2B;F63G6728YGbGOQDUggCSGhrSSVat831ZLrWd/3vR/eqiSRABsbSQieXygqsk6ePOfkyfxQ8dfzvA8hhBBCPrpc152dnR0bG6uvrx8aGpqdnW1vb89kMi0tLYZhNDQ0CCF0tBdFURRFjuMwxoIg0KGezvgAKKWklEII27arBx8YGOjp6XFd9&#x2B;67725ra7s575AQQgghHyoK&#x2B;wghhBBCCPlImJmZaWpqGhgY4Jz39vY2NDQMDw&#x2B;3tra2tLRkMhnDMFKpFOccQBRFAEzTBCCEAGAYRvU4Ukq9Wy0hhJTSsiz9rBBCJ4Ou687NzXV1ddXX12/atCmVSt24N0wIIYSQ64DCPkIIIYQQQm6C&#x2B;fl53/f7&#x2B;vpWr149MDAwPz&#x2B;/evXqQqGwbNmybDZbzfWEEGEYmqapoz1NN&#x2B;cyxqr7YCnvU0oFQaBr/aSUAGqDvyiKOOdBEOil&#x2B;pRS8/PzyWRybm6uVCpduHBh8&#x2B;bNa9asuaE3ghBCCCEfKgr7CCGEEEIIub7m5&#x2B;eVUn19fS0tLT09PeVyub6&#x2B;PplM5nI527ZzuZzjOEqpKIosy8I7C/cA6FwPgJQyiiLTNKv5XRAE1bZcKaWU8qpMsDbpq/1V9/zWTucolUpXrlzp7e0tlUqPPfbY9bsbhBBCCLmuKOwjhBBCCCHkQzM3N9fQ0NDX1xeGYbFYBDA2NtbZ2ZnNZi3LSqVSdXV1uotWF&#x2B;IJIZRSOqHTQZ4&#x2B;jlJK/6HOGNNJX6VSiaIok8nox7Zt66fetbivOo5Dp4eVSsUwjOrUjiAILMvS&#x2B;&#x2B;grqb6kUqlcunRpfHx869atnZ2dN/TeEUIIIeTDQGEfIYQQQgghv6FisWiaZk9PTzqdHh0dXVhYaGxsdBwnm82m0&#x2B;lkMsk5tyyLc&#x2B;66rp6kYVmWDvJ0SCelrMZ5OnELggCArterRoHFYjGdTuuThmFoGEa1Rk8IUY38fN/XpxNCBEEQj8dRkyH6vj80NNTW1haLxfSetm1X1/Kr7lYqlSYmJkZHR6WUu3btSiaTN/7GEkIIIeQ3RmEfIYQQQgghv1qhUOCcT05OhmE4NjbW3Nw8PDzc3Nzc1tYWRVF9fb3jODpcC4JACKEfvyu94p6uwqsN&#x2B;6qiKNIbqwvzFYvFVColhPB9Px6Pc8712nw62kNNAqiUmp2djcVietRGuVxOJpNHjx595pln9uzZs2HDhpmZmfHx8UQiUa3dq5b1oaYveHZ2dmBgYGRkZOfOnTSolxBCCLmFUNhHCCGEEELI1YQQs7Ozly5dWr16dW9v7&#x2B;TkZHt7e2NjY0NDQywWq6ur07vpZfIYYzq50yFdtZe2VCrpcrwoioQQuspPSun7vuM41Wo&#x2B;ANWsrVKpXFtJV&#x2B;3GxVIwF4ZhGIaJREIfXCmld5ifn&#x2B;/q6urr6zt37lxTU9Pjjz9&#x2B;2223cc67urr&#x2B;9m//dmRk5O67796xY8fy5cs55w0NDblcDoDruvrg8Xi8tq5Qx5rj4&#x2B;MLCwubN29esWLFdbzjhBBCCPmQUNhHCCGEEEI&#x2B;0RYWFiqVSl9f38qVK/v6&#x2B;lzX1TV6K1assCwrmUzGYrGremaVUnrQrWmatUV5esgGY6x2Soamq/k451cV8VWfRc3yfAB0228sFtOHqs7VLRQK8Xjcsqzu7u7R0VHXdV3XnZmZAbBjx4577rknDMOzZ8/&#x2B;r//1v86ePfvEE0988YtfXLZsGYD5&#x2B;XkhxNTU1IkTJ4aHh03T7Ovre/XVV5ctW/bUU0899dRTTU1N5XKZMZZIJKIompiY0HV/YRj29vaOjIzEYrENGzY0Nzd/yB8AIYQQQj5UFPYRQgghhJBPCr3y3aVLlzjnpmnOzMzMzc01Nja2tLSkUinDMHS4ZhhG7UJ4mhAiiqLqjIsqHfBdlfpVlUol27ar0zDeS219n1JKCFGNC/UIXV3Ql8/nv//978/MzNxzzz1TU1PHjx8/c&#x2B;bMo48&#x2B;&#x2B;sgjjyxfvlyP7MDSIn1//dd/fejQIcuyHnnkkQMHDqTTacbY2NhYOp3W79QwjEKh8NOf/vTVV19dv37917/&#x2B;dV2HWCqVdMuwLlHUjcBTU1Pj4&#x2B;PlcjmXy23cuPG3&#x2B;RQIIYQQcl1R2EcIIYQQQj6edMlef39/c3NzuVzu7e1taWlJp9PZbDYej2cyGSGEXtguDEPdZmuaZm3Ap13VaavL&#x2B;mpr9PSveOdifEKISqVSnaqhRVGk97EsS&#x2B;eJOtSrnmJiYqJQKAwPDw8ODi4sLJTL5eHh4YGBgTvuuOPOO&#x2B;/82te&#x2B;BmB4eHj58uUAPM/7u7/7u5MnT8bj8a985Sv33nsvgEqlkkgkdCVgoVD41re&#x2B;9cMf/vDJJ5/8&#x2B;te/ns/nV65cOTIycvjw4a6urmw2u2HDhsbGRtM0d&#x2B;zYUS6XdS5Z7Rqen5/PZrNYSg9LpdLY2JguJzxw4MD7x5eEEEIIuVko7COEEEIIIbe82dnZXC534cKFRCJx8eLF9vb28fHxXC7X3t6uV8dLJBKxWEzv7Pu&#x2B;Xj5P/3pVlgdACAFAZ3bVfWrDPv0SHfDp7E8PtK0&#x2B;W5sYSimrdYLVRl3XdaMo4pw7jsM5r134b3Z29oc//OEzzzzT0tLye7/3e3fdddfCwsJf/uVfnj9//umnn3788cf1wT3P0&#x2B;/o&#x2B;PHj3/nOd3p6evbs2fP00093dnaGYRgEQTKZdF331KlTp06dGh4e3rhxQUmTqQAAIABJREFU4759&#x2B;5YtWxaPx3XgWG0QrlYOYqmsz/M80zT1Djr7KxQKmUwGwPz8fE9Pz5UrV1pbW&#x2B;&#x2B;8887r8WkSQggh5LdBYR8hhBBCCLnF6OXnxsbGDMNwXXdqaqqxsTGdTqdSqUwmE4/HdQomhNB1dr&#x2B;yBq02ywvDUCd3VwV2AHQoFkWRzvV831dKxWKx2o26dk8PuNCH1WVxo6OjU1NT27dv1yFdPp//5je/&#x2B;Ytf/KKtrW3Hjh1//Md/3NjYyBirZmoXL1787ne/&#x2B;8orr5imuXr16unpaQB33nnnk08&#x2B;uXnz5iAIoijSAzoAjI6Ofvvb3/7Rj35k2/Zjjz328MMPr1&#x2B;//sO&#x2B;6&#x2B;&#x2B;gh5ZMT09/6lOf0tV/hBBCCPmIoLCPEEIIIYR8pM3Pz3d3d3d0dPT09JTL5Xg83traCqCtrU0IoefJap7nMcbedVm998r7rirZq92tVCo5jmNZVnVVvtqYr1QqVU9dfTaKolgsNreko6Ojra0NQKVSOXXq1Isvvrht27Z9&#x2B;/bpdOy1117r6upatWrVwsLC3/zN32Sz2XvvvfdP/uRPqk3BV65cOXbs2OHDh/v6&#x2B;v74j/945cqVUsoXXnjhH//xH6enp&#x2B;&#x2B;99979&#x2B;/c/9NBD1axNlwcyxqrL7V1XruteuHChWCzmcrktW7Zc79MRQggh5NdEYR8hhBBCCPlIKBaLyWSyq6tLSuk4ThAEExMTjuO0t7dnMplYLJZMJjnnV62pp1tWwzCsr6/XW6SUhUIhFotV&#x2B;3Z/pdq&#x2B;3TAMwzCsFs0B8H1fB4iVSkVnf3ppvyAI&#x2B;vv7C4VCc3NzGIYrVqwIw9A0zVdffXVgYOAnP/lJX1/fn/3Zn915551r164F8N3vfndqamr37t3r169PpVJhGD7//PPPPffc3r17x8fHM5nMxMTE888/v2bNmgMHDnzpS1/KZDKlUukHP/jByy&#x2B;/fOnSpQMHDjz88MPLly9PpVL6enzf193Bui23OqBDj9T47T&#x2B;R9&#x2B;e6bjwe7&#x2B;rqGh0dbWlpyWQyq1evvt4nJYQQQsivRGEfIYQQQgi5CXRxXE9PT2dn5/nz533fz2az2Wy2qalJz4qNx&#x2B;M6fdNr3nHOq9VqOpubn59vbGzUW3RtnRCiVCql02kdCIZhCKC6Nt&#x2B;70gvnXRUgSik9z4vH44wxvSRf9dS6&#x2B;u/w4cNHjhxJJBKPPvpoa2trpVI5duzYM8888/LLLz/00ENf/OIXt2/fLoRwXfd73/vez372M8uy/t2/&#x2B;3e5XO7MmTOGYRw8eFCHiTMzM3/xF3/x6KOP7t2713GcYrE4MDBw/Pjxc&#x2B;fO1dfX79279&#x2B;67766vr6&#x2B;WHNYOAFFKVSqVaqgnpdSL6107YOR60MWD&#x2B;rYDOHLkyOTk5IoVK7Zu3apbmAkhhBBys1DYRwghhBBCri/XdR3H6enpkVIODw8nEonx8fGOjo6Ojo5EIpFIJHS6V/uSq6ZeYCngw9JYDMaYrizTBxdCWJaVz&#x2B;fr6ur0btVmWNSU5r2PcrkchqHjOPF4HEvpIYALFy6cPn36/Pnza9eu/frXvw7A87z/9J/&#x2B;09DQ0Fe/&#x2B;tUHH3xwbm6uoaGhWCym0&#x2B;kgCP75n//5Zz/72fz8/J/8yZ88&#x2B;OCDejZuX1/fd77zneeffz6KolWrVv35n//56tWrfd/P5/Pf/va3Y7HY1q1bt2zZ0tTUVHtJvu9HUeQ4jmmaQRBIKU3TNAwjDMPqgn2VSsUwDL29&#x2B;sIgCG5A4qZHeVQn9i4sLPT29vb19W3evPn222&#x2B;/3mcnhBBCyHuhsI8QQgghhHyYKpXKzMyMzt36&#x2B;/vn5&#x2B;dbWlpSqVQ2m43FYs3NzdU9hRBRFOnmU9d1dWh1VWFa7VjYWtWJurpzljFWqVSGhob&#x2B;/b//967rbtu27emnn960aRN&#x2B;VdJXnWkLoFQqvfHGGz/84Q9/&#x2B;ctf3nPPPQcOHLjzzjs7Ozsty5qfnz927FilUnniiSeCIHj99df/6Z/&#x2B;6dChQ3/2Z3/2la98RZ9C/5RSvvTSS//xP/7H/fv3f/nLX9aL2QVB4Hme4zgzMzPPPPPM9u3bt2/fbtu2rsWLogiAaZpzc3PZbNbzPB07Vi9bv/aqZQeVUvl8vtq8LISojvT9lQNJfnvlctm2bR3F6s9ax6PDw8P9/f2e5&#x2B;3du/cGtBITQggh5FoU9hFCCCGEkN/QxMREOp0&#x2B;d&#x2B;5cZ2dnf39/qVSyLKupqamhoUH30iaTSZ3TSSn1dItSqRSLxar1etUpt/pXpZQehssY08HftQlX7Ut0Sui6biKRyOfzuVzu8OHDf//3f//aa6/t3r37D//wD&#x2B;&#x2B;9917O&#x2B;fsPrFBK6ajRcZwois6dO3fmzJnu7u5EIjE5OXny5MkgCPbu3fvQQw8tX7782Wef/aM/&#x2B;qO6urqFhYXnnnvupZdeunDhwsGDB7/0pS8tX748FotNTk6&#x2B;&#x2B;eabL7744uc&#x2B;97m77rork8mkUqnqiRhjugZQv/d8Pq/L4mZnZ2snjWhhGCqlLMvS3cSMMb0coVIqk8nod1SpVBzHqTb2CiGuDUavH704oOu6pmlWhxEXCoXe3t7Z2dktW7Z0dHTcsIshhBBCiEZhHyGEEEII&#x2B;dV09VZ3d7fv&#x2B;0qpcrk8Ozu7atUqKWU2m02n06lUqrr4nR5fW01/dI/tVSV7&#x2B;q9QneW9z7Tcq/avvgRLw2ellK&#x2B;&#x2B;&#x2B;upzzz33wgsvrF&#x2B;//hvf&#x2B;MbmzZu7u7v/6q/&#x2B;am5u7vd///cff/zx91m2r7bjtdq6C&#x2B;C5557r6upav379gQMHLMsaHh4&#x2B;dOjQ9773vb6&#x2B;vmXLlj3yyCN/&#x2B;qd/qjuFFxYWpJQnTpyIxWLT09MrV65sa2szDGPZsmXVkFHXDxYKhUwmA0AI4XleIpFgjOkuYH0lOt/U/cu6Rq96Yfpx7V2KokhHgbUL&#x2B;WEpD73e03irKwbWFk7qxmoAYRiOj48PDQ3NzMw88sgjtIofIYQQciNR2EcIIYQQQq5WqVQKhUJ3d/fq1asnJycnJyfr6urq6&#x2B;sbGhps266vr/8oxDfVbE6Hbi&#x2B;99NJ//s//eXh4&#x2B;ODBg3/xF39hGMY//MM/vPrqqw0NDd/4xjey2azrui&#x2B;//PLzzz/f19dnGMa&#x2B;ffuefvrplStX6gRNh1a1Uy/6&#x2B;vqOHz&#x2B;ez&#x2B;e3bt26Z88eAAsLC/X19TMzM2NjYwCam5tbWlqud6x2a6lti56fn1dK/ehHP9qzZ8/69etv7oURQgghnxzGN7/5zZt9DYQQQggh5KbxPA/A&#x2B;fPn8/n8yZMnC4XC8ePH9WzclpaWZDLZ1ta2cePGlStXtrS06Hkaeo28MAyDIHj/WbfXVXUER7XFtVwuv/nmm2NjY4yxFStW7N69&#x2B;957771y5crp06fb2tqam5vvuOOOxx57bNu2bcPDwy&#x2B;&#x2B;&#x2B;OKLL74opWxtbU2lUkEQGIbBOa/mmNlsNpfLSSlnZmYKhUI2m9V1eY7jpFKpXC6XzWar84JvwDJ5twTTNKMo0o29iURCCNHZ2Tk3N3fixInGxkY9VIQQQggh1xVV9hFCCCGEfDyFYTg1NTU4ONja2joyMuK6LmMsl8stX75cCNHY2CiE0E2XAIIgYIxZlqWU0tnZVemVHpRRzbYA3PSKtmrzb7WT1PO80dHRv/qrv3r&#x2B;&#x2B;ecBHDx48Kmnnlq7dq0O6TSdZh46dIgxtnv37q1bt7a2ttYWKuoEUzfJXjswpLbVV6&#x2B;RV21eJqjp5AXg&#x2B;74QQgd8URSNjo7m8/nx8fF0On3ffffd1MskhBBCPs4o7COEEEIIueVNTk42NjZ2dXUBMAyjUCiMjIy0trY2NTW1tLRwztPpdDWbe59pFfovQ533XTsc49qd9W4f9rv5dVXDviiKrkrclFKjo6OnT58&#x2B;ffp0b2&#x2B;vDjfb2tpyuVxDQ8OGDRvWrVtnGEY1mapUKrZtm6YppdQrDALQa&#x2B;FJKYMgkFImk8mrTvGuqSjRdCJ81f2RUp47d256etq27T179tzEslBCCCHkY4zCPkIIIYSQW8yVK1cqlcrAwMBtt902PDw8NTW1atUq13U7OjqSyaTOpKoxihBCCFE7AUNXsektasm10Z5&#x2B;lQ68agdBcM5rS9tubtR17QX4vl8dBuK6bhRFtm3ruj&#x2B;llO/7ekU513WVUtWu0tppIbWqncJa7YJ077PbJ5wOTHWvt96iv0uGYczOzuqS0qNHj7quu2zZsi1bttzcqyWEEEI&#x2B;fijsI4QQQgj5qLtw4QLnvL&#x2B;/P51Oe57X2NjY0dFh23YsFtORyrUVZzqnk1JWJ6VetUO1fk0LwxAA57xarfYra9b08avB3w121YJ9qIkvGWNCiNrbIqVcWFjIZDK6dq9cLjuOY9u2TkKrPbzVY0ZRFEWRzvWEEL7vc86rMd9VyaAQQkpJRWpadaaw/rU2BtWDj&#x2B;fm5tLptGVZZ8&#x2B;eLRaLCwsLBw4cuHnXSwghhHwMUdhHCCGEEPIR4nme7/vd3d0NDQ0LCwtDQ0ObNm3S9Xr19fW6/VZXqAGwLEtv0QvJVSvvanMowzB0GqW36yysmr8IIbDUa/mu0V61GbO2ZfW96uBupGozsn7vOr7U0yGq&#x2B;aO&#x2B;&#x2B;GqCGUURY6y2hVlv16M5DMPQN7D2sO96Up2W6i1U0Pc&#x2B;VA0ApmkWi8V0Oh2GoZ6FIoQ4efLk2NjYli1b1qxZc7OvlxBCCPmYoLCPEEIIIeTmWFhY4JwPDg7GYrHBwUHGmOM46XS6sbHRMAzHcXK53M2&#x2B;xo&#x2B;/EABQG1uymp8fRpInq48UWM3P9zvvJ4fnRq7nv3XyVBiFW7fdsWxZ482&#x2B;IkIIIeSWR2EfIYQQQsh1t7CwwBjTa&#x2B;1ZluX7/tDQUGNj47Jly2KxWEtLS7Xa7ub2xn4CUdh3ky3diNcOv&#x2B;F65bq6&#x2B;o0bN6TS8Zt8VYQQQsitjMI&#x2B;QgghhJAPWRAE&#x2B;Xy&#x2B;p6dn&#x2B;fLlQ0ND4&#x2B;Pj7e3t2Wy2vr6ec55KpRzH0V23Ukq9wFx1mTMpZRRFur20upYcuX4EgPeO2K7dzj7wH8/qPU7AAEBd88QnLe0TWJiZrW/KQaG4kB8aGiy7Zdf19j304M2&#x2B;MkIIIeRWRWEfIYQQQshvbmpqKpPJ9PT0WJY1NjbW2to6Pj5umuaqVatSqVQ8Hk8mk3rP6sJ51869fVc04PXGoLDv5hLlwIjZqN5UhpMnTqSSycmZyfXrNizraLuZF0cIIYTcmijsI4QQQgj5dRUKhSAIhoeHb7vtNj1LtK6uLpfLZbNZ0zT1tFZdtQcgCAI95EEX6OlRpFcdUBf36QkSeN9BGeSGUTU/cc1jQ4kPdrhrP833//ObGe/37MdPIMA5hIBhIAyklDwemxkbGxobZwqBCHffd&#x2B;/NvkRCCCHkFkNhHyGEEELIuygWi67r9vf3NzU15fP56elp27ZzuVxDQ4MQIp1Ox2IxXbVXO8L1KlEU6VI&#x2B;/asQQj/WM3Nv5Nshvz4K&#x2B;26oSJWuXEk1NiIMwRlMU9c2lgvFudm5mfnZibGxnXt2NzY13ewLJYQQQm4ZFPYRQggh5JOuVCrFYrHe3l4pped5nudNTk52dHS0tbU5juP7fmNjoxBCR3tRFEkpdY2elBJL5XgAlFJKKSllGIa2bdfGf0opvVE/DoKgdkk&#x2B;vUJf9Qj6Vyrxu0Gu/VuYvb352uCP4YOFfRIGAAYFwHiXCFHV7AkAHJ&#x2B;w2SwqAjB/ZTbbmANjXrnii6guUwdAKTUxPZPPL3T39OzevbulgQb1EkIIIb8WCvsIIYQQ8skyOTlpmubo6Ggul7t8&#x2B;XK5XM7lcoZhtLS01NfXW5YVj8d1TheGIef8XUv2AOgW3dot1cyudh89WlfX8Qkh9NF0oqc3RlFUPQWlezcBhX03lQo9BgbTCFzXjsXBGcAqbsUyLcuyJHipXHJ9v&#x2B;fy5f6Bvs9//kBTffZmXzIhhBDyUUdhHyGEEEI&#x2B;zqanp/P5vGVZly9fbmhoAKCUyuVyjuMkEolkMmlZlo7Yrg3vyG&#x2B;j&#x2B;kfmeyWYQgjGmE48wzC0LOvmXNt7hH3XvkS/KuKMgSkoCcnAODgA/asBA0AgQtuwAAQiUEpxZlkG91w/HncQSdPkgefbMUfHfGLxp4wgAM7BYp&#x2B;wsK8iKxa3GBgACSWhOAwGBvAgCgBmmxaAhXxeMfaLlw7dvm7t7bfffrOvmhBCCPlIo7CPEEIIIR8Ts7Oztm1XKpWFhYXR0dF8Pt/c3NzR0ZFKpZRSTU1NCwsLjLFMJqMr7GpDKD0og8K&#x2B;D9F7hX1hGNZuqV3T8LrS2eJV16OU4uyas7PF63zXuk5XRiZ/v&#x2B;&#x2B;JF3qWZengD4AfRo5l6nO4pYrjODIKTcs0TAM1YZ&#x2B;AEFAGjDhuXOj5URAhBAAwAbk0psbg4MDi51LxXNt2TM5LrlcqlS6cOlkoFO67777W1tabd9WEEELIRxqFfYQQQgj5OBgdHT169Gg8Hl&#x2B;3bl1LS4tlWYlEAkClUrEsy7IsPfS29iVRFOkAqNpmSz5E1fnC126/Km67MeNKpJTXLoOolKodoPHO5975WAilRyfHHAYoBSFUFAkAlmUaBioVP5Fw9O6&#x2B;L8IwMC3Ltk0uAf3PgCxFPGkCUOVAGspIODDgu25kG7ZpR5BFt9gcr7tet&#x2B;AjyYdQUAAYGIeBpZCvmC/FYrGYbQKAAuTSx2NgYmLixIkTqVTqwQcfvFmXTQghhHyUUdhHCCGEkFue53mxWCyfzx89etSyrFwut2HDhlgshqUV8RhjU1NTjY2NhmG4rhuPx7E0RRc1EzZoybwbrzqT5L3WRrzeZ3/PsE&#x2B;qxW3sHcGf3nxVOCklOIeUcD0/FnOMpWeDQNr6lwiQmJ2c8Vw3m61LNNbpTCsIPTvmhIz5oQ&#x2B;LGzDi&#x2B;GTlzmX4HNxYXNmQYynsY0AUKdtYXECxVPChkMo4MCCEyOfzw8PDQ0NDW7duXbly5c27fEIIIeSjiMI&#x2B;QgghhNzypqamzp49u3v3bgBzc3MXLlzIZrM7d&#x2B;5cWFior6&#x2B;vbdEtlUqpVOraI&#x2B;jg76bkTZ9MevCxLrq8kefV45IBcM51trvYRApgKWZaDNv0vAwhIeViwscYwKAMAPABBpi66A9QgFNzGgkEAMNwT&#x2B;8L332&#x2B;WCqWCgXTMG3TGBkdiSec7du3P/Evf4e31OsF&#x2B;oLAtW0bsU/i129pLAkAIIJSkikOvvSED4RL91YBQGAHeox1EASDg4NDQ0Plcnn//v3pdPrGXzwhhBDy0URhHyGEEEJueYODg6dPn7Zte8WKFZs3by4UCm&#x2B;88cbU1NRDDz1UX1&#x2B;vowFND4LwfR9LBX16zTiq6bsBFgdcRNFVAZ9SynVd3XZ94/2KsO/aobw&#x2B;AKCay7lKBQHjXEnJDDMKfLMhAQCl6PjRo//1v/7XrStuf/TRRzft3a6XoZs90/fTF37y8ssvb9t116c//dCGffeAY3GZPgPlciWZvDn34Waphn1KKabY25t0nKo/mAhwAQNwgKWsPp/P19XVlcvly5cvT09PL1u2bOvWrTf&#x2B;&#x2B;gkhhJCPIAr7CCGEEHLLGxwcHB0ddV23UCjE4/FNmzbFYjHP81544YWdO3euXLkyHo9zznXGVC6Xk8lk9bW61Ev/RUQDOq6f2nkdtbMvfN&#x2B;3LOvGr5molBJCSCmlbeOdMZ/&#x2B;EkjX54YBvrRmXCTgByqK5i7O1NfVGZlMmM&#x2B;ffuutU6dOzc3PxxwnnkjMzc5OTk7u3LXrC184ULdxBcYX/s//8H8mXXv//v33fOXA2/kgw&#x2B;xrZ7717b&#x2B;vuO76e7Z85Su/y1Y0oBK6kRvPZj5h8zn0goYSsqaarySjStmsTy&#x2B;WTAIYLXedOWMb1tp160rrjHg8HgRBPB6PokgpZVlWf3//1NRUb2/vo48&#x2B;Wlf3yVr0kBBCCLkWhX2EEEIIueUNDg56nrdixYrBwcELFy4AWL58&#x2B;caNG1Op1I9//ONkMtnR0bF&#x2B;/XoAeg5vFEU3bAgs0ap/cz777LO9vb1zc3OO4&#x2B;iO2jvuuOOBBx5oaGi4rhdQ/dCVUmEYep7neV4QBI0dHXi3sG8xeHKD2SszY0PD/f39o0PDc3Nzq5MrTMP0fH9kZGR4aKg&#x2B;mz148OB9Bw/ABoDB10&#x2B;fPHVybGz8nnvu2fX4ZzHnn/jBoW9961ubNqz/8pe/vGzdWjCGpD3w&#x2B;tGfHX5pZHh4rDy7du3az/zOo/c8&#x2B;AAswBdIfcKaeSWgFCQDAySiQmXwYt/Q8PDpo6fy&#x2B;YXSTL5YKkWVQEqVdOKpVOpz/&#x2B;HLu3btSiQSOqaXUlqWJYQol8vz8/PHjh3btWvXihUrbva7IoQQQm4mCvsIIYQQcssbHBwsFotbtmyRUhYKhXPnzk1PT8fjcd3V29fXd&#x2B;bMmba2tvb29s7OTs/zbNvmnOuW3kKhkE6n32VIK4AbNbIjqnnM3uMnsFTlJN9v72u7Tg1Vsypazd99vg/LWhw0od&#x2B;u7qHkYQlA5CgJGUFx8Jg0F4&#x2B;gVN4AoEzYHDwecgAjVh5AB4xIRVbRgmEAJlxXNMSUVCXTBBCFJcdykl7Y09Pz818cyi8sMLDZ2dnACz71qX0dHZ2HjxzZc&#x2B;9969avyzU3SymVYWJxhq2UekKrBONwBCABAXCAQZY9no4B8GUURZEVjwGw82&#x2B;/3ZpZD4uPJ0/1/&#x2B;AHP&#x2B;g/e7Guvm55cys3jENnzxqGsW/j1t/9yu/y1Tn4QAYAkAIiqCQAjJwb&#x2B;Mfv/ePQsdOpdOpP/49/m9u8Ua8iN3P60l/&#x2B;5V9WAu/JJ57c/eTDcBVsBi868otDL730UntHx8GDB5u3rESIyd7hl19&#x2B;&#x2B;fTrx33fX79i9W2rb1u3ds3yzuW9QwM//MEPi4H3&#x2B;OOP3/mpvTCWzv5r023IOiDk135D8M77AECKt39hvPq5q9ojaPqxUIACGBirPY4f&#x2B;I7jLH15QxGGBpMwTX2ySEjGmMEdAJAmpIQPGHzxCPrIHsp5L3lobm5yYmB8YHJyou9K38TE&#x2B;BU5Y1pWKVZIJVNmi5HOpO1Gq6mpqbmzKZfLyTbe1NzU3rgugQRHTkFx1HFwJsA5psfmBocGpqdGNq5fv3bzxg92KwkhhJCPCwr7CCGEEHLL02Hf5s2bdbFeEAQjIyPnz5&#x2B;Poigej99///2maQ4MDLz&#x2B;&#x2B;ut79&#x2B;7t7Oy0LEt37FZbekulkm3b1Tbe6nxe6KXErnPkd1PCPk1KYGm2rA59mFcAYzLGqhdmSwYhAAOGUeF6aqqhoBKhAaDPmmFgy2FxcF40oBQMBwCSPAzDaSNI8qQNCSAhJaKob2jwtSOvjQwPM8aS8UR7e0epXD5y5MhnPve5/Q/uz7U0AyiFvpLKcCwTpqsYGPQ6dtbi0IyaN8Ah/KAk/HQ6HQFX5q&#x2B;0FXNnjh3rHRrwPf/MpQuXL3fv2rPnD/73P8g2NcDB6Js9/&#x2B;W//Jc6M/bYYwfvePgBHe15I96h7/zTj37041UNjV/72tda99&#x2B;zuDaciciAUrAAVREnn3vx1cOvTg5N/KuvfvX2&#x2B;&#x2B;5DnQ0AHl7/6fP/7f/9b/c&#x2B;sPfzn//8qt3bAKjZUnd3d3dPz8jw8CNf&#x2B;VIu15hqSIMtXXkAuBEcEzPzv/jlL1544QUWsw8&#x2B;dnD3p/cjyfEBl&#x2B;y77mFfEMIwF2cW605bY/EAQRC4XtEweCphg3H99squl4jH2eJOZhQETBicc2ZYACb7J7u7Lw/0Do6MjIyNjM/Ozu4Zb3Yrrs&#x2B;8WCzO6pFKpZKd8abm5vatbclEgjXBsR3XriilpCUMw5gwZhhjMTNXX1/fmF6bNJMG6oUSNoy5ObcxG5cR&#x2B;noujoyMZjL29h07mJ0EIYQQ8glDYR8hhBBCbnnVyr7qFilluVy&#x2B;ePHiyMhItcRvYWHhzJkzvu8/8MADlUolFovF43EAs7OzuVxOv0o3lhqGUQ34dOfvdX4H7/H32LtvviZ5vGZD7etqB1DU/lzKf3QyFEEpJQOllG9mFJBwFRRgC3BW5D4AHwUbdga&#x2B;iIL5&#x2B;al8vjBj&#x2B;Zzzbc5W162Y0kimUuBOVHF9oSzLshvqYRvzlZLruk590nUroRQt2eZEoMAAzr1iseviBT8I1qxf19zSUnG9RCIWCVWpVJx4zDKN2jfHdEIllyr7GBAqALCX3rzCRN/gkSOv/eC/feeOO7bsuf/&#x2B;u&#x2B;66M726FTbAAH9pCIaLf/6b/9lzpktE0Tf&#x2B;9f&#x2B;W3bUZDHCACMXzo688/9Pz587Xr1z2h3/0R9hQD8AFisVScyYFAGVVHht78dAv33zzzbb29t///d&#x2B;3WxvgK5isMjP75//3/3XnnXfu2HnPylWrjLSzeHPLIa&#x2B;zFq8cUPmg53LPW8dPXLxwoSHbkM1mWzvbV69atWLdGiPtgEF6gqc/2JdN1H6atSnvO25f9RLAa7I&#x2B;yRc/ewCyZiLJYnQIBaCib5yMpJQJaVvWUgas3j6xLv0MACGRrAAAvKVRxVfE2Nnzfb19h3/yUyWVUfGCIIgrxOPxpO1wzsceLGSzDStWd65YsSKWjoVh6ME1DCMyQ855ZIZSSl95QggBAYaYaVdcN/LMRDzR0rCuMZtLoo2BhYEVt&#x2B;Plkq&#x2B;Uqk9nFhaKF86dGxkd2bL19k2bNn&#x2B;gW0oIIYTc6ijsI4QQQsgt79qwTwvDcGpqqqurq1QqxePxHTt2mKY5ODjY09PT2dm5Z88evXybbdvVRE/Pbahd0e/jGvbJSBiGwZkEICNPiMiyDTBeRpwBicVqw6hSKHS7o4VCgVtROp1aFYvHYjGDC8Mwy5wDSIXNYAyVsOvkyZ//9NDFixfT2dxtt605&#x2B;Ltfbl&#x2B;1XBiIhJQGY2ARJAez8xXTccAZOAfX9WWQQnDTQE1NYhiJMAgTiZiMYJhgEoWF0uVzF86cOTM&#x2B;MFypVNxiaWJigjG2Zs2a&#x2B;/ft&#x2B;8zDDyNuqKI/cvzys88&#x2B;u1AuPvbYY5t3bB8fHh4eG0kmU23NLYyzhjXtYJg7fvnv/sf/4JHcsmXLQ3/wtJTSSHEA6Ft46bln//nQ89u2bdv1Lw7cfvvtqo4BMD0AS7maJ177&#x2B;YsXLl3s6OhYt2H9bdvvAIdaqLBsApVIiMjIxBbvu5SIcTeIDNOwGYOxFJNVUzX96cgFAAAgAElEQVQBGNBTeqGWErsPOKDjeod9BXAThr6o2GKtH1QAZgBsMdELDQCQBgA445iZWhjovnzx0sWxy73TMzOqUBRC2G5QV1fXWZ/NNTauaGxua2trzjUiEe/d0m&#x2B;aphWzOOdFr1AoFjzlmpapHCml9OEBUJY0DJNZjDMGKZUCophSylKNyWQyl1yVTCbTvAUAh62UKi4U67MZCAwMDpy/cDaRSOzcuTOV&#x2B;oAN0oQQQsgti8I&#x2B;QgghhNzy3ivsAyCl9Dyvt7e3p6cHwIYNGzZv3lwsFo8ePRqLxVatWtXY2Og4DgDf93Whny7uq4Z9N6CNd7Gz8r1O8s7t8u2pru945p2LDr79sMLefnZpIbsIAIcvIZUqcWaYCADoLGoWlTzyaiRfLpdMlsyk06qlLWEkLGQAZGRi8fgKeRMAhPINZggh8/n8wuB0V1dXz4vHz507t6djw3333bfrkS8gl0AMYEACCJcCLxPwlLAgpPBtHo9xL4RjwZSAAhNABISADYgQjgXgyujExQuXSqXSbStWrduwAYIjzpGXL/34xz/5/jMNudy//J1/sXLPDsQxf7bvpy/&#x2B;/MLFC1Y8tnLlysbmJsMwBvv6R0fH5iam7tl5z2f2fqptw/rzrxw&#x2B;9NKhbrO8deu2f/XIF&#x2B;MtOXBMnuz6f/7&#x2B;r/3A3/vUI/v27Us0phVgRsI0DQRApYJ0TZ8tw8KV&#x2B;VQmbdpmbZ907c9qm60ERNkTUiRMx3DMtyvjFLwoiqKIWaZjfeCB0DVN2u&#x2B;WDjNgKRDUe5YBADH9c7EtWgIAkwBgSgAlKAAuFIBMYNs2jwDXE5VAOI6ddADA1m&#x2B;sBChgRpR7ey&#x2B;&#x2B;9sbFixeDqeEwDObDguu6pXiYzTYk1zU2NzdtfWRPIpnwGhgYCo7PGPNNIaW0MxO&#x2B;CNxypVQquWWXAXWpTF1dnVdyOWcmM03TNBmXUoZBGIahCn3btkwej6IorBgAklZzIh5fvWzrXH6uo24DAIl4qVSqTzXpL9qbx1&#x2B;fnZ9bu2bt6jXrP&#x2B;DdJYQQQm5JFPYRQggh5Jb3PmGfJqWcnZ3t6uqanZ3VXb3pdNr3/TfffLOxsXHv3r2xWKw21FNK6V9vzICOmxX2RRAMFQsWgxeoYGZ6rFAo9EcTiWRyjd2UzWZTTiPA8ogDYEhIyDrfAcC4BYYFExJ6CC0Y4MvQKsl8Pj93qre7u/vSz1&#x2B;PonDX3Xd/5rOfNTYtR8pGHMO9g1fO9k1NTQ1dmbJtu35Ve1tbW&#x2B;v61e1tjX4E24SlUCwGacOGBQjdXuyzuFN988oLmG2DAwEgAY7K4PT/9zd/f/78&#x2B;c89&#x2B;NCBLz2JpiRMgAEB4IUwDMT5YkspcOKff/7c88/Njk78m3/zb1ffswtJ5N3iiy&#x2B;&#x2B;ePbl1/sH&#x2B;lvrsq3Lltm59J49e1bvvbO&#x2B;Pl0x4FYqacOyHUsnoiLwjbgTlF0pRKwupe&#x2B;273rK5I5tgyMIIqmU7SxW6PkAlsr1rKV38fZnpNtgayrvPmphXyNiAAIFtVR7yIDZ2aA1bl&#x2B;6NHzp0OunT58O&#x2B;sd8308FijE0sDCZTDYsb1q3bl37tlXZ9g40cYCNyCnHtvPpMIqiebOilPLNSEpZUhdM07JMU0oZekEQhlyCc56wY1IqCKWUZBJSShlJKUXM5ACYshljXCakFNKLi0iE5djatWuXN20KRcSiZMJJMNgV11Vuqa4hOz4yduFiV319fTbbcNvaDR/wHhNCCCG3GAr7CCGEEHLL&#x2B;5VhHwApZRAEw8PD586dA5DL5Xbs2JFKpV588cWFhYXbb79948aNlUrFsizLsgAopaSUjLFqid/1JN51a7VA7J31YnpEBvDOCI9d9Zp3paMleAAEyhKSoQJgQU6Oj4/P56ekUts7DsZisSCWYIAuV4sHDIzpkb2&#x2B;HbGlU9lCQgFGwvcQhCKeMHRQ5Y0HI8Mj85eHfvbTn/WdPL1mzZpHP/vZNWtuGxocOHny5OtmkXGWClkYhsZssVQqGSVfSvnFJx&#x2B;/6667Gu/ahLSJOCCQZ7AsJCQgROj5pmmymL347iKAARKIEIzmv/vf/2dXV9cXP3Ng11cfQ93S0n5mNQMDAqDslkqlX/78pTdPnnTzhSeeeHLnrt1oSiMF4J0NthwIQpGysFSXZ0L6oW&#x2B;4YSyViqSsDnJRSpVKpXgywbkhIEUkTNNavEAZhlHk2I4ED2XApLJM2wKTkCoUYLBNK4qiQArOGLdsBoSQQejXW/H3/Jp8ELWzOmq/FAISgAGOpWCR1Y49ufb7I5eSUwA&#x2B;MF0aOXLs5MmTF7rO&#x2B;L4/F&#x2B;XDIBT1Rlt7e/vGlW2trfhCWzqdTiVjQohKaT6MwmSMJ5PJSvGKaRocfhQJpnzdQi6lDJ0UABEJ3/MD1wuDAJFUUi3LNUkpEQohBJcwDMMyTdMwp9hkFEVSRJwzyzAARL4Kg8DhdZZlsaiuddmyjvQmAB5YHPE46nzPMw3LsOIvHzqUTCeamltXrlz5odxkQggh5KOJwj5CCCGE3PJ&#x2B;nbBPk1IWi8ULFy6Mj49XB3f09/cfP368oaFh7969Sik9nxeAEALA9V&#x2B;wDzcr7AMgUJxcmLzcf6ZQKCxf2bpx5cakXM&#x2B;5UQQDYIBFEBnPgGFAKgCho9jS&#x2B;m62kFBKsSTjUEB/38TRV46eP3&#x2B;&#x2B;TjntHe0Pbt5hmmb3sROvvnq4sjBnWVYyEV&#x2B;2bNn6P3hy5cqVyzIZd6ESjExX3Mr4xd43jh8/d7HLNM32rRsee&#x2B;yx9Q/tAEdRwbFhewKmsbTQIKIgNA0LJlAC4pDD5X/4h3946xevb9&#x2B;&#x2B;/V988SmsaEQ9UPDccjkWj7FcEsXg9ddeO3LkMGfc4Lwp27Bxw8Ztm2832nJQgA/ksPjABCRQ9pFxAOSDYiqZDgE3clOmzcBMCQgByxJC&#x2B;L6fSCSgm745D8LAsmwAEkpIwTjnS0FjBCgoA4wBBiCUsJgBQIenijH98QtIBXBwBx&#x2B;ODy3sCwFXTnb3Hz16tO/oW1NTU0axEkWRaaIxl1u&#x2B;edUdW7d2bF2VymZ95lfcyuFMXxRFUJFlWfGYwRkL/bzrenUp0zRNk4dKKYNHpmECQkRRUZmGYZrcABQTSkqpgiiMovzMnBNzMrGkbduGQiSEDIWUspIpA1BKiEgoEQGwmGMYRuiaBud&#x2B;yQHQ1ri&#x2B;tbU1ZTWZMOOogwIYD33fcuKXLlwolt2xsbFsNvvAAw98SDebEEII&#x2B;WihsI8QQgght7xfP&#x2B;zTgiAYHx/v6uryPC8ej99///3JZPKNN94YGhrasGHDpk2b9ICOKIqklLZtV1&#x2B;o23uFELri78Mq&#x2B;pOAkAKAwQ2pZBCGnHPLXGz6VG/vpqQUFl8sKxNCcTBjKQeDhFfxTG6YMQsKwgvKpXK5XG6t64CxlGQZEiaHFSjPE4lQQQ3OXr50qTsfza5YvnzFqo400llvCwDhAAyGrncrAgB8wAH0gnUmoDB9pvvMmTPzPzkfBIGTSBZLpdGgHE8ksHnFtm3bVn1ml5Ryenyst7c3f/itN998s30&#x2B;2nrHHY/&#x2B;y68m165GZuk4AHxM9A&#x2B;8dfatY8eO9XVfzmTS&#x2B;3bveeKJJ8yOZnhAyztCsSozRBDg9CtvfP/737/SM7Jq1apVze1BEJyp9Dc0ZNs7Olavvm3dhnWdncthQQaS2zWL6umRvhxgkDaEkNL3nXgcClAqCAPbcUqRH7McARnIwAQzuWUCoQhtXjNB49do8n5Hm23tJ8qu3kdvNvABv1TXHG3pLaqla3xHLzorejAM2AaAwOQKcAEBmC7icdglIAL0RN0BiO6enlde6OvrOzs9KES00Gym02msq29tbb39s3fW1dVl2xOxWGx&#x2B;fmR0dDTyivF4vCmzgnPOTM65IQwoIGBCKeUxoaACrqBUyJVSSjAFpZqKvHoPFEIplYSvFKTypJSR8MIoVCrknJuWYZrmvBEBYCxQAGMVJRXgK6W4YlJKFdlSSq6SyWSytXllc7w5g40AAMuPvJiZATA1teAHwUDfkBRy9649ieQNSPMJIYSQG4rCPkIIIYTc8j5o2AdASlmpVLq7uwcHB6slfpVK5ZVXXpFS7ty5M5PJcM6rDZvXdSavvGbL4tTTKLBMC2ASUkhpcM7BlQJnb1f2CYHA98MgyCRTbOmJoZ7&#x2B;Y8ePH3v96Lnz5/av37Vh44YvfPERa1kDDKBUQYMJQPFyySufHTzZ39dv1bM77tjSmm4GkA22AJA2lEJ5utLX11c41Tc1PW1zQ0jhtSTWrl277o719Q31mMlfmZ6&#x2B;8uMzJ948ceFyD6DuPvDZx3/nd3B7A0xMO7AZDGC&#x2B;KHG2/&#x2B;jRoxM/Pzo7O9u8Zs2nP/3pjZ/5FJKABDyFFIMNuLh46q3XXn3ljTdOBMXivgf2ffnJL8XWdqLuPcI&#x2B;AQDuWOVSd7ecLTc2NrZmcgywtjW9Iy5bCrpUuLQmY/VZBbhhxRGxWIwriDDkYMw09UsiBqGEZIqDc0CoiEtlGRa7dtbtr/Hh3viwTwGAkkopKQHoeJqBsUqoTwMp3bhtgOlVBXVFoV3A/FBh&#x2B;nDXmdNn5s8Pzs/PNXgLnHPWWrd69erknctXrlzpbGmpa22dcIeVUqFTjqKokB8r5AsxW9XX1cd5I2OLqxAGTEohXERSSuUY7xr2LSubCgCEUlAIgcWfoagopYTypZRKhQCYAc74tPIYwFgAxjh3AcZZsHQAGCoOQAS2Uipu1yeTyXbrnpZcC4MtIaOIO6YN2J7nlwqVrosXIy9qb2/fdPttH&#x2B;yeE0IIIR9tFPYRQggh5Jb3G4R9WhRFV65cOXfuXKFQiMfjmzZtamlpyefzzz777Pr16&#x2B;&#x2B;///4gCHRln35QqVQSiYTnebFYzPd9Pcb3Q6DTjghhGHLGLNNkDEqCGUtNvHxpN4XF&#x2B;Rw69zLefjkARICUUkrP9crl0ujoaG9v7&#x2B;lv/zxfKGy7&#x2B;64vfOELy9atQmMaFuBHcILQ86bdqTAMU83xuni9QOjBq0ddqVSePdb36iuvTHXPtra2bt6zf/369aNDsz09PUMnLw8PD1/xKs1NTesevv&#x2B;&#x2B;&#x2B;&#x2B;4zndmRkZHyiZ5jx47Fx0tbt23d&#x2B;elP1d&#x2B;3DWnAgetgfsFLmqxScfuPnjh9&#x2B;vTQM8daW9s23bdj3759zl0rgKWcSUApzA4OP/fsc6/96CeZTObpx568Y//&#x2B;aE0GgALDO3Mt/da5vg8hwBaflrF33FcplcHfTsKUgh8EtmVxzhgQRpHOc0vlEuc8EU8AkFAcLIzC2oEtjDFucAZuSPX2RfzaH&#x2B;67eM/pKh9wJsx7hH3QA2dqu3mXDq&#x2B;EZL6EZS6uVOgCboArhTOnTp04cWp0dPRKvlCulLltZzKZ9OdXtne0b1mzZvny5Y1xR0klg3wURdKphGFUdPJSqknMlIrFkuk6jrPWaGeM6dRZCUgpVQSlJFcmoCA5lIJiSi1&#x2B;nyOTKaUEIqWU5AFjTJo&#x2B;Y6wS5QEI7ilAMF/vA6VQzgFYHHzCXMYY5x4YgwykUpwxxlgUSN/3lWDcMBJifWdnZ0f2NhMmkODgHGkAStimYfZdHrzYddHi1sMHP/3BbjshhBDyEWZ885vfvNnXQAghhBDyW1lYWAiCoKWl5YO&#x2B;kHOeSCTa2tpM05ycnJyYmPB9v729fffu3UNDQ93d3YZhpNNpwzB0WZ9SyjCMKIpM06wW/f369H&#x2B;yXjvhNwiEYXDOYVqGYXDGAQZWXYpPLj2o/qojP71DhNAPoyAybRMMMBkzuRWzk5lUXSqdSqXu37ijWCgcfePYubNn/dDrzDZauQxMDgsqCEZnRgcHB4fGh8pemcXh2M7c&#x2B;Pz4&#x2B;Nj5V948evSoEVm7d&#x2B;&#x2B;&#x2B;4&#x2B;49Tl0ml25gjKtyWCqVir6XSqU67tiwadPKpuZ0OpXe2NiRSCQqY1cuXbrUMzyYKId2a1OsPo4YkgkzYZvpVKy9vqWpqXlDffvk1OQvXjt8/nxXKMSyukYrmYACLHgVb/hy7/mu8&#x2B;Xp2bbW1p3b7spsXC9143BNmlVtW5YShlr6PVyc2qEsCClFJIylkM/1PNfzHccGwBgYY0IIpWBwbnA&#x2B;OzubSCRs2zYtE2AMiIQolorJeILXMLihz8SvCdd&#x2B;Qx9W2PceL1r8suknlIKUEBJSAkwIwZkJg0EgGJ&#x2B;5fOzkm0eO/N1//9sjR4709w96npdIpzdu2Hjwi4/969/7vU0P79h6&#x2B;9a2luYoiir5Bd/3IQMppS8rQkShFTmOrRJgjHkqCMIgGdhRFIpIKiUZGGPM4IZhGGpxTUB21eVGUFIpISMphEQEKMUFAwtVoBQkCxWgmAAglVBKxnkDNwzO9bBsPUAlhFIGRyREFEVKSn0WwzBN0wyKsUKxWKq4PM5TVpaBMTi&#x2B;9B0jCaCpob69vTP0w9NvnTeVlW3M/CY3nxBCCPmIoco&#x2B;QgghhNzyfuPKviopZT6fP3fu3MzMjO7q7ezsHBsbGxgYsG1727Zttm1nMhld4VUt9/sNzsIYuyrsU0qxQCcygA9EEiZfDEMiwAFmygOXL1&#x2B;8eGl0aLhQKPSWJ1csX7Fjx467tt&#x2B;V61z2juO7ITcMWBxCgTNd/BacHHU978hrrx957TU/CDs7O/fcf//Oz&#x2B;1HHCjJt9448sILL4TS279//57770V93fSEnBgf7/vZ66&#x2B;88mo0W1y9enXTuk7HiTU0JuLxeEe9s3z5cr6hETEHKb9UKoynOgLgNoH8QoW91vvGG8d7XzpWKBR2fuq&#x2B;7Tu2N&#x2B;2/G3UOjCiKwiDBGWOXZ&#x2B;b6&#x2B;vsGjpy8cOGCM3zFtMxOK5mIx1N1KTDMp9HU2Ji6Z93atWv58sa4EWtHGkvB5mKD6&#x2B;KkCQHDAIOUMoLknEswqaTDeBiFACzTqr3RQRhGIjItyzRMBQgZSQXLWJz9UfJd0zQNw6qexVAQUcSE4rYFBt/1Q6hYLGa&#x2B;V5fte/1NfVVWW7X0mV/lA0d9NeHjO3JIqSAlIt3Oq&#x2B;cpM0BBLzTpozQwe&#x2B;YnPzty&#x2B;Eh&#x2B;uA&#x2B;Axyt1mbq6bR13372j&#x2B;YHNy1paZuKh67qjpSvpdNqOxaSSksGEKVVQLpeXpZK&#x2B;7zuVMue8XgillBX4SqqT9hRjzGCMM24yxhi3FADYjEPBkEopxfVkF6WgUDJiUimpIiWV4oIxxkzJOQ&#x2B;VJ4UIpa&#x2B;U0gWcQgkpZUI6ClBSSiWVEkopvT6hYbAgCEQUcM65sTg82jCMgEWFQkH4Tjab7WzcnKvPNWAVA7dQ70YVW6ZidiwoR/lC/tjho8lUYve&#x2B;vXr0CiGEEHLrorCPEEIIIbe83z7s03zfHx0dPX/&#x2B;fBRFenCH7/unTp0yTXPdunWJRCKbzeo9wzDU&#x2B;3yg4&#x2B;ussHaLlFIpZUQGosWSvajkjo2OjgwOXblyZWJkdGJ8Yqivv6WxaeXKle1tbelUes1921KpVENzE2wOpqe9KuhcSyyNvABmRqdOnjp58s2T6Qn/4GOPrVi1uru7&#x2B;7Wjx86cPs0sc&#x2B;vWrb/7ta/a2Wz/xTPPPfecHTeeeuqp7NpVcF0k4zNjcub180ePHr147C3Xddfes2XXrt27HroX2aW6Ql6A4yDlR1HQbTaawGqg4qJuNITrTv7yja6urh&#x2B;/9NOWlpbNj&#x2B;z93Oc&#x2B;79zRDkCaCKLQN60IcAcmz549F1wYcGxnS1Nbc3OzMpSTSnlZM5ZMBp31DJiAz8GXIYF3C/tUFOn19ZQuIQOTQKSEs1gSCd/3A983DMNxHNPUC8MhksLgxlJvq&#x2B;TgENIwjKVuYOl5LiKZSCTgh3YsBgWEQo&#x2B;zkOztLup3&#x2B;3TfY/vNCvsUFsM&#x2B;w1i8Bv0zwtEjZ44999PuS5dicwuc8XoWWZZ1/2fvvf322&#x2B;t23oZYbIrPeZ6/kFaGaZQtIYUo&#x2B;57reoZtptPpuGVJJZ3/n733DpPzKu/&#x2B;v&#x2B;ecp8zMzvaiVS&#x2B;rLllWWau6SDIuwraMbUxMETZgmwQroSVvLiDhF&#x2B;AlDQiQBJOEGIzBjsEFkLAt44otq1uW1fuuykq72j7taeec&#x2B;/3jzIzWFUgMtvJ7Ppev8Wh3&#x2B;vOMLvtzfe/7KyMpZdIrAKhRSgiRVArA7soBIoLWWhNTSmsSShNRheO&#x2B;ruwr2CkCNEkiIqZMLwxjTLNIShlpjwhMaABSS6UU5Uw9jtHmxEphV8ZISsWghRCADsNIyggAXK61RpRUWjO/JpVKtTTPGV03mqNSwJI&#x2B;83yvvnoYlAbjPZ1dz21&#x2B;YcyYMa2trb/rcYiJiYmJiXnnEMu&#x2B;mJiYmJiYmHOet0r2AdBa53K5/fv3nzhxolzcceTIkbVr11500UWTJk2SUtbV1eH1zN1/47kMpzcc3b59&#x2B;47t2wcGBlxuWbadspxEIsGl7urqSghr8QULLrrootSUyUgC1aX7S3j9/dlsNlGRqmpoAAfMpGlISknf87a&#x2B;&#x2B;OKvfvWrE1v2LVq06L3Xv69p6vjC0Z71L6zfvnH7wYMHRw0bOWLEcKEwODgwuaVl5bXXYnIdAFQF8Ly8F3Z1dR198dDWrVvzL53M5/Nz582/&#x2B;OKLx161CNUMjikHAQDkgWxw5szJU6c6qlrGTpg69vSp3l27dvWcOLlp06bB7q7JkybNWTC3tXVe06TRADAoYDM4ACBt8wBaQiooG3YCCoArg0w26wQyVV&#x2B;v7TTKw7PFUdCSu2IMFkFrjxMH96ElpDsYppIpblmgUoqNoILAC/x0VTUYoHUgI8dxzOEjSV7Be&#x2B;iRNevWrZt9wbxPrv6kAIIwTAln5/Ydz/zqycOHDycrK2fPnr3g4gtbWsZGQ475G03iDr3Oh8g&#x2B;KilZvKJG4xW3H9L1&#x2B;zvzymSfmd4tPeXAwOm2452dnSe/uT2TyR6T3VEU9o2QkyZNnnb97EWLFqlqPxfmzgwcHBgYTLJcVVVVtctBZOXTlm3Zdsq2LfCElDLjS8/zpONalhW6FgBfkCYdQhPR&#x2B;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&#x2B;9vSVMreKQUhIs/ftHHjr5/7dXNz8/JLL50waRKAIAwc12FgURTZlgugs6/75z/7&#x2B;T3/de/BgwcXtS688cb3jm0Y/sADPy0M5q644gqRcB9f9/iAn7/wwgs/8ck7ykfwHS37pAYA4tA6OHXmxRdf/PWTT&#x2B;/YsWNZ9wzf9/mY9OJFiyesnF03ZnSudiAMw6A2193d3T14mDHWXCOqq6tTXGmlKnWjlFJpRgQNm0BkJS3LykglhCgIhGGY1SFjjFzLEqKu2wKBoIhIcwVAC8nAIgSvK/skC4qvmQAirTU0ERFJpbXmBCGExYVUyve8IAiC6ray7AO5WmstudKaM1trzUCMcSKpSVsWdxxnMLE3CiNZcAFK6BGCC1FoiKLICRpaW1srqD6dqNAhE7YNsgCAOydOnEilUtu2bXNdd&#x2B;nSpf&#x2B;DAxITExMTE/P2EMu&#x2B;mJiYmJiYmHOet1z2AdBae5536NChI0eOAJg6deqMGTOklGvWrGlqampubh43bpxlWUM7N8IwtG1bKWW6O4ZG/4iIiDh/o31vEQBdNB4cgPF5VFC5XO6phx7dtO7Zo0ePtgwfPWfOnHe999r6cWNQBUj4oQyCsPtA2549e17&#x2B;5dO5XLbKSsydN&#x2B;/Ca1dUzRiPJLzu/O7Hn3/iySfTdVU33njj8PnT4GvY7PihQ7t27d64cdPObS/X1Na8e9mK1tZ5QTY4cuTwgf27uru7e/p6XdcZP3H8rFmzJkyeUFdX13bi6MDAwJH2I0eOHOnP9nHOlZYFz6tuGVdVXdU6b97ixUuam5uNaioW5oqzHSbFgWUhFLrE2XoRC4AGb29vd93KdEWFY1ckk8lCIUylXBCUgrBesevwVYFKz/OSyWQURbZtm5ZkpZQpUeGcm2fs7e11Xfczn/kMEV1yySUf&#x2B;tCHjh079txzzz377LNbt26dMmVKZWXlggUL3v/&#x2B;91dVVf3kJz9Zt25dbW3tP/3TP&#x2B;3fv//uu&#x2B;/esGHDpZdeetttt7muu2nTpk2bNq1cufKCCy4AUCgUbNu27TcTdOb1DP0cXru38RXQG1x/gxFgJvMApGUrpUKR5EBFBERAFmDACZx&#x2B;YecTTz9z8ODBDFPJZLJzRtsFF1yw5OIl48ePFy5TSoUIiEikRG9vb2f/KSllqjpVU1PjJh0GZuc5EQBORJo4iDQAgoZiDMQkQJqFRKQpBBFYGkRaU3GbHgNjmjH4YUYrzURoWYJYIGVEFHHOpbIBEAhUzLoSaSLigpufDgWEvOwrj/GCmd8rgrkEoIhQ2uVnepOHg0BskDQR6yOtGXlEJFQKDDXulJEjR45MLWBgDA0a2iJmMQHw02c6&#x2B;3r69&#x2B;zec/7sOdMmT3mTQxwTExMTE/NOI5Z9MTExMTExMec8vw/ZZ9Ba9/b27t69u6&#x2B;vz0z1jh07trOzc/PmzXPnzm1sbGxoaMjn847j2LZtijuiKDISsKylfoPcAd5I9jEF7Qf2cY0AACAASURBVKvB42dO7Dq0ZcuWw7v29fX2VY0ZdtVVV128coWosiAACQRASPDYmR07Xnji6W0vvng83z9m7Jh5V7/rwiVLmhJ1v7jv3pf27Lxk6SXLVl0HCdiAAvzg8OEjm5/ftHnLlnxPZtKkyVdf/u6Zi&#x2B;argT7P8zq7Th88eGj/oX2dnZ2hDmzLnjF75qxZ502dMTWRSGS9jJLKTtiO4wSVqVQqxTkPgoBxlnAT5XeltIrCCIAQwrIs8yH48mTCSkjSkYyOHD5m23ZT44ja6tpSps3O5XLpdKXnhY7tCFESW0S&#x2B;7wdBUFNTo5QKgkAIYdt2&#x2B;RMGEIahuWLbttbaqFXP83bv3v29733v1ltv7ezsXLt2re/711577csvv2zb9he/&#x2B;MWjR48&#x2B;8sgj69atq6ysvOWWW6688sq2trb77rvvpZdeuuOOOy666KLt27evXbv22LFjDQ0NY8eOPXz48GWXXbZ06dKqqrPNrUEQuK77G0&#x2B;nN6pjfuWN3uD6m8g&#x2B;grZdAIPaUko1aAEOdGD/r3fueWzDsWPHevoHoihqmDhu5owZE24bXldXV1VTSYAXFYi0tjVnjLus4HuDXn8YRWRp27aZAIAmu8Gcy0oprZnWWhmPxxQRiJnO3ICICBGIGEuXXisRKa1JU6iJLFspqYh5AJM67/teJD0GKJ0w8o5zzjkDY6ZBuCQVS8IPZDo3CmoApjW5&#x2B;BkQQZFJeYIImohKyk8DIGomEFhGawJ6icjIPiYTSiqXRldXVzek59TW1FQnWgSEA65B&#x2B;XwhmUoxiL7&#x2B;vi2btnAmrlqx4jce35iYmJiYmHcIseyLiYmJiYmJOef5/ck&#x2B;AFrrIAhOnDixe/duIhozZsy0adPS6fQPfvCD2bNnCyGmTp3qOI6JmAEwKbOhdwfwxpk&#x2B;gwRAYCgpP2aUn5kAjYAcOg4c3Pj0c9u3b&#x2B;98ef&#x2B;Y0WOmXHD&#x2B;ggULJixpRbUDF1oiFAhCbflycHDw5JZd69evP7PncBAEE6fOGDlq1MnuU0EQXPuBGyZOn45aBwC8EIxn&#x2B;wa3btv61GNPHThwoLG2YfLkyR&#x2B;&#x2B;9cP1DQ2ocgBEA7lCoeCmnERVFXQAx5VB7sSJk6e6ToGosqYqXVGBqrbq6upEImkLS8DyZCGXzzOw&#x2B;up6CRkEvu8HURRGUiopldK16Zn19Q3ZbK4ynRbMATAwmK2prtHEgyBwnQrP8yoqKgCAEIRyYKB32LBh2Wy2srISrwzKmZRcNputqqpqa2vLZDJGvPb29t5zzz2nTp267bbbFi1aZNv2N77xDaXUBz/4wQULFvzVX/1VV1fXsmXLRo8efc8993R1dV133XUXX3zx9u3bf/azn7W0tNx6661jx4595JFHNm7cuHXr1lGjRn30ox9dsmQJgFwuVygUamtrbdsOgiCKomQyOTS49xvPpd/iZIB5768Pe/VNgiCQSlZYFYwbaQxk0bXj0LMPrTlx/Hjb8QOe56XGVc&#x2B;fP3/RymWT5s3rD09zzjQjrRQJsoSlhdJa56M8Y0wxGUWRF3lhGEotQdSUqgcAmEYMizGAcTAQNIE0QiLSCAGASQBRxBljggvGGREppZQKldauy6WSRD4BYZQt5AtBmNdEVdUNJWMLQikEW1J7KP7r7Mfh6wwRCJq0plc0jygAVJwBVijpQmUCgshr0sCgNrIPxJQVSUlBJec8IUZWV1cPb5zUkGqsUxf7ARIJACgUVEWFCAMcOnxw10u7pkybMrc13uIXExMTE3MOEMu&#x2B;mJiYmJiYmHOe36vsKzMwMLBv375Tp06ZiN/06dM3bNhw6NChmTNnTp8&#x2B;PZVK9fT01NfXM8Ze5fsMrxrnfCVvKvsKAAES4YkzJztOvvz4r1966aV9J9vHjx9/yY3XLFu2LDGunjQoASlhBxAukEPuROeJ7XuOHz/&#x2B;6xc22Y7Tfuq4m3BX/fFHFixY4IyuQyFChQ0ABe1ls2c6urp7eirsVGNTY8OIBiRcmJhauUOWleZumS5f6tAfHBzkNcc459lstlDwbNvmnDuOXVtd23H6VGVlZWW60obNSu8IADCyf7C/troeQMH3U4kUIApeIZWsAtDfn927d2/3mZ5ly5cnEsm2trZCIdvX1zdz5szm5uZ8Pm/mc/fv3&#x2B;/7fk1NzZQpU4QQO3fufPjhhysqKpYuXaqUeumll0aNGjVv3rznnntuzZo1559/vjko27dv/9rXvjZmzJht27bdeeedyWRywoQJx44d45wnEolcLjc4ODhu3LgFCxaMHDly4cKFGJLFi6JIaz00vjd0NPu3aWs5O4sKMMZ&#x2B;g/L7rWUfgDAMXe6AAz7yXdn9z2xbt25d4USn1spNspaWlvMva53V2ophKfjeYIVPRATNOWc2A&#x2B;BFBT/whSss22IWCBRIP4wipSUANRgyxhgTnHMubM45Y5wxpkgSiBASgXjEiuO6zA&#x2B;IM8a44LwY0NNaEpHSgdYaPOSMSVXwfC&#x2B;MPBBVVjeU35AmIq01aRAprQGw4iju2XcfsrzWWmultdZk9h9qxpgmCQJgRnpNvo&#x2B;IqCz7iIjYIBExeESwmKuUoqBSa62DWs55ZXJEVVXlBU0ft21EEmGIdBoAlMTgYCZhJ1/etbOro2/JksVNoyre/FjHxMTExMS8vcSyLyYmJiYmJuac5w8j&#x2B;wBEUdTR0bF79&#x2B;4gCJLJ5MUXX5xOp9evX9/b2zt69Oi5c&#x2B;eitMfNeD0j&#x2B;H4LH/Rq2WeGeVWoHEewEFAABzRQUG0HD&#x2B;7cufPgc1uOHz9eocXUqVMWX3PF5IsWyzQsG1kODdgStgU7BBXUwNZju3btevqFZ48ePXLe4rkrV14zZek8FCKkbWjA6EdCkCloScmKFFIMCkopLgQzO/cYwjC0HLNfT2soRcpiFoEAsMA1YtP3AcB1ISV8X1dWvlpmaY0ggJP0lZKO7R5ta&#x2B;vt6b3/J/cfO3Z83NhxNTW1S5YsmTlzVmVlZUdHR0tLC4BTHacfW/fod7/73ZkzZ9bW1q5atSoMwx/&#x2B;8Ieu61599dXd3d1btmzJ5XJjxoyZPn366dOnjx49qpQaOXLk6dOnz5w5c955533wgx/MZDLPP//81772NcdxPvWpTy1fvnzSpEm9vb1PPfVUJpNZtGjRlClTLMsyOUETRrNt2/M8zrlSynVdczSjKDLTxIwxx3HK4s9smjOLGl/La4/7m9/&#x2B;dR5hyPXXnkABUPBRa6zXptNr1q45vG17f39/Z3iyeVjzxHdPveKKK&#x2B;rm1SlSPdTNGUtG46JIRioCETOb7zgYY8qIM0bln5jn00FkFGVxnZ4mDQ0iqSIAxCXAwCVjnHHNwMBNp65RbWdfZxj5WmvOlbAsQhiGoVIhGPPDwKhPzjjjKI&#x2B;8RzI8&#x2B;36LBb1gQMQ9I/uUUqU9fZoxKCVfd4xXWiEIVBw0LhARwQdg2VwrRZoDkBELw5C0EJZV41XPmT1nuHNeiEhgnA2bYzgApkQmW&#x2B;g50376dGd1TTjz/Ct/y8MXExMTExPzh0f8zd/8zdv9GmJiYmJiYmJi/kcMDAyEYThs2LDf9xMJIaqqqkaMGKGU6unpOXXqVBiGra2tSqm9e/eePn2ac97U1CSEYCXKgb43TX6dbWyls2k6CMZNCUERAjSvbWgYO3Lk5BFjEslkZ/uJl1/euefooTNH27Muq66p40mbAToiy2JCgVk8WVs7dsrUeTNnZgYHX963U3Ax&#x2B;6L5sAWYSUEBjEHBsm27woHFQACBc8742WQf5zzn5cwVBs4Z0zDBK&#x2B;ZwK58nxpjrwrLAGISA6zKlQIQoQhiCMXAOxmBZUBQ4tvvsr59dec3Kkx0d119//e233X7dddeNGTN206ZN//AP//j888/Pnj177dq1d9753ZMnT15zzdXTp0/v6uo6dOjQpEmTpJTZbPbAgQPLli1bsWLFlVdeOWLEiA0bNuzZs8e27csvv3zKlCnz5s1bunSp4ziPPfaYEGL69OlLliz57Gc/29fXt2XLFiJqaWmpq6ubOHHi3Llz6&#x2B;rqTAwzDEOzWFBKaVkW59yUb5RXLnLOLctyXdd1XSMHTZly2ee&#x2B;Lq897kP3DP6uvPY&#x2B;OR&#x2B;pBKws9mzZs&#x2B;EXj&#x2B;/YsSPf22tb1qyFs95z3XVL33dZuq5uX8fuw4cPDwT9nPMo54ZhYMwmAFOF4TiO53thGHqeF4SBlJK0llpJqewhJzMzoT7OGecAcSGEYEIIYZnfAAxcCMaK6/pUMYCnSWvGzXsnLgSYBoFxWJYlteJF6VgMPyqllFaclbY1Fk99c50UouKcr9noV/ot0ZDNfaUEJYE0UybxBwJYBABMmVcildIajDPOzVG2OOc1Vs3mLZthV4yqG2mhfsAfcES97/uOcNyEXVtbJaMon&#x2B;/ev2&#x2B;zV9jf2BRP9cbExMTEvBOJZV9MTExMTEzMOc8fTPYBYIy5rjts2LD6&#x2B;vqenp6Ojo729vZJkybNnj27oqJi586d&#x2B;XxeCJFIJLhpDC2ZnbJeeT2McgN7pewzQ4xKa8EZLEAADpBioipZVVWdbq6vra6GK4LQH&#x2B;jvsxJOiomK&#x2B;toK1yaLaSASyEKmQo4suelUU0NDJsidPNUxatTw&#x2B;uHDYAEWg8XAARuwEarQCz076UCABIhDMyJGCooYLNvmnOviZjQyw70EsmCFYZhMWmCIJKTU2Wxu&#x2B;/Ydnh&#x2B;kUhWplGU74KI0CwwI4fT1ZadNm3HHHZ/cu&#x2B;fA1i3bfS&#x2B;cNHlqU1PTnDlzV61a1dbW9q1vfWvEiBE33njjo48&#x2B;unnz5iVLltxyyy2TJ0/&#x2B;7ne/OzAwcPPNN9fV1d17770vvvhiFEUtLS2O4&#x2B;zbty&#x2B;VSl1xxRX19fUbN268&#x2B;&#x2B;67bdv&#x2B;xCc&#x2B;sWzZMqPzOjo6Ojs7Ozo6qqurFy9ebJbumcMkpYyiKJFIAFBKmaBZueIjDEOTziv/EYA5uJxzc8vyjV8XpZSUUimF0sK&#x2B;3zzzW7os/4Ozp8Urfp2QsCS6f31ozT0/Pb55F/dkojrZ1Nzc&#x2B;qHlE1vP624s7Dyx75Q&#x2B;MXLqmNHD6pQb1KbHJtJuqqKiIllhJSwFKaVSWqWSKdu2Xct1bDdhubblOtyxueP7haKwIzK5Py7AOWOcLIsLiwvBGQdps55PhbIgVai1NJW4RBpEmkgIUYr6MSLSGgxccNt2bMu2LWFxLsBAmrRWWpEQvHimEZU28WkiLSkqNu0yVjwTSROo9D2jshA1n7GmBJENcki7WidAKdIJogqlhVKOZgRuKx4oSNgBT&#x2B;hQnRgxsfJkV8fWw8&#x2B;yRFVzTR1YNbdB3JEAYNU2NI4YOc4LeVdXX1/fieHDW/573jYmJiYmJub3RzzGGxMTExMTE3PO8wcb4x2KKe44evTo/v37AZjijt7e3iNHjriuO2bMmGHDhjmOU779m47xqiHXzo7xGqdmmRV5pfCf1OAcPAQi4GR3pq/fTjjJujpUu0i7kQsAg1JxzlzOAVR0AjYg0Lur/aHHf9bR0fHej/zReQsvAElYApxppcDPrpAzakkqycC4MEbPVDGYV0AMjFCMVjEwW7mc4/Tpnh/96EfHjh279dZbp0yZcv/99//whz9cuXLle97znpEjR2SzuTAM0&#x2B;l0dXXKuJhsNl9ZWQFg187df/XXfzV58pQbbrhuxowZpoXjueee&#x2B;8EPfpDL5f7iL/6ivb39wQcfnDVr1i233JJIJJ544olbbrll1apVY8aMueSSS0aOHLlt27Z0Ot3S0jJx4kTP80xJrjF0ruv29fXV1dVls1kA6XTaWNeyyysUCqlUqnxoMpmMubvv&#x2B;67rmmCm1tpE/6SURvCZGw9t23iTg0tEYRiGYWhGdx3HKRcTvwn0mktzB/7aX2dwcG/7&#x2B;rsf3rFjR5PHSeuJs1puuukmtqAJyWSnc7i9vb0H7cOGDWuuS1iwXEwKo1ApJTgHmNLKElbCTni&#x2B;xzjj4Ma2aa2NkyQmQUQoDvCSJiN8NRRjjHFNRFJFYRSGYSCVlNoTgluWYwmLcxsM0MycLVJKIsmFYExprRkny7L80AOMNz5br0EAkXql5iOCBiGEZwp7mVkIWNoJyLn5vxozwKvKU8S&#x2B;ZuaRAdKIABBCAjQ8ANwKGeeRyodhCKZs266ksL&#x2B;/r9KZmkol812jamqqp425prqqigV1yQRjGpzD9/tTiVQme3Lvnn19fXz48OFz5sx58wMaExMTExPzhySWfTExMTExMTHnPG&#x2B;L7DNorQcHB3ft2tXd3W2KOxoaGgYGBrZs2TJz5sw5c&#x2B;b4vp9IJIxaKhd3mD&#x2B;acVHzMGcfsHj5iphYsRvDXOYAAEkAyAmgZAodpW3BLQlQaccfAwgYAFwgrzY8&#x2B;&#x2B;yTLzxZVVX1rpWXz7xgHliktY4YOZatwABSIA5uEwCEYeC4LoBMZrDkvzzbsTWov6&#x2B;/oaEBAIEYmFS9YHC4AyBUoR/46VQ6l89xwe/4xB279&#x2B;yeMGHC&#x2B;HHjp8&#x2B;YvmXLlkK&#x2B;MHLYvEsvXb58&#x2B;UUA8vmgosLN5QoPPvTQ/fff9773/dGVV15eV1eXSCTuueeeu&#x2B;763nvf&#x2B;94//dNPnjlz5l/&#x2B;5V&#x2B;OHj26evXqRYsWGUPn&#x2B;77jOJxzM/hZTt4ZB/eqLpQwDIUQQoiyzgNQbvgdinm0oanM19atSCmJqHwoicg8XT6fJ6K77rrrwQcfZIxdf/3106ZNq62t/clPfnL48OHrrruuoaFh6dKlFRUVUkpz9yAIHMcxVjEIglQqBW2GUYkxphnKY9zFo6804xwaYT7vJFMAsDt65Ps/eHnTljAIPBXMmjVr0S1XT5g&#x2B;vbMh59hOvzWQDbNe3zEZRaNcq7qqWiXqzTo7Ik2KNBkPRpwJAIzM7GxpYx8QqDxjTJPWWjEBSwgFGUWR41pSqkiGBBKW0EoNDA729/fVNqSSqWQqmQYQBDIMQqJiBJJMgQaBIIkI0ESkmTLXtdF8xS7dUqMuFBERVFHYESSPzLhuSf&#x2B;VL4u3LA3zFpN9IYUmcgiACc4Y0xQprcEDIlLIak3EC5wzbinOeL7fsmzbFpqImFZCiCq3MZlMtg6/WkAITAUAGkUEWwHAgQO7TbXLJZdcYsKhMTExMTExbzux7IuJiYmJiYk553kbZZ8hDMPjx4/v2bNHSlku7njyySc7Ojrmz58/bdo0czNj96IoAmDGSF3XjaLIts&#x2B;aqf&#x2B;27DP9oJYs3p/y3oHDh48cOZw/nGlrazt87LBUsmVmy&#x2B;WXX37egvOTlZVIMADESGmlOBMQBPihX&#x2B;kkABTy&#x2B;VRFRRSFtu0Egb979&#x2B;5Ro0Y&#x2B;&#x2B;tijjPNVH17FwLzA8zyvrqau49TeLVu2PPPMM7Zt33jjjaNHj777h3fv2rVr5cqVH7rpQ/f&#x2B;5N4ffP8HzcObv/aPXxveNNyX/k/v/fW2bdvGjRv3gQ98oLm5XkoQKSHEwGD/xz/&#x2B;8Ww209zcfOTIkUQisWz50j963/tGjhydSCTCMMxkMkYyRlHEGLMsSylFRK9quiiH7AYGBoQQlZWV5mMvq1WlVHlod2BgoLKy0sT9wjBkjCUSifIyO/Nzs5WPMXb69Om2trZ/&#x2B;7d/O3LkyGc&#x2B;85kbbriht7e3rq6OMXbfffdt2LAhnU5fcMEFSqlNmzYdP378mWee&#x2B;fKXv3zTTTfZtv3jH/94/fr1e/bsqaurq66uvuqqq&#x2B;bOnTtz5kzT8vGKYOAQt6cBpZVUSmutpXQcVwVhMplk4NAajCMIDn3/hSeffLJtz37HdUeOG3XJJZdMunqBXV/f3&#x2B;gxxgbYgIKCPpPP5ay&#x2B;Hj/wa0ZMLg0gC8GF4FxwiwEyUkTEiBGVYnbEAJIsFJwTtFIKTAshiGmlpB/6nDMNTUSMM1NdUigUFPJCCNtyLNsW3GaMMwgwRJHx0JoIgDTFGgTSeKtknwZIkyLSWpcmiIGIRVprInDGhG0JIYgpIu2HGQDE80TFS7AQgE0NYAw6iKJIBr7W2qFKy7JG1s6rrq5urrioyq4SGA2AApBGIkHZbPaFF15oaGhwXXfWrFm/298dMTExMTExvwdi2RcTExMTExNzzvO2yz4AWut8Pr9v374TJ06UI35RFLW1tXV3d7/73e/mnJupXpMdsywrDMPSnO/ZZN9r5zdfhVAcQEEAgPF&#x2B;KQBAOgS0xqAHBtRUQMrdJw/v37ffb8&#x2B;k0&#x2B;nahpqmpsbho5trmhvBNYBcfrCiogJcBGGgOXcs21TzRplMMpWCEAM9PTUNDdmBgW3btn3zm9&#x2B;cPn36hPHjZ8&#x2B;evXnL5oH&#x2B;gQ&#x2B;tWtXc3Lx69R1bth257j3vuWblytmzp/z933/7xRdfvOaaa5YvW/aZz362paXl5ptvPm/m2E9/&#x2B;ottbW0LFiz43OdWg&#x2B;Pv/&#x2B;Fru3fvfs&#x2B;1165YsaIinSy/tfb29nHjxgE4c&#x2B;ZMU1MTQJlMpqqqunyD8j5EswDRaDjzq0KhwDlPJBLlRpQy3d3djY2N5u6JRML8thypM8r1VR9yX1&#x2B;f67of/OAH&#x2B;/r6vvvd744fPz6RSJgE3759&#x2B;x588MHHH398/Pjxq1evXrBgwQsvvPDjH/&#x2B;YMfZnf/Zn&#x2B;/fv//73v&#x2B;84zh133LFhw4b169crpe66667m5ubDhw/39/crpX7&#x2B;8593dnZ&#x2B;4AMfWLRoUV1dXRRFxhED8H0/AQHOIAQYM5Z3aLKveKYYvxtEJw4e3PvXa9qPtR8aPNHU1DT1hiUrVlxJcxrDMDrpZAkakAJWEziAyryMoqgt6iz3bAguOOOmH4Ozsl8ueUdiYIhUYAkBpqWUGpEQggmttQ4i37Ztxs2kM4ExIpJSScqFYRhFinPu2AkhLK1JSim4IJCp5gBTICKmUSrUAJmlgJI0UbGcWg7N65V0HiRTb5TsA84OApvGXiJyKnNKKRmZshCYjYBaade1zLMQaaUDs29Qaw3LAsCZZIwJRpxzi1Kc8d4O3tjUNGHYpSOGjajEbAAMKamR5kWJv3fv3vb29nQ6PW3aNHO&#x2B;xcTExMTEvF3Esi8mJiYmJibmnOedIPsMURR1dnbu3r27UCgkk8nW1taKiooXX3yxt7d3wYIF6XS6qqrKxLiIaIireitkn6cgBCIAAFfgXLoMgOWbnwASKKrFSEaRVeGg1AeiwbL5rOMmHcuxiLL9/X4Q2LYthKisqek4fvy&#x2B;&#x2B;&#x2B;7bsmWL7/tLly6dP3/&#x2B;0aNHn3zyiTlz5nz4wzev&#x2B;9WWp59&#x2B;uqqyavWfrh4zumnf/ravfPnL9fUNN99yc1tb2ze&#x2B;/o2PfvQjH1q1atvWrd/5zncymcz8hTNHjx69cOGCyVOmWEJwzh3X0oq4KCqmsgMtTRCzbDabTCZNKNIsvDPNuUM7MYZWZEgpc7lcdXX10NV4xsgQkRnLZYx5nmcUWy6X45ynUikA2WzWcRzXdc3LeOCBB/7jP/5jw4YNK1asSCQS2Ww2k8ncdNNNnPMHHniAiG677baFCxf29vbefvvtiURi4cKF06ZNGzlyZBRFc&#x2B;bM6e/v37Bhwy9&#x2B;8YszZ86sXr36wgsvtG17YGBg3LhxSqmqqqqhXrL4FozIYyApJSPGGBOCMxYGgW3bCCJu2cWsZza/4fnn935xTRiEp/XA&#x2B;PHjF37s3dMvujBolvlC4UyFz8EBKSHTuZAxNCnbdZxTfMCce1oppbRWymTqHNthKDbu8lLvLgOCyLMsi3GKokhRKDhnliZCKANLCGKIokgpzTgDmFY6WcmDIAj8SJMW3AaYlDqKItdxirIPKNlKDUCzt0b2aZKmCAcl5WdkX8Q6CSAyDTG8tO&#x2B;PeV6OMca44pwzfva&#x2B;kZGCOmSMCU4MjCJbKVXjTqqsrGxKL6ytrq3ALAHBkAJQ6Ourq6srH8SNGzd2dHRMnz59&#x2B;vTpr/f1jYmJiYmJ&#x2B;UMQy76YmJiYmJiYc553juwDoLX2PO/QoUNHjhwxEb8ZM2bs3Llz7969I0aMOP/884mopqYmn8&#x2B;b3W1EJGwL5SndVyg&#x2B;whDlZ1oOemChOMWLSvO7AACQ8yAEEhY4ly4AZIAIUb20LQGlCaCSWSq6xXwuR4znsrnm5hHmJ/39gz/72UPf//73P/axj6XT6c2bN//iF7/4&#x2B;j9&#x2B;femypY7lFDzvU5/61PRp0&#x2B;bOnTdm9Oiv/u3fTpgwYdXNH66prf3bv/3bnu7uCy&#x2B;88ON/fBuA733v&#x2B;08//fQll1xy880379u7N1WRmjp1sueFyaQDaD/wLWENGb9lWivOrcHBQdu2jXQrD9u&#x2B;qvvCzNWaXKQQwjgrU6YBIAxDz/Oqq4thwFwuF0VRbW1tJpMx87m2bZd38J06derRRx9ds2bNRRdddPnll1dWVm7atOnRRx9ta2uzLKuxsXH69OnXXXfdnDlzvvSlLz355JOLFy/&#x2B;u7/7u66urs9//vPHjh17//vfr7W&#x2B;9957m5ubv/CFL5iC4Llz5z7zzDMnT56srKxctWrV&#x2B;eefn0qlylbRLHBEyTxiiNk8O1wcEsqTtAKMcRgNao61JDCGUIGL8OSpX/ziF13/8jLnvKMmM/O8887/k4unTZ92qrKHMybhW7DTcDTI0iKKIhE5jDFUFOtWlDa77JRZO6ipZJzLHzYrmmDLssCUlFIh4IxpFmmluMU450qTUpIghOBaQ0oZynxpBJgxZtpLAIJUIQBAEQhMlvJ90LAJJdlHksjIPiJEKG33e6Xs02&#x2B;4sw&#x2B;ln5MiIk0KBC4A8/a02VGoOQkACTuttdIhl1JqKUhrkABYyq3iXCSdxurq6vqqyVVVlS4bzsGVAmMQZ89EMEYMTAC&#x2B;b4Q6zMHt6Ojo6OgIgmDUqFHjx49/3b8lYmJiYmJifq/Esi8mJiYmJibmnOcdJfsMSqne3t49e/b09fUZ5TdhwoQ9e/acPHly9uzZI0eOVEqVvQ&#x2B;3BP7nsk8BUoIp2HaQoMAPckmeQCIdasfmRCh4Bde1wihUUVhZVfXwww/d9Z93BZG86MKLzjvv/CeeeMK23Fnnz7rmmqv279/f0dHR1dXV3t6eyWR6unsty/r7v/v7KVMnn&#x2B;k888ILG/7mb/6/m2&#x2B;&#x2B;ub6ufv&#x2B;BA9u2v3jppZfe8pGPkNZPP/30ggULGhoba6orweB7YSLp9o33&#x2B;AAAIABJREFUKEnCYvm8zxhLpVxASyVlJM3b932fMea6iULBM5rPfHom8tbf319bWwsgDEPf940e1Vonk8mh47pRFJkKiHJYsr&#x2B;/v5yb6&#x2B;/v/9znPrdr167ly5d/5Stf8TzP3DeZTH7nO9956qmn9u3bV1dXt2rVqquvvjqdThNRVVXVnXfeuXHjxu3bt3/84x9/3/vet3fv3q9&#x2B;9av9/f2XXXZZTU3N1q1bm5ubP//5zzPG1q5dK4T44z/&#x2B;YzMRnMlkOOfpdNq8OyGE2c8YRZHruuVeDsaY4zhaayP&#x2B;zP5Bx3HgSwiruKaxtKyRiBiYjiLmR1qT3zeolOo8fvKnP/1p9boCEfUOjxYsWDDjtsVjWyacSfXYcHxkAwTMV5yzKlQLweGLMAxzIsuYqV/mTDDOzBQvIyICkSZNWpM2/bdExADBBUEqrcAiAKHygiDo7umyLAucg8CFZQlLE6SUybRlCcuybICZrlyzIVDKCKBSNUdJ4YEIzlsi&#x2B;8CJtNYkldJEUmtTKw1N0vRba6210kQkyGKcR76yhJVwKtMVFdWVDdXV1VVujYuEXfpuAWBoAMBQN&#x2B;TrefbSwM12QK0ty/J937btnp6eYcOGrV&#x2B;/3njexYsX/8by5ZiYmJiYmLeWWPbFxMTExMTEnPO8A2UfAK217/umuAPAmDFjpk2bls1m161bN3ny5MmTJzPGTONEKVJFAPhrZN8rdB8gIVAu4jDTkDYALLl&#x2B;xYSWlkvffcWVl65ogAXAKihYwnf4y3te/ulP/uvggQOjRwxPpZLZ/n6Affsb33r22Wc2vrD52PHjqz/xydb5rceOnvjWt7914MSRVR9e5djOnXfeufKalddee&#x2B;2x9mNr1q6978f33n777deuvHbq1GmJhNjx0p7Tp09dcMF8x1Y1NTUFryC4cF1XE8kochxHShlFUTKZHBgYqKmpAWCuKB0ILgAQSCsCA&#x2B;cWM0OWAFDsLC6P1prR3aHr&#x2B;VAKxA0t6CiPRb9qB9/g4ODmzZu3b9/&#x2B;0ksvrV&#x2B;/fvbs2atXr16xYsXQxzl69Oh3vvOdJ5544qqrrvr0pz99&#x2B;PDhr3zlK&#x2B;PGjbv00kv7&#x2B;vruu&#x2B;8&#x2B;27b/&#x2B;Z//eeLEiffccw&#x2B;ACy&#x2B;8sL6&#x2B;3vf9hoaGcgHrqVOnRowY0dnZ2dzcbB6Zc14uBjEBOpMrDIIgnU4P6WIuHV0iIuLSGD5NQZANvEKhkPcKYRRFXuD7XkLzRDKhMgXXdf2BzJo1a1PP2b7vnxldWLRo4YzbZk&#x2B;ePLkX7bkol1C5IAhYVimtFKsGkCU3krI&#x2B;lTaTulxwLorKjzHGLW70GRF0UaURQAhNvC8EEROKQAVvMJfLEVOpVEUimWKMERljaBGRH&#x2B;bMw2siJZUpR2aMcQEiIkREWlNoxnWJCCxVkn369WUfiEiaIwxAFv/35XUKOoi00pK0BiPOOeeMc54902jbdsJ1XddN2G4ikahwKx3HaU6MBcCRJoAjDTAODkAYA6nZWbFHgCkwZmBMgnOIoV&#x2B;/CgwpjSmHNwG0tbUVCoXdu3e3tra2tLS86d8WMTExMTExbyWx7IuJiYmJiYk553lnyr4yAwMDe/bs6ezsLE/1btu2rbOzc/To0S0tLel0&#x2B;i2RfRmOex&#x2B;89/6fPzxp0qQ/ueED58&#x2B;cZYWA5/vVqZOdJ19Y/1yhUJg4buzp06ceXbNm9&#x2B;7dE8aM/5NPfOLiJUv/9V//Zc/u/U1Nwz76kVtHjRr1pa9/dTAz&#x2B;P6b3j9//vxfrv3ltm3bZCQnTZ78rkvfNWrUqKRrMwavIJMpiwFaQ3AdhIHruBgyphpFkbAsXqq/KBQKtm3bti2VtEyDsNZhGCYTJkXFpZKcCaWVVjCqzoT1zKAuALOPL5/Pu65r3F&#x2B;hUNi4cWNXV9esWbNMBWp/f38mk7n//vsPHTrU3Nw8d&#x2B;7clStXHjt27Atf&#x2B;ILv&#x2B;//n//yf2bNn//Vf//X69evnzJlz5513&#x2B;r6fSqUKhYJJFK5bt&#x2B;6HP/zh7t27m5qaJk6cOHXq1FwuN3369Hnz5lVVVSWTyXKcsBwqJKKysyunt8xsrOM42Wy23AWMUlwxiqJigg/A2WCj6/t&#x2B;X1&#x2B;flDI806&#x2B;k8mQYRVEIzTlnQnDB04lUNptNEE&#x2B;lUnIwl0ql4EePP/64fMTPZjKnR2RaW1un3Tpr5oyZJ9W&#x2B;tvZ2FLrr6urG1oxMV6YjqoyiKM9TjLEk4yBo0kRamelWaCKSWgJgHIxxJorb&#x2B;8AYixiRVjpkDMLWmiiT6xscHAwjv6amprK6moEFodSahLAF56HyTBEuAcXFfwwAMyJPU0haawq11hoREdhbJPukjswAL2PMsrht245jW5Y1tna5ALdQDM9ycAcJABo2A7NQxcA5KmGmpgF76LdtaDdK8VIBMAnHsuwzR7a8NbIsdk2NTHt7&#x2B;5EjRwYHB2&#x2B;44Ybf/i&#x2B;NmJiYmJiY/wmx7IuJiYmJiYk553mHyz4AYRieOnVq9&#x2B;7dQRAkk8mLL744nU6vWbOmtra2trZ2xowZxogYsaWUMsOevxNGLeVyuS996Ut9fX1XXHHFDTfcIIQoC7itW7c&#x2B;8MADg4OD11133ZVXXnnXXXfdf//948aNu/3226uqqv7zP//zkUcemTZt2gUXXLB06dLW1laTRwuCwLKsspwqGw3TdOE4jrGO2ZxXmU7m8n4qlRAMUsPiUIoswQAEYSiEsIRQWnEuCl6QTBbDd7m8V1FRLORVRAQYO2TUiiSSjAlAEjiDCcJJRY5gWuGLX/ziI2vXep4/onn4Bz/4gdZ583bs2PGju/9t9R13TJs27acPPHDfvffecsstc&#x2B;fNW79&#x2B;/b//&#x2B;79/9atfvfHGG5966qlvfuubURj92Sf/7JaPfDRCgFJ&#x2B;i4MB4JoBYMwGAM0BQDMAkBpa6woPpaLc0iuyAEAL4DV6NiIIdlYbmcuspwuFM91nwijMB4UgCHwlCQSLcc4tcouarThfa5QblFSWZVmWpaTinKdSyf7&#x2B;/gMHDtj3Hj906NDgRDZ27JiJH5mzYMGCl/tf1EoNq3GbGpuqkPB9nyHNOfe0DSDiJiBJBKC4p08TIGUAgKBBoGLYlEAkRcr8pKjhijIO&#x2B;cJgLpcHonRlpW1zKSMuWCpVkQtyZvrcKDwCjBSzLE5EmqRWWpNJ/BEBLPJQbM1gIA6ANCNAKwYiTYw0aQ2tNRGIiEc255xzi3POYBMRKUFEI0aMtW0nmahM2AkL5uziGjqB9O/6VXpLyOVyZpQbwJkzZ5RSv/zlL1esWDFq1Ki35fXExMTExPz/ilj2xcTExMTExJzzvPNlHwCtdT6fP3DgwLFjx0zEr6Wl5eDBg&#x2B;3t7Y7jzJ07t6mpCaX8V3lXXRkzplqeWn1dMplMVVUVgCeeeOLb3/72pEmTbrvttunTpw8ODnqeNzg4uH///j179nR0dPT392ez2dbW1ssvv3zYsGFNTU1CiLVr1z7&#x2B;&#x2B;ONTpky56qqrZsyYMfSRwzAMwzCdTkdR5Pt&#x2B;Op02djKKIlbykgUvTCUdAIWCn0wmZCQdx2KAH4QJ1wHM0kDXC6JUMgGg4PnmCgFBGAnLsjjLeV5Fsuj&#x2B;Mvl8VUVFBHiRPHL4yCOPPPKrdY9FkayqSHf3dF/xrsv&#x2B;6H1/NHb06LvvvvtnDz00f/782269ddKkSd/6&#x2B;v996OGHk8nk6tWra2tqlNa1tbVTpkyRUj7//PO/euKJXDa7cNHCy951WXNzcz6fbxhp9rIxAjEwBggj70JFREwVh4vBBbgFBm1nATBwAoG41trIJsdOQWsdKk1kMQEhjLDMnT6TL&#x2B;Sz/YPZbDYs&#x2B;FEU6lAqpWpqazTpiBSRlhyccbLAGHNYsqg7TSsuL8o&#x2B;8woFF0TEGUsmk17BO3HyhPtfJ7dv3941yq&#x2B;oqGi4bvxNN93Um&#x2B;o8depUY5Vd39BQjaSUEaM0kc4rWwhBtkNUyvaRMhE/EAmLA2TEX0nSEYCIJV5X9gmLfD/QZGpSQs/3tZaWZdkp44UJhFL3rgYQhD6INBmjq4nIRCEts5VPk9ZaKWitSTMCcWYDjMGoSWHigQCrEJWWbSXcVDKZTCTSDhwLCQAhiIMLJBgYivfiAJxiW/Xbg9niZ77RQRAcP348DMOpU6ea&#x2B;f2YmJiYmJjfE7Hsi4mJiYmJiTnnOSdkn0FK2dPTs2vXrkwmk0wmW1tbGxsbN2/enMlkRowYMX369CAIpJSVlZWvaqHFkLV0r/vInuc5jmMGRc3Oux/96Eff/va3GxsbwzAcPXr0kiVLFi5cOHXq1JqaGiklY8z02JqleIwxIxNNDwZK04gmbDh0C54hm806juO6LghRKAEEQZCurBgcGKyuKZbhKilN0bCSUliWlopbAhpBoeCaLg6lgjB0U0loHQSBm0wCGOzvf3798w888OCmTZtGjRrZXFnV2npB6wWtjY2NDQ2NDaNG5fv7X9y27Z//9Tue5y1ctOj2j9&#x2B;eLxT&#x2B;8i//cseOHddff/3iy5dXVVd5Be/AgQNbNm8ZOWrkksWLp0&#x2B;fMX7cOMYgWHFdYD6fF0IkE8m8Di1uiWJSr3iMpJTpRAIAe1VSD0DwyoKGs4cHKKC/v6&#x2B;/vy8z2J/L5TzPi6Io6VRqIqZDABZCzrnNNWMsDELOORdJS1gQKc44MQeAsnNgxSlazkq2D8y2bbMHUHBOBNd1zFFgv&#x2B;5b9/jj/apba904u/6jH/tY3dzGTCazo3tfXX29U5NOJpNVTg2BeMRs2w5kZIJ3pQ195fydLsXxqJj7M8k&#x2B;VgwBlooyUKrLUGDMxDGViqRSVMwJ2mdvX6r5AKiiooKIlFZal88rIkJUCEAwgU7OLSG44A7j3CsEQgjXSSYSiWSyIpFIuCwhIISZWi8eg6IKJBAr/lwARMWjyQFmv/7R&#x2B;kNQTr&#x2B;aPxpRfvDgwdOnT48bN27mzJlv1wuLiYmJiflfTyz7YmJiYmJiYs55ziHZh1JxR1tb2/79&#x2B;wFMnTp17NixBw8ePHXqFGNs&#x2B;fLlyWTSCDsAr1V&#x2B;b4JReK9N/5U7K16lC4cW2vq&#x2B;r5Qymm/o84ZhKKVMpVLG2iiljL8wTxEEgS0cLl7xCn0viKKwsqoSwODAQCKRcJOJKAgZY5ZjSy&#x2B;wXBeACkNhW77nP/vss//1X/f19vU1NjauXr16YGDg4Ycffnnnzi9/&#x2B;cvLL7007Ot77LHH7r77h5ZlXXTJxT3dPcdPnpx9/vmLL7xo69atDz70kLDEpz/96auuuWagv7&#x2B;9vT1yRWNTU21NTSqZimSkpGIMSbc0KaykJSwAQRgILizLMtvXJEmtlQC3hW0KMgq5gmVZru1wPkT2adN6jCCr&#x2B;/v7&#x2B;/r6Bvr7c7lsGISZzABjTAgIYVmC8dLdOLmWbSVsZlmWhYA0MYoAkCLOOeMJIQSxJBjTZBNIO7mS6ysKPw4GxhKuWygULGE5jq2U4pw7tqO0Gn7QWffYuv2n92SzWTaKli5bNm3FzPEzZ&#x2B;RZ1pfeyf7ubC6bsioSiURNoqausi4T5GDUmskxMsYYASwIvNI7LA/zEgD1BrIvjHzbcTgnKSWRtixLCEZEUnFzmmlNxusZ5aeU2b6nixXTJqrH4HKHMcaZEJZwbNdxXMdJWMyykTDJP1YamjaCj0EM&#x2B;UlR7RHAYRNIgxNpkGCccQgG/nbJviAIHMcxX6KhTTIAjh8/3tfX19XV1dTUNGfOnLfl5cXExMTE/O8mln0xMTExMTEx5zznluwzaK0HBwd37drV3d1tpnrHjx9/6NChI0eONDU1XXjhhUMNnfkPNrMs780xdRAmOeX7vta6qqqqrA6Hll2Uby&#x2B;EGOoTze4/AJ7nJRKJ8jJBzrnprjU3MzZQSmlx0X3qVOOIEVAqDAInlZJhYLnuQG9fTX195Ae264Cx4&#x2B;3tBa/g&#x2B;8Hs2ecBQBT5np&#x2B;oqkQYfv3rX//e9/7z85/73IoVK5pGj0IYgbO//PO/2LJly4yZM/7x/35pcHDwB3ffvXXbtuXvumzK5Mn7Dh7u7DzNLGf58uXz5s&#x2B;vSKdtxzXKSpPOBSqVsAFEkhyLAUUtlM/4tm27jmBleUcgBRYAohQRM0SA1EgWPyWd9Yteb2DA87xch08EggQBTIIxJhQDEw5xxpjQjDFiqlQfAZGqJiJEXCnFIsEYc5ESlnCYg7MZQQIARgyQlUFxiHeI8QNjruN4nmfbjuu6YRSSJsdxGENlIX3s2LG2Tdv27NljBfn6&#x2B;vqJF5/37vfeMDgcyWTyTCoEmIDOhFmvszsMw&#x2B;ZhDaZN5Ow6QAYGaFLmIzmb7CMCwLgsuT5Q8V9EgOCcc262OiqlhCU4Y5oIMll8FCo&#x2B;nLGGSmrGmeBCCGFZtm3bQlic85pkffHGgJGlbMgQrrk0R9akBC2yOGOcc8Ze8XUoPcKrvxG/&#x2B;Tvz&#x2B;0QpxRgrf&#x2B;PMt0YpFYbh8ePHd&#x2B;zYMXny5GHDho0YMeJtfZkxMTExMf/biGVfTExMTExMzDnPuSj7DEEQnDhxYteuXVprU9zR29t74sSJXC43fvz4sWPHuq5b1m2s1Gz6RkgpzUK9N7nB0NBfFEVhGJo0Xz6f55wzxkybh3ltZrzX5MjKA8IAzAxysUUkCPv7&#x2B;z/753/&#x2B;s4cf/vo3vrFgwYKZ58/a&#x2B;MILBe//sXefUXJe553g/ze8qXJV526gARCRBAmCWUORClQYJduy5aBgWZac5PVofY69c45H9syetX32zEizGsm2bPnMruWxNZK9eyxRshVoJWYFijAJNNBEaqJz7q5cb7r37ofbXWgCJE1RpECAz&#x2B;9DsVD1VtVb3QWy&#x2B;88nRPfff//9D9xvB/xt37790PXX33fffd&#x2B;9/973vOfd73znu&#x2B;bn5z7&#x2B;8U94nvuKV/ybfD7/J5/4xP79&#x2B;&#x2B;&#x2B;666477rij1WqlKg2CzEB//z994f8Lw7BvYOD666/ff/U1QakExk0cM883acqkA8biOImiyPFcKaXhAkCSGsaYI5CmiDohYyhkN96XStHthE4i5TBxvvYrQmO9ura&#x2B;1mq2Tp85pZRKkzhJUqVttAcG5kd5AIxpxhiXRgjBpeacg6cADEuMNoYpzrl0hBSyERkwJo0jhPB51nEcn2W44CpUNjiDAZjhfCPeizMtdCv7eHdkH6R04jh2Pdd1nCiKASMdR2tdaOdKpfLUI0e&#x2B;fe&#x2B;3a7NT9Xrd3Vl47V13Hfrlf1sqFhczUSfqCAlHyJyBw9x6e&#x2B;2iNl5jAClFdwFtN6wDwJ8h7EviOFVpmqZGG9t3bB/m8uLGifNNjIOxSrGHAQBjYByCb6ZwfGOZxtaVtxxAmMS2sZdzLiDtwD4A4qnxnQFssaC4ONUzMObpbv9xsZn71jA9SZIkSTKZjF2b02w2T5w40Wg0enp6Dh8&#x2B;fMlOlBBCyBWHwj5CCCGEXPYu37APgNa62Ww&#x2B;8cQT09PTtsRvcHCw3W6fPXv2qquuUkrt2rXruTxPtVotlUr2CZeXlwcGBrTWcRzborxuhGdtndMXhuHWAzqdDgAhRLeIzwYTNig8ffr0pz71qePHj7/qVa8qFApf&#x2B;cpXGo31D7z//e//wAe&#x2B;8c1v/qf/9J&#x2B;azebdd3/xEx//&#x2B;Pe&#x2B;9/09e/b8/n/834eGBn/v937ve9/73gc&#x2B;8Cu/&#x2B;N5ffOKJY7//&#x2B;x9eW137wz/6w5tvvqWQzzMgCDKcsVq9dvSxx7XR62vr1157bblc7untDQEFLSAA1NuNTJBxmRelkWDSEYIBqYLg4JuBXboSeUUPBqZjmGPnttkvNKABuzxYAgaodarr6&#x2B;HEfL1eX1peWl1dbbabDHB8x3Vd13eUUolOtFLgRkopHSmETP1Uby6aMFxxxiANZzxKIyEEl5xxzjgXQkjHlVLmrlqK4yhqukkco1NRSrNOPlVpOdMDQCJkjAnR5Ixx0WGMRfH&#x2B;7sw&#x2B;u6LDhn1cCKWV4ziMsThJHMeRUkZRJLlf6amkk2unT59eHzt3Yny83W739/ff9PbX3HLLLbkbhsFZy2korTqqqbWWno3s7Dg9vTFVD91u8W4p3kbcJ7pVemYjPrO/PVTXa2EYMSby&#x2B;bzNi7U2nPNyts&#x2B;eOeecQ3JwtqVGD&#x2B;Aa3deEARzYRtuN0YQXptmbv6loDa03zsF283IGLs6X8l1Q2Wc23gP404&#x2B;4fNHFcSyl7K6utjV99u0tLi4ODAx0Oh3bsH/kyBGt9eLi4tvf/vZLc66EEEKuOBT2EUIIIeSyd1mHfVaapnNzc8ePH2&#x2B;323ZxRz6f/&#x2B;d//udyuXzzzTcHQWAr&#x2B;/7VTt5ms9mt7NvadQtAa23niG1d8dFtFm40GplMRmtt6/U6nc7c3FwmkxkcHLSZIOe80&#x2B;nMz89/9rOf/eQnPwngF37hF26//fblpbkPf/jDP/2Od/zKr/zK6Ojopz/96c9&#x2B;9nM/&#x2B;453XH/4hr/5H/8jitNf&#x2B;qVfeu973/v5L3z&#x2B;d37nd157110/&#x2B;7M/ddddd330ox/9x3/8x9/84Ac/8P4PtNutbCbbareymSyAdrudyWQA6DTlUob2PFUshHDgAojTxJOeAThgDJSCKwGgXo8KBU8kQAw4gALE5vWWqq2uVavV5cWl5eXl9ZXVer0WxwkDhhFgs6GVCcYZAzdgTJkUDOB2c4TZGJ7HWOorY6ChADChhRDMAee8WC7m87lyT6VcruQKBZ7JwFY&#x2B;iuNt1Zg6szY/Px&#x2B;uB8YYT/UyxhAxxpnD7M6NBhgYaxtjUn1ws8eWwX7HGQAmhNBG2x7tJE0zQeC4bqvdzmVKnU67L/ZyudzK0Yl7v/3t6dnZNEkWnNY73vGO63/mlZVKpZMNhRCpiMCgTLjxvbetuti40EqZ7h3n7zHM6KcN&#x2B;zqdqN1uu443MDBY8IoAUigBzmE/chuJHABsBK7duXuMbanj47gwjTObr7IR3LHuBYDzqe7m0eeP2QgpL2jmvWT7OYCLCnK7ozC7H3IriqLHHntsamrqxhtv3L1796U5V0IIIVcQCvsIIYQQctm7AsI&#x2B;AFrrTqdjx/bZEr9t27YtLCysra3t3bs3m80GQYDNVtxuWLB1D8APq1arFYtFAJOTk48&#x2B;&#x2B;uja2tqdd965c&#x2B;fOv/3bv73nnntyudzhw4e/&#x2B;MUvXn311W9605ve&#x2B;ta3cs5t6rewsPCxj33sgQceOHz48Cf&#x2B;4k&#x2B;mF2b&#x2B;8P/4wx/84Ac//3M//&#x2B;//t39//30PfOITnzhz&#x2B;uwn/uRPvn7P1x/5/vf7&#x2B;wY&#x2B;8z8/s75e5ZzXonqpXCpmCwwcMPa8FZSA3agAPLWls5XAcZjtPZZm42hooAP4gNq8BYABQsAHap3a/Pzc3NzSwuLKykptvdrpdIxSnIvA84IgEJwrpWAgBFciUkppo/v7&#x2B;5dWlwLfT3TieV5iEmMQqyhNU9d3M5kMGKIoYgWZy&#x2B;XKPeWeSk&#x2B;xUiwWiplCHq63MfbPuOcvIQB0xJyEANRydXn6yXMLCwtpO&#x2B;acO9qTUroqo7VyVEZKKbSXqtSolDHGhe1/5Ywx&#x2B;zUSjmSMg8HYzMiutJDCGO16LkulSlVB59ut1tkHHnv44e/ES8v5fH7PjVe94fWv733D1cjlWnKt1Wo5BamNNtrYDRla6yRJ0jT1PB/YGIyHjZZlxhjT4cb4Pq01wB3HDYKs73kC59/j1u&#x2B;YhN7yEdta07f5PbrA1k/uj/57CdNbnsheymc8&#x2B;KUkSZJqtTo&#x2B;Pr68vPzWt771glJcQggh5IdCYR8hhBBCLntXRthnKaVWV1ePHz&#x2B;&#x2B;trZmI7&#x2B;ZmZmBgYFsNlssFovFoud5tq82juNardbX1xeGoeM4W&#x2B;v1nqO77777oYce6nQ6/f39AE6ePDk7O/u5z31uYmLir/7qrx599NE//dM/ve222770pS/99m//9lve8pb3ve99d9xxh837ANx3332f/vSnv/7wNz/5Z3/2lje&#x2B;9Utf&#x2B;dKH/8Pv9/X1fui3/td3/PQ7Hnzoodtuu63VbOVzeaW077nNVsdxHO0auZm/bA31AM02y7YMtFLKJk/SDQDoFFGciBRSSl8y8I2ATy1FCwsLawsra2tr1dX1ZqMxM3mKMUghPc/zPY9zbpRK07SQK3Q6bQ6WyWRUmjYbTc55oZBvxtVsNtNstcAQZHytdTtql8rlaqNaKhWHRob6&#x2B;vsczxFCVHoquYEBZAAhwDZWapx/BzaQPB/2GRgBg5acFhASHIBGsri4MPPk9NLiomppMObprJTSR44xZhKptfLcbjjFwGHrCcFYolIhhHQcIQUYsxtvjTFcwHEcrlwAPbwspUyn1qenp888cmRiYmKhM7t79&#x2B;79P3XzLbfc4h/sy2VyK50lO5xRKZUkaXcg49raur0ipRRCcGY7iFHJ9TLOGbhtReWcO8zdUqlHYd8Lw4b4YRieOnVqampq27ZtNMWPEELI80ZhHyGEEEIue1dS2IfNftvJycnjx48DGB0d7XQ6i4uLIyMjhw8ftvP1ujtz4ziO4/hZlnI8iziOlVK2YLBarX75y1/&#x2B;i7/4izvuuOPd7373oUOHfvd3f/e&#x2B;&#x2B;&#x2B;5785vf/KEPfYgx9qEPfahYLL7zne987WtfCyAMQyllq9X6wjf&#x2B;KQiCPVft3r17j4pVIVvgQK1er&#x2B;QL7XaUCTxgc17e1nTIQCvAYKMvuXvv1p9M7fUG4GyujljuLE9PzU1Mrq6uLk7NhmFHtSPGmMcFY8zmPLVibIw2BtzWvgnBOQOYrYXkQoRhqJXyfM91XWPMTKUjhRSC&#x2B;0Ewsm2kt7c3W8h5nrfjqp2CiVgnYdgRUmbdLAAD45sCsBFRKZVqrbHRBiztzYzD5l1m850BMMIumJhIkSysPra8vNRYaTWbTVMbllL64SGlFOtsE0Jkssc2BtqBgTPOOROccSYcR2udGs1sT68QXHDGmNYhYyzkjjZaIuu6Tl/HU0qZM3NPPPHE2OOPLC8vd0bkdYeu2/8T/&#x2B;aGwzewkuScq1TV6rXVlbVmq8nAHcfZsWOnEMJ1PcdxJHf45kIMBsnOp3XP0EW&#x2B;5bv2jDWmz/Q7xw9dk9ot47zgqS&#x2B;&#x2B;xfJ&#x2B;2Be4VLpjN&#x2B;fn56empjqdDmPs1a9&#x2B;9aU&#x2B;L0IIIZcfCvsIIYQQctm7wsK&#x2B;rlqtNjY2trBnVPJOAAAgAElEQVSwEATBwMDA6OjoN77xjUOHDh08eBCAzfvsFDA77P95vER3Zh&#x2B;AkydPfvzjH5&#x2B;amvrJn/zJ3/iN3wDQ6XS&#x2B;/OUvf&#x2B;lLX1peXp6cnLzrrrt&#x2B;/dd//brrrmu1WjZejKIo9VgYdXJeHgAHj9PY4ZIx5oDFsXIdYVKoWEufA0CCVAKAYGDd4Mhs7s0QmylNgtXF5dnZmdWV1eqp&#x2B;Ua9sbq8vL6&#x2B;rsLYdZxSkA2CIG600zRxNfODIJAOAwTjjuPM8jUhpRDCaJ2o1GjNuRBSaKUz2YwQIk1T3/cHBwcHBgaCINAHy47rDA4MONJdXF3s7emz&#x2B;VOkI5e7urudFgCgoHxV2jhpBs5Nd0vsRuBkAAOlYGyaCWhb9udqzrnABACBRQDTCzPzc/O16bw22mleEyeJk&#x2B;wMgkCbhxkYOOecMSE45&#x2B;CMMWY4U0qlWoExLoQQdjmFyeVcY0wsPQBpLFSaDoS&#x2B;63lDbdZsNGamTx87euz&#x2B;uX/RWldesefQoUOH7jgcZDLZTFY6kjPuul7gBABSaAYmLqrUM1pwzrrT97TRdoiflFsqSSns&#x2B;5F1J2zaK3Ecj4&#x2B;Pc87jON63b59N9gkhhJDniMI&#x2B;QgghhFz2rtSwD0CSJDMzM2NjY3EcB0Fw9dVXnzt37uzZs&#x2B;9973ttSNdut33f37oE4Dmy3bhJktiNHNYXv/jFj3zkI9ls9o//&#x2B;I9vvfVWu8y3Oz4sTVMhhH2h7rJRDWiYTqMJIJ/NQwMJIDczmRQbLbfdgXq21E0DBhsHhxpJcm7s&#x2B;MryyszU1Pz8fKveUFpLzjkXeQfY3BGrkGqtU5MaYwrlnNZaMw2wVCdJkoBDSln1jZCCMa6U0szksrnewf6eSs/I6HbHcXoH&#x2B;nuHh&#x2B;FIxDEYg&#x2B;NEQgGITOwxN0biwK2164yxXFBoJ22AZZ2MAUuR2izMfUpbaGo23hi0SRhjApKBM9gvqa31WwEArAEmwtk4jRmvCc7Xl6vzc/PVWWG0djo74iRx0oEgCOKmYpxzwYUQtq1ZAYBJtJZSCNdxHJcJrrSKkyRN05SHBkZI3/c9Dkdr7XPP93yWKMdxfNcRUiihPM/L9xa9chky3XL&#x2B;DIAxDAwMAsBmdzCzG3oBOC4HbIq5uVfjufz28K98GLfGc8&#x2B;0c&#x2B;biCM/&#x2B;WT3rC1x4O7toAchLk23jbbVa2Wy21Wp5nielnJmZmZycTJJkcHDwwIEDl/ocCSGEXDYo7COEEELIZe8KDvsAaK1brdbJkycnJyeDIMjn83v37r3//vsrlcrrX/96PHUD73O3dVfv8vKyEKJSqcRxDMBxHFstaGNEOxPQDnrb2jWcpimAMIkzQYYDSinBRBLGqp34xexGJlNNEUgA4EAbCNA8ubC2trY4v7CwsLC0sLi4uFhfr4ZhWCmWAAgwwblg3ABGKa11hmkwMM4458LhQkjuMM75en1VOraIkEtXBEHguJIxpvrzQ0NDV&#x2B;3ZPTIy4uZz4AKcgXMYBc8HA9IUMBurcpVaZ&#x2B;2Mkzlx&#x2B;sTRY8dOnTo1Ozu3uLR06NChd73rPbuvukrCARCa2GUuA4tN7OuMMWAMnIOzFIBBqKGdjZjJrgiWWmujhTFGhTOdsFPvTDYbjWZ8ut1ut8PZOI57Cr3NZtPUy9Jx/PgqpRQPe7kQDnzGYFdz2G5gBWOMMZwxxrSNdDmTUjqu6zgyEaExENLzfd/3sq7r5pyM63r5UgV2Y7Gz2TotDADFI/vzP&#x2B;ecMwEgTXWaJr6f7X427O8HW5fhGq0BMNt0TWHfi2N&#x2B;fn5oaMjmfd0bO53OuXPnWq3W1NTUm970pq07fAkhhJBnQmEfIYQQQi57V3bYZ6VpurS0dPz48Xq9HgTBbbfd9vDDD2ez2VKpdOONN25N7p677qqN7h&#x2B;VUo7jGBsucd5t8m21Wr7vb90BorUOwzAIAqaMUYpp3qzXc&#x2B;UyzGZNX82As3ByYW5udvr05PLK8tknTq&#x2B;trfWLfBzHWmlHOo6UnHNPSM/zkjDqtvYKMM65I6UUcim7YoxJmDLGxFJzxmLPMMayg8VKpZIdLPX29gzuGtm&#x2B;fVT4stVuV7IDAACj0tRwJrm0pxNBSQgFrLer56anTp46&#x2B;fjRo2fPnr2pZ&#x2B;/b3/5Ts7Pz//EP/uC2W1/x8Y9/nHP5a7/2qydOnHzf&#x2B;973i&#x2B;/5peJgDxKAb6RSiZsAYAgBMNQBMNRSpBydGHGnXW/U6/VarV5vdFqdOI792r4wjNptm42WhBDM5ABwLQB4TDlS&#x2B;iJmjDHV1lo7fmCMse3D4FwIwaRgnKXGCMEhuAHAmOd7&#x2B;UIhm80Wd5SFEIHiAAOTcF24DECNMwAxACDQysDkIwHONpboagPOzidpBlpt9u6y8zcCgKthjFEKjDHOwZgt/2Pi6UM68zTh2tbphVsvbYv0D7t2dusCkKeueHk6zxQlvjR1l2uvrq7mcrlui/2pU6eEEKdOndqxY8c111xzaU&#x2B;SEELISx&#x2B;FfYQQQgi57L0cwj5s5mtnz549deoUgOuuu05rffr06b6&#x2B;vmuuuaZQKPywT6iUEkJ0l/nawX&#x2B;1Wq1YLNqmQmwO9bNHaq0BcM6VUoyxjaBQIw1D6frLs/PTp588MT6e1qPTp0&#x2B;ltWhhYSErgnw&#x2B;x2MkSZILsgDykdRaC85d1&#x2B;UGcZIwpaWUknEphMOFMUYnqdKag3HO2wOR73u5SqG/v79vdHBkZKQw0sPzefgGQQBHQWsIo6FOnzt74sSJIw8&#x2B;1tvbu3f/vuuuu2776A4AjbizsrLy/37hH776la9Ozc/u27dP&#x2B;u7U5NTA0ODrX//6gY7/R3/0R&#x2B;9617vvvOPOE8fH/9vH/9ttt77CGNNotNdW16697tBv/S&#x2B;/dfMdrwCg2ynPyMRNNEysamGn0&#x2B;7MVavVavVcs9nqdFaM0VpFaZqqJE3TVKXaaJOpH3A9z3VLDCxOMlprjryUkqVMOtI1qdLaQ0c6jjRRqlIIqbVWRgNMONL3fTfwHdfJ5HPlcqUy0I&#x2B;8DwbojWmBineE4yBm9nsBMLgMaVpzHQAhtIEpQTDAs8mf7TA2BsYAvBuUmRSMX5SbacDR9sNnlwIDgFZpqqTr4OlQ2Pf8bJ2eubq62tPTAyBJEgC20b5arVar1Vqt9thjj/3Mz/wMTfEjhBDyLCjsI4QQQshl72US9lla61qtduzYseXl5SAI9uzZc/z48XK5PDIysnPnTiGEHepvC/SSJPE8G76cj1fOt08as9F&#x2B;qjmiFFxCInYMAJ22GGMelwAQe0g0FIcB2kACrKM9uzw1cXJhfiF6fHx1bW1lZSGOY8/PBIGvkFGp4kGPNjrkDEDihmAsEU2tTV80aGASEcKg4zU5Z&#x2B;2gyRhrZZqc86SgCvlCYVtp&#x2B;&#x2B;jo4I7hSqXSM3g7jClkg1YYFXwPAAfmFubPnBx/5JEfLC/Mg&#x2B;FX3//LcRx/9&#x2B;Hv/M3f/M3bfv69r3zlK4&#x2B;Pjf31X//16LaRD3/4w4evO6iUFpz/P//9v3/mb/56/4EDf/Affm94ZOTPP/lnn/zkJ3/z3/2fe/bsfvTx7zYajff/&#x2B;s8NDw3/w5f/6ujjR9fbE7lcbu/B3ttuu23Xrn4FvbQ&#x2B;Xa1Vy8dHwk6n0zJpmjJVNFonHT&#x2B;OYqS&#x2B;MQZKMMYk54xzDmNguNPinNutw4oZMGaHESoOAMpO5eNgjBkGAJnhSi6X6&#x2B;vr6&#x2B;3tzeVyjuPYistuEkRebpRSAIQQxpi1tTUADz744IEDB/bv33&#x2B;pT40QQshLFIV9hBBCCLnsvazCPiuKoqmpqbGxMa31tm3b4jheWlqSUt55552e59mZX7Y6L0k7gGEMQojN/QraGMOZBAAtkabQDiSDgW4lzWwipeMzA4Ab01hbWzq9vLS0NPXYQrVarU83VldXVb2VpinXsTHmIA&#x2B;UUkrHggvpupyLRLmpUs3YEUIo35VCxl4IIBFNY0yp2cMY017qeb7bx/v7&#x2B;3I7gmKxuOPmnYVCXgwF8D3wGICCAtBQw81G495vf&#x2B;vRI0eiTltwMTLYf&#x2B;edd/7Xj/zn1ZXVt735Tbe/8nZuzL59e5Mo/sSffOLb33nsbW9722/&#x2B;5gfDMPzof/nP4&#x2B;Pj73vPe97zi&#x2B;82qWJCTE2c&#x2B;fM///Ow037Xu9512ytfCWNaTSebheFIU3BX1&#x2B;q1lebZUrFYC8/Nzc3Pr41HUZSg2mm3w6RujNkxfSBJkzRyACNMmTGGOKeUygd9ZrM5l8Hu2GCcs0xeG2NSrdI0jVSijdGCc869fNb3vUypUKn0lPt6KpWKKOYAJCzhnG/tmCYvc92wD0CapisrK4VC4etf/7rrugMDAzfeeOOlPkFCCCEvORT2EUIIIeSy9zIM&#x2B;wBorZvN5vj4&#x2B;MzMTBAE/f39e/fu/drXvnbttdfu27cvSZJMJhNFkdxSEbaxQkJDK80NB4DO5mJcAApYg/rO4sLCwsTpExNnz64uzHU6HaEE4ywXlJTWiYmUUtptOI7rZGPHdc8leQbmJ1prnY005zzHuXSckK8DWM8/CaA&#x2B;eDqfz8vt9Vwulx5YyOVyPYX9lXK5J3NTT09PP25hYBLDBoabjNaGawbGwQHG0ZbQ&#x2B;rv33VcoFka2jfzg0Uf/7C8&#x2B;KYT49d/8jcGhoa/&#x2B;81f7evuKldLnPvd33/r2tz72sY8d3H3zww899OB376tWq16Obdu27Q1vu/Nn3v7TGq0IMUMoIBQ6ABJ0Ogh7zPr4&#x2B;BOtauJ5Xrgi1tfXebOcJInb7q9Wq8lKljH4uheAa3KO68703geAweWcS5YTUkiW4Zw1ai3HdX1PCiGMiZW2m4ZZNYp9z88V8pVyudLfN9DfX&#x2B;7vc3I5SLbxLTH2cuOHcuZuNKWmaWqMse3Sz2PbMrniHTlyZHV1tVQqHThwgLp6CSGEbEVhHyGEEEIuey/PsM9KkmR&#x2B;fv7YsWN2XcbOnTtnZ2cBHDp0yPf9QqGgN0MiDcBowTg3gEF9dnVufn59YmF&#x2B;fmHuxOQTTzxRX1hnjG2PRqSUgcuklK6tAUy5MSaJjOO60ucAQqzFSZywGoBGfifjPKtgjMnFRkpRkI7reQO7CuVy2d/XKZVK1f5TKlVrwRmtdXXbGWNgoorWOjAH&#x2B;vr6dvW/puyUJYY1tEl9KSRs1aH9MTX2AaDTQSYAM48/&#x2B;NB/&#x2B;b8&#x2B;2mw23/jmf/vu97yHCXbkyJHP/v3noih2PfeWW2556&#x2B;t&#x2B;dnTvKDh0GPOsARDrdQYW89ri4oKSbcCcnRpfWJg3ImWM&#x2B;7XZ5eVlEzlpkrSWmOM4RbajXq8VzQ6AFdloLpv1dW8cx6otjDEr278vpZQiAKATJ1UKygGQ8XPaGKMTAwSB7OvtHdk22NvbU7ig15JtjpHrLu/FU4bOKaMAsE0vxmeGXL7s726MsSRJHMd58sknq9Xq5OTkzp07Dx8&#x2B;fKnPjhBCyEsFhX2EEEIIuey9nMM&#x2B;AFrrTqdz&#x2B;vTps2fPBkEwOjrKOX/88cf37dt36NChKBGex5lAqqA0pICt9Lv/8/c/&#x2B;MADZ&#x2B;59PEni3e6A53nZSDDGnDYzxjAVpWnKVMQ4ly6X0mmKtjFmPbOslKoWph3H0T0Nz/PCTDmXy/u74oGBAba7nsvlOpUa52yptsI592IvVSpoCcF5WWR936&#x2B;ZJaN1GubjOEK0LZfNDhRuKZfLO3puFxAO7C5dKA2jAIOEz2VllgEJ0pXlpS/cffeD9z2wtLS4c/uO4eGRm2&#x2B;46dWvftVAzwCATtjWSuvsdxto5lBs6db0iZUkTXKdvpmZmXw0WK1W&#x2B;Xqu0WjEy9zzPBbJ6enpTM9ST0&#x2B;PdNxWq6WMCYLA8QLOeaJNkiRxqrXWGoxz7nqe53nzvGWM0RowxvUy5XKpr7&#x2B;/VCrli0GlUhkYLiOXBQsBgMVQSrMexhljzABKK601DMCYdCW2rK4wxmijjUHwdA28tsTvx/FhIi8xdivOBcmvMcZOcnRdV2t99uzZ2dnZarX6hje8wbbwE0IIeZmjsI8QQgghl72XedhnKaVWV1ePHTtWrVbt4o65ubm1tbXXv/FtnEs/w7EZLTka2oDHWDq79IMv3Pv9739PTdYYWDYScRxnElcI4QnDGBMmNcZopgC0nTAIAjFqBgcHvX1JpVJBT1NKURUZY9DMzXHO1srn0jRdcqbjOHZynud5BV4UnPstHkWx01JK67pZCoIg640IIXV7KE5i094O4Nrdb&#x2B;ypVHqD/QCMQarg2/I&#x2B;1BLELlwNLSAAcLBG2PCkmyRxMSgACKPw3LlzaZy02q0p9g8LCwtxXXPO1LpbrVbNShBHcTEZSpKkl40GQcDqfpqqctCXz&#x2B;fqyVFHynqzCYNST08URWvVmpROtlAEYBhnjHMpHdf1PN91XT2UGxwc2LVrT2nb4PlVrxEQAAB4CgOoBoyBa8C5MSXGN2OaLXldJ4oZY0xwwcXW2yUAwBhjJ7VhM&#x2B;jZ2H1MXn7sh4Ex9rSTHJvNZi6Xi6JofHx8fn5&#x2B;dHT04MGDP/6TJIQQ8pJCYR8hhBBCLnsU9lla6yiKJicnjx8/DqBYLA4PD3//we&#x2B;/&#x2B;lWvLvb35AsFmyQxwBg4bcABWpj&#x2B;3qkHPvPlRx89kgt5pdLTZIlSSsSx0tpTsMsiGGOL8VIQBHyP2rlzV&#x2B;4m1dvb2youpEka9f2LUioyDW2M8lJHSu1mOONRmk&#x2B;TJGwHaZpw47mum/ED13WdiGutU1VP4sToGmPMc4Qj5cp8ODg4uHfkzm2FbT72AEhRSkxs2HqMKIfAwCS63Wy2vMi0Wm293q7X643Zlbm52RzzlldWokY7TRMxd3u5VFqtrsRRPLy9P0nStepCsVSqt1eLhWKiW81m08vIbDYbRp1mswmz2/M87nIhRSySJIlNBpVKpSPDcqnUM9o3MjJS2VYplUqO6wCQtq3YAIkxGkwwWyqZRjHnnDsKQoDFAIAUQIw8wDZXoxhlNIxhjEl2Prgx0Eppo7U2JuvS1l1yIVvKhy0lfvZycXFxYGBAKVWv18vl8pkzZ9bW1k6ePPkTP/ETpVLpEp80IYSQS4fCPkIIIYRc9ijs20pr3Wg0jh07tri4aEv8HnvksZ6hocOHDykpCvmc3QwhY5gQLAE4sIhTX3vw4S9&#x2B;48zZM8j7gHG14ZwHhgNQSmmtZJ9brzdmvScLxWLxFuzbuy&#x2B;zV2WCzKL8lpQSfso5i0SolAqNNMakusQZ46gIIQR8rY1KkjRNM9pjYEx0GBjnLRhwowATiL52u83jkf7&#x2B;/t3Dr&#x2B;7N9qQoNRvN5eRkq9VamJoVQtQX1trt1uqT844ja1NLAHgzTtM0z30ppdBMCJFdfU0nDLO5wHGcWnNVCBHknDAMIZPAD2Ld5IwHOa/dbrU7zXw&#x2B;7zrXcM7L/eVKpZLtze3buzfYU4IGMgAAB9Bay4SBKSgN7YbZ8wV9mxkeFOACAHgKwIZ92kRKKSN7sbmHw8AwgIEB0Juz&#x2B;Tj4Uxp0lbqgjk8ppbV2HOfF&#x2B;sSQlzC7U/vi26Mo8rbs3tFa289Mq9VaWFg4cuTIzTffvGvXrh/fiRJCCHkpobCPEEIIIZc9CvsuFsfx7Ozs0aNH0zSt5HIDg31Hjx0bvXrv6I7Rcu&#x2B;AAJcQAERds4CjDrhoPz7/&#x2B;c9//uHPPNLf319gbrvdzkWu53lu5KZpKjw3TdN2tialXM086bru8PWFgwcPNl71ZBRFTbWglEqDdSmlcmMwMGEL3mSSJiZOYeBK5khnIXC00TLtGGMyKmKM5SMBoNjuMzCF5lVSCL&#x2B;5q9Vs1udEtVYzc0PtdqtRa4Zhh2supfC4yxhz4QCGKw4YrjkYuGGMoRHMcC6YlIyzhAltTMS4ARqp9gPfKRRzuXyhr290&#x2B;&#x2B;jOvXuHh4LWKLCZ2tlaO5usyO44ve6lJSMAm5s1BACw8y3S9sCtP16zi65vvcTFP4nTaD7yo1FKLS4uLi0tzc3N7dq16&#x2B;qrr77UZ0QIIeTHjcI&#x2B;QgghhFz2KOx7WlrrVqt18uTJycnJIAj6yvni8MDjjz2&#x2B;ffeug9de52onVWkWblyLXOFBAi3AQfsrK5/&#x2B;9KdPP3psaGiojxcbjYYTOlI6nTgslkrtbK1ara4EE/l83vQ2jDH97xeVSrk4KFzXqZvZdqcT8TbnIlHgnDssYJwJDRgIKDA2LeA4Tt6D53lZFYdhyFY7nU6neTpqtlp6ptxsNvnqSJIkaJZVmg7iRlv&#x2B;BoApaK25YgBc5kghPOFJIYXhWiuVKKVUWlkx2iTGMMbcfGFwaGjoqt0DA/2jt16PAPABABywA/EYmmX7T4DCPnL561YCzs/Pr6ysTE5O7t27d8eOHb7vX&#x2B;pTI4QQ8uNDYR8hhBBCLnsU9j2LNE2XlpbGxsYajUYQBMOjvcv1ahzHN9x0UzaXy7AsAAm&#x2B;urreWy5DATManfChu7969xfvFkuJ7/mFdiGTyXhRJk5izrTnealTjaIw4mtSytOjte3bR4ducYeHh5sjZ402tfwM5zzVKYBCWBKc97V6wFiu7RttonO5Wq22MtdaXllprzlRGKFd0FpnWa8xRiQuwFwmhBCSC86YG5/lXGjJjTGhMEJIkw88z1vXURzH6yrWWvN8plwul/p78/l87sBVw8Mje/ZcVSg63eBMK2gdSynBNQAwDaOhlTGGIQc8bSaXANg6fW8zyrNhoIANMAHAAWBwPvKzzMbR&#x2B;sKbcNFBW9EiDvIjq9frhUIBwOzs7NjYGOd8586de/fuvdTnRQgh5MeEwj5CCCGEXPYo7Ht2WuswDM&#x2B;ePXvq1CkAA7v7Hcc5Pv7EwWsPHj5ww/LqSjkoZTK&#x2B;6mhjjBMKGCDE&#x2B;iPjd3/q78&#x2B;eOTPIhqIw7PMGq9WqMUmxWFRerdFoaLdeKpW&#x2B;kzmby&#x2B;Uy&#x2B;8KdO3cGh&#x2B;ulYqlemE2SRLqi2WjGM2p1dZVPoVqrYjHtdDrOyqAU0pcV3/d8M6CUVo1sFEUZ9DqOk&#x2B;E5xhgSnSapUcoY0xesGGMio9JUdbiRUqis77puZdf24eGh0WuvHt23DyMlAGBABJTPv3GlYDSkA7DufL3EaM24Aecb4V3qbzy2i8I&#x2B;ctkyxtTr9WKxCGBubm54eBjA&#x2B;Pj4qVOn8vn8rbfemsvlLvU5EkIIedFR2EcIIYSQyx6Ffc&#x2B;F1nptbe3EiRPLy8tBEAyM9K6ursVG79m1e&#x2B;dV&#x2B;wyMgpEQDDUALOlIKXlV/eMXvnDvZ74ZhmG2lsvlcvk00263edTxfU/yKI7j9cBEUeymaT6fHy32ZbNZGbphGK6tdJRSHaY5Z3EuEkJGblNrvW81m6ZpmDpK6ZgXpJRpkBdC1FgIY5pONU3TtrPsSMcpKN/3WVAsFIqDoyN7du8ZPbC7b9t2lDzAJmwIGZRWEdcc3AZwpQ4AQAAMEIAxbbRVmjLPAUyEFEACpaE7CBMkB8IeYKMVF3ZDLpcAwB0AmgNAYr&#x2B;AAAAXCuezQYbzbblbQrqn9PFu7QF&#x2B;LijsIz&#x2B;SOI6llHZfRxiGAGwP78MPP7yysrJ///79&#x2B;/df4lMkhBDyIqOwjxBCCCGXPQr7nrswDKenp8fGxrTWiqXXHb7&#x2B;1KnTlf6Bw9cfdoQbplEgwxhRfiNLE1Bq/XtTd99998l7TzPG8knAOfdMCgOBDoBOxddaiSjWWmcSBsCLfQMDlQFD7DDOecdvG6NbvKaUuqZWdBwHsgCgpYI0TdvcA2NpjmcymWBIDgwO9O/JXrXrqtKeHvT2wt1cOco2i&#x2B;oYEMcm6wAsksBmGGen8JXsSD1lAAOfA0h5AqCBNgdLYQAkUAAUNICR0AUo7CNXuGq1WiqVlpaWHnnkkd7e3kqlQl29hBByBaOwjxBCCCGXPQr7fiha62azOT4&#x2B;PjMzEwTB6PDI5MKicORV&#x2B;/f19/dHUvhceICGzmgOpbDMEbCv/dcvjo2NVU&#x2B;scM6LSrbbbU&#x2B;rfD4fNhwpJfMbBibiK0ZrOFoIwZE1xrA4o5XmqcPAXC6FEPdWJj3f97NuLpct9eV27Nix6&#x2B;odIyMjO6&#x2B;5CpzbjNFwGGMMAwNrMwYg1VDKSBhHcpcBgEmUFGJzzYW2bwypagcAYBd6OBAAWAyVpo50ASAFUiABOMABhvWCPR7YzBKdLZds64IOAwCpAzx1ycZmOLel1XfrD9hMdq&#x2B;aZ73ExuuK5/RdJOQZKKW01owxIQRjDECtVisWi61WSwjh&#x2B;/5Xv/rVcrlcKBSuueaaS32yhBBCXhQU9hFCCCHkskdh3/OQJMnc3NzY2FgYhtL3t2/bPv7kRKlYvOXVd6ZKVxwXgBcnTDpoAwCa6Byrfvt/fuORRx5xG3GhkHdV2mw2AzlgjFHOOmNce1UAKSKltYodAFIVHEeWgp6&#x2B;vr5tA8Plctl95/5KpSIHGCQggBRwAL6ZtHHAGMMBwDAAqBnmsK27b5&#x2B;yMxeJhtYwGpzbaXctGTNsbO/lYDDG1Q4YEANss/zPXhoAFPaRK0oYhr7vK6WUUq7rKqXCMMxmswCMMYyxKIo8zzt16lS1Wl1dXd22bRv9m5MQQq48FPYRQggh5LJHYd/zo7Vut9unT5&#x2B;emJgIgmD37t21Wm1mevzwDTeN7twpuDBw2mEr6xcBMBuQNXDvPd949FvfeeihhwpONp/P9cRBFIaNqJUqhYwolUrBUD6Xyw8f3LFzx86d1&#x2B;8ZGhkxHjMwMVIO7m7EaIS8XCiljDHdOjt7CwDOefeWC44HIMRG7Ku1tjkd31zeorXeer17POfcHmnvStOUc26PjOPYdV1jTBzHnudprdfX18fHxxcWFnp6el772te&#x2B;eG&#x2B;fEELIjx&#x2B;FfYQQQgi57FHY96NQSq2srBw7dqxWqwVBcNWu/sceezxfLN188y19/cMAqtVGuVQ2bW0MhK2ee2L57/7u7ybGTjUajev6dg8NDu65Zt&#x2B;Bq6/Grn7kABcwgB215wKAFkobbRgA5kA&#x2B;87kQcoVI07Sb7hljbAb3tNGePcDmd1sPsI/iT93ObPtzGWPNZlNK6bruxQfYNl7Hcbp3RVFkjGk0GjMzM4VCYXl5WUp5/PjxbDbb09Nz66232tI/QgghVwwK&#x2B;wghhBBy2aOw70ektQ7DcHJy8sSJE7heqOIAACAASURBVAD27t3tuPzIkR/s3L334DXXFvJlAFwjjZRMBRxAAS0DMPiA2Rh&#x2B;B2x2tHJAbUZ&#x2B;trlVMnC22a5Kbarkyre1qg6A1hoAY&#x2B;ziUK/LRn5sk70xDEMppZSy&#x2B;yQXpHvdlwvDkHMuhBBCdDqdxcXFhYWFTCYzPT3ted7q6qrv&#x2B;77vR1GUJImUslKptNvtZrN511139fX1vUhfB0IIIZcEhX2EEEIIuexR2PeC0FrX6/WxsbHFxcUgCPbs2XNu6knHd4YGtu3buy9uxq7rcgB6y&#x2B;S7EJCbIR4DBCDwlNI9x4AxcA1AqTSO4yDI/djfGSGXkq3Rs9efNqq74OBu2&#x2B;/FB3eLBO0T2pF81Wp1eno6l8u5rru2tnbmzJmBgYHV1dV8Pm&#x2B;rC22GGASB53mDg4O2QXhgYODo0aNPPvnk7bffvn379hfhfRNCCLlkqI2CEEIIIYQAAOe8VCrdeuut09PTY2Njx44dy&#x2B;ZzvZWBo2Njs3Nzr7rjNUwAGjrWSbvtZXPwAA&#x2B;Jd/4ZNoqRNLQxrt2Ua7dsGA5AcCfwaWAfeXmxqVw3tuumfnoTNiv&#x2B;hBCO4zDGpJRbR&#x2B;91Oh1b9CeEaLVaU1NTQRBMTk6WSqXZ2Vk7py&#x2B;Xy62trUVRlKZpEARpmu7fv19KKYRwXTeXy&#x2B;Xzedd1hRBKKSmlXd8xNDS0urp6Kb4qhBBCXlwU9hFCCCGEkPNc1921a1d/f//JkycnJyenz03u3bNnZXnlq1/5p6t27&#x2B;4v9PQP93ulHAwQGnibCwc0lDYckJIJDg4WRQnnXHDAAMZwxiGefmAZIVcku1gDW1ZtAOhGeLbf9mkfqJSq1&#x2B;tRFDUajXq97vt&#x2B;tVrt7e39zne&#x2B;09vba7t0kyRpt9tBEIRhmM/nC4VCoVDIZrO5XC6Xy9lkEIDjXBiv245ge2&#x2B;tVms0GhcfQwgh5HJHYR8hhBBCCHkKznk&#x2B;nz98&#x2B;PDw8PCxY8cmTp3Wgt9w4w333HPP6&#x2B;56XT4tQukgCDQUd2RTtYSQLncEBwM0jAGUUY53PkHggDEmTVOtted5z/LShFwZuklft6ZPKZWmqeM4tkvXHiOESNOUMWaHZjLGVlZWhBBTU1MjIyOdTkcpFUWRUuqJJ57IZrO&#x2B;7xeLxSAIfN&#x2B;30V4&#x2B;n7fbeLvLQLAl4&#x2B;tWCNoqwu7GD1viJ4TYutiXEELIFYPCPkIIIYQQ8jSklIODg6VS6ezZs6dOnXr8kUff8OrXTk5O/sujj954/eH9&#x2B;/dzR&#x2B;ok9d0AgIFRUAxg4A6EZBIwymiVajA4XHDOqYCIvHxcsGcjTVMAnue1Wi0Ac3NzCwsL2Wx2ZWUlCIInn3zSGFMoFDzPazQavu/39fUZY7LZrOu6lUqlUqlkMhnHcbqz/GxOZwP0izd&#x2B;KKVse283cNy6LSSOYxsyOo7juq6t9SOEEHIloQUdhBBCCLns0YKOF5XWem1tbWxsbHV1NQiCQl&#x2B;pWl0rFIr9/b17du2VxqgwFL6volj4XhKGwvM446mBYFyDGUDDMDAAqdEBozIi8uIyWwCQUna33AKw6djWIKz7wG6Zm713611KqQvyu&#x2B;5D7F3dyMxWzKVpaowJw7DZbC4sLAghFhYWPM87derUyMhIFEWu69rHaq0dx8nn8/l8PpvNep6XzWaLxaLdrWH7bdM0fWEjOVvxNzY2Njc3t3///h07dryAT04IIeSSo/&#x2B;NQwghhBBCng3nvFKpvOIVr5ienj569GhnqlPsLxeLhR888qhWZlffQFAoqCgSngelHdcD40prA2aYAZg2ShkjuQCYpKSPvDjiOGaM2fq1iyM5znmSJHaJrT3MHmObZG07reu6nPNWq9W9bh&#x2B;rlEqSpNt&#x2B;biPCbpgopeScx3Fst&#x2B;JOTU3lcrkwDBcXF&#x2B;1Tra6uDg4OOo4TRVG73d62bVsul6tUKrYV147bcxyHc26zv0wmo5Ta2pmLzUF7hBBCyHNE/9kghBBCCCH/Cs657/u7d&#x2B;8eGBgYHx&#x2B;fmZmJG&#x2B;Gth2998PsPObuvLRSKA8PDEFx3OjyT6dQbQaEgGIOBZpBMMAYNbcBoQwd5kbiua690y&#x2B;W6eZzjOFLKC7rIba3cxVsystmsvWLjNrGpe4AdfqeUmp&#x2B;fX1xclFLWajXHcSYmJsrlsuM4S0tLcRxrraWUQRCUy&#x2B;VisZjNZoUQmUymUCgIIeI4LhQKtvrPVvZtrSJ8lt0dhBBCyHNBYR8hhBBCyMvFyspKb28vgCRJnscEPc55oVC48cYbBwcHx8bGjh07tm1oe61W&#x2B;&#x2B;53vnPLK24/cNMNPJOJarWgXIJKIR2VplowwQUADp5AMzCAEj/ywrMFd93ivmc/2Dbe2jjPBoK2YZYxFsdx9xnsFotOp1Ov12dnZ/P5/MTERLFYPHv2bLlcXlpaqlQqtkHYpuGu69pKvSAIcrlcoVAA4HletxXXJo8AfN/HRfV6NvjrliUyysYJIYQ8XxT2EUIIIYS8XHzzm9/4hV94J4B77vnatddet3PnzufxJI7jbN&#x2B;&#x2B;vaen5/Tp0xMTE2kQ3PaWN0WN8HOf&#x2B;/ubbrl534F9AGJlXAfKaB1r7sARAoAE9fCSF4vWunt9a0zGOY&#x2B;iCIDdaGELAC&#x2B;um&#x2B;suuxBCLC8vT05OSilXVlbiOF5aWrJT9uyRk5OTNtEbHBz0PE9KmclkgiCwKzVs8Gf37doA0a7mwJZozxYG2jxx66lePENw612U/RFCCHnuKOwjhBBCCHm56HQ6n/rUpz74wQ8&#x2B;&#x2B;MADH/3IR&#x2B;7&#x2B;4pfK5fLzeB7OeS6XO3To0PDw8LFjx44dO5a049Ht2x9/7LH52blDN1xfrpSx2Vlpow1qSyQvqmf5gBlj7Ay&#x2B;7mbCNE07nY4xZnV1dX5&#x2B;PgiCMAzz&#x2B;fzx48cbjUYQBFrr4eFh&#x2B;6iRkRHP83p6enK5nOu6pVIpl8vZlbg22rPPafM7G8ltPRkhRHfMn63ae/baw62p5dZVivQ3iBBCyHNHYR8hhBBCyMvFtdde&#x2B;4H3v/&#x2B;Xf/mXc7nckSNHlhYXn1/YZwkh&#x2B;vr6XvnKV547d&#x2B;7EiRMLa0vbDx5IU/2thx/asXPnSF//wEA/BzjjSFPYhbxKwaXMgrzwbEb2tA2waZq6rtvpdI4ePWpH7DHGqtVqNpuNoihJEhvDzc/P&#x2B;75vQ71sNmuMKRaLhUJBSul5nk2uoyjyPM/2/17ggjCuW4vXXQHc3f9rb&#x2B;ye5MW7gy9&#x2B;C4QQQsgPhcI&#x2B;QgghhJCXi8APZmZmJyYment7BwYGn8fYvgtwzoMg2L9///Dw8NGjR2dPnw6CoLe3b211tbVeU2m6bXhoYy0HYzCgFR3kRdKNz&#x2B;zy3Onp6ZmZmcHBQduQOzMzUywW7R4M25Brt&#x2B;u6rjs6Ouo4ThAE2Ww2n8&#x2B;7rssYs7PzuvmdXY8rhPA8T2vdreCzbAtwd0PI1nI8bMZ8W6v5utEe24TNgX0Xt&#x2B;tuzQdfhC8bIYSQKxOFfYQQQgghLxfHT5wQgs/OzvT29RWLBT8IXpCn5ZwXi8Vbb711ZmZmbGxsZW4mSZLrrrvugQfu27Fjx&#x2B;23395KoqwrwzD0fd9mJQDiOO72&#x2B;f6rGxXIpdINmy7IoboLLmwi9kxD5bp7M572Ljsjz/7Rzrm7YGdFNynrPkOSJJzzNE1tP6wxpl6vT05OOo5jG3JXVlZyudzMzEylUqnX6wDCMOzp6clms77vFwoFuzojl8tprZMkyefz2Nyxa3d04KmVd3hq1d7Fn1XOeTfpu/jNXnz8BU/evfFpG3Up4yOEEPI8UNhHCCGEkCuUAVID51//Vdl0FAuu/N7SZrN57733Sik77U5//4Dv&#x2B;z96Zd9Wnuft2rWrv7//5MmTk5OTk5OT119/fa1W&#x2B;8u//Mu3vOUtNmqxC0kBcM6TJOlGJLY78gU8GfJC6YZNW9tRAQghutPosFmtdkGwZeM8e91uue3WstlYTQgRx7HY1H1Us9nMZrNbq&#x2B;GSJGk2m81m03Gc2dlZu0aj3W4vLi729PQEQaCU0lrbSXxpmu7Zsyefz&#x2B;c2AbCXNlK0hXu&#x2B;7/u&#x2B;b9NDO4Pv4ndNCCGEXI4o7COEEELIlens1x5fe3Lxpl96Lc89W6QVLTUn7jt&#x2B;9c/d9mM7sUtlfn7&#x2B;&#x2B;NhYJpPp6&#x2B;&#x2B;XUvb29r6wYR8Aznk&#x2B;n7/&#x2B;&#x2B;usHBwePHz8&#x2B;Pj6eJMlrXvOac&#x2B;fOHT169I1vfKNSyvd9e7BN&#x2B;mxatLUwiryk2FysG35tTcS29qs&#x2B;bW3m1mq14KllpDaSs6szAMRxbIyxbbaMsXw&#x2B;3&#x2B;l0VldXJyYmMplMtVrN5/MTExPbt2&#x2B;fmJjwPC&#x2B;KIjtKb&#x2B;fOnfl83vd9z/N83w&#x2B;CYGhoCFtCSRvt2Q259pQ451vrBy/4W9DtsaWFGIQQQi5fFPYRQggh5EqkMP29U9//q68brW/9d28CoOpRdXqluK1XFp9SQdZYrB77h4dfDmHf1NTk7OzM3r17BwcHlVKZIPMiFdM5jjM8PFypVM6cOXP69OmxsbHBwUEhxD333HP48OFKpWKXn9r0J45jxhiFfS9ZWyfNYUvJm62kw1NL/xhj3UUT3SI&#x2B;e0scx/bZuomeTfcajUYmk&#x2B;l0OnNzc9lsdmJiwtbuAXBd13GclZUVKWW73fZ9v9Fo7Nu3r6&#x2B;vzw7XC4KgG8x1awOjKOpuvH329vCt5791ewYhhBByuaOwjxBCCCFXIoGDP/2K1lrj0b&#x2B;999ZfeyM8fuJLj3z///76ntcfevUfvGPrgYyzmSMTT3zhBwd&#x2B;&#x2B;uZLdbI/HjMzM61W68YbbxwcHFxbWy33VF7wyr4uznkmk7n22muHhoaOHz&#x2B;&#x2B;sLAgpRweHr7//vsHBgZe97rXua6bJMnq6urg4CCAtbW1SqXyIp0MeUHYqXb2OmNMSvlMtW8XxIL2Sjfbbbfb8/Pz09PTuVwuiqJ6vV6tVguFghDC7tZI0xRALpcrl8ulUkkIkc/nbbpnEz2lVKfTsbsyHMe54DS6EXZ35UW37/hZpunZ8BHUwEsIIeSKQGEfIYQQQq5Mfddvv&#x2B;1X3/DEVx4988&#x2B;P7fmJG8Naa/7YuZWzC9tu2r37zYe7hxWGK07g/f/s3Xd8XNWZP/7nnFunamY0M&#x2B;ojyZIs27IsV9wbtsGYxEAKAcNuSAOyye53N8uW3/e3G5Lspuym7CabJQmbhJBsgIQeIITihjG2cbdc1Gz1PpJmNPX27x/HvgyyMWBksM3zjl9&#x2B;ja7uvXPu3Ctsf/Kc8xx7Yte0G&#x2B;fDFf3P/Ewm63A6a6dNdzgcfn&#x2B;&#x2B;y&#x2B;nieb6xsbG&#x2B;vv4ivSOlND8/f&#x2B;HChd3d3Y2NjV1dXYWFhaOjo88880wkEmGzfRVF0XUdk75LX&#x2B;6yegCgqirP85RSOwE0DEPXdYfDwXp3GIahqurY2Fh7e7vX6x0YGHC5XCdPniwqKorH4263O5FIsAm2rE&#x2B;u1&#x2B;t1Op15eXlsrT17Ei5bjy&#x2B;bzeq6zgbAcZwsyxNaeViWxd7UDvsm9MFgPT3sb529D8Z8CCGErhgY9iGEEELoCjR&#x2B;KhrvHtYUPa8k/8Bvt1d/dO6c21aOnBpsfGLX5n99tGpNA4in/2Ev&#x2B;Byh2qK8siBYcGWHfYGAX5blKVMqAcDhkN0eNwAcbWwEsOrrZ12kN6WUOhyO6urqcDh84sSJvr4&#x2B;p9NZWFjY1tY2OjpaUVFRUFDgcrlSqZTL5bpIY0Dvhd2/wt6i67qdqbGIjU2bNU2zv7&#x2B;/s7PT6/WyubddXV0&#x2B;nw8AhoeH2UzekpISnufLy8tZfxi3252fn896NL9VnWkmkxFFccLjwRJG0zTZSnxshDzP8zyfW34IORHehHCQmTB11y4DxDX7EEIIXdYw7EMIIYTQFceEA7/dfuA3W0M1xaZu9uw/GT85nFcVWv/9P491DbW/eqLjlWMVa2ee3pmAvyIcWVgD51vd60pQU1OjKIokSgBACPH7/QCwaPHiv/6rv/rfhx7yeDwX760ppT6fb/78&#x2B;X19fUePHm1vbxcEwePxdHR09PX1zZ49G5O&#x2B;SxbP83Zepus6i9Iope3t7dFo1OFwRKNRAGhtbQ2FQgBgmubY2BhrbltaWup0Ot1utyRJoii63W6n00kIEQTBXqWRtcc1DMMO&#x2B;9jcWxYgQk5nD1VVTdNkiR473G7vax/IdjjnhdgNOiZU87H3sr/E&#x2B;j6EEEJXAAz7EEIIIXTFUYzOnU3uAl&#x2B;sZyQ5FOMEfvO//n75X28MzSxb&#x2B;pcf6Xq97eDDr7wR9gHIHqcr7PsAx/v&#x2B;qKmZKktSS2vrVQsXAkA4HAaAysrK8UTid7/73ec///mLPQBBEMrKygKBQGtra3t7&#x2B;9DQUHV19cGDBx0Oh9vtLi4udrvdqqqyHEfXdZ7n2dRLVmNlx0wXe5wfLHbh9pf2QnJsxuvZ&#x2B;7Osyq5xy83mzklVVUEQJuzD3lTTNBa6sQ9cVVVN02RZHhsba21tzc/P7&#x2B;/vlySps7NTluV4PO5yuVi4RggpLi52uVzsVjqdTofD4fP52OBZRw7WD9eO8GzsvXIv&#x2B;a1u8Tm7uOReyPk7crxVpd6llu7puj7hQli9Idsy4acg96lgDY5ZZjrhKUIIIfRhg38GIIQQQuiKI3KWaS6&#x2B;ez2h9Ojjr/UcOHXi2X3dr7es/Nsbp6yur1nX0P7K8UTnqKf89DpxDr871hUtWVz9wY56AsMwJnciodvtvv4jH9m&#x2B;bdvtt98OAFOn1rLtK1aseOThh&#x2B;64447cdKC5uam4uNjj8U7iAACAUurxeBoaGkpKSo4cOdLY2EgIyWazbW1t4&#x2B;PjM2bMcDqd7MJZA1b2JTvWDmVyQ40rz4SMhgV5pmnaDwP70q59Y1mP/cKyLEVRNE1zu91wJieyW1VATmRmz1dlgR3LmFRV7evr6&#x2B;npYSV7kiQNDg6y5hgDAwNs2T6XyyUIQiAQyMvLc7vdLN2TZdmOZQHAMAxWdpd7LTgx9p1gD4B9y&#x2B;xSRFVVWfYty7JlWZqmsTUT7XnWrGTS/vH5oK8DIYTQBwn/GEAIIYTQFYcDb1mweFZFfn1p3cYFr/7w2eYXDg4c7XruHx6sXT&#x2B;3bH5NywsHDz/yyrJ/uJHtLnvkxMDoOz999GhvcGbJxRk6AEB/f//LL7/kcDimT59RV1c3iWe&#x2B;556/23TLLV2dnZHy8qqqKraxqLioq6tzeHi4qKjI3jMUCv3Lv/zLl7/8l5FIZBIHwHAcFwqFli1b1tHRcfz48f7&#x2B;/uLi4u7u7pGRkUAgsGDBAgBIJpNutzudTuf2W5jw4krF4jw7O2NTTe34bELZl6ZpdvDHEh9JkiRJsksC2cd19qJ7ADAyMtLW1hYOh&#x2B;PxeFdXl67r4XC4o6OjtLR0fHyc7ebz&#x2B;URR9Pl8kUjE7XZ7vV4WNtkL&#x2B;bGI0E4V3&#x2B;o2se4ZpmnKsnzRP8HLn10Cmft5Op1Oewe7hFMQBF3XNU1jSV82m2UNTD6QYSOEELpEYNiHEEIIoStQyazy6MmB/PpS4hKW/9&#x2B;bqlbVv/aT53v2tzU9f&#x2B;DklqOczB959LXFf7GB84gA4Ah4oicH3vnJT245oiWzRYuqLtLgn3nmD08&#x2B;&#x2B;WR5JPL8889/61vfLigomKwzh8PhT3/mjh/84Pv/8Z8/zMvLAwDLsoaGhizTisViuWFfIJCfTCR&#x2B;&#x2B;pOffOvb356sd8/FGnfU1tYWFRU1Njay8jE2wzebzdbU1BQWFiYSCY/HY/dbyJ2xeKWW9TET4rzcijk7U7Nf2x&#x2B;F3Y6WHcKiH1YdZhhGJpPp7e0dHR3lOC6ZTFqWNTw87PV6CSGxWMyyLFEUWSPd6urq/Px8SZLcbjdbho8VkWmaBmdCKJYq2u/LxnD21GC2s502YmXfO8Fy3tzVA9mNtj&#x2B;9bDZrmiYL/ti0d47j2N1hdZcf1MgRQghdOjDsQwghhNAVqGRuVc&#x2B;Bk/aXxUuqP7HkL/f/9OXjz&#x2B;7t2tMCFFIjiVe&#x2B;9&#x2B;Tyv97I&#x2B;x2eQn86mniHZzYS6uDx7v4jHTcu&#x2B;iIAGHGF80qT2MZ3fHx8165dwfzAvPnzBUG4&#x2B;&#x2B;67HvjlAz6/f7LOv2nTbbqu//u//9vHPvbxmpqa1tbWgwcPEkKsM5mabcaMuh//&#x2B;L/&#x2B;7u//3uVyvfzySxs2XD9ZY7Cxxh0LFy7s7u4&#x2B;evRoZ2dnYWGhYRhHjhzp7&#x2B;&#x2B;vra21lypjPgwrkeUWx9klfgDAcZxpmrquw1nBGQv42EY2LXp0dLSjoyMUCo2OjlJKm5ub3W43m/WZTqcppS6Xq7S01OFwuFwuttaew&#x2B;FgNWJsTzgzkZxlhRzHTQhY7To&#x2B;TdPsesPcvO&#x2B;Kv1MXyYTV&#x2B;lhca1kWz/OGYWialjuHXRTFTCbjcDjs2dnpdNowjIvabwchhNClD/8MRgghhNAVKFRbcuqVYxM2zrt7bWTx1L2/eLl954l4z8j&#x2B;32y3LGj41DJnwJMdT4MFQAAM6N7ZrGWUKdfOOueZtbQyeKw71h0dOdqbP7Ok73C7K98bqCuerJF3drabpllWFjl44MCsWbNmz579yO8eufvuL07W&#x2B;TmOu&#x2B;22259&#x2B;&#x2B;ul9e/c99NBvVUU5dvRo5ZQp3ryJy/MVFhVVVFa&#x2B;&#x2B;MKfPnXLrSMjI9/65r/&#x2B;3///nyZrGLlEUaysrAyHwydOnOju7mb1ZS0tLel0uqqqyufzsTmJ52&#x2B;/cMWwp9/Cmy&#x2B;ZFTbmNqlgi7ipqtrR0SFJUnd3t9vt7unp4Xne4/EoijIwMMDCu0Ag4HK52CcpCILb7fZ4PBzHsanBdk43IZ5jCwWyecHs7dh2u&#x2B;6MHTWhb4YdTuVWI&#x2B;a&#x2B;wPq&#x2B;d4J9jPZcacYwDHt&#x2B;bjqd1nXd6/Wy4C8Wi7W2tvb09ESjUa/XW19fP2PGjA9m6AghhC4BGPYhhBBC6AokOERX8KzmEiYMHuva8MPPnnhs94HfvjJ4rGvfg1ubnt8/789Wq2kFNAtEMtY6sP17TyWHYp&#x2B;dXy3mO88&#x2B;s&#x2B;iStIwCYG377pPz77h6sLEzWFM0iWGfrhuSJJWWlh050phOpz91yy2//93v7rzzrknMuURR/OQnP3n8&#x2B;PHh4cE9e15fvnz5ipWrgsHghN0kSfziF7/405/85FO33Dp3zlxd01gN0WQNIxdr3DFnzpzi4uJjx44lk8m8vDyPx/PKK68sXLjQsqyioiJ78b4rG6WUNdlg6Rsr5uI4Lp1Oy7I8MDDQ19fncDiGh4dN00wkEoqieDwetoJbLBZzOp2sgq&#x2B;goCAYDPr9fru7Lsvy7JXgcqvw7CYelNJsNssSJZYiWZaVzWZ5nj9nM1w2cTi3su/sB/WKX2NxcrHPk2GlnWw6ttPp5DhOUZR4PN7T0xOPxwsLC10uF8/zp06d2rVrVzKZZCFvX1&#x2B;f2&#x2B;3GsA8hhD7MMOxDCCGE0BWIusWi&#x2B;ooJG82Uevh3O8e6hpf/401Vq&#x2B;tfu&#x2B;/5U68c6z1wavM3H80rDbZvO1q&#x2B;ZFrX7mZCYLxvtH3HsdobF5zzzNVrGg4/vKP15cMDR7tkr&#x2B;Pq/&#x2B;/jkzjySCRiGIbT6TAMY9qMGb/85S/nz5u/ffu21auvnsR3AYAZM2ZMmzZt/fpWQklZWeTsFf1Nw7h6zZpvfP0bHe3t3jzv/PnzWdIXHYl2d3XPmTNncscDAIIgFBcXBwKBtra21tbW1tbW8vLyI0eOhEIhNtuUtXxlO1/BERJrs5BOp4eHh30&#x2B;35EjR1wuV09PT2lp6cDAgNPp1HWd4zjWN4MQkpeXl5&#x2B;fDwAej4eVerF0j037Zev3sTPbc4RZtJcb&#x2B;dmv7VCPzd4lhOQmvLqu281DWN1ZbulZbhGf3R3Y3sjOfwXfuMliB6aZTGZ0dDQajSaTyenTp/M839TU9NRTTzU2Nk6bNu3jH/84&#x2B;/APHDiwa9euJUuWbNq0Sdf1AwcOsCX8EEIIfWhh2IcQQgihKxGB4jmVE7ZRpwiE7LrvT3NvX&#x2B;0q9a366iembK/bdd&#x2B;feg&#x2B;cHO8defzunyy669reg6fqP7HYNMzWFw&#x2B;dM&#x2B;wDgDmbVhx&#x2B;ZAcvCanheDaesiZxxT6A/PxgKpkcHRvLZrM7X33V7XbPXzB/69Ytkx72AQCldGpt7Vt917Isl8u9atWqJ5544pZbbmEZzdGjR3/1qweqplS99OILd3zms&#x2B;FweNKH5HQ6Z86cWVRUdOzYsZ6eHlmWk8nk7t278/LyVqxYEYvFfD6fvT/rHcFqoAzDeNvGHROCJ3tj7uKAdo2bvVvuOnq5bw0ALA5jky7tvMxujwsAiqIIgsDq9eyTsMUHTdNUVZW1su3t7R0aGgoGg11dXaIo9vf3u1wuURQ7Ojp0Xc9kMh6Px7KsqqoqWZYdDgfL9VjiRggxDINVPua&#x2B;y4Rpv/Dm1q65V5T72v4czjnf9vwr8Z0dxU54owvAMkf2mnVrmbCMI5xZ3PCCW9DaU6dN02T3i&#x2B;d5&#x2B;5NkNzf301AURZKkVCrlcrl0XbdnW&#x2B;u6brcrYe1x2UlYGw12LSwq5XnerpMdGxvz&#x2B;/1w5qloamrau3evoignTpwYHBycO3duIBBIJpOpVGr9&#x2B;vWLFy8eGBh46qmn5s2bV19fzx7UQ4cOjY&#x2B;P8zw/OjoaCATmz59vJ61w5l6c/dEhhBC6gmHYhxBCCKErlOOsqIKDVX9/484fPWdoBtsQWTk9smz67h89d/zZfb0HT73yg6flPJcgi5Grpp565ehbnTjUUJYXCcV7ooQQTuQFeZI7w06ZUtXa0lpVNWVoaPgTn/hESUlJW9vJtz/sTXQAHsAEMC/473ssI9h026Z7vvKVj3z0oywk2/zyS0cbG2&#x2B;44UZJEr///e/de&#x2B;&#x2B;9Tufkd/&#x2B;klObn5y9atKirq6uxsTGbzQYCAU3THnvssTVr1qiqysId1lMCzsQllNJkMul2u9/2omx2Qjch&#x2B;WKNKSZEVywusXMfO1hkmZ0kSecMtuzZx4ZhsGYXIyMjvb29PM8nEolsNjs0NBQIBFjSFIvFTNPUNK2wsNDhcLDF9Vwul9vtFkWREMLa5gKApmmsaQOLb1g4dcEf&#x2B;KUsN&#x2B;ljrUgAgHUaYXOWc3dmAdy7Or&#x2B;qqvbHyJpE2z1J7LJEFqeyFyycBQD2RhzH6bqeSqXYZGq2lJ4oiizpMwyD5/lsNsvSXlZ0mUwmzhbjZwAAIABJREFUs9ns2NhYNBodGBjw&#x2B;/0zZswIh8OKosRisT179rjd7kgkcvLkSV3Xa2tr58yZE4vF0uk0W0WR3WtKqSRJlFLDMOrq6o4fP/7YY491d3cvWbJk9uzZLEbM7fQCmPQhhNCHCYZ9CCGEEPoQKVkydZFqeMvz39jEwaK/uX7Kqvod//mH4ZZeT9jX9Pz&#x2B;ymUzlERGHUmJ&#x2B;ecODiqW1B56eIhwNFBREKgsmNxB3nLLLffe&#x2B;9VP3nxzJp3u6empq5s5PDz8DtbL0zNWLKGM6FZW0dNZfZwnAhCwwPCIIY4KIanKApPCORYiPCdN0wjA7NlzBEHYtnXr0mVLAWDf/v11dXVXLVggyfLhw0d&#x2B;9rOf/c3ffCUej&#x2B;fl5b3n634TSqksy9XV1QUFBcePH&#x2B;/r61MUpbi4eOvWrU6nc/369ZlMxrIs1pnU7/frup7NZs&#x2B;T9LFV8HKbxrLIxl4izTqDfcmaV8CZqrEJ7WhVVTUMQxRFVlvncDhYoMOSKRYAJZPJeDw&#x2B;ODgYDAabm5udTmdvb6&#x2B;maWyBQlaH6HQ6g8Ggy&#x2B;VioZ7D4XA6nbIsm6bJGqqysjKWPbGTsxHmDsYeNlyJk2TZjbDvnb3d6XSyBQ1ZksVu0LtN&#x2B;uDMtGVN0xRFYbeSpb3wFmWJrH5QUZRsNsvukSAIgiCw8NHpdMKZ/shsGjXP816vlx2iqmoikXj66af/9Kc/ybK8du3a8fHxxx9/PJFI/NM//dOCBQt4nvf5fLW1tcFgcPv27YqieL3esrKyUCiUSCTYqFwuF3vqWI7McdzSpUtPnDhx6NChZ5999umnn77uuuvWrVs3c&#x2B;ZMNlQ7c7ygjx8hhNBlCf&#x2B;jjxBCCKEPl8iq6WdvDM&#x2B;JfPzBL594bE9eafDAr7cef3avO5SXGh5/q7CvalX9oYd2VF9dX7N2tqvMP7kjnNXQEAqFAWDTbbd/9jN3VFZUhEKh89RtaZBKaMMZLaGb2bQas8DkqWBZVkob5TlhLNMzRJpNy2g0nwk6K71SYcQzhwJPzpv6jY6ONjYeveHGmwRB2HjDjb/85S8WLloEAMlkanbDbEmWAeBjH/vYTTfecPfdX2xpaWlra7v11lsn93MAAEppXl7evHnz2KzekZERQRAKCwsffvjhZcuWlZWVUUpZVwpRFN1uN8tWznmqs/t72B1vz7n/WzWNVRQlt1uFaZqZTCadTgeDwd7e3u7ubkppIpEwDGNwcLC0tDSdTvf09BiGwXqnsmI9SZJEUXQ4HF6vl00Fza0lZEEem6HJhpfb2TZ3bqaV40pNc1hwNuF22POsc6fushm1F/YuLLDL3cLOxlJg&#x2B;7SGYaiq6nA4JEliTxSrJdQ0zel0jo&#x2B;Pm6bp8/nYDd2zZ8&#x2B;&#x2B;ffvC4fC6devy8/MppYIg5Ofn19bW/va3v50zZ866detYEvf73//&#x2B;xIkTU6dOFQRh7dq1kiQpisLeLpPJsOGFQiE2BnbJLOJkE4cjkciXvvSl5ubmw4cPP/7440888UQikaioqBBF0Z7Pyx6Y3DnRCCGErmBX5t8JEEIIIYQuwPRPLASA4nlVuqp1vtYEb10kFZ5eyjuEmTctrrlm9tnf1cayw809&#x2B;VMKpfD5ppSexxfuvPN/7v8Zz3EzZ9b/8Y9/rK6ufqv1yLIQSygjqp7iqOB1lITdUyhQDgQeRBXSAJYB&#x2B;rgymFKjY5musUz3UKq5dWRzgWda0FlV4rgK3mLBQZ/PV1JS8usHH/zc5z//sY9//Lvf/bdEYnzCPvn5&#x2B;eFwwW9&#x2B;8&#x2B;tbbrn1&#x2B;9/7XkdH&#x2B;z/8wz9ejKmCoihGIhFWH9fR0dHX11dYWPjqq6&#x2B;Korhq1SrWm2JkZCQ/P59NyTz/2XLX1yOEsEXfWKYDZ&#x2B;bwwpl6KMhZpS6bzcKZQrNoNNrd3e31etvb203TFAQhFouNjo76/X5WXWiaJotoQ6FQfn6&#x2B;z&#x2B;dju/E8L8vyhFzJfgs7ubOHCjnFemx77if83lfEu/SxXDW39YfdO5gQkslkjh49qihKbW2t1&#x2B;u9sMSTtTHhOM40TVahKcuyfSq20B77ks2iBYBMJsOaqMiyzG7oCy&#x2B;88PTTTxcXF3/yk58Mh8OEkObm5l/96lfr1q27&#x2B;uo3Fty0LKuurk6SpN7e3qKiIgBgHVc0TZMkif2Ya5qWTqdVVbVXfmTPJKs9ZGWn7LlVVdXpdFqWVVBQ4Ha7582bV11dff/99/f392ezWXZO&#x2B;5EGAFajemE3AiGE0GUEwz6EEEIIoTcTYMXf3rDjvCGKM9/jKfQPNfXUfOSsprQmHHl05/4Ht5Yvqb323//swrp3LFiwIBYb&#x2B;8EPflBdVZVKpa&#x2B;&#x2B;es05Q7SUOZxRxx2iOySVAQgTkjsRTlefOaQQSCZ46LjZNa70940fiabb20a2h107Kv1LS51zACYmiZTSmz/1qc7ODsMwiouLV69anUwmAaCstHR0dDRnnPO3b9t&#x2B;5513lZQUD/T3Z7NZnud1XWeTGScRpdTtdjc0NJSUlDQ2No6OjrpcrhkzZmzdujUYDLLIL5vNnud9WXDG5OYduUFbbqzGcrRUKmWaZk9Pz/DwsNPp5Diura0tlUoFg8FEIsHzPGvQwXGcz&#x2B;errKxkE4pZyR6b1Wt358jNoViSyFbxy41xJ7THnXAJucNjk4vZJ2NPTJ4gtwbwcmfX9&#x2B;X&#x2B;IGiatnPnzn/&#x2B;5382TfMb3/jG6tWrL&#x2B;zkrKwSAAghdjWcjS26x2bRsmUiDx069Nxzzx08eDASidx5551ut5sQUl1dHQqFGhoaamtrAWBgYGBkZCSdTh88ePDQoUPLly8XRZEtyOjz&#x2B;exbNj4&#x2B;3tHRUVJSwlqvwJk1BNlsYnsuOWM/HvacblZduHv37uLiYlboWllZ6fF43G43WzTQvkD7DBf2ESGEELq8YNiHEEIIITRRYHrxxh9&#x2B;Xs&#x2B;qb7UD5xHzq4v6GzvP/la6L3bs6T0jp/pjPdHg1OJ5X1hzYWNYt&#x2B;4ar9fb1toaChWsXLny7B0y1pgFVkAupnD&#x2B;tfwYCgBeGvE6IqWOeWN6&#x2B;0DyePPwC3Gl95S0fWbBTW4&#x2B;KEJ&#x2B;7gE&#x2B;n8/nO123ePdffGmgvx8AVqxc8eCvfmXvM6th9rZt29Lp1PwFC17Zvp1lbT/&#x2B;rx9dddXCZcuXX9iFnwfP8&#x2B;FweOnSpe3t7U1NTYcPH66oqBgYGHjxxRfLy8unTp1qz&#x2B;48x/WftZ1VbAmCwOqkWJLCSvYKCgpaW1s5jhsYGKCUsnK8TCZjGIbD4WDlezNnznQ4HGw2Lju5IAi5VVQ2Fu2xQi177Tme51n8xyI/ALDLuBhWbJjbWoENmHXqsOOet3LF9OuweyXbHW9VVdU0LS8vzzCMeDx&#x2B;8uRJdiNEUTzPPO63wlrlEkJYj112eCqVEkVx586d&#x2B;/fvj0ajo6Ojuq7PnTt33bp1U6dOZWvztbe3i6JYU1PDSgLb2tp8Pt/s2bPZIJuamkRRvPnmm0&#x2B;cOHHixImlS5ey&#x2B;8V65rIVJ3/&#x2B;85/v2rULAO65557Fixez8dhPEdufVfCxsbEiR13X7aiX47h0Ot3S0qIoSlFRkaIoR44c8fl8c&#x2B;bM8fl8Z38UV&#x2B;pcb4QQQhPgf&#x2B;4RQgghhM6BOHnBeb6/KRVML23bfOTs7cMtfYJD5AQeTGv7vz817bp5rlLfhY1h4cJFCxcuOue3VEgCWG4aZCneu8T7&#x2B;Rq/r6bUO/vk2I7&#x2B;xOHdXff7HZGpwbX5wlSAczQXXrRo0d69ewFg7dq13/jG14eGhsLhMABIkshWrJs3b/5Dv/0t2zkYDL366qtLly0lZPKn9FJKnU7n9OnTS0pKjhw50tnZGQgEdF0/dOiQYRjV1dX2anoTsMyILaYGAIZhJBKJwcFBh8PR0tJCKWVFfKztRnd3NyvyKiwsZG0fWPcMWZbZ&#x2B;oC5PT0IIbnlgWytN0opOxv7bm7IwpIaVu5nd07IrSuEnKK8CUWIlmVpmsa25xb65a4rd4XJnXmqqurQ0FBfX9/o6Oj69esVRTFNMxgMBoPBQCAAF9RwVhTFZDLJ6u98Pt/KlSsjkYggCM8888zIyEh9ff2CBQv6&#x2B;/sffvjhnTt3dnd3f&#x2B;UrX6mqqtqwYcPLL7/c29s7MjISCoV0XR8bGwuHw8XFxawVTCaTCQaDixcv7ujo2Lt377p168rLy2VZ5jhOVdVQKKQoimVZAwMDdiUsW1CP1ZNGo1H2KLJBSpJkB9npdDqVSiWTyXQ6zdr7apq2Y8eOvXv3Dg8PU0qvvfba66&#x2B;/fsJlTnjAEEIIXdkw7EMIIYQQuhDh2pJTrxw/e3v/4Y6rPrc2snDq/l9vVcYzhx/ZseSej072m6sUqEgC7/EsHlo&#x2B;O7&#x2B;gOrDy&#x2B;OAzQ6mmbacOzgh/NOJb6CKlZ&#x2B;88d&#x2B;5cAPD5/DfeeNOWLZtvueVWAOju7na73ZZlFRUVjY2NDQwMFBYWjo&#x2B;PT506lSV9&#x2B;/btmz9//nsc59kopT6fb&#x2B;HChT09PUePHtV1PRwOb968eWxsjM2llWWZRRuKorD0LRqNdnV1sbDMsqz&#x2B;/n6O49jESRbbSZLEmuG63W63280CPk3TPB5Pbnnd&#x2B;eUGfxO6x&#x2B;YO/uydJwQxb5XLTOjDa288z5zfy52iKGxVu0wm4/F4MpnMo48&#x2B;2t7ezvP82rVrg8FgNBotLy/Py8tjMSillBVRsppNFhSm02mO41hk1traunv37lQqtXjx4jlz5sRiMY/HE4/Hm5qa7rzzzkgkks1mn3vuuWeeeeaOO&#x2B;6YO3euy&#x2B;Xy&#x2B;/0bN268//779&#x2B;3b99JLL912222hUKi&#x2B;vv6FF15gX7LZuLfeems2m3U4HP39/e3t7fPmzWMZ8ZEjR1paWiorK9m1AEAqlQqHw7fffnsymXzmmWceffTR0tJSv98PZzp&#x2B;RKPRVCrF83wymWS1h7qui6LY399/7Nix2bNnx&#x2B;PxzZs3r1mzhlK6cuXKvr4&#x2B;QRDKy8tLSkoAQNO0Cc/JFfM8IIQQeicw7EMIIYQQuhCe4oDoksCa2OKi99Cp0LSSpX&#x2B;30dCMHf/xhxN/3DfpYZ8OBn/eXrrvhuwmZQsK7&#x2B;hNHzg29Iem6PP9ySPzim/P42om7GdXV33pS1/&#x2B;&#x2B;te&#x2B;tm7dNYIgHDx4sKioSJYdLBBpajohCMLRY0ev/8j1ABCLxX7zm1/39/d/9KOTHncCAEiSVFlZGQqFmpqauru7Z86cOTY21tzcXFdXRyktKirq7OyMxWLZbJbjuNHR0WAwaJpmMpn0eDyRSMRO95xOpyzLXq9XVVW2mJr9uyzLdqWe/b6sNA9nRL4/WDrGlrEDgMLCwqqqquPHj7/44ovLli3Lz88Ph8OszTGLt1RVVVXV5TrdRzuVSrF6TPZlIpGIxWKHDh3atm3byZMn/X5/RUWFruurVq3q7OwMhUKapsVisZdeeqmsrKy4uJjneZbQzZw5c8GCBY2NjWNjYwDg8/mWLFnywgsv7Nix4yMf&#x2B;UhPTw97YCRJopQePXr08OHDzc3NlNKRkRGv17tnz55rr73W6XRqmub1ejOZTCqVcjgcN910U2tr67Zt26qqqtavXx8Oh9nIR0ZGVFVNJpOnTp3q6OiorKwURTGVSg0PD9fV1S1cuLCqqqqwsJBdVE1NTVVVlWVZ9g/p2YkwQgihDxX8OwpCCCGE0IXgRV7ynmOxvLHOodfue758ce3CO685te1orCea7o07S/Im751N/qx&#x2B;Gu8RAWepc1lBxYzjI892xXZvaf&#x2B;3uUW3lbtWAJxjVbiCgoI/&#x2B;/M//&#x2B;lP76uoqDx&#x2B;/PjGjRs9Hg8ANDTMfvXVnXl5Pr/PX1paBgAj0eiRw4cy6fRFCvsAgFLq9XrnzJlTXFzc2NioKEpJSYnT6ayvrx8eHo7FYoQQNjw2xdKyLBYM2eEdi0XY9F4WJ&#x2B;Wa0FiDmbC4HrrYWGkbK9nzeDyBQKC/v1&#x2B;WZdM0A4GA2&#x2B;1m9Zj2nrlTudnMWftLt9tdVFTk8Xj6&#x2B;/u3bt3q8XjuueceWZZZgSqrtezu7m5paYlEIkVFRSwlzGQyDoejtLRUVdV4PM4KBpcvXx6JRI4dO9bS0tLU1FRdXR0Oh1k3j66urmnTps2YMWPq1KlNTU2bN2/evn37q6&#x2B;&#x2B;unLlSo7jMpkM69TR09NTUVGxadOmvr6&#x2B;LVu2eDyeBQsWVFRU9Pf3Dw4ONjQ0rFq1qr6&#x2B;vrT0dKWty&#x2B;WaNWtWXV1dbtbMlvOzH0hVVSGngwdCCKEPJwz7EEIIIYQuhJzn8pWFzm62a5lW36H27d97cu7tq2/88Z2/uvFbqZHxSQ37LlbMJECgIf9TBe4ZOzv/a2/vAwN5jQsLvgDn6v6xePFij8fd3NR85513LViwgG2cNavhvp/8d3V19aJFi1iC1tXdNbV2WvupUyyCAYCTbW1V1dWTP3JBKC4u9vv9ra2tJ0&#x2B;ebG9vLysr0zTNNM38/Pxp06axBd0AIJ1OO51O0zRZsmNHJBNa5dogZ/4jebNJvwr0Vtg0arZoXSKR6OvrGxoaamhocDqdqVTK6XR6PB5RFMfGxg4cOFBWVhaJRGRZZrN62Z21yzM5jispKamvr9&#x2B;4cWM8Hn/00UcLCgo2bdrk8Xgsy2LL7bW1tbGAmDW0te91Npt1uVw8z7Mtfr9/xYoVTz755PPPP5/JZD7zmc&#x2B;wx6mlpUWW5aVLl06fPp0Q4na7t27dappmc3PzzJkzi4qKDh486HQ68/Ly9uzZY5rmsmXLFEXp7OwsKCgIBoMAEAwGV65cyQZvNyDWdZ1Fz3aQl9thxn6e2Q/aFdOeBSGE0IXB/08SIYQQQuhCuMsDtdfMPnt75KqpBOD1X25&#x2B;&#x2B;q9/3vN6qzuUd1kFQ1KhNH9d9b2F7hkH&#x2B;v73xc6vDquHz7nfzJn169ev/8QnPlFeXs62TJtW29XZOTg4MHvOHLalu7t70623cpQbiUbZlvaO9h//149GRkYmfdyUUlb3tGLFCrbSGWuk6/F4WL0eq3hir1noYyd9rMxK13WWntg7sMYa3Blsbu&#x2B;kjxy9Lba0IrsdJ0&#x2B;e3L9/P8/zrN6N47hwOBwIBCilsVjs5MmT3/zmNx944IG2tjZBEHie13WdxWSUUkVRAEBRFMMwli1b9md/9mdlZWU//elPt27dqihKOBy26/hUVWWtkMfGxjRNY49NNBp1Op3l5eXsIdF1fe3atU6n86GHHtI0raioiGXczc3No6OjLDc0TXNoaIgtatnR0bFt27aOjg5FUT7/&#x2B;c/ffPPNixYtYuv0rV69&#x2B;rOf/ezy5ctZfaIgCE6n0&#x2B;FwsBOyx5Klltls1g7y2CNqP8y5AR8&#x2B;qAgh9CGHlX0IIYQQQheoaGHV2Rvn33H14Ud3UosOHOl46v/8T/XqWc587/s/tvfCS6csLL7TJ0d2d9&#x2B;f0WILSj9XLC&#x2B;cuDYhgMvtzv2yqro6z5c3MDDAWgTEYmNtbW3Xb7je4/Wcam8vKi4GgKqqmu9/73vj4&#x2B;MrVq5atmzZpI&#x2B;cUpqfn19WVqbremlp6fj4uD05lzU/lSQpm82yBq&#x2B;SJNlHnT0t1y7uw&#x2B;mQlwI2c9ayrH379jU2NhYXF7PGLxzHFRQUiKJommZJScn8&#x2B;fOfeOKJRx55ZHx8/K677vL5fGwdRhYXGoYBAJRStm7jtddea1nWvffe&#x2B;4tf/EJV1e7ubkEQdF2vqakZGRnp7e0dGxtjDzMAjI6O9vX1&#x2B;Xy&#x2B;efPmsS08zzc0NFRUVBw/fnz27NmapiUSiWg02tjYaBjG0NCQ3XP5k5/8JCFkypQpgUCAEBIKhTiOY4104czUYwCwLEtVVTYGXdcJIQ6HI/fJFATBXpcwm83KsiyKoqZpLPIjhOi6zp5tXFASIYQ&#x2B;5LCyDyGEEEJoMuXPLFnyxfWeIr/kcch5ztD0EmfRWWFf1vwghvYuCBCYGdi0svIe3czu7PxRZ2rr2x7icrkWL17q9/tZ0NDU1DQ0OPirBx8MBoNNTU1sn7w8L6Vcbe20LS&#x2B;/HIvFLsbIKaUs3Usmk319fePj46ymz&#x2B;PxsNyEtWuwkz7DMFjll6IoqqpqmpY7KZLjOLviD6dGfiAsy2I3CAC6u7sPHToUj8erq6uvuuoqAKCUlpaWut1u0zRFUZw7d&#x2B;6qVasGBwdfeeWVrq4uAJBlmSV9pmmywj1JktxuN&#x2B;tXe80119x5553RaPQXv/jFoUOH2NKN1dXVdXV1Q0NDO3bsYA9PNBo9fPgwAGzYsKG6ujr3SdiwYcPdd9&#x2B;9fPnyQCDg8XgMw1izZs0XvvCFa6&#x2B;9lhUbTps27aqrrmpoaGBJn2EYLpeLLTjIOu2y/I7VlkqSpCiKKIqsso8FiGwMmqZls9l0Os128Hq9oiiy8kN7vrkgCJIkYdKHEEII/yRACCGEEJpky/7xxlBt6cDRTjWZnbZ&#x2B;7tnr&#x2B;jX9cV/11bN43yT32Zh0Nd6PSJz75ZNf39V1X7Y4Vpv3sfPv/5df/vLQ0BAAaJrW1NQ0c2a90&#x2B;kci8WONjayHVih3PTpMwRBuPvuux555HcXb/CszW5&#x2B;fr4oiqwujHXRpZTac3VZVsJxHCHEjv/YONk&#x2B;52zQwSr&#x2B;sEfH&#x2B;4MQYk&#x2B;kHRwcHBgYkCSprKwsEAiYpkkIKS8vt9O3VCpVVFREKU2n08lkki3bxzp7sBfZbDaTyciyPD4&#x2B;bhiGJEm33nrryZMnn3322XA4zOrjOI7buHHjH/7wh&#x2B;eee87lclVWVsZisZ6ensrKyk9/&#x2B;tMAoOu6IAisa8f69es3bNggimIsFvP5fJFIpLq6Gs60bGalhYZhiKLIKvjYUC3LEgQhm82ymj42TlbT53A4VFXVdV2WZVbKxwr97LI&#x2B;Fj3bC/mx51bTNJZNw5kKwdznGSGE0IcNhn0IIYQQQpOv9qb5tevnmKZJRWHi9zTo2tOSiibm3bnmgxjauxNxrdpQ69p26t93d//MNPXp/o&#x2B;fs0UvM33GjKlTpwLAzp079&#x2B;/f/&#x2B;lP39HQ0CDK0oMPPJC7G6V03vx5X//G17u7u/Ly8h544IHly5bPPTM7crJomgYArPMpS0YkSbJjPrYPS1jOPvb8LTiwQcfFwIpdiQVgzxi3Tv/ukBygg5ZVR/uisYHRkkDhsrmLRVFUFMXtdodCoUQixfM8WCDwsq6RdEqTJW/AX0hAMDTgOSCWSEU1a6Z4WeAABkb7RFEEzjTAdOe5PnPXZwzOSCaS/SMDvnyfy&#x2B;9ec91af4HV0tLy6msv7trDzapduHDuVRUltaAAcOAQHGCBQ3aYkBZlMCClAfh8&#x2B;QBgNwK254bbW9gLlh2z54e1AYEzLaHt705oKDwhbs6dV24fmPsYT0iuEUIIfQhh2IcQQgghdHE4OHquXExPZZOD8c7Xmud9ejVI77I6TLN6dreULq19P9diKZQWLK/4m52d//l6788Fzlnt/ch5duZ4HgBqamo4Svv6&#x2B;ubPn7/&#x2B;2vU/&#x2B;8lPxscTXq8HANLp9ImmE9OnT/f7fMeOHVu6dGk0Gt23b&#x2B;&#x2B;hQwc/dcutLpfrfboqdJnQVYOXOCAgOETTNNPptCSKDqeDtb8AgOnTpycSKU01BIETRe7o0aOSJLLSP54HVvNHKaiGKnKnl8bLZrOxsbHoWFSSZI/TM6Wy8sYbboyPx4uLiwGAo5wsyCuWrFixZAUFhwVATBcAgPEBfgwIIYTQu4CzDxBCCCGE3ldqMjvaPjjWMdj68pF3e2y8c/iFrz7UvbPpYgzsPEocS5ZEvmxa&#x2B;us9Pz8e&#x2B;/3b719S8pW/vcfv9wNYuq4Hg8GDBw&#x2B;wb8myvHv3rl/8/OfJZFKSJI/Hu27tupUrVz322OPf&#x2B;953t2zefJEvBV2iCJgETCA5v6gJ1ORlAsQAagIxeBGcLoFwxmhsKJNW2Bp8&#x2B;fn5paWFgkiio33P/vHJF19&#x2B;bOq0ohs&#x2B;vjxcwAOJGzAIJMYJMQd1c5Y4MhA7sOtIf/tQJqYqcd3n8IPGydSxYtGKNUvWBVx&#x2B;zuI4XeAsmogFtWwQTBcxXWCAngVTU8E0gBpADSAqEJUAJUApOCk4P&#x2B;jPDyGEEHoDhn0IIYQQQu8rTuQTA2OE0qNP7Hq3x3btbon3jg4d77kYAzu/UueKq6f8s2Gqe7t/3pd57W33j0QiixYtAiBjo6Mc5V584U8AQAjhOW7JkqX79u2966676&#x2B;vrAWDFihXFxcWKovh9/r6&#x2B;3qNHj170i0GXFcswDEUBIJGyspn19aZpPv/H58diYwBgWZZhGGxFv4MHD37nO9&#x2B;ZMmXKpk2brlt/HQBkNUUQBQAwwVSyCgCEC8KrV6/6&#x2B;te//ld/9X8i5WW6ZlB6etKw0yWzicMcR00dvF4QRbAs0DUAC3gJqCQCj62ZEUIIXQZwGi9CCCGE0PtKCrtL5lWfeuWYqb3LaYGa1bHzRF5xoLA&#x2B;cnGG9jbKXavnFPdtb//uzq4fLyvni&#x2B;Srzr8/W0dsSlXVZz772YcfeXhsbEzXNN0wZtbVlZaW1tXNCAZDAACE6IZBKS0qKlqzds0f/vCHurq6zS&#x2B;/vHbduvfhotAlQwEA8qZ2NuT0b8SkAgDVq2urVq9dGU&#x2B;Mneo6&#x2B;R8//Ma1114zZUq10&#x2B;k8sO3w5s2bTZ00NMz&#x2B;/Ofurquro5aYyaiWJbN55YYGIg9gQWo8xXGc7JJlWQILeBbemQCmZVlAOAIAlJ5eQdA0wTANQgnwOhAAU7UMg/AOAABDhDMrDHJsuUEREEIIoUsEhn0IIYQQQu&#x2B;3tf98829v&#x2B;Z632P&#x2B;ujlLHM4PHuwNTCkrmVV&#x2B;kgb2tmYGPZbSxA/0P7e6&#x2B;b0NNhQThtz1EkqQN119fXVMTH48fOngwlUpmlOx1GzY8&#x2B;&#x2B;xzVy1clLunruuBQH5eXh4h5OSpkzu&#x2B;uuOzn/tceXn5RbsadDmwLHKmJQUnisuXL/fl&#x2B;To7O5998emnnnra4/HOmTO3IFy4auWqiorqysoKt8sHAIYOoihy3OnSPEE8veKey&#x2B;OyTOtN5zcAKAD35pYrFBIJXZR4SeIAznQMoZRQCm8&#x2B;GiGEELoEYdiHEEIIIfR&#x2B;C0wvWvj5dZz47v4mlhlJjPeNli&#x2B;pfddtPSaTY0HBl4dSzT3xvZvbv3VN5b08vH1kSQipra01TVPJKhXNE2iKAAAgAElEQVTl5Xt277766jX/9aMfffXer/L8xGa4GzZcDwBTKqf8z/33T5s&#x2B;DcO&#x2B;Dwnypn&#x2B;Y5CRvLIWzQNVUURACocKVawpN3bhu462yLI&#x2B;OjFpgBQIBURBZB9pU2iCESCJluZyqgW4YPHAGn6ZAASydGpZpEkpM0xA5UTGzEicDWBZYBMAAwzANkYruPDewNwZLVQ3TNHnK8bwAhJswQFwYCSGE0KUG/2hCCCGEEPoAzP/MmvLF097VIaloQsuovPzBTxdcGvmyz1HRGdu5f/A37/woSmltbe3XvvENn8/n9/vD4fCWLVvO3k2SJABwu90ej6e6uoZt7OjomIyBo8uPaRoAFhAQRREIZZtMywz4PW6XEIkUFBcVetyiJEEmY5oWOB2cQ6aUgm4AAIgiOB2cpoFhGhZYAMARSjnKE17gRAAQeBEADDBUQwUALqeDtmmZqqrouiGKkiw7eFG0LKzrQwghdBnAyj6EEEIIoQ8AdQvBWaXv6hBd1QAg3jNycUb0Lvj42oWlX3jp5L0nhp4NyBU1eRvf&#x2B;bHl5RXBYMjlct12&#x2B;&#x2B;1PPPHENddcCwDkzXMoAcCyLFEUi4qKACAajT7y8MOqqt55112FhYWTeCHoEmJNrPFkKAVg9XUApmlYlkUIpQIHoFoAABYvggWGBZbk1C0AEwwAIGBwPFhgAIAFJieCAk4DDIutxgcWACFgAYABOscKIDjIQBIACCVZ0EQwgAARRRNU1XIAATCpBRQMQ&#x2B;A5SrIAAJA0waCgAHAAJRf5A0IIIYTeKQz7EEIIIYQuG4TS4eZeMAA&#x2B;6KagFe6rpwX3HB9&#x2B;Zm/vAyXeeU7yLpIOl8sFADfeeBMAHD50qGH2bMMwAN48NRLAsiywLADo6urq7u665dZN3/72t/7u7/6&#x2B;tPTdhaTosqYqOuUo5SghwNE3nnvrjRcsCQQCrLGu&#x2B;abDQVPVrK7rQ4moaZmmabD/WZZpWaYFYBoa5TiepzzPCwIviqIkiTwvuIBQSjnCU6CsopCVFRLgAEA3DbAsjrMo8AD6hDdFCCGEPlgY9iGEEEIIXR44kQcC8Z6Rtj8drL5&#x2B;zjs6xpqYoE0esrjkSwPJ47Fs5/aO715b&#x2B;a8U3O/qeFEUb7rppnQ6AwB79uxOppKG/pbtiVPp9PLlywcG&#x2B;l977bWbb775vY4dXYJyJ8iyZfoIAAAvcQAEwLAALDBMsCwwLMvS0i6OB1FiB6QAQIcBA/TR1LFsNpvItCUSiYzWq&#x2B;s60DQhFJwFpmmapmEYhmFopmlalmGBRYhlARAwKccJAicIAsdRSqlfqpRkySkXOGSHAMUCCCKUEiAUAgBAqNO0LDDcHD3dkxeXR0IIIXTpwLAPIYQQQujy4C32m4ZJKHntv5&#x2B;rXtMA8tunC7G2IV7k3eWBizEeHvLml3z6pbZ7u2J7jkQfnR38zLs9gyCIeXkiAJSXV0QikdbWlnPuVl1d3X7qlGHoa9asfei3//tex40uMwROl&#x2B;8BAFAgABwQ4B0AAJoG6XQ2melNJpNprV1VVYN265quWoOGafASeL1elydPlmRdClqWZVmmZVkWmGBZQCwCkEyNa5qmaoqu64ahZTIZRcmqqjpiGpIkyVJckiWZT7rcbp9TcrldVJOcgosDSgkQAqpqSjy9aJE6QgghdCEw7EMIIYQQujx4igKy16FntcETvVu/8/jyv/4o75PPf8jQie6uXc1rv73pIg2p0r1mavC1tpEtjYOPVwaW59HqCztPXV3dd77znZdefCkajQaDQYAzPVgBAMDr9c6bN&#x2B;&#x2B;Ld9313z/56fIVKyZl5OgSRXJ&#x2B;BxUAdMgAAAGdALVAAwALdB0MhT6f0TPxuJpIjKsZGYAIpFBy8i5poShJLinicrlkIQ/gdM2gRRIAAG&#x2B;s2QcABgBobkU3dU3LarqmqkomnU4mE5lspt/8vWZlMmqbltJMOCiPO3zeInfak&#x2B;&#x2B;a7hZcAZjNA8/TCJWongUgwEvv34eEEEIInR&#x2B;GfQghhBBClwmJls6d0r6ziRCy&#x2B;2d/skxz3qevzqsKneeIgaNdx57es/brt4J4kUqP6OLSL/fE92f0se0d39845UcA526z8LYqK6fc/KlPyfLp&#x2B;FLTtNML&#x2B;QEAwF13f3HZ0iUf3XjDRze&#x2B;i2Yg6ArAAwcAJhgG6Fk9nUwmYvGxVCplOlp4jhMFr9/vdxUVu2SXA0oocABBAAKQb59BVUHXwOEGON3ow8qN/AQQBCo4JBEkAJdp&#x2B;i0VspqmBawZiqLEE7GxsbF4MpFKJrPpAYEfSbodHMflUSEYDJV4IzwHHA/YpBchhNAlBcM&#x2B;hBBCCKHLRvXVDad2HCccJzikPf/z4tCJnuVf2VhYV855xXPsnTUGjnalRsajzb3B&#x2B;ovV1EKC/BkFN&#x2B;zr&#x2B;WXf&#x2B;IHW8edrvBcexvl8Pvv1iy/8KZvN6oYBAO3t7bW1tffdd98Pf/ifq1av9ng8kzBudKk5XdPHYjgVAAAUALAgq4OeVEYymayiJxVFyRpJnail0j9Isux2u6U3B9kWWJZlmaZuWiYhGUo5UaKiBLzuyd3JflNNNSjHcTwAOT0GCSzggZJ/0kTN7zqe7xofVbfHYrGkdkhRlEGl2QJrzNw1Rn0Z9WAoFPLx0wTgAaZd3M8HIYQQese4r33tax/0GBBCCCGE3pNYLKaqakFBwQc9kIvOV5x/5Pc7DU0HAE7gx/vHul5r0jJqXoFfCrgm7BzvHNn/6y1KQglPKy2cXXHxRhV21nTEd2hmdiTVNjW0moOJI7kAxUXFY2NjiqrOmjVry5YtlZWVDbNn/&#x2B;53v9M0bd78&#x2B;ec/dnR0lFJKKe3v7/f7/eFwmBBCCAEAy7IIwfXVLmHkjQm27PdoYmBkdCQ6MphKpTiB5OfnR0KlJaESryfidEgcR0wDTAssAEJYXkcIIZQSjnIc5SihFlimZfJWTpUDy/UoAAFOoJQ7HfOZhm4aBiUWEKoQwgMvkWyenOdypUSPRPhRIGCZqiiJguVJp1Kj/WY8HiemW3RKEi1&#x2B;3z&#x2B;s94QQMjQ0lEgkgsFgbs6OEELoCoBhH0IIIYQuex&#x2B;esI93S/FTQz372jjhdHKRiaeGT/T0HjzldDvdfg/nfKPEj1pk/4NbtYwie11Tr3tn3XsvCAVJll3to68o&#x2B;rhmZSOepe/9nKFQaFZDg2VZJSUlx48f4zk&#x2B;HA5rmvr000/euum28x&#x2B;LYd8l4eyZrSxQMy0CJLejhWVZlmUZdFwjKR1SAJoJqgrpvqHek11tY6NJAN7vLSsKV4V905x8MYUC0/KLhFIADoCnwFPgCXAA9I1fhAKhQClQDjie8Lnfe9Mv8sYvwlHKcUApECKDJhmaZLkdNC8Ppoa52QF&#x2B;fgG3QlPy1dGSuDXGO3zZYPOw1dJO/9BDt0jgofygBGDBGMl4gVBQzlQoGqBxYALokM1CxoCEBeoAyCOgOoEzAHhFA90AywCwUhQ0sBJAMgAEQAcQdAATgKYz2XiWFzOgyxZnGEAVAA0gBeljowO/2tr/p0P540D4cDIfVIBz1fq&#x2B;&#x2B;W5g2IcQQlcunMaLEEIIIXQ5WXjXtR27muI9I4RSAKAcl01keg&#x2B;cfLFruPbaObNvXRmoKWLr5on5zvD00uRQLDkwdrFHVeW&#x2B;&#x2B;rDzkdF0e0v0hXlFfy7DJASv4XA4FAoRQmbOnPnfP/7xN7/17VAoNDIyNjY25vf73/v50QeCUgIApmmy4DU3e&#x2B;WAB6A6aINDA6lUUpKk0pJSl8vLcZxwulyUAoBhGYZhAM9d3IG&#x2B;OaykQN2iWxKlKe7K/ECgPT4wHI1mjYTT6QRRGB&#x2B;Pt/efSoWTNf5CB3WAwIFhgU5O/2PLAkUFQzc5py6AQMA4c3aiW7phGpJugCQBscAwgHvLLtsO2RkDI2soQEXTBA4AsgAUXnzpxa6ntsiyfKD18NSpU5VNC6qmTHHL2DEEIYQ&#x2B;vLCyDyGEEEKXvQ9PZR8AyAFXwdSyjlePZ0aTlOcAgBACQNREdqStv2PHMUEUPME8wSMDgJ7Itr18xF3gm/WxJcBd1Io2TpIcJ8e2WZYZV3qqfOsm5aQsCQqFQpZl/vH55zvaO7JK9rrrNrhc55spjJV9lxwCOaV8pgWWYaiWZVLOpAQIMQmxNFA1w0hnU/F40jRMh9Pl8wXyXD6BOjgQAHgAVslHKOE4&#x2B;taR2KThgHAEBLA4ICKACMDz4HJwTo8zTARiZGRdtzjdZ&#x2B;mSmfFk1OFxtVuHjOxSRcrpfNQQRCIa8YwiOEWBA1EgokVAt0RO5ED0Zjk/cKJBJYsHIoBBgVKwKMcRHghvvyWb2UwAUgZwDjJu&#x2B;kQnxIHrzYAiAA8wCi88&#x2B;szw8XYgXE9fL0eEgqWzK0vCb/vjjpV9CCF0BcOwDyGEEEKXvQ9V2AcA3ki&#x2B;w&#x2B;mI9URjXcOUo6zEj1BiaEZqJNF3qH2sY8hXmO/0uh1&#x2B;174HtzgD7lmfWELEi1sJ5RcrO5M7M1psNH2y1N/g5ksm8eRTp9b6fD5NU9etXTujru78O2PYd8l5cwsNy7IIWBzHUXI6stMNPZEZj8Vi44k4z/GhUH6eyyfyIgFigGmCaZhggWkBpYRNvoWLH/YBnJlurBu6aZqE6gDEhBQAyJKeH84nzlQ8Pp5WRyVJknlnOpPJxojJGS65SKQiT/wAIIou07JUXec5jiPAcRwYOlgAlAcdUtG4YFEicmCYwAFQalEAABMIALCf2NPLGBIClBKTUJ40Prf7ySeeGGnu5eL6a1t2NLc0ezVCKTGpOWfOnMh1i9xukWLYhxBCH2I4jRchhBBC6PIz87ZlgeqiPfe/0LWnJR1NCE4JAAghhOPSo4mWlw71Hjg557aVFctmBCoLtIyqpRTJJbzl6XQAC&#x2B;Ctv//OcHOLbn&#x2B;x9V6eSocGHl5fseA9nm6CmTNnVlZWnr&#x2B;mD13aTACwQCcEKGcBGACmCWY2m1EURdUNl8Ob7w8JgsARaq/qx7NYj/IWWOwfL&#x2B;9PWGuaQOnp6bbE4g0DqMVzHBAS5gG8xOEFkPNCou9Uz3CrOqao4R0GqKPZdDbWnoZMaUFpISgAIEMxIeA03Voiy&#x2B;kukCkYDgCAfhjedejFwztnz55dd8NSECm7UM4kAMBZJgAAC6ZZkZ7GgQ6cSaHXOvi/Lx57fW&#x2B;8KNLsfL1FGZVlB6FWOp2aNm3KrAULXD431d/7jzNCCKHL2Pvyf4khhBBCCKHJVryw6qZf/MWKv7mhdH6VMp5mLXoBgFBqqHqsZ2T3/S9s&#x2B;7cn5DyXZZqWdXa7hDekh&#x2B;Itz&#x2B;9/70OqcK0KuqqBkP7E4VHtxHs/4QSY9F0Z7CBPN/V0Op3JZBRFcblcXq/XITp4wltgaaZqgjnhKPbLssA0z3XeSZX7FhwHPA8cB4QAJZQnHADoYDjBWRuprayspByXTCYppbIsq6ra19fX0ds5okUBIJ6JAwAIguB0gIMCAVBhuKnr9YeeeOqpp7Zu2zo4NPj23TQAQGHpKBzet6&#x2B;zsyuQH3C53UNDQ0VFRZFIxOlwuF2uupkzPTU1dnNhhBBCH1pY2YcQQgghdBmb87nVlctnvPaT5ztfPTHWNSQ4ZUIIEEJ5LhtPd73ewvGcO5x3/pMkh&#x2B;L7f7116sZ573k4XEPhzVtOfcuwrFe7/nNj1U8xdfiwe9P9NwGAgAlAAAzN0BQlYxiGKFKH0ylLPgtM0zQJpRwIHD19sGGahBBCODsiJOR9eax40yCEEgIAxK7ys0AgMgAADRtZRZJ9MkCVN8QHK48rjZYBBkiUiBk93Tfc69ROkVI14pgHYMIIgMCDBhCH5pd3b9u&#x2B;XTvQrmqaIHP5gh8ogA5ZAhwFwbQ/KgDeBIAsAADILg4MgGHjtZ2vqvGYy&#x2B;Uaiw3xgrX4hlWy7Ij1VWQzmfLZ06BQ1ngALOxDCKEPNwz7EEIIIYQub76pBRv&#x2B;447mJ/cefOiVrt3NhmnxkgAAhFLLNPWsQd6umUFyMNZ3qD3a2BOsL32Pg6nyrNnJ/7eqJ3vHD/ZlXy&#x2B;WF77HE6IrkmEZmqbphs5zvNvpBCAmAAHK0QnPqsXR0yvXvc8jZOsJWiZYFhCTlRSe7jRi6GDxlkN2GJAywZR4aXrVjPFE2cDAQGo8I4gCzwuqqoyMjkiSFAnpYJkgc2BB7yvHHnvssY6mDqfDUQggiqJpmel0msWIEy/9LIYOyvh4X1&#x2B;fy&#x2B;UyTSOZTs&#x2B;fP2/p0mVSgQwWQMwEnoATAEDTQcB/5yGE0IcY/iGAEEIIIXR5sc4ZfFRdPaty&#x2B;YzX7nu&#x2B;9eXDQye6RadMOMpmTL5tS4rkUNzUzdaXD58d9qnRtBh0vpvhSTWBtUeHHheoo3HwseJyDPsuS5qmcRxHKQUAXdd5ngeAdDrtdJ5&#x2B;GP4fe/cdZNd13wn&#x2B;e8INL3XOCamRM0AQBEmApAgGibIomxJlW9LIQwd5bO/Ks64tjz01ntnardkaeXbHY3tFy/bIokXJsqQRKVJiECMyQOTcDXSjcw4vv3fTOWf/uK8bDTCATYsgAZxPoVqvb99w7u2G2O&#x2B;L3zm/sNWJ53mm&#x2B;X7moMo5r5RTLLpewTCMikRleDIJSUrrC5E5Hz9KEg4ASjkBKOPhJgBQYAyAAQlOEwAUEgDWJH4tke4bD8YDIcxoxDSNimJdmShHvh5BgB5x4Pnn97y4p1AolClOA0Fi5sTERNou0jJbGoABFwAQ9izhikLKcM0&#x2B;BeLDV5wJBlGp7n38Aae189SpU8JVTXe383ZbMZAASFB4QBDkwAgn8/pLq2mapt1kdNinaZqmaZp2w5N5/8i3X7/tK/fd&#x2B;2efW7xj9VvfenXgUKeTKRoR6/0cnh1JEoKuN05v&#x2B;8NHropZzr9wZNVnthgVkfc/mA2Nv3Zx6mVfOiPZkwU1FCW/yLa82octTPEMwwiCQF65Nl6Y9LmuGy4BaZrmeyR9b8&#x2B;kFRQUfN&#x2B;nlEbsCOOX20OTG38l8SiiC1oW1KCGgDCYHEY1GggYsnTkzJnOFy/u3bs3M5mprqqSSriuOzY21ta2oHpZZXNzs&#x2B;fBcRSrICqcK6wUQEApIJWUAVUcjACcIF5fdf/DD2LFnTu6u/unx1dv3AQO34MRPmsKmJyEj/pjEJhqmqZpHxUd9mmapmmapt1YCCAANndTz66zJ/5pd2Zo6sGvf6nt3pVt21ceevKl888fHjzSZUauXXjlZApSqFTvuDedN6vnNMFQ6Nl9ljCy7ovb3//4ImhoTGzsSx/whXN2/Jkt9X/w/o/VPnJBEBiGAZQKQhljAKSUQogwAeSchxtd15VSRiLvFgTLuYGTVFJKpZQUAoZhGjx8G6KkkoQQcnnHORHV3KYyb1v778PvNBheJbj8moR/6dhV4wmTSkusI55nR4ocnMADQNxyAJlXe3a/cHDs6IhRtKpjFcRDRk3btrXkl7fu2LEjvqypblGzsEEN4s383fYhmKKMU0iqfCQoBYXP4AVeYBrEJGxxPLFo3bJcFhVleYICdWqVnR&#x2B;bYOmCvXABuWp8mqZp2q3nhv83NE3TNE3TtFuNgDf3Uz/pXHztVGZo6sT39/S/eQ4AGLb&#x2B;wcOPfP031n7&#x2B;rmh1wi&#x2B;4733CupUthEBKlZvIzN2e7Z1K9U2efebQfEe4su4RpSQhtGPyRYXCfA/XPkKzNX2MsTDUA&#x2B;D7fpj9hUlfsVgsFouWZb170oe5WZ2CUkopKaWUnHFeSvrmVLHd&#x2B;JRShmHwK2spsoNDBw8cPHPmzPT0tFKq6Diu6y5fvvwrv/Ebjz/&#x2B;&#x2B;OL7t9Qtaw5baYRP2hE&#x2B;AE64VCoIJABq0Nl3bJxz13WLTgFCghCjoizcTimVmez&#x2B;/ftffvnlfHfPTfJANU3TtH8BXdmnaZqmaZp2g2G4olgvPTTVs&#x2B;ecAmGcvfn1Z76wqs2qiwOoXd/66N/8zumn9/Tu61DyXc4FAFi8Y7URs1Qg8hOZqhWNs9vHOwezY8nJ7mGZ82l8Hu09WyJ3xMzajDsopX8ps2tJ2Sfnd4faR0pKGa7W5/s&#x2B;AMMwTNMkhORyuXDqLmMsnMA7dxW/qxFJwn4W4aRSBYASENOcM7VcggIkTAVJMOfgd6tImFNnh/ezVuC/hA1gJrJUQNhEZHa4FKXhl/ZgigGgiBGAhgFekY9emOg7NahSzOYxkxjRBbGNGzcsf7C97rZ1QcyHCXiB5/tmYICQGCOGFIQZAChnnid4eLuTaqy7u35DG2zTsOzZ4UiCfMGLGKbFTNqf7H/j9MT5ntVma11za1klv7L2V9M0Tbu16LBP0zRN0zTthsMCFDlKRVVWzPaLHmUUwOiZ/gNPvnjvf/z87K5rv7R96c71Ztl7LboXa61s3ri4/&#x2B;AFJ3NFFV5hMpubyFBGx84NNN6&#x2B;eD4j5DsW/OGZ8We6p18/NfYjHfbdcK5qzUEIcV330KFDp06dymQytm2vXLly69at9fX173aGcGauKlX1EUJK5wwpWVockNArp&#x2B;ve4ArFQiQSCTzHMAziqf7&#x2B;/p6eHqVUxLaj0eiaLSu3ffGX0AxIcNMAAEpNwwgb8Soo0zAL0jeoQQgMg4UlvAPnz73yyqsbnE2btmyBZSNsaKIU4YRzHghwhvGR0ZGRkamx8Y6OTjKxvqyy6aN8CpqmadpHTYd9mqZpmqZpNx41p71pYlH1xi/uOPDkiwSMUjpwuOuqne2GsmuecPnDmy/tOpsemJy7sX5NGzMYIRg51TvPsA8t0e2VCxbWx9d0Tr406Z2qMdfN63DtoxI23whxzg3D8H3/6NGjTz/9dGVlped5&#x2B;XzecZwTJ06cPHnyscceW7Vq1bucSc6eUIESQhjlwEyRXNgkutSQAsBsxdx7C88pPuC9zcc79QyZacc7M&#x2B;TLn8/Mw&#x2B;VMAT43QIgEI4VsNmrFfN9zRVBIJTvHujeNjFmLysHoGFwGVsmJVMIIOIQgXkCiUYMQDlAFSgAfmHRHj1y8tPtERIlNDctpmQ0B34IICAO4SY0iQJE80hcbFRG3wjk76XRlUQvUXIeHpGmapn1M6TX7NE3TNE3TbjwGomLOWnjbv/ZLzRuXyEAyi7fevvQDnLB&#x2B;VQuAzheOTpwcUIXShMq6DW0Na9uUQrJ3/AOcM0ZaN9Y8sX3BHwrlXXtv7eOBEMIYk1J6nhfW4nV0dHzrW99KJpOVlZVtbW3bt2//6le/umXLlq6url27dl3jdKo0iZfMLCPn&#x2B;/JynEjCEr8P7WauI&#x2B;EDQHibQRBIJeCLbDYrpQz8IJwHffz48aeeeurQG68D4OAElICUjmGMWBYAzjiA2TbIqeT0&#x2B;PhEKpU&#x2B;fPjw5NiY8AAKAgQCvg8pAQY/j67u7mKxaNv29PT09PQ0/I/iEWiapmkfGzrs0zRN0zRNuxGRrJ&#x2B;8/FmEPfifftWImpHy2JJ717x9b5m9RtxW3loTrysfPTfw7O9/8&#x2B;i3X8/1ToXblz&#x2B;8SSmZHZn&#x2B;wANtjtxZb60HUAogfPhTBQQzy69pHz/ZbBaAYRhhg46vf/3rABa1Lzlx&#x2B;tSlS5d27dr1w3/&#x2B;QfuSJZ984KGu8529F7ogAQkvVwhfKC&#x2B;ABGACJiEmozajJpmZUWSYlFCUVvMjIAyEARTwDfgGJIWk4U9HQBDMdpoQgACkCWkqFVEqohSUQnjF0nUBBbiAC3iAh5myQT/8k4GbguvC88OzhceFXxQQAqK0fwAEUJAKUkJIiKD0RwaQAlJASgQSAYVH4TF4DF7awgQNQBIBbDOooX4Fkm4iWp0xpvyygsunC2S8sVCWPTF66f855/7dYHUxUj1tU882vFjgUSgbBocU1BfUFzQLJBUcqNHc6RMdBo02jlm9PznODADIQQaW9JkrKcAwVciyxsYJSpOuQLTc65tC9rr/0GiapmkfJzrs0zRN0zRNuyFVGHU&#x2B;crOf1m5o2/zlexvWLqhf1Xr1rgGOfXe3M/ZeAYBfcK24LXyR7J84&#x2B;M2XX/6z7/W/cT5IOYt3rCaUunnnXzJUkVXJjtHzPzl06C9fOvjXPzv096/s&#x2B;2/PHf7bl/8l59Q&#x2B;JFLK8vJySmkQBK7r7tmzp6amZuvWrf39/S0tLevWraOUKqUWtC2oq6vlBp&#x2B;YmJCuB8AwSi1c1Hu3g/moEALGwNjcSkLxIU0IDq8QjTQ1NdfW1qZSqXQ6bdsR27YB9Pb1fufp7&#x2B;x7&#x2B;WipaW4AbptgEK5bGl4gwABGkMLgwIDneaZpRqLRYqFQSDvCgQsXgElLrU4qyhMrV65cvmIFIXR0dDQ5nYQupdU0Tbu16TX7NE3TNE3TblBGMZgyeHz28x1/&#x2B;iv9u8&#x2B;bNbGrd&#x2B;S4tPvsVPfIQ3/&#x2B;5Xc&#x2B;k4/hEz3FdIEAhLNiOt&#x2B;7v2Oic2j1o1vb7lhml0XntlaYN4nzzx8&#x2B;/7MjmaHp6d5xZjAjYjrpghExb/vX95OI/nX040UIEcZ2SinLso4ePZpIJFpaWupravt7egd6&#x2B;wYHBx977LH1Gze8/upr45OTAsoJvKhtgrMwvZKEfJCfl7B7LAVmF/HDnP&#x2B;Z81ERAKBzd1KXX7LLG2Y2UQAIGKGgFNyTXtjHlwrQYKb4IVwxcE7rXS7f8x7I1RuqiAiE4OHbqwAgQJSsbF/YvaApNT1WTWLRiJ0emPI9r9xKUCe/&#x2B;6kfNLlk0X2bECkNeioiLUAw31d&#x2B;fdhrOCMyEcnKzVR6rKwYjE9PB0U/WmaXwwJgCVksFmHGbAsL7lz/QODsns719vTKuELte41d0zRNu&#x2B;npyj5N0zRN07QbVZSXuUhf/pyg7Z6V77jn&#x2B;s/fef6nh4cPdr/D1xQG37p46gf7iqk8oQQAoVRJmR1NHv/erl3/9VluGX7xg1cK&#x2B;ali50vHLr56crJ7FIDwg2K6ACDwAhl8LEvAbm2EEACu64Z9eIvFIue8qqoqEonk8/lkMgkgFos5jpNMTjc2Nra2tkZjMQBSSiUloMLJvx83gRQAlFJydj08&#x2B;aFVPoQthjmiLS0PPPDA8uXLU8nkwMCAFMKORDjnnuv29/d973vfO7Z3b5gbuq5nwQbAwZWaKY6MsGXLlq1btz4SsSml2Wx2YmIcAp703MAllEZjsdJ0&#x2B;DIsWLigshejHI8AACAASURBVKJSSFEoFOb&#x2B;v4KmaZp2C9L/lKppmqZpmnaj4ohOFM81RsqvuefyX95y7rnDP/7dJ7/4/T&#x2B;qXNE4u13m/N7958/8&#x2B;GDfWxcABK7PDE4YBQhhzM254&#x2B;cHmcnTA1Pjx3vrVrXBmvc/FftFd7J7jFsG5QwAFAglSinKKCFvq4/SPmphN96woUShUIjH4wMDA0EQJKenN67f0LqgraOjY3R09Pnnnz/Xcb6qrqa&#x2B;tVkSAkBQKApKCBhR868pCOjl2bUEBDNnKG0tnW5O6R2ZU&#x2B;Y3p76Pz/mZKqV6DACy4AaMGCHEtOFB5gDHo1Vm6f1Q&#x2B;JFIAAjrEt8tiJ5zrSuwgEOC&#x2B;gBgc0gJxhCllTtW31Xm27VlqWSqhsRHRkZGLg36jt8GO3u0&#x2B;0zd3g01i&#x2B;iWZouZeSgPHoFJaFkBYIAdQe3atvuLO6fS01NvdkZ5vELEEKCM2BAzI5RADpgEKbjRuFVRmTASBgwxU&#x2B;OoaZqm3Yp02KdpmqZpmnYDa4gszcvxGK275p73/bvHvv3L//mN//Lj&#x2B;/74scr2Bj9TdNL5nj3nTv/4wMjpPiUVN3nlsqZk37ibLRoRC0BY6Cd8UUjmfvK//v2WJ3Yu3bkh1loxrxFKId1sgTIKwC96hm14eYdy9g5xifYxwDkPa98IIZTS5cuXnzx58qc//akUcs2aNTvuvWfZsmWvvPLKM888U1ZR/vnPfZ4SCkBBhW1kQ67nRkzrI7uHd8Jn3vgwCgh0dHR6meyGzZtQ&#x2B;Qua6iQVGJ2ZgUwAIAzcOFl618alSzagWETKO7Fr91F5cHx8PMjny8rKzp4798wzz9zd8lh9WyMAE2YSuQgic9&#x2B;mRSsq6&#x2B;vrR/0zlNJ0Jl2dbfCR6e/vtwr&#x2B;0NBQJullMhneX0ilkuPdfalUqrxQgO/rsE/TNO1WpsM&#x2B;TdM0TdO0GxiBUfDSMbv2HVYRu1LF8vrbn3hg7188N3lheP3jdwlfDJ/qneoazY4mlVKEEELJ1t95MDuSPP&#x2B;zI4NHusyYXarFA5RSyf6JfX/5074DHVueeKB&#x2B;dStLmO93iEopIUEIoaRx/ULDNgBkx9KEEKV04PexMzuN17Zt27Y3bNhw/Pjxo0ePVsbLPMeZHJ9QQgZSUM7u2r793k98QgJe4DHGGGGzC&#x2B;t9gJpNFxKABQKAh/V64U9HuOJeqYxNAKBz1/Qj4SJ/DJhT6Tb7RR6eWQEgMAAYLsCAEXnu9cNTw8MVrrnwwXUAYBAAAZEAFKMAjPcc7ZwKwxIPoCABgYBQjIERYSoKYlkAwBQxolE40Q2LPmUurX1z1y7jjRGTm7mR4Z5d5xcuPVP/YGNVIwFQhQTYTOvqLJAGJt06VlWDmmBMHPynN96iuyCzk5OTtdROpZJTBZ8AarIopDSoKmexCiuGMnt&#x2B;T1/TNE27ueiwT9M0TdM07cZWbbeMOxfr7GXX3PPOP/p07/6O/kOdb379mXh9RSGZU1JRSgghUshIZayssXLV5&#x2B;9YvGP1/idf7D/YmRtLGdFSakAZKyRz3W&#x2B;cGT3dt&#x2B;7xu1d/5vayJe&#x2B;rCwBhVMlSKrL5i/dUtzda5dHsaMrNFpj9vhND7XoJk1/DMMImsHV1dY888oht2yeOHN23d993vvt0seisWrfmK//qK/ftvF9CElBCSDjx1hc&#x2B;ATEYN42P43fWhy8CizEUUqnTp88MdnW1NLeUwr5/sZnZvSpQASMmADonfzd4aQSo5Kse2rZo0aL9/T8Y6O&#x2B;3TMv3/QMHDjY2NjVVrQ5yzsD4cNFx&#x2B;s9053J5Ou6Oj48bOTU0OFgvrUK&#x2B;0H/hQi6Xi9oin8vleSSdTkszVlFRwU2TBoFtMs/zstkcshINenF2TdO0W5cO&#x2B;zRN0zRN025sFBFCaIAcR/wauxLc80eP/vC3/9rLO4VkjhAQRkGgpFJCNq5bVLu8GUDthrZHv/nVU0/vOfPjA337OyhnzDQAEEplINLD00f&#x2B;4bX&#x2B;Ax1bntjZsmWpWR1972ta8YgZswPXV4EcOd239svbAVSvavrF3Lz2ixYW5THGwj4bSqmVK1cuX7787PGTvu8rRisqKmob68vLKyQglZQq4MygQCACmxkAVCAIY9eqNL2aozybWDRQlDGE/WCyDhJ2WNknDEVASKlGT0hIIQmjrOB5tmlTAikUDQgANZT2fd9sqUEAEgcEhEkARKEkGCsCgNM95vdOxgr00qGz4ye669YukYpQStOywCkP3yAJOBQkDPEIiIRUSikFAkopZXPeRoU3avk2AJMhBjMIW/uGRYc&#x2B;KAUYIAAOCMBDpK3h/ke/&#x2B;PJzz42dPGwYhn02/9bYi7HvvuF5biqTUoDrB8VC0fHCi1JTqriKCUfwKVWuItFCsYJUJgqoInbBiCKnvFxgcZtTpQIVgYn3biWsaZqm3ex02KdpmqZpmnbDq7WWdKcPLCm/85p7Nt&#x2B;1dNtXH9r7Vz8TXkA4g1JKKClkTXvjus/dadVcjgvXfWn74h2rDzz5Uvcbp6cvjRpRi1AKQihjTqYwcKR7und8xSc3b/jV7ZVLG9/jl0peYVcvachNpCklJ3&#x2B;w947ffahs8fsqCdQ&#x2B;DsiMDbfdBiGEkoxzSUtJHiMsfCmVDETAFIQQkMqaf0Nem5TW&#x2B;BNBwMDhCiRsoDSNl1yZHRIQzISS4RbP921iAjh27Fj3pUt333N304rlAKQUABMIDFAKigiQkxcvdlFKy8rKBgcHh4aG6tYu8X3fsixOOQMF4AgnymQABQUQwsAo6Ez9IgUgoYIgUFISQighhFLTDcAYGMdMhw9PQQhEOYoO8hPZqamp4uDU5ORkcSJVKBQSx8ilS92UUs55Op1OplKUS89zTdsUQoIybnBCeBAEYayZy&#x2B;UIISIqGKOUUoTtj5XK53KxWNy2bT/wC4WCkopSOu/2KJqmadrNRYd9mqZpmqZpNwFSG1s46XbXWEuuuevWr30qM5o8//yRQjLHOJNCVLTWbvz1He0714HATxYzw9PVq5sBOMn8A//3ry/62fFjT7/Zf7AzcDxumwAIpQByY&#x2B;lTP9zXd6BjyxM7F9&#x2B;zJtJY9m5XXP7JTT17z1HLUEKe/Oe92//kl9/nXY0e7WnYvAhAfjAVa5lfYxDtgwkXUpy76F7YqQMAGGOkVO4npFCUUEJ8z2ecWYQbhg0JzjkkEFxr0bu3MUAVQAVQ8DA63XXhQvvGTSg3EQEAyqjC7Fp9igABIQABYxIEAgQcAQAMnbi055VXqlS0qXYJTE59Rm0EggoUoQARCyanx7r6kHGi8UQyVxgdHIcPw7YgEacmACYRIzaUmHkiKBXKKQIp4QhQCkYNYlxeus8H8gwScIB8kWaz6enpienpXDZ76eIlx3G8TL6QL8icUywW/bzjeV7cWOT4blkkbpimlRVSqbgPIc0YieTdXE76hqEcUzFJZcSMRKKKSAUl4xBKMM9XUikGKDXkFKoSPBK3CLFszm07YtclIF3g49UgRdM0TbuedNinaZqmaZp2MyjjTX3FI&#x2B;VW1kDimjvv/A9fiFYmTv/PA4SSsuaq5Q9vWvWZ22FRAJd2nX3r71/5wlNfU0Ie&#x2B;vtXFt&#x2B;zeuXnti7esXr/N17sfPnY6Kk&#x2B;I2qFjTsIo17Rm&#x2B;gc2vXnz/Tt79zymztrljaS6Dv8ernuc9v2/fXPilNZytm55w5v/8PPIHLtyq9sz9S&#x2B;v3ph2&#x2B;882HTn0q7XTqYHJ3f8&#x2B;8fm/2C0&#x2B;XnHsI8QAjcAZ2E9nYKilIbNMayw624Ye0kJSiGEcl1Sfo353VdxhW8yAwBs89SJE6&#x2B;//vonFVl&#x2B;x9Yw7CuNbU5LjLmVfpTCsigKgItCoTCdTF68eHHzpUuV1cvCtzsGoybMQAYAeHn5ooWLLnReKDhuVVVVKpUKT&#x2B;I5QpgKAHGEaRhekAfAKDOsOamZELANIJyNK1Hw0un09ORUJpPxjw7kc/mpdCqbzWacYrFYzBYKjuNYzAiCgHqSEhqFwRg1DYMz5uRdKaXj&#x2B;67rxqW0LItJIUSQzWYpIbZtU0o9SrzAT6fSExOTNbxSSplROShFVBCx7UQibllWeW11eUVFZay8rrZ28YKGWF0d1tZCB&#x2B;Oapmm3Nh32aZqmaZqm3SSaEsu7k4dWVO685p4kyrf&#x2B;zkMN6xflx5KN6xbUrmqDSQCIrHfup4fHzw3s&#x2B;vNn2ratuLT7XN/Bzpbb2hMLq&#x2B;/&#x2B;40cX7Vh16O9eGTjYWUjmjIiFMBJiLD&#x2B;V7Xz52ODRrk1funfFpzbHF1RddTkaNzd98Z7X//OPrLidGZk&#x2B;9vSbm377/msOsmffuf79HZmhqUf/8rf7D1489aN9C&#x2B;9a1Xbvyg/0bLT5Cdt0XLHJuPzGgRKKmXyvlNr6Qvo&#x2B;JQYYoBgx55f0AUjAgES4Wt/Iie7Boxc7K04tX7AaiTgIiAkCKFAFzDTc5QoIFCFkpj1vgOJgRky69UZlrne66&#x2B;DZLSvaUU6ZAiUoIgCFxYCEsfae7WNTE6&#x2B;9sqtQcHPJPBzQGEzK4AIAPA4PNi1DeJMO4AMOkHZRLIxc6E2lUlMjk5OTk8V0vlAouAXH87xy1yg6RadQlFKajCcMo4JEgIhbdJSi4exaRilAhBBCQFYKzrkQwvVcnylKA9cv&#x2B;sSTTJmG4SIoFouK8Yq6iki83FYqD2nb0aqWiurqmvaa6paWloV1rdGKCiypAQAXoKUpz77l&#x2B;0EQnZuSapqmabcYHfZpmqZpmqbdJAwkamOLx92OOmvFNXfmFdaSh9ZetXHkZM/QkS4p5PF/2j3eOeyk80rKXX/&#x2B;zKf/v98C0Lxt6a9sW3r07147&#x2B;&#x2B;zB/oMXjKjFDA6AUCq8IDUwefBvXgpn9TZtWMQr7Lln3vSlewcOXeh/6yII9n/jxU1fuve9i/vcyfz5nx52887o2f49f/Hc2NkBI2Lu/n9/8sUtS0lM/wb7Ibo645tLSqEkAMUpgEBKIQRXsCwLjFHGECA1MKAcr3LJtaeTv&#x2B;3CAAAHxdHRgcFBz/Mudl0c675Uv2jdlc0wJJQCmWl&#x2B;CwLMbAgwMjI8Pj7GOZ&#x2B;amjx/vmNj8QFeHi8URDTKHDg2sSEBodBetvPhhy90dHec7yhLzJl&#x2B;rgBXIuNDqemhoWwum5yYnpyazEymUqlUIZl3io4hmeM4XqboeR4ThFIaTm0mRSoCIaUEIKX0PA9SCSktzgkxaDhgBakkpZQQks1mE4mEEEGxWAQCSqkV4fX1Da50o9EotTihJFJe1tra2tjakkgkmm/fCAOoAgjghZknAZtJW8PqQwEAhmUY1jwnUWuapmk3F/2rkqZpmqZp2s2j2lx8PvlKxEgkaPMHODxSEQeIAgAydqYPAOW048Vjt711qeH2xeE&#x2B;m3/7/sXbV&#x2B;3/xot9&#x2B;8&#x2B;nBqbMqAVCQAjlrJjO9&#x2B;7vmLgwtPrRO9Z97s7y9rrZyZZWbeyX/uK3nv2Dbw4c7sqNp7teP9X&#x2B;yMb3GIkVj/gFj3FGGL3w8xMEoJwNHuk&#x2B;9vQbm7/6wAe4Ne19mg373qG4j1JGKEipss5kFIwrP4AqFdv5I2P/9O1/9DL53/qt34qtWzy/CwuEi/2dPng8MzAZDXh&#x2B;LD10oa/&#x2B;7nUwQGMAoAgRioRNMxSIAihhEhACnAMCoihMn1uB4XtFZzLnpR1eGzcpMxQCyvMQcQsIPDALddVtixePTkxKX06fH5z0JoUQTt9wMjltjmRTyVQyMFzXdXLFQiEf5D3f97lHFKAE45QmlEmpbUgqhFS&#x2B;EEImKykl3OCUUmpIAoBJKYlSnqCMKUqkFI4MpFTgjHNmYDoWjfkxO85issY2DAO10dbW1oYlLZWVlQvaWq2aWNi6F56AzUBdWFbB9ABEw&#x2B;UJJQMwRa0AKgJCANt3CSFJ4kvI&#x2B;vcxnV/TNE27WemwT9M0TdM07aaypPL2jsld62rqP8BvetVrmjd/5b7d//VZqVTL5sWDR7qVImbMnOwamQ37AFSuaHzkL584/6NDJ76/p/9gp1LglgGAUKqkzI4kj3/3zf4DHbc9sXPhnSusulKH30hDYsf/9uj3/9V/p5yd&#x2B;P7e9w77YNOtv/PQs7//TSWEXRH38o4Uktt8/PzQfG9K&#x2B;8DeIe8rFaip8EsEhHEOAK4Dyx4fnzhx4kR1NBFbPM&#x2B;kD4APGICNnp6ebDarlBJCpNNpBLNThS9fHoCExOzKfeE0XgOWbdfU1ExNTUnhU0KKxWIUsCOl/XPI1RetwaFB80RhfHxidGTUdd29e/dmMpmBdD9jXI1NSSGrs2o6OS0i1ZRSDkYI4YoahmFzk1JKi5IQwiVXUJCEc2YYFqU0xx2AEKlEIFxfKKUMBUKoDHxKqWGYjNsRTm3bjpYnYtFYbXtlY2NTvLk61tKCpdHSLUQBDvilv7tiInP69Gk/V6itq1t42zIEAczSvSilGOEzdy8lGAMMIyzo8&#x2B;cubqhpmqbdgnTYp2mapmmadlMxUb6gYsOZqZfWVD9yZRuD9&#x2B;X2J3Z2vnR8qntk9We2RmvKL7x8vPW29mUPbXj7nis/t3XRjtUHvvHCxddOTXQMmlGbMAoQwpibc0dO9732f/1g6f3rN3353uqlTbAIgOY7l7Z/Yu2Fnx8fOtqV65&#x2B;Ot129uh8Ab6pgVkcBLP30xvV7tx//zpttty&#x2B;tWda0969&#x2B;WtFSs/xTm&#x2B;b/SD4epAQQNrWQBJhZeS78DrHwk7ABbPiazfkyBQBxOekKN5Q&#x2B;Xm6OMXP&#x2B;0v542/7q8qawwezcn4&#x2B;rflYIIZjtgAsEFAAKUADiUISAQgFKEZpKpypFBVL&#x2B;W//4Utmw/PSTf&#x2B;TasIQLFRaJQjGqFARhAGRpLASlSbmlUZGoAGAU0LCoZThSmZkuRFzmjmUxmUJLBfEACs4pFQTEQIAkB4D6cHCmC8CvtBofXrLSf&#x2B;Tgt8drT9sibRj7xjAcHXa6BwcHxZSRTCa7hpKO69oZr1AoSOkuluUjaTGyt4dwCirri1VKqppUUCviOd&#x2B;CUoqCUKI4CIhHfSmFx6VSKsuLBEREpFIIVCCFFEQCEBYYZyrG7EhElDHDMOJtDUaiLNFW1dzSUrWgrqamJlIW5&#x2B;A2BAAHcEB9wINHJTcpjQUAB7IAIPePnv/RrtyF4aamprfu27169erVD3yi9PS4ASZBaOXln5XS97lWxub8cGiapmm3Ih32aZqmaZqm3WzKedswOd&#x2B;fO9QWv2O&#x2B;x7Jy65Gvf&#x2B;XV//OfF969cv2X7vnuY19v37nerI694852Xfy&#x2B;//T4ou2rj3z7tf6DnV7O4WHjDkoA5CcyZ587FK7i175zfaylAsC2f/PwxVdOeAX3zDMH7/jap95&#x2B;znPPH97wa9vD1sCf&#x2B;JPPjZ3pX/HJzct/ZUvPnnNlTVUL79INOj5epJKxWBwZFHsu9fX1l5eXtzS3cAZIgBDQMNQjhMCRvpTS4KXGEQoqzCbpnBATCbZu3brI3e6&#x2B;vXudfJGxa3dtvsq6jSs2n9482X0snU6/&#x2B;eab4rXXz8sBAP4k81y3Kq9s265WppRSEamgIpGIEKIoA8/zXAeMM9M0Izzic0ilAhVIKYNAEBBlKEoplFBSCikUFAixLCseiZuGacTMSCRSVlvZ2NhYs7ixtaXVaK1CwoYNECCiQIlPJaA8CAEhlKCE0pmczoRJKXwgcOG6IkYYPPT09AwNDYlkMpPN9BtufV0dHAemqQKfcAMgMgjmNk7RNE3TtJD&#x2B;b4OmaZqmadpNaGXVQ6cmnjH56Qb76i4c11S7vvWOrz5c3l4H4J7//bPlLdXvvf/C&#x2B;1cv3LH64DdeOP&#x2B;zI0PHus2oTTkDQBgNHH&#x2B;6d3zvf38&#x2B;jPzqV7XWbVyw5L61F189efp/7n/HsK/rtZORitjyz94GgJdbO//D45ULagHc/&#x2B;8/nx1N0dgN23mAXC6lm1OuN&#x2B;NyudtVR139cu4uYUBWmmjLyNXb337UnE/eo6bvHb/AfQCIGQoADWsPKQXgBMIyOIDTZzvHBidWrVrVVl8OF75NBWQgAiklYcykFqccFBREQXEBQmYW/1MAkDOYlMrgqFyxcMU91tHBvq7zZ1pMmYqgIgrHAgV8QHBpgymgfs6xggEotdI1ynHnndtO7Bnu6&#x2B;sb6OxyHCcVy1VUVNTKREA4jSrGkSW&#x2B;7weu7wkhnOFJ27ZrohHOORLS971esyClHFF5w&#x2B;DM5JTSgAilILmijJpx245EEhU1VVVV1fU1jU2NDU0NFRUV0ZWtmC2cpACZqbcLf2ApmXlJGBiAgFgSsBSkhJUHLMBB6sLgwV3HfN9f17pSKnnk2Jl01onVVBcCn0TRtrwdURsAsaPhOSnlYu43Sk/e1TRN0wDosE/TNE3TNO1mtax2x7HhH8cbquO0ab7HLnpgTfii5e5l7&#x2B;sAA3d87VOLd6w&#x2B;8ORL/Yc6c2MpI2oDCBt3FJK5rjdOj5zqW/&#x2B;Fu1d95vZP/MljfYc6U/2TU2eHqldf0UjEGctOdY0ef3pXGPYBaNy6ZPZFoyPmeyPah80yGACknP7&#x2B;ft/3qqoqw&#x2B;0SkoFRxsCgQAEICN/3o0aEgJDZpFOFrTkUMwgLa/wMlDU21tbW2j12JBKZ94AEFi9vHW1oGBoachwnEonEYsr3fccpCiGJVNT3DMooZZZlUUpjvEwp5fpeOp32XY9SGo9EE7EYr6kCoIhijMcqYk1NzS1LWuvr6utWLoFlI0bBAQrQmTgvmAn46EzMR0sPAgpKBQpKUkUpLZUyzkRzgRCmAMBQxNmzZ3/yk58opc6Un&#x2B;CcjfeM&#x2B;L5PbRozY8u2rV&#x2B;0alXpOAXleSRqBUFAuH5Dp2mapl1N/7dB0zRN0zTt5mSjen3DL50a&#x2B;&#x2B;m6hk/HSMN1uGLdxgWP/u1XT31nz6kf7es/eIEZjJmlxh3SF&#x2B;nhqcPferXvQMe23/1kTXvj0LGeUz/cf9/qz889Q8/e88VU3is4qhCQ6Nt&#x2B;U7XnPanz40POqaeb&#x2B;ahQms0adlctrco3s2QfxZVr89ErCrfI7J4zy/2R97m/Kp1/ngIJgM0GWDOXCQAF8Ol8OlmwitwfdzAMlIOaFqOAhB8orggzAEEj4MjOrtU3c9sSAGFDxWKx6I0H2WzWHSukxzK&#x2B;gieUoGpm7JQhAAQHkZBwOQCYAQB3ZgXA0oAcSLfAlG/ahh21OA88z/NjAGiOBb7vFxEAypAghEQ9ZZqmWW7F68vcSqusrIw0VSbiiTXt9bW1tS1trdG6mrAtRni/Xi5jRkS4BiWIhFKSKEqIAx6OIfymSqmIEFKqWNi7RnEyu2aikAACBl/CEjDBIIE8cHZi/PVT9SnCGJ&#x2B;aHDQNM95Yxx1nsJiLx83P3Hs3EhGIQIqAmrZPwQDC&#x2B;dwqTk3TNE0L6bBP0zRN0zTtphWjDc1lq8&#x2B;OvbSl4dcIrOtz0XVf3r5o&#x2B;6oD33jx0u4z05fGjKhFKAUhlDEnUxg83PVC71PR6jJKSc/us/d5n4N5OanIDE0Fru8X3LFzAw23LbrivOIDBFTadeK6bj6f932/p6fn1OEz63asCWNBQsEZYXNTRwPwganc9NR0ZmxqfGwsOTaRyWRGfd9xHD6NXC5nO8bk5KRPfM/z5j0Ujp6OC4ODA4V8IUJJOp2e5mk7EplOT0WjMaMiGovFyyPctuwo45TSje3Lq6uqm9uazaYmNJXDBuIAnXmfFP5s&#x2B;oACDIDBLCsDMDtjVkmpKGabFpPwDwFjhDEOwHE8SginhDI2M4OaIGyfMveYHHpPnjxx/EQ0MBhjhmEsX75s085PFIvFzpGBqqrq9jWrw52pbQMwLUuXuWqapmnvRod9mqZpmqZpN7O22DapxO7BJ7e1fMVE5fW5aGJh9YNf/9LFnx479vSu/kOdgeNx2wRAKFVAdjTlZIuE0cxIcvhod9O29tkDmzctgVJ&#x2B;0ZvoGLoq7MsOTDrpQu36tutzC79wc4rhSjV9M4GPmrNPGANdrtFTVxx9daUeBZ3dKq/62tXbwu3h/nM7YlxxwKy3L/5WSuxKw6KzZ3clDArlyGKqWC9iZKxw/pk98UGnbmNbvLwctsUCiXwhl85MDI&#x2B;Oj41NDY85ruNni67rSsdzXdfNF13XNTKOcBxO4xEhAmZUEVLWmKinkYQn4cHmElSBSggJIqlSMD0AkoXPwQRg&#x2B;wCAfv/Cm/vHpocLfpa3NXBKo2VVVVVVKsara2oaGutramvr62ubm5tIrV0K2gAYAIFvAUAOAFDuB5TSsJRx5glLAI50oZSAIgQghHOuoABRREDCViQgDISAcBACYtjm7GODBKSEVIDiJiezV2cQmfHhwjgq&#x2B;NR0VnqZmra2dQ9tWfToRnhoyxTiNVEYCHyfGkwpAcIA5Jy8YZgmu2FXsdQ0TdM&#x2B;NDrs0zRN0zRNu8ktjN89Veg9M/6zDXW/QhG9btdd&#x2B;ulNi3es3v&#x2B;NFy&#x2B;8fHz0dJ8RsyibadxR9EBI4Hr7n3zx3thnq9ubSJQBaLl7WdXihtEzfbmJ9FVnGzrWc2nP2U/9t9&#x2B;4buPX3j/f94vFQnNZme/7J04c7&#x2B;vrs46WgZBiLp9MpeCLaDQa4aYQwssWPNeVRU9JaVHOGKMSUsqYaXmeF41GCSFpx/d9TwSiUCjMdyTHfv7zgwcPJgJRVVV5x113bdi4ka9sRrWNKMABAhQAT8EgkACbU143QwACinIOQAmplJIUBEQQoZQyqQFAQs1&#x2B;BKCgTJi4nN0BAJ1zUqUUAAICSq/ozBKUgkBm2Y2NjXfccUfPua6Jycm2tralq9eAAxxxOxpW5fq&#x2B;HzENAE7gG9yI2BFyZZcXTdM0TQvpsE/TNE3TNO3mt7nuS8cmvntg6Fvbmn&#x2B;TYv5NDz4oVmZt/3efXbxj9aG//3n/wc5iMm9ELGC2gyzpP9j549/75uYv37v84U3xBVUAlj24cfRMv5stXnWqnr3nenafhSNh35ABx5VddMPoRwHwfNc0TCIVAbGp4fmeZZgAaAAoBIHgFvN93zAtx8vblu17nmGaUFT6ASUUFCQAAhgKsGYmOzMoIRWThDJAep5nGiYIJYpASkYIAhVInxsGKIFSUAAhc4eocPVrYgJAWDxnUSCsSwQYRT5AmWE2Mz7grAAAIABJREFU1jfkD5&#x2B;uq6sToNn&#x2B;8cSop6SkUkYlFBilHqEBoSSQhCCiWJRSqhRUoBQBAYnm01V2ouD5pmmhKjE0NJRzHRphHnyTABwQgSAUnLuBMLmZR56DCxhSiYpw7b9LcuLs2dMv7TImskNe/vb1ty/59J18bRMi8LMwomE3XyQvDPz8&#x2B;z8UIthw3x2r7twW1DBu0RSDhJLwOXg8fCKKAyCUkpm6PEbobB3m3I8hVno2c7/bl7suK0IAqDlP2AoXLLTDniQE8dii1u2L5F37du0WQtRU1/lLDSMB&#x2B;GG/XiYJrFg0fOacG2qmrvPtPZo1TdM07Yb8VUnTNE3TNE2br021n7OM2MHhb7mYvM6Xbr5z6a986/e3f&#x2B;0zzRsXO&#x2B;m88IPZL0lfpPonDjz54s//7HsDuzqClLPwrhWUEeHNjU7gTuSHjnblJ7MjJ3qu8&#x2B;A/bIZhAnBdL0wATcME4HkBFEDBLZZJZgzTAiCFzBfylFLPdQFQg0MCvgIFTITFX4EnhKsAEEYJLa1xaJomwva3SpViVk64aZZeKyWEkEEgpQwL0ObFEYhwWI2NFZWVUCocG2NMSQlCOGOGYXCDE0KEFL7nM8YoowCEEAqKUiqlLDpFxpgUIpfLTU5OJJNJKBWNxuyIbdv2TL3czO1wE4AbeAA4mJAyTPGmzp9/8cUX&#x2B;/v7E/E4ozQSsSvr6iABF0YC8AEDKODYsWNnz545ceLEPz711H/5kz&#x2B;dmpz0HQGAgvCZSgiB674gXrjUHyF37dy54957V61da5QnAMAgsPRalZqmadr86Mo&#x2B;TdM0TdO0W4S1qe4LewefPDn649savkgRu86X3/zVnYt2rN7/jRf69nekB6fMqBWmG5SzYirfs&#x2B;/8eOfQms9ubdqw2IxHhHdF2pKbSGdGksLzu3efabxjyXUe&#x2B;S8Eu7KD7SwOCiAiTCIsuIADwmGDowDYSPYPv/LqK5/&#x2B;0i9HIpFIPAFAAUK6EAABHMAicIGkP94xWFNTw5sSiJYu4CrfsqwAIABTVApBPQJOSkFW2K9FAYQyThHGfITMTfvmrvlXnNPx1sLMpFRAMngAamhte9NkXXw8l5IE8YYy0udQShlnlDJFlaLEVUoCkkpCiIPA87xAEYMbHhWOcLLRQiKR8I24bdtmXY2plKy1gvYKNCVgoUBUoISEDSAHSUASvCwPp8JFlWkjh6F9F849/erYyQ6DMQOcLa1p2LYSCziA4oiAUhHFUQ4cH&#x2B;r/&#x2B;WHWNVkbjSbdNPMYd3zDE3aMAbDDR1OUKF3qHZQq6d5eSifp1V&#x2B;&#x2B;4iMwUwsZPmEDAiDhFocABK4lFRSDgkEMCIXAklJIaQpQyoAI3qmO74otusBP0zRNA6DDPk3TNE3TtFsHRXRHy789Nv6dF7r/4/aFv1fOFl/nAVStbPz0X/3muR8ePPn9Pf2HLigFbhkIG3dImR2ZPvb0rku7zzKDZUdTcw9M1FdQziilkxeGr/OYP2xSSkopsS0AU91Dff39Kxcuj7RWhWHT&#x2B;Ph4LpuLVpYBkFD5XN6wTMu0ZgM7lfF3v/TGa6&#x2B;&#x2B;WhjJLFy4aN1dG9esWVO1ugkMjDEAQeAb3EC4bBy/Yq4uhAAhoGFKRUAAqUDnlxjxML1iuO22LWVbx/fs2TOeThuGWcZ5eHdSSgEFqDANm55OxmJRFrOi0SiJGPFEwojahJCmBbGmpqbyxtbGhga&#x2B;uAUxoAIAYJYuxAgVUADsmclJnueFwZnTOfXc88&#x2B;ljpyMRCKGibHxseV33rlh4wYAKOKtt9565ec/X1/V2tLaIi4NT01N1VRXK8CNyc2bNlfX1iJauoYMAho&#x2B;Dfbhz3&#x2B;aSVdnNxBQAuXBY2AcREFRyhjlVBf2aZqmafOkwz5N0zRN07RbCl1X91lX5A4OfGtV7cOtsbuv/whWff6OxdtX73/yxa7XTk50Dpkxm1AKEMKYm3PGzw8SRicvDg0f7GratAQmAWBWR9s/sfbss4cyw9Ol&#x2B;Zg3nDCeCyu8CDDTe9ciPJCS&#x2B;4DE6OGet3bvVoumN2/dioU1GJne84OX0um0P5E3KmOKk2g8XhQBBVhREUqoQM&#x2B;prv3Pvt51&#x2B;my7UT/cdzY9OJ46N3THrz9Yt6yZRLnjCWUaASgDGOcoAh4wlgOhWBIFZZACQQDGQAiUCoKAmQbeaU26sAKRh9V&#x2B;PgBwCwBcwEVQneBlW1rWTd/XG8kO9nV3FTI1dkRIKYIAUIxRy7LMiGkYRlWisq62rn5hc0NjY0VjTX1dPa0rgw1YsjTXWAIEkFAChAAKUIhKBiBGiOcIYTDTACuSMl6FAnpf7TjzD3tSp/vLvFjUiF4wxitbGzZ&#x2B;fqe5oRE&#x2B;UuOTk8/tTb5&#x2B;8HRFX088TiH9QLm2MTY2Fm9s2PTJB8Kkz1ZQUhJJQCioBGa6bLzd25czDM3N5MjbPoa7zD1IWSBh916YpbxUATAADk5nvgNqZqU/&#x2B;vYrzvX2Yj9N0zTtFqbDPk3TNE3TtFsLR/m2xt8/Ov4PZ8ae82udRYm7yHVs2RGyGxKf&#x2B;D8eX7x91ZGnXu8/2OnlXW6bAAglAJRUuYnMC3/81O1PPNB&#x2B;/7poSwWArV996Oyzb3l5x0sXzJrr11P4w0YIkYGEYCpT7O/vP3X6dLZ36lLPpUxmqlAo7Ok48slPfcqoiAHw/EBKaVqlB0UI5Ghh7969vT29jY2NVbJiYmJiYmLi1MlTFZva6pY1SwGlFA1TK1XKgCb7BnqPdwRBsKHuLjtRBsYghPB9ZpoghHM&#x2B;30X7BJQ1857CXLHsMeOxFcnx7u7uvsPnTcOIx&#x2B;O1tTXNzU1tbW1lzY0oT6AC8AAOWAAHAoTL6l3uu0IBAlAQBgBuKpPL52LxiF1eDgIzwsKoFJwhXzj/Wudzzz3nHh&#x2B;1TCsai2YyGWGKBx96cP3t6wAgJ86cOXO&#x2B;43zbgjYq7SAIamqrKysrp4rTrucuXr6sfP3i0sORklB6&#x2B;c1RIGYrCj8sMzV9Vz1wNpMyBghEIBhjhFCiAzxN0zRtPnTYp2mapmmadivaXPevu&#x2B;yXDg/9Y6Z2ZEP14zNLuF1XC3euWbhj9YFvvNDxs6NDx7vNqE15KelQUk33jO/5i&#x2B;f6DnTc9sTO&#x2B;lWttWtby1uqnUzRK7gmbsCwT179UoAAUAAzDORRmMr7wzkrA5Uu9AycjSRYLp8rV/aS6ha4AIVRxgEUpGSUmiYA9F/sy4wl2&#x2B;sXVFZWVo0hZpMxViiOpId7h5ADjcJk3AMA&#x2B;K40LAoP/Rd7j7xxoFAoTJY7mzZtbFq4EJQROTO4d1iLrpRGlZawC5O2QAGAKQFIQiWQpdLk1KoHqVm0pnxRw&#x2B;T6R//UhgIElARRAJ0pTiMY7evv7x&#x2B;srKxsWtgSK4&#x2B;Fk3MLKAgpbVpGQbiAkmAeEMi&#x2B;N9/q7e0po&#x2B;bKlavKF6xAVYJxIItC17lDhw6dfq0zNzHRKmqZx2TgRa2y9rtWrrl/u2PA8aXs6T&#x2B;xZ19dd7K2rvaIzLa1tt322KeWLVt2sjBUMzoSbatwE1AUhIAzSoCAEQAuAyxqwZt9AjMlegQAIWT2NZ3zdfdtvXEv9&#x2B;K9fOuXH6gM6/VE&#x2B;JEAMNScIxhMcHAopQIQAMbcBRTfTali9PIVNU3TtFuTDvs0TdM0TdNuUe1lD1o8cXrsmbHs2bsW/F6ctH0EgzDJtj98ZPGO1Qf&#x2B;5qWBg5258bQRLcVKlLNCMnfx9VPDp3o3fOHuVZ&#x2B;5vWHtgp7d59xMIY7Kj2CoHw7PD0yDg6FQLBQKhWgsWs7KU6lUJptRSrW3ty9ftgwmkJMoo4GAyWgYtU2NpC9dunTHtm23/dvtSACHnfTp03v6T5w5c4ZSGhamSXll6sOQyWT6&#x2B;/szmey5Z4cpJfUNDcy2ZyM&#x2B;13VM&#x2B;106U7wLBUjIQAiTUxDAUwCprrKlACUAA2EzeaEAFC52nH3hhRcOnzja3Nx8533bV69aVdNYl4glDBiMSho2/ZBQCowCJh0cGNi3b396aGzhwgULFq2uqa7JB3x4eDg5cnF0ZIRORWOxGCUkl80monZba9t9v/Fl3l7pArZBM4GfTqfXNjaOjIxYzQ0LFi5Yt&#x2B;121GMrq4CxWpQBM5NkSWmAQkoJSshHkpWVnpIC1OyigUEQ&#x2B;AwGvREnrmuapmkfGR32aZqmaZqm3bJoa/Quo8k&#x2B;OfLDZ879L&#x2B;sbHl9X/avvvlbZh6h&#x2B;08LP/u3vnnxq95lnD/btP88MHq4cRyiVvkgPTb31P17tP3RBSUUIlJrvTNP3xwVQWg3QmVk7DjMVj6VeumEeQxQAl3ie8hKyLJdM8iy168tBgABIwHX8gvBs245IBgAFgCKXAIC4AoBIGNdxCaBoMBfCjLDIyvo7H7tvlKTG9l2MxWI5KELI2u0b6h/eBBOoohIeZ5QrqoIArlnoHfQms/V1raCABFbZ5Uu31Dw/GJuKNbU3wYJEKemjgMEoBDAaZIeTJBWUIRL3SCuLs6IAUcQwIOAJx/r/2bvvOCurO3/gn3POU26de6f3CgMMAwiI0gSkBbCXqNF1N9Ukpmiy2d1fsptoEhOTTdlNNtH0xJaiSbAgioUoKgLSy8AAw1Smtzvtlqec8/vj3LmMINhALOf9yovX8Mxzn3vuc&#x2B;&#x2B;Y4fP6nu/X9MgXSo7djFeXijECAP5jBYCl8nsmBYAgECSAbL6XEMCQ7Rq64eGa4CBRwEHOi1Hx1/q5I2mxTV1HNv7DLj1CyrOv/rd/sXMEBQQ4AKJTguRM4YWXfDhYOG7PupcPHjzYV7PZ0A2vTR3HzuAZRiw7GuIm9B3hOhESE1fNXHTpMmN2hnBsf0yAMc/kso9&#x2B;8ZP7ztsVPXDAsi3PsjK3yGEBTX7GGQHnyUaByepFYYCMjsiVR7V&#x2B;AIAFEDkxxHUY0yhHwhWu5Wq6ZsCF64Lq7ZQQCg8BAXwCQriGEIKyMcWShAMAcQAk41j50/aqnzkytuueruvJd&#x2B;ENx4&#x2B;qpk9RFEVRYZ&#x2B;iKIqiKMr7wcjICKW0vv5IdfWUN/XAPPPczLKKza2/3Nu5ujdaN7PgxhArPyuJwTkfXVixqPrlu59o2FDT19Cp&#x2B;zyEEhBCGYsPRpu3HJIJ4LuHRjQ4Tt3hw71HesaPH19UUcrSTNtyTY/OZFDmJtvPwT3pRYQczsAQCJiBioqp06bW1w91dHRklWZfcfkVxRdUgyaH5FL5pghBNA0JtLa2bdu6raura&#x2B;EADwaDdltbZ2fnpoOvBIPBwoKC0YvDFZwSChdggBAaY7bjDAwMZFRmm6YJjycVLdHTOvY1bsU9hsejy9EXyZG/6Le3b99uO47GRXo43BGPHzlyZFxpFvqAnNe&#x2B;jpYRPG/hgvNKpxw&#x2B;cKB&#x2B;456DBw/GOiOu63b3dAcCAQDRaCyzOOu8WbPOv25x3qQKEBBdT6Z3PlZUPbEoq2j&#x2B;/Pn1PT3jx49nAQ0YjS/ZKYPjZFFkKnfjQnCAMI0mEpZglqEZVDMEBEAYAyPyH1bJ8wkIYQDISUdqKIqiKMoZo8I&#x2B;RVEURVGU94O2trZn1z9Tf6T&#x2B;y1/&#x2B;14LRrOcN0pG&#x2B;oPBrh4Nrd7b/6fmGH&#x2B;QFq8/L/SSF/wwt9TgjLRFrJJ4&#x2B;KQ9ApKVnxQ/&#x2B;&#x2B;fCaHTv&#x2B;&#x2B;Hzz5kNO3B4d3EGFgBVNGL4zNjdBpnOjpXCjB0Zr&#x2B;mRkwwiQ7OVmWh4IoD1av&#x2B;nQ9pe29UzrvPByb26g2KEOBYvDcuCYhsHADErsmEtPUjLJwSlosoNbaXDGvPPsw92HO1t4jrf0yguRCwAxgxDAASeAluAwDFhw&#x2B;get9u76zt7BHY19ff0k1&#x2B;jr6yM5vssWzS6vLAeF6zo603S5JZUBFMjQSyaPmzhnWkdnZ3plenp&#x2B;DnQG7gIElDKqOa5DNA2v7i731hABAkIBAeK4MBjgYO/e7Yc7GnlA64kOBBlrHe4LhdImz52BPJijHQyPkTcsDQBBMKNy4vyCyRWZB2qPHmro7e1JNAwDgB5LT0ubecHkRYsWeSdmAeCUc84FF4QQjWmgQL4/mO8/xy1Kjv4AOHcJIQCnjIjk&#x2B;0kBEDkOWAaTtBOEwc2Sb5LrgusWJRQEghGQIAc4mixYCfaMBuYMLDZN02NqjDDBuYBgRFdzNRRFUZSzQoV9iqIoiqIob53jOM3NzQAqKirO4ho0TWtqbPztb37LKC0qLLz1S19&#x2B;C9epTLt4fNril1r/70jfhgPdT8wv&#x2B;XxeYGqQlr3hC/A4uj3IfLO/YTZu3L/rLy9d/8CXY5GRjT9fe340UXnpzPKFkzfd/eTBp3Z27mvW/SZlDKOzEd5FCBzHGRoaOnr0aFZWlmUlIGAaJgAHjgYtNVlV9zL7JNeQIaCckEGBjIqSiRMn7ty5MxKLJvoHzKwQOIgBATBQFy7kbI6hWCwacxwnkUjohHLuRnp60kKhmYvmL1q2DAETApxzyOKyFAPVs2aV&#x2B;HOHBgcH0gazi4oAwOVCcGKahBBN005eg/jmeEwvIFxwBsrkJyISO1h7sKm5iVHGAEpIdnb2zJkzJ0&#x2B;f9jrXsoA4YMI/IX/WhPxZbXOj3T2&#x2B;mK&#x2B;nra1PDJaWlpnnFsgPnTMSYyGTUUooFULABtzRGj252dkFKKjOIMCTQzJOYsz3ZP0fo4wQ4oLrmi6AwSFn0G61bXuEtQwNDQVHxofD4awM3e8LUEq54C4XhMj50oqiKIryjlJhn6IoiqIoylu3d&#x2B;/e3//ud6FQaMXKlQsWLDgra9i3b29ZWfmMmTMrx48vLS0tL3/rsSOBb0HhV1szNr3Y9L8bm&#x2B;/K9FaUhM7PDVTneKooAid5kB1Db3&#x2B;ssTta2xdryPCUT826miL4Bp8xejRS&#x2B;&#x2B;SOtp31L/zPo7mTizv2Nj31jT99bFqZNz9twdeuLF9Q/crvnmnefDAWGdG9Z3ZecD8FRqv5ZE0jkSVfDoBklZnFACACAiDHBgDNTKvMqzha2FieU1KYlQcBIWxKKAM47BjiADTio5SysTujiaxiO5YDORRWwk7TdKQho6o4PLGwqbNx/&#x2B;HaqSXnaf7kblIuW77Jy2R6SyaPy5pQVFdXN0CcvNy8ourccePHzV4yH0UhMMB2fDoDXMe1KdNAKARgUpg0OLc0KFCABEwTFCAUjHG4riCUUFlbd1oSKu64XAhdNwgF5yBeklmWW3J&#x2B;VVdnZ2IwVhfpDhYXTlo2C4WABeJSADIbkyGcRQBA6BA64AUhoxOj0zy&#x2B;SUWIIyuekUUAL6ADNneJq4VMCy6Re6cJkW3xCMAFDBfJyj4KUAgBzjmldHRyrjPm3QEAiByAgAICLgHRwMEgwEk/gAhebuhvaO/f5Dou0aMu5zmBgMf0m6aPgAGEEgZKQEaLFV91Q1X&#x2B;pyiKopxZKuxTFEVRFEV56woLC2tq9uXl5a1e/bezFfY11DdUlFeEMzM/89mbCwoKvF7v27xgoXfuRybN3dr1i0M9T&#x2B;1s/1O6t8RkwZL0uSYNBs1cr55u87hOzBGnbyjRMWJ198cbBxPtkXhLwh706RlHB7efk3ddke&#x2B;80eEWp9J54GjTxgMgZPOvniqbNykeGUkMxl74n0dX/PCfARRdMKHoggnbfvlMzWOvtGw5pHkM3fuuadvnABrgRUXFuI6q9tLSUpobAGDZtscwBYQFywsPBaGUxuNx4vG95mVk0zcKGIYOC2AIFRRMnDhxV0fD4OCgTPqidtyjewDYrs1dcNfV4Js4e05GInDgwIFo10goFJq84txQXh5yTABIWDAMwBVCMMYISHK6qzOaFRLAMOHYgIBhEAoihC3k5tbTFkVRTTPAALiOsG3bm&#x2B;FZvHjx4kmz927f3tHUtnv3nvTKsolTpgLAKTdnEySXz10ASOZzNqADOsAhEo4QghgEABeccy7AKWUaSVZWitTYkTEvjr1Oj0ICQAgIAUpByLG&#x2B;i90D3Ucj9T09PYPRQdt2snK9JaWFpb5SQzdoaqiJ4KfzViqKoijKm6HCPkVRFEVRlLcuJyfnox/7eEZ6emdX59law5EjdStXrQKwePHik53T1NRUWlr6pi57Xs7NlZlL93b8vS92pHPkQOvQDp&#x2B;eRQnTqcdnZI4kejg4F07M7nOFLXdEEsJidv&#x2B;w3W3zmJU7UhFc8brP4s8KEo2Bc81gbbsamKEBqHlky8wbL8w&#x2B;p1ieM&#x2B;uzyysWVr989xONLx2I9g2foYkH6bKOzwCAEQAANwDAYwCA7gCAkQBGJ0kIwyaGDgEzz&#x2B;fN9LmmnLQBL/XBQZpmAiYGnEhfnxchT5bf9Yx5sjGVfRTUhStAiSw604ESX97M8eM3p4WHbcQAjjSdaBRxxn3M4IzFErZf49RHsy&#x2B;Zmn3JVPAxqRIBHBdMjvrlhAhNFgVSAkDohAvOTMY5qAbL5VRjGoML2a9Oc4SjkdP0DwQXoJTJnddMMAEQINtEyJyaNbvaxeT2OXpOOko1SwN34RmTjIkxf9pwBAQBGJjM7ijgwuUhXfYhFJCvkTDweGLEY3rAqAsNo0WZHACDyy0C4goIzik0RhmR5ZpiTOQ35qMlBDgH1xxKqcAwgAQ6bdi9ifWdA52dIy/Zmu31V2QHAoXhfyoKFXmS1awMcmO0EASC0uN2nsu/qXm5iqIoypmlwj5FURRFUZS35frrr&#x2B;ecO47z&#x2B;qeeGW1tbbt275o7Z27qiOu6jL2qamnt2scXL15SVVX1pq4cZhMWFH6tPb65e7i2MfLykNURt/td4fTFGrlwQCiEAAEBk03ndGqaLM1gvrzAlLC3&#x2B;I08Rc6M0lkfXbzxricYo3lTSo7uOALACHp6Drenwj4AGZMLLvn5p2oe3LTv4U2nmqD6DiK6DgAEhmEILmLRKGzZGI5bIyNGuhfAppdeWvP44&#x2B;ePm3nFZ/7lFJfiyemwsC1HNzToKCoqys3NtW0bAOKuFjQBDA0PhgNhAIwxyujog&#x2B;BaYBrAABfCtYhpyEEijm1rug4gYSUYMzSmEUoYYRDJERSGrsuSOduxdU1HakLFaSEEAMexQYjGDMMwYIMPJ6hhIiNICQpzgjJajcfg8590YDEBYWAyh&#x2B;PgAhygTL7CUbZjASCMekyPEIIks1ThCMjCPDpax0dAXFceAIBYLOH1vHb9qRgt6yOEyA&#x2B;cJaxoNFpzsIYLEUPMcZzMkLeiojxXK2FgrnAJSV6XUYrUNJB3xadVURRF&#x2B;WBRYZ&#x2B;iKIqiKMrbYhhGR0eHYZyxKbGvJyMz645vfesP99ybm5srj9TV1WVlZmZmZaXOaWxo&#x2B;N6mO&#x2B;&#x2B;7//63cP18z5x8z/njMpf0jBxuH949EGsdsXtG7F5GdYdbQjgGCzCiG8yf7ivN8U0qTJvpYWEDWa9/aQDA7E&#x2B;vOPT0rpHugXM/utgT9h95fl/Z3EnjFk858czq6&#x2B;aOW1Qt3t7mSMdxKKWpuEc2bgMwyFyDMSrAufALAgBRgAAW0NY9HIsHsjKR54OApUPX0UciDCzs84t8nfvRY/VDAC5gU0MEMYj2nQc2/N/aWGdX3ebtdtYF2kcrZJWX4JxQucWTcnAKmDDkS9LDyV/O06py49TJLMoBB4LJqCs9EObgBNTQDFmtJuM&#x2B;JwBbliTqINAEOAEHIJM&#x2B;AKZhChABLmcNC5IczwuW7NCnabosvGNI9bB7&#x2B;wi40DT5iuT&#x2B;W9Agg&#x2B;AgRNY2cgYAhgEbkOn02AZ3GgSSXRQ5PVbtRyAE4A4RjtF/zJgaA0AFIAQRFAKMCACUEBDiJFcQBUCgUwaSvCq8ponRacuCA3JdFAASbFBjGiAcQODQCEaaIn9pam5K8KgQwo&#x2B;V&#x2B;QX5xTkXh7SQgGnDZkT&#x2B;F4COeQUn3srTd3cVRVEU5eRU2KcoiqIoivJ29fR0x6KxjPPPPyvPPnfu3Lvv&#x2B;vnll11606c//clPfgpAU1Pjzh07PnL99alzpk2b9srW3w4ODqalpb2lJ6F&#x2B;UuIPlJQGlsbRMWi1A6InesSgPofHBUTIUxQyCxnRPch4nQZsJzAyfRd9/1&#x2B;23fOP0rmTxi&#x2B;Z9ucb/7fq4llG5mt3uPPkvbX1HyPjp1T9F6VUxn8GYwAoAWUEDpDgcAgYeeYPD7z44kudvb2LLrxw6fVX5VbkaxpcF7IUDkL4fL70jPS2tnbRN0iy0hDjIARxsm/fvvT09Gg0Gu&#x2B;JNzc3lzilmsaInCksXj/wyc/P9/v9cDk06loWY8dVs73rEQJCBARJvVQZcfJjxYOporez&#x2B;MIsC7oOQpDs7yfgOIA41nAy7sYjia6enp6O4fbh4WGv38jIyMgLTcgIZXrgc&#x2B;FSCB3vmlaSiqIoiqLCPkVRFEVRlLeDc75j&#x2B;/Ynn3zyvLOU9AGYO3fuhAkT9u3b99/f//7axx//9rfvSE9P3/rKKwBi0ei2bdsWLFw4b978Z599Vgj&#x2B;uld7XR7keYw8ADnGTLyR1OoNyJ897jyNeXKDABb&#x2B;6&#x2B;V5U99ce8E3i3MuJ1cAcF1XFvolhmyfV9cA2IAFMIoBUfPss&#x2B;t&#x2B;&#x2B;3emaT5C9j61patraPHixZMWzTbTAY1brsVjlHq96Z5w00Bjf0tPRmYaGEUUXTsOtNW0XLvs6qGhoRf/8uzu9dsLv3K&#x2B;TkwwlozACAgIBZM1a8kBsKPzZwFkLZ0hKorsTCqAqCAGkb31qCZ3MTscABUUgEYAwNE5jvWEIwDICW9N8lmSxWwUr1Vp9qojb&#x2B;O9FZQBgggOCMiNsERgtJpPgCa32RIw6ACc5JpHVwaw5O2Q5YgCAPixPbG6LjD6jxkqH5Es/ju2aHkdnQAAH7OfduzLMvTREb2AS&#x2B;BylzOLECIwnIA7iK09kZ6Ovhf7&#x2B;/uF7fGbxQW&#x2B;K7OD2fmBRQwggMtBaA8FBdLf8C1TPfsURVGUM0v9P42iKIqiKMpbt2fPnqeffqq3t2dgYOBsrcHn8/3&#x2B;D/fMnz9/eHj4xRde&#x2B;OhH/&#x2B;WvD/3VME0AwyPD999//&#x2B;DgYG5eXkXFuGDw7ZbFneC0lWTlnVsmvyi5sOpkZX2nRSKRIIQwxlzXtW07taU3GNSPpUGyf1ws3tXVWVhYWD15cllZWTQa3bt37/79&#x2B;3t7&#x2B;wAICB/zUa8XQFpamqZpkUgEHIhjoL5x586ddXUQZWZjAAAgAElEQVR19UeO9Pf3x6Kxnp4ex3H4aFYlhJCdB09x&#x2B;84555zcggx5jkbee4VjhCS73XEuuOtyzjm4eFXiRgghJyaS7zQZBXK4LgQEo0wjGgMD0DPcU99QX19f39XV5bpudnb2hAkTKisrM9MzU49mFATEPVnHQUVRFEU5G1Rln6IoiqIoylu3ceNLL7zwwsc//onOjo4Tv9vQ0FBSUhKLxQKBwBldRkVFxT333vf3v//tjm9/&#x2B;2hLy0MPPTh//vz169cvWLBgz57dfX19xcXFYxvVfcDJDbycc03TCCHxeLy5ubntm490d3fnLTp3wRVXoNIDgViVd3r5Py3&#x2B;939qaRhqXrspYWwcfGn/oT88PXW/U7BiReiyEujAIDBosyNWsFNrTtSzfnG4r6G&#x2B;vn7voX1t7e0dRztyc3Mjke709HQijpWucYAkZ8GCuGMyP8oBOBACMMO6C7jJejUBEAbiCGe00o0DyVo52WdP/lo/2tmOAa&#x2B;aDJGslUtOph3jZOMjTiz2e5N4snLQ5RCEOwKCC5cALqMMTN4MHSy1Nj5mJ&#x2B;yrPqZkTK3hmKV7XtXf78SHieRVR7&#x2B;m8EPWEaYOSyzOObdpvwbNRT8AB8MJxBu6Orq6uvqjeyghGeGq9PT0Qv&#x2B;Hs9OydZ4DAc45EUTXogDA013HGe27qCiKoihnnwr7FEVRFEVR3iLHsXfv2lVTU3PffffOPPfcE09oaGjo6OgYiPQvX76CaezEE06j9PT0T3zik6tWXfTtb31rzZrHBoeGvviFz69ateqcc6YPDETKysoCwaAcRpFqV/fBZJomAM6567q6rgNob2/fsWNHoqmpvr6&#x2B;VgxlZWVl&#x2B;&#x2B;ZkZASIB14v&#x2B;BDy84PFH/pQfl5erRvatXv3zl27hoaHhxKliUScdyb6&#x2B;vtibUMDAwMjTsx13S7RZ5qe4vElCxYsGGrpN01zxJtnmKamaYSmdse&#x2B;0Yq20Q23yRyLEnrSeO5diRAip2QIAQjBAVe4gggK7VV3QLzNsStva42UMm00LO23&#x2B;lu7j/T29nVHhoQQvrCZk5NblFscpmEvcgFwDkqh63R04ZwIwTT1rypFURTlXUT935KiKIqiKMqb1tvbm5mZqWn6uHHj&#x2B;vr6aw/UlldUpL4b6e8Pp6cDePKJtVdedfX69evTMzJnz559pldFKS0sLPzRj3980cUXPfzwwy9v3PjQgw&#x2B;GwuHikuJzzpkeDAai0ajP53vuueeWLl16phfzbiaEcF1XTupwXZcQkpeXN/Grn3vppZc2b9v2lyfWrrDcecuWegY1RIBIgo6MdNfU1WzeXNvULHz&#x2B;Bo0ebj0c/HVzLBrz2HoikQBHVmamN9NjcctOx5y5c1d87JJgQc7w0e729nYyzEOhNMPQQal89mS1mgCELPNDshKNCgBc1t9FGTh8sqPcaGs6gIJwADAEgBjknwRAhpCVdBSjbetkUPiqDI2PrQp8A3dqzHXebFFo6lGUUlBKhXAJhRCWsB3XFYJommYQL0DgAi6n&#x2B;pi5LmOK&#x2B;eT&#x2B;WHfMSuSfPk6OrXDMmWOzUDmVmEAA0GQrRDHmJCrn9PYDiKF&#x2B;OD7UGa3p6&#x2B;3tjTbFYjFvthkOh3PNf0rPyAhjmhyfLAChNVHoRL4lbg4RAi4BwatGdLzq3oqTfUNRFEVRzhAV9imKoiiKorxp69c/29/f/5nPfPZjH/&#x2B;Ex&#x2B;ONRqN79&#x2B;5xXVfOfNi0edOkSVXl5eWXXnZ5S0tLKByqqal5B8I&#x2B;KRgMXn75FYsWXViQn//A/ff39fXed889hw4ePOecc0ZGRkzT/Mc//nHeebPS0kLvzHrebWS/PFnTB8CyrIKCgrKyMrRjUk/vnpr9HR0dL2186UDtgeG2vo6ODu8Itx3HdJimaZaAZVmuzjwej0a0QDBQEi4EIXDFuHHjsqbkB4JB7/QMTyCAAh8SbqAwu7IgGzJT0pLDTI6FfRidO/FGcC6ES9iZrQ89jfjYObwgIISBgQDCclzXsV3XdT2apmky4ztr9YoJnojFYp3DRzs6OjqjB13X9aZr&#x2B;fn52YWZ2Vp2AKUAXAFCoAECMKBzcO4kCCEMSNZovqfKLRVFUZT3PRX2KYqiKIqivGmNDY0/&#x2B;9nPLr3k0oLCwi988YsDA5FbvvjFr331q1/68pcLCgo2b97c0d5RXl6&#x2B;cOHC&#x2B;vr69HC4rq7uuCusW7du2bJl2hnb/RcOh2&#x2B;77fbLr7jitm98Y9/evU8/9dSOHTtGRqK33X57pL&#x2B;/peVodXWou7s7Ozv7DC3gXYIKWS0HAC4BJxCEcEI8slNeL7w&#x2B;LwaBKIaf3t69pSbc43gdf7SurWNHreu6gUBgmDv&#x2B;oJ9kBDXDHPIIQzfSinPy8vJyq4Lp6el5eXlZWVk&#x2B;X3KiiNwonXw&#x2B;z3HBXDL5OnYCAdho677kdxkAUx46bkgJpbJqD&#x2B;RYjZ13zJ8nNq97jVo8ipN95xTeWqNHQ5YXEvkJly/SBhCk1NbsuDtsxeN9fJBSqmmUMeY1QmOeTQPAwTi4Bh9GNzKPXYkzZgAvAHKsHNAR4By2EIIQntoBPUTiFJQSOUinzUIi4h4eGRlubKq1bdu2KKU0HCzJzsrOySpP09KCGJPOv6ogr4Di1f&#x2B;Kep0A9q1X83HOMfYDA9i2bdu2YRjyPx1CCMuyTNOUX&#x2B;i6rvpyKoqiKFBhn6IoiqIoylswadKknp6erq6ugsJCxlhGRubMmefe/s3bjx49es211yxbtvypdesAdHZ0xOPxcDisnVCQdd&#x2B;99&#x2B;bl5U2fPv3MLbK3r6&#x2B;8vOJXv/71Y48&#x2B;9qMf/bC3t/fee&#x2B;95&#x2B;eWN06fP6OzsnDRp0iOPPHzTTZ8&#x2B;9UXefw3&#x2B;XAFGAALbgu4BgP3rN23c&#x2B;PLQpkOxeCwB7vF4An5/Rka6aXo8Hk/lxAnpGRmerHBBQb5ZVQg/AIBggAzoum6apiznlAWD77N7dYboTNd9Qdfns&#x2B;1YIpFIWDHHcfuHhxljmmaapmEaAZ3oFJSCCnAAIjmWBAKjO57p8Y0PBYSAoAABTVYRjtnaK7vyDblDkUgkMlIzMDA4HD&#x2B;SSCTSwkYoFAql5YTD4aBeaMJkOO1Dq98Ey7LktGhCCCGEc&#x2B;44jhDCcRyv16vruixK5ZzLgc6macqIWTajdBwnkUgYhpGqXVUURVE&#x2B;gFTYpyiKoiiK8qYtXrLkhz/6ocfrTR257PLLv/udO9Y89uiBA/svvHBxPBEH0Nbe/uQTT1x00UWEHV9uUzW5asvmzWcu7HNd9&#x2B;HVqzVN83o9n/v85y&#x2B;6&#x2B;OLbb7/t&#x2B;eee2/rKKy0tLa2tR13H2bFjh8ynhoeHX3Ne8Pbt2x3H7ursuvSyy87QOs8cDsJBOAEnybmwEh1NiAQXoKSjtmXjSy/t2bs3mB&#x2B;sqJhWOq4iMysrOye7uLgEWX4wIA7E0VN3qCvaWyzyoVHZnS3kObYPWiZ9qqjq5OQtpwBcDkYZAAaN6bqhu4YVt21n0Orggset4XhCgAjKGKOEUhoI&#x2B;gkIJYSB0WSWKuv5GEDGztsVsDm4O9rfj0M4sKxEImElHMep736cc&#x2B;44ruu6RJi6oWeHiwzDyEqbbpiGj03z6V7qagCS267Nd/L&#x2B;HCNL9lKfJRkly8nRqXOEEGOPxGIxQogsL2WM&#x2B;f1&#x2B;13Xf6XUriqIo7yYq7FMURVEURXnTgsHgF77wxUQikToyfvz4e&#x2B;697/9&#x2B;&#x2B;pPNmzc3NDSMGzfud7/97RVXXtnd3R2NRo97&#x2B;O5duyGwbfu2FQ0NZeXlZ2KFjuP84x/r9&#x2B;/fHw6Hr73uI&#x2B;PHj7/77l88sXbt7bff1t/fv2HDhr1795oeTyIe93i9&#x2B;/btHT9&#x2B;fFbW8Vt6a2trH1/zWHdPz7mzZhUUFJyJdb7zKJBwHJ1qhkGQwO5duxKWde011yxYvgy53uSmTwswRnMkA3ZD&#x2B;5///JeW5uYV11&#x2B;9dPlyhDWYsG2bUiqzGFmEdRZf1HuIEMLlLqF8dGcu8xperwGvnztwEnYiHo/H47FYNGrbFud8YKAfhMghH5RSSpPzfQ3DS0BABAAhOOecC1tw0dHZSgilVABwueM4tm3bruNwPzdNMz3s83q9HjPk9Xj9KDBhAoUABHwuOHcAAspxFt9MOjrFZWx8nDqYSCQ0TdM0jTGW2jPu9/sB2Lbtuq7H4wEQj8flQUVRFOWDSYV9iqIoiqIob5HcN5dy6WWXFZcUP/roo7/&#x2B;5S8bGxu///3vbd&#x2B;&#x2B;LZgW6u3tdR1n7JmGYTz77DOhcPi3v/3Nd757Zzwe37hx4&#x2B;mdkGua5vTp070erz8YsC3L6/WGQqHrb7jhwsWLf/iD/37ooYeGh4cTicTnP/&#x2B;527/5rV07d/V09wT8/guXLBl7EUpQW1vb399/6ODB91zY51DYFLKyj2DsqAiAu6AaKOCgt7c7Myu84KpLrRwwBkHhOIBXMEZ0OSd30N3RsX93y95YPO7P9iBXgwa40DTtuIDPdV3Oudo&#x2B;mfQaeRkFoDEvACH3oYJTQuVtpGAGYOhuUAcPxl24Lo9ywXt6WznnrohalmO7MddxXG5xzh2bCsFdl3PORXL&#x2B;MCEEsm&#x2B;dTMQ8psZ8JqWUEGQFrzJNw9R1AgK4o4OQ4YJTUIKYBsCUBXFyFMfZeR/FKIyOipYHGWNCCMMwZMBHCHFd17ZtQohhGAB0XU8lgCrpUxRF&#x2B;YBTYZ&#x2B;iKIqiKMppM336jPHjK&#x2B;fMmfP73/3&#x2B;iScev&#x2B;/eey&#x2B;97HLvsmVt7e3yhLa2tmAwWDGu4txzZ5VXlHtNDwDXdb/x9f8qLyurGDfuNC7mkzfd1NTQSDUaTEv2IGtuasrMyvrMZ2&#x2B;&#x2B;6KKLn3vuH0NDw6v//re9e/fl5eVedNHFnZ0dqbDvhQ0bFi5adNHFl9TXN2Tn5pRXVJzGhZ1dHMJjmMmqPQsZmZmxaC&#x2B;GRvRCvxBwXOg6qMyO5G5RjVVVVd1wwz85jjNl6lQAcGDFEoZpYnRDpazsk4VnZ&#x2B;llvccQEEIJQLjgnLtCCLDkfmsAslufTr0ASnJKAHBEHbgOos5o2Ocx0zjnruu4LhcQdPT&#x2B;p2otKSgDY2CyhDDheBijIvmmcgEQCHJ8378xCzxLXNd9zbk9juMcd1wGmvIhMhw8cuTI9u3bQ6HQ0qVLZYmfoiiK8sGkwj5FURRFUZTT5mBtbU9vDwG97fbb518w/xd33dXZ2VFeUXHnnd9du3btxRdfvGfPnvRwePacOV/96teYxtKCQQB&#x2B;v3/pkqVPP/PUZ8d97jQuprCgsLCgcOyRdU&#x2B;t4y5PWIlbb/3SgoULGxsbH398TUNDfVdXZ2tr6zXXXidP6&#x2B;zs&#x2B;OlPf7J16ytf&#x2B;bd//9SnPpWdm&#x2B;M6770WYJwQTggHBEnGdgScgHNBQEbnpRgoKSs62NF7qHZf7oRpQgjOqAZNIwyAqUOAawGaNjF/ScUlsCz4DBDXYYR5DACcc5mznFjlp7wWCsBxXEIoTdbzgRKAQAgInjxJCAiAc3BwCGEYAMBgMcCEAw2jYzcABs64gAAIASFgBGR0Zi8BIEAAIUAA&#x2B;IgX/FWrkYEek7kuSbiuI8gQIZQRl4AAZ2dQdSrRkwN2ZW8&#x2B;WbUnj9u2zRijlA4NDXV0dJSVlcli0oGBgV27dv3&#x2B;97/PyMjIz8&#x2B;fOXPmWVm/oiiK8m6gwj5FURRFUZTT5kj9kd/85jfDw8M//vH/fOELX5w2ddrLL7&#x2B;cm5cXGRj49re&#x2B;&#x2B;cILGzo7uy5atWr2nDk5uTlDg4O6YQghhoYG//PrX9&#x2B;6beuZXt7Glzbu2bO7oKDg&#x2B;uuvz8nJnThx4qOPPfaNr389GotufWVrIh6XpzU3Ne/atau/v/8r//bvuXl5AKh&#x2B;rGCtq6traHBw3PjxZ3q1ZwgjDICdcHRTg4GMjAxd16OxKGOaBs0FAGHD1qBBNoQDwDkAeL2ggOtywhlNTlE4rpTvxPIr5TialgytBIcQAAElIARCHDuHUlAKEAqACxsACAcIgdxZLdM9ARCajPaOBXwunFTwJzdwp1JYzsH56MVHj4DKmS1EYzpgyMMC/GxltzJBjsViAwMDw8PDhJBgMBgMBgOBACFECCGjvVgs9uKLLz799NNz5sxZuHBhQUGBnNUrmxR6x8wOUhRFUT6A1O8iiqIoiqIop82kSVV&#x2B;ny8QCBxtaZk2bdqFixdXT5kS8PuXLVv285/97MCBA9nZ2Rqj1153XTwer6mpOWf69H379v35z3/0ef0rV60808u79LLLTNMIBoOpboNTp077wz337t6167bbvuGMNhYcGBxY/qEP7di&#x2B;PRqN&#x2B;ny&#x2B;559//sILL0xd5MiRI62tre/&#x2B;sE9mPRSECEoEh9wjKgQnnIMbXm1kJOrXfHllhWk54WEnGuAAHJkaOSCASwAGgHJQ&#x2B;Vuz4xCAwgIAJ/BaPd1U0jeGTO9OCM1GQz1ZjJc6eKyp4mglpvyTyfssTrjbY1PWMUGhJo4/UX6X0zbKNAoPAIgAIMAZJQCHcAEYhAHEgADnoEy&#x2B;9xBCOI4jK&#x2B;kAuK6bqrB7g&#x2B;TA61QKPPavtm0D0HVdNtobGBgIhUKEkJGRkZdffvmJJ55IS0srKipqaGi49dZbA4HA0NBQMBiUrfq8Xm8ikdi9e3dtbe3AwMB1110XDocrKipWrlzp9XqLiore1CIVRVGU9xn164iiKIqiKMppU1FR8dWv/SeAcDgkj2RnZwO49dZbOed/&#x2B;uMDFRUVW7Zs&#x2B;fKXvnT55Zfvq9nX0NCwa/eu2gMHD9Qe2PDChl/&#x2B;4pfVU6acueVdddVVWZmZ2Tk5oVA4dTA9Pf3CxYsffuTRp556Sh6xbXv69OmM0v6&#x2B;Pp/P98KGDXm5uZOqqlIPOXz40Jlb5JknhBAgSO4j9RlFRUUeVQn1fkdJ6h8&#x2B;nDu2EIImqzxB2Oi4DrmzeEyaRwgZO3HlzSZ9AGzbNgxDJn3xeFzmhqm/BoNBAJFIJCMjIxQKCSE2bdq0bt262traYDA4bdo0AO3t7U1NTUVFRfJkALIfX3p6uq7rO3bsoJS6rvuRj3wkLS3NNM3y8vLUmYqiKMoHE/vmN795ttegKIqiKIrytkQiEcuycnNzz/ZCACAnJycnJyctLTT2YFpa2rnnzjpv1nnz5s87WHtg9erV3d3dB/bvnzJ16s6dOznnd9zx7ebmluf&#x2B;sf7D11xz3AXj8fixDmdvDyGkrLw8JyfnxG/5fL6ysjJZ8Tc4OPjzn/&#x2B;suKi4ubl57ty5zzz7jOu6U6dOPXr0KKXUse0XX3pxxYoVb389Z0hfXx&#x2B;llBDW0daeE0rPy86RWz5BhCysAhEAs1zb1HVQ6JRlFuWBUbhEdvajlNBk5Zkc5Jv8n0sIQBwQgJhQszjeiBM&#x2B;t2Pv6NjDdIgQixCbEIsQlxCHEEGISwghRBBCUptyR/9nk&#x2B;SwZU4Ijp2T/BPHnQ/CABPcANcJNSnTCB2zEgYQCCSIDlAL1DmuKkJW5L2F1y/zQdd1ZSQnJ&#x2B;cKIbZs2fKTn/yko6Nj/PjxPp9PCEEpjcVizz777L59&#x2B;8rKyj7ykY9ceOGFiURi586dpaWlRUVF8iK2bWuaFolE0tPTLcsaHh7Wdb2npycQCEQikZ6enhkzZuTl5b3&#x2B;G0NIV1fX0NBQVlZWOBx&#x2B;3fMVRVGU9xBV2acoiqIoivJOyMzMXLlqFQBC6b59NRs2bAiHw6tXr/b7/AcO7K&#x2B;cMPHOO&#x2B;/c&#x2B;sorkf7&#x2B;cHr62Ac&#x2B;vHq1PxAIBPxLliw9oys0TXP9&#x2B;vVLly6dPHnyQCSy9vE1juvu2rVzyZKlkcEIgK6uzv37a&#x2B;bOnefY9hldyZkmG72lsptAKAS/CThndVHKmeXaNtO00YEgx45zB5RBDvYghIELUJFs/&#x2B;e6csgyALnT9i1n7nJaLudcfk0praure/7554eGhpYvX15cXJxIJIQQPp9vwYIFEyZMqK6uzs7O5pzn5uZWVlampaWlivU45729vY899tgll1xy4403zpo1q7e3d8eOHc8884zjOOeee25FRYXc8Pv2bpiiKIryHqbCPkVRFEVRlHfUig&#x2B;t&#x2B;PVvfvO3v/61p6dnw/PPFxUVjYyMfPP222659UsXXXzxwEDkuPPXr3/WMD0DA5HFi5ec0ZGvhmEcPXq0o6MjLS3t&#x2B;//9g0998hOxWOypdev27t173vnnASCEvvTSSx/60IpUrzXXdQ8fOjR2h&#x2B;&#x2B;7h8aJzgl1QQQgAAoIQYT8C1xwYlAuOKUUfh0awDUg2QlOTm2VL5KM6R&#x2B;n0zHfUF7HyW7TmBv6qlPG/oWPOdM99t1XnT92ti454evjzxfUBkk&#x2B;igubEgKiu67LdMO2XAKm6YDQHBuU6LJnH2NMxnMAjpvE8sZFo1Gv15tq2IfRxn9z5sy544478vLy5E5/0zRlC7&#x2B;qqqrKykpN0zo6OmQtrd/vj0QiABKJBKV0ZGRk//79f/jDH7Kzsy&#x2B;55JL58&#x2B;cDKCoquuuuuxoaGlauXCn7&#x2B;r211SqKoijvDyrsUxRFURRFeaetWLGyalLV5s2bI5GBHTu2p6WlrVu3LpGwfD5vdfWUT3/m035/IHXy0qVLh0dGWlpaZPOvM7qwiy666NM33TR79vmtbe2zzjtvxowZd991V1tb2/Zt21etXHHLLbfIPEJw4di2puu2bd9//33f&#x2B;e6dZzSFPO0EBACd6ESmQZrakPv&#x2B;l0rrOHcBAkIBwjQNArrBxGg4punJjFHu2009Sn7C38KADp/PByCRSJim6fP5Ujt5x48fP378&#x2B;Gg0KhvwCSF27drFGKuqqpIbfnfu3NnY2FhUVJRIJOTPneu6pmmGw&#x2B;H8/HzDMCKRSGrux&#x2B;TJkydNmtTX1zc8PDw8PBwIBE65KEVRFOV9ToV9iqIoiqIoZ0FJaWlJaWlpWdn999332GOPZmVlPfnkk4ODA4sWLbr&#x2B;hhvGhn2XXnY5gEQicaaTPgDZ2dlXXHnl9777nWgs9qmbbrr55s9dfdXVt99&#x2B;2/79&#x2B;7e&#x2B;8sr/&#x2B;3//sWjRYgCM0Vg8HtR127afe&#x2B;65psbGsvLyM722N4tyUBdMvLpKTEBACAgXnIA4hABCZwRCgBEAFgFGN/TKX5STN33MRZL1fSohfNPGvhNjvwYAuAHgtUr0XvW1M&#x2B;ZRnjf13MIywSAEBAfTAQ5QDA4MGx54TA/Rjl3Z4U5XZ6frmLm5ufKHLpXxveVQ23VdmR7W1tZWV1fLrzdv3lxbW3vppZdmZmYKIbZu3drT05OXl5eTkxOLxY4cOXL48GFN0&#x2B;RYD8dxHMeJRCLDw8OdnZ35&#x2B;fmhUEjTNM75yMjIwYMHCSE&#x2B;n6&#x2B;urq6lpWXSpEnvrfxdURRFOb1U2KcoiqIoinLWzJ49u7S09OKLL66rq6urq&#x2B;vu7iouLsnIyBh7zuDAwNHW1vPPP/&#x2B;dWdJHP/rRgYFIQ339ig&#x2B;tCIVCoVDoF7/81fr16//ff/x7e3tHX18fAJ/PLzckejwezsW&#x2B;mn3vwrDv1Dg4A&#x2B;OCc851qtuWpZvm2V6UcgaltuGS0S9aj7Y3NDZkZaeVl5ebBrNdR2OUgPT39&#x2B;/dty/gy/Z6vVlZWQAcx5Fh31vYzLtv377Kykqv15tIJFpbWx999NFwOFxYWOg4zu7duzdt2jR9&#x2B;vRAICBn43R3d9fV1YXDYY/HY5qmnK7b1NTU2dnZ2toaiUQaGxv37t1rWVZfX9/ChQtlweDRo0fXrFnT0tISi8V6eno0TVNJn6IoygecCvsURVEURVHOpry8vFUXXRSNRkdGRmKx2Il7dY8cOfLf//39B/7053AodLKLnF433/w527bl9kMAoVDoqquumjdv3vfu/G5vby&#x2B;AYDDIGFu37smVK1d97OMfb2pqemcW9qZw5nDNsXTONU7kiFZonHIdFKl6PQIwBkD3JJM&#x2B;Y8yfSaqO77Q5dhNjMUvTNF0fc6dPsjvWtm1d15EsjoPctZpIJE6RzaYa7Y3dikt0dHV15eTkyBisoaFh7dq1zzzzzIoVKz73uSmWZRlGYHBwMC0tbWSIP7n2&#x2B;crKymnTpsnrmKbZ0dHxyiuvzJkzJycnJx6Py723cm3Dw8OEEL/fnzqSWvPmzZs3bdpUV1d3xRVXEEIOHTq0ffv2VatWFRYW2rZdVla2ZcuWw4cPl5SUxGIxQkhmZub27dsPHjzY3d29a9cun89XXl5eWVl51113PfLII7ZtE0LC4XAkEonH48FgUEaE69ate/bZZ48cOQLg&#x2B;uuvN1VsrSiK8oGnwj5FURRFUZSzz&#x2B;fzpcK141iWteGFF//vpz&#x2B;57bbb35nF6Louo4oUIUReXt6Xv/yvA5EIgJycHJ/P9/e//731aOuiRYseefjh1JlqDKhyarFYzOv1er1eALZtM8YIIafoR6lpWiKRIITouk4IkVNxT5FnyZrT0XgXGLOFNicnR/714Ycf/tWvflVdXV1dXT1jxgz5LADkx95xHCGEEEKOxQgEAoSQrVu33nfffQ0NDV/84hcppakYMZFIbNy4cfz48WVlZaknTSWSg4ODhw4dks8rx30YhnHkyBHDMILBoAwNX3755eeff9627a1btzY3N/v9fp/P19/f39fXt2TJkuzsbI/HU1pa2tPTU1payhijlFZUVOTm5k6ZMkVW9vX19TU3NzPGFixYcPHFFxcXF6fSRkVRFOWDSYV9iqIoiqIo72rNzc133333z3720y984QsZGZlnZQ29vT0vbHjB5XzhggUAZs&#x2B;ZQwiJx&#x2B;Pf&#x2B;/6dkyZOWrx4cerMw4cPGboxZerUs7JO5d3PMAyZlAFIbTg9xbZTQoimaXIXreu6tm2bpnnq84/7rmx4xzlnjMViMSGE4ziGYcydO7eysrK6utqyLBk1ygjSMAxCSEdHh23bqeT66NGj&#x2B;/fvDwaDR48ezc/Pl1ejlEYike3bt0&#x2B;cOFEub&#x2B;zzUkrT0tISiURLS8vGjRtt225oaIjH4/fdd59lWS0tLW1tba7rhsPhvr4&#x2B;TdO8Xm8wGEwkEoyxvLy8kpKS6dOnT5gwIT093efzEUIKCwuzs7Nl/Nff35&#x2B;ZmQnAcZzp06dff/31GRkZ8&#x2B;fPnzt3roxE3&#x2B;LboyiKorwvqLBPURRFURTlXe3Fl16sKK8oKy07WHtw7rx58oL6KWcAACAASURBVOBAJNLV1VU5YcI7s4be3r67777b5/P29HTffPPnqqurAcydO/eZp5/esmXLubPOTZ3Z0NC4aOHCd2ZVynuRTNxkdZ4soKOUnroMTU6n0TRNCCHzQVnfd4qHCCFk4CVTQllqh9E4b8mSJRMnTpw&#x2B;fXoqFpQXPHr0aCgUys7OLigoqKurGxkZkd8dGRnJz8&#x2B;vqKjo6OhobGwsLi6W9YO2bQ8NDdXU1LS2tno8HllCmEgkOjo6WltbDx48uG3btoGBgQ0bNvz4xz&#x2B;ORqO6rhuGkSpUNE1TztUtLCwMBALhcDgcDhcVFRUVFU2cOLGkpCQrK8vn8wkhlixZIoQIhULxeLy7u/v&#x2B;&#x2B;&#x2B;9vamr6j//4j3HjxhFCVq1atXz5cq/Xm7qNaievoijKB5wK&#x2B;xRFURRFUd7VbNv&#x2B;wQ&#x2B;&#x2B;P2XK1MHBgdTBxx9//PE1a37zu98FAoFTPPZ0yc/PB0QgGBhbu3TTTZ9mlH3nO3fYtpM62NTY6Myf/w4sSXmPEkIYhiEzOMdxXNfVdT0Vxp3o6NGjL7/8sqZp8&#x2B;bNy8vLkwdPUdknd7DK&#x2B;j7XdVM9&#x2B;wDIzpgejycnJycrK4sQsnv37lgsNmfOnKGhIcbYY489lpmZuXz58oyMDK/X29PTwzl3Xdfv919xxRW6rm/YsGFoaEg&#x2B;u23bnPNYLLZ79&#x2B;5f/OIXWVlZbW1tLS0tTU1NQ0NDfr9f1jBaljUyMuL1esvKyoLBYFpamuM4cpDuhAkTysrKdF2fOXNmZWVlIpFIS0ujlDqOY1kWY0zTNPly0tLS5Ev49a9/feDAgYMHDxYVFWVnZwNgjI3tACDTRtlSUFEURfnAUmGfoiiKoijKu9q111z31wcfSnUcAxCPx1/e9PLjjz&#x2B;&#x2B;edOmZcuXvwNrSEtLu/lznyspKZUZjaTr&#x2B;qduuumSSy7Z8MKG1EHHde&#x2B;55w9f/erXjh1xnBOjnL6&#x2B;vuOGDisfEEII&#x2B;SmSqV/q4Mnyu7q6uvvvv9913YyMDBn2ua77RqbiUkpTp9m2bVnW008//cgjjyxbtuzGG2&#x2B;UMdzatWsjkcjs2bPT0tIIIS0tLa2trbNnz/b5fIZhDA8Pd3V1dXd3m6bpOE40Gk2FaJxzTdN0XZfleOvXrwcgdwfLLC8cDsuQLiMjw&#x2B;PxFBYWlpaWmqaZk5MzZcqU4uJiXdfl8mQ8t2vXrnXr1pWXl1922WXp6empHxnGmGVZtm1rmjY4OLh&#x2B;/XpK6apVqyZOnOj1eoeHh2Xcb1mW67pyeapbn6IoiqLCPkVRFEVRlHe1latWPvCnPyUS8fGVyU27lmXpmj6patLOXTuXLV8&#x2B;MjIiJ4GeUVdf/eETDzLGCouKrr32utSR8vLyf/vKv44bN/6aa66RR9rb2iKRyNTRwaYAamr2PfTgQ7fdfvvY6FD5gJAJlxwsq2lafX19NBqdMmXKyc73&#x2B;/2MMblDVm7OHbs/90SyJZ/rurITX2pD6/79&#x2B;//&#x2B;978/9NBDnPNly5bl5&#x2B;cnEgnLsvr7&#x2B;zs7O7OysmKxmMfjIYSYppmdnS1nhhw&#x2B;fPiBBx5ob29va2vr7&#x2B;8PhULz58&#x2B;3LEsWDwIoKCj4xCc&#x2B;8dxzz9XX13s8nqKiIp/Pl5ubW1JSEgqFxo0bV1RUlJaWZhjG4OBgTU1NNBotKipKDfcQQgwODj755JPbtm2rqakJBoOp0DMejxuGQSk1DMMwDDmu95prrunv729ubg4EAoODg5mZmXID8tjxJurHSlEURVFhn6IoiqIoyruarusf/vCHLSthGMnYghBCGf3Kv/173eFDAPbt2zd79uyxD4nFYgcO7LctRze0mTPPfY2LnlZjC/fmzZtHKb3tG19f&#x2B;/iab9/xnZKSkv5I/7onn5Bhn5VIGKZZVTV57949/1i/fvmHPnSm16a828h9qbIB386dO3/3u99lZGScIuybMmXKypUrbdsuLS2VVYFyrO3Jzk8kErFYbGBgIJFIhEKhvLw8XdeFEAcOHOjo6Jg5c6brurW1tVlZWV1dXVVVVR0dHVu3bvV4PPX19QcPHszNzR0YGJBVcnl5eY2NjevXr4/FYtFoVAhRUlIydsCIzNn/&#x2B;Z//efLkyXKKbmFhodw7rGlaLBYLhUKu6zLGOjo61q9f/9RTTwUCgRkzZmRkZMipxACeeeaZ&#x2B;&#x2B;67b8qUKddcc82VV14ZDocBuK4rkz7O&#x2B;cjISDAY9Hq9jLEbb7xx69atq1evrqioyMzMlBdxHIdSKocayxTyFJWSiqIoygeBCvsURVEURVHeA2TSJ6t4/H5/e3u767p79uxpam7euHHjzJkzx&#x2B;7da2lu/vp//ZdtWSWlpb/4xS&#x2B;Nd7Bbf2Fh4bXXXXfvPfese/LJ/fv3f&#x2B;zjH7/iiis7u7rld59&#x2B;&#x2B;qmly5Z7vd5bbr3VtuzUo1568cVweno0OnL&#x2B;&#x2B;bNPcmHlPWxs9iS3ddfV1f3pT3&#x2B;qqamhlJaWlgKQodjg4KDsapfahEspnTx5cktLi8fjoZTatp1IJNasWTN16tQpU6YkEommpibXdauqquT1H3nkkerq6hdeeEHTtKuuukqO4h0YGOjr61u2bFlpaenq1aufe&#x2B;65HTt27NixIxaLNTU1Pfzww6Zpuq4bjUaXLl3q8/kYY6WlpZmZmZZlrVq1qqGhQe7Ara6unjlzpqwulD&#x2B;JQghd1&#x2B;fMmSOfvb6&#x2B;/oEHHjh8&#x2B;PB11113ySWXyBe7ffv23/zmN0NDQ6WlpVOmTJE/qjKkI4QUFRXdcMMNM2bMmDlzpmVZ8jqp6jxKaWoisDw4adKkn/zkJzITlHFhKm1P1feppE9RFOUDToV9iqIoiqIo7xnPP//8kiVLKKXnnnvuj370w8GBgS/dcsvwyPBnP/tZXde7uroc287OyY5Go42NjQsWLCgtLbUs&#x2B;50M&#x2B;wB861vfzsnJ/b&#x2B;f/qSxoeF/f/zjRx95ZOq0c4QQLnfXrn1i3PjKqqqq&#x2B;fMvsKyEPJ9z/tiaNYMDEQAq7HvfSAV8cnBtitfrjcVi27dv37NnT1FR0cqVKysqKjC6/VYmfYSQQ4cOAZg0aZKmaYFAgDGWSCQ/MAcPHnz22WdjsdiUKVMsy9qyZUtJSUllZSWltLu7e9&#x2B;&#x2B;fQDa29uzsrI454QQx3FGRkYMw2hvb/d4PLW1tU888YTP5/N6vYODgwMDA36/3&#x2B;v1BgKBioqKCy64QA7kraqqKioqCofDN998c3Z2dlZWFgBCSDwe1zQt1Q1wbBmdHM7LOWeM2bYtZwcDsCzL4/FUVFSsWLFiypQp8rXIyI8xNmPGjKysrMzMTLzeDlz5LMFgUE7vxWhCejrfNkVRFOV9QYV9iqIoiqIo7xm6rj/00EPXXnvtNddc89e//jUSiWzY8FxmZta/feVfb7n1S62trUODg6bHnDp1mmVZ199ww5QpUwPBd2Jc71gej&#x2B;eWW2657LLLbr/ttg3PP7dt27ZQKPydO&#x2B;74xm23cSE62turqqoO1tbmF&#x2B;T7/QEAlNLu7q7Ojg6v19fU2BgKh2XVkvKeNraab2zwJ5OvqVOnuq5bXV09ffp0eTwSidTU1CxatIgQwhjbvHlzV1eX1&#x2B;stLS2VDe/q6&#x2B;uLiorkXAufz&#x2B;f3&#x2B;xsaGl555ZUHH3zwyiuvzMzMbGlpefHFF9esWbNly5a&#x2B;vr7ly5fLmbymaaanp/f19f3tb39LJBKMsXPOOScej2dlZRmGUVZWlpmZmZGRkZOTYxjGnDlzQqFQdXW1XLlhGBUVFXLwhaw3PHHQrXxpjuPoun7OOedkZGR0dXUVFxfLZFDX9enTp2dmZobD4bS0tHg87vf7ZVwox24AKC4ulpc6dXKXmkwSCoVkVug4jgr7FEVRlBOpsE9RFEVRFOU9Y968ebffdtv&#x2B;mpqCwoKcnJwJlZWJRCI7J&#x2B;dPf/xja1tbVlZWZeX4nu7e8847v2ry5NWr/37hhYvPyjp1XS8oKPivr3/94osv/sY3vp6w4g8&#x2B;&#x2B;Jenn35q9uw5wyMjAHbv3tXe0b58ebJn3&#x2B;c//4WdO3d4fb59&#x2B;/ZxwS&#x2B;99LKzsmzlNEoV9KWSPsuyhoaGHMfJzc2trq5OBWoDAwOGYTzzzDN//OMf/X7/zJkzAQwNDTU1NfX395eWlqalpcm2d01NTT6fLxqNjhs3bs2aNZs3b25padm9e/eRI0fi8XgikdA0LT09vbm5OZFIeDwe2a3Pdd1QKHT11Vd7PJ7Vq1ePjIxceeWVEydOnDBhQk5Ojq7rgUDAsqy2traNGzfG4/FUNz2MbozlnCcSCdM0TzEFOLWXtri4OBXeyYd7vd7Kykp5E2R9okzoGGOy5FDXddd1ZZ&#x2B;&#x2B;U99V2aww1bJQJX2KoijKa1Jhn6IoiqIoynsGY&#x2B;yGG29ceMH8oqIi0zRvueWW4uISRtm6J59c/&#x2B;yzmZmZB/bvLysvB3Dnnd&#x2B;74SPXNTY2lpWVnZWlbtq06cUXX/jP//yvxUuWPPjggwdrD9bU7Ovp6Tl8&#x2B;PC8efP8gcD&#x2B;mv3Ll3&#x2B;oo6OjtbV11qxZBQUFubk5zz///KaXN6mw731G5lx9fX2NjY0lJSUy8CKEGIZh23YoFAIQCoVisVhfX588MyMjw&#x2B;v1Hj58uLe3t6OjY8eOHd3d3U888cTRo0cbGxuHh4czMzPj8Xhubu4FF1ywf//&#x2B;lpYWwzAmTJiwaNGieDxOKZ0&#x2B;ffr/Z&#x2B;&#x2B;&#x2B;46Oq0/2Bf8&#x2B;ZM71nSvokIT2QEBJapEoogigqFtYuKq6Luvu717KWVXeveNd2d3Utq6iLUlwBdQHpsPSSAEkISShJSO/JJDOZetr8/ngu585GF5UWkOf9h68zJ2fO&#x2B;c6AL/TD83yfUCgkNcxmZmZWV1fn5ORkZGQsWLBAo9FIKWRfX19FRcXhw4c3bdpksVhiY2Nhr71AICCTyWia5nke4j/Yqg8&#x2B;1HeHYLAsS1GUlNxBESL8CMJHQghMB4YklGEYKSKEicNnb8uFDwJTSuBM&#x2B;GwchBBCSIJ/PCCEEEIIXUmyMjOXLlu&#x2B;YsXyUaNG5eePjIiIIIT89cMP33/vvaqqKshB/vKXd/7jP/5z/oMPfv7ZkhdfepkQ4nK5IFK5ZCZMmPDG66&#x2B;VlBwpKLjmV7/61fCcnGef/W1zc/Phw4dmXz/r&#x2B;uuvV6nVhJDu7u4vli/Pz8&#x2B;PiYkhhOTnj9y0cdOlXCe6SMJ7eAkhgiC0traWlpZGRUUpwzaRFATB6/X29PQIgmCz2crKylpaWqqqqjo6Oqqrq3fs2NHY2CiXy2EYrlqtDgQCFEVFR0e7XC6Hw3HHHXdMmzZt7dq19fX18fHxubm5GRkZFotFpVL19/f7fD7YO8/tdh86dGjx4sUKheKOO&#x2B;7QaDQsy0ozbZYvX75p06aMjIz8/Pz09HSpUVc6kMI16EEWRRGSvvCwLxQK0TQtlexBeCe9UWoEhi3/VCoV5IkkLDQ8e1mfdBmM&#x2B;iVn6vvOUmyIEELoqoVhH0IIIYTQFWbmzJkpKSmxsbEajQbOTJs2PT4&#x2B;vrS0bP/&#x2B;fV9&#x2B;8cUnH3/c3NQ0c9asb775BmqRDh86FBcfn56efskWqVQqFz72WEgU4XhKYeHadd9&#x2B;vHjxhx/&#x2B;taa6eunnSyOsluuum2kwGE6eOhnw&#x2B;1Vq9dGysuG5uQOqpVpbW2JiYi/ZstGFAr&#x2B;OUsMpz/Otra1lZWVms9nj8dA03dfX19bW1tTU1NbWVlFR4XK5amtr9&#x2B;3bR1EURHuEELfbbTQatVptbGysUqk0mUxGo1Gj0URERIwdO5ZhmOHDhzscjqFDh0IW5vP5ZDIZhImdnZ2lpaWtra11dXUnT548dOjQiBEjHnvssYkTJ5IzyRp07NI0rVarZ86cmZOTA4M4BEGAvl0prYP7Q2YnhW7Sh4WfMgzDsqwoinBzKYbz&#x2B;XywdSAMG4GTDMOEQiFRFAVBgJke4QO1vwuuCS8nlLbwQwghhAbAsA8hhBBC6MqTmpo64ExGRmZGRubkyZMFnl&#x2B;6dOnKL7&#x2B;sPnVKEMW9e/dOnDjx0OHDJ0&#x2B;evJRhHyHkxhvnSBNUu7q6aJounFo46/pZL/7udyVHjrj73ffde89NN92cl5ff7/Go1OpNmzdlDs2iaTo80dizZ09UVPSkSZMu5crR&#x2B;YNfQUEQpNSvt7e3sbHxjTfeMBgMbW1tbrcbQr2IiIi&#x2B;vj6appVKZTAYNJlMQ4cOdbvd8fHxWq1Wr9fHxcWlpKRAg218fLwoin6/X6VSQRtsIBBQKpUcxykUCrVaTVGU1&#x2B;vVarUJCQlQDOh0OtVq9Zw5c&#x2B;bOnVtYWCjld1DuGgwG77///oKCAhgVIu3NB0k6y7KQ3AmCwPP8vwv7RFHkOE6lUikUCul3L4wVlslksCq4DO4DTcGwZlgPRH4DqgXDSZeFQiGIBc8eDiKEELqaYdiHEEIIIfTzER0d/fwLL4weM/bDv35QVlqqNxr/8PvfL1iwYObMmZ8tWXL291ZUVERGRtpstgu4Hqlhc9PGjY1NTadOnvjs86Wffb505cov//vVV5uamj799JPY2NjsnOxbb72tqrKys6NzQLESx3H/9YffT9r&#x2B;T0LIiRMnMjIyLuDy0MUDfbJyuRyK&#x2B;2Bmi8PhqKmpaWhoCAaDOp0uOjpaq9UaDAa9Xq/T6YxGo91uT0hIiImJiYmJsdvtZrMZBtfC2FmKokpLSzds2OB0Oh999FG73W4wGCCAg0gOgjatVgtrSExMjImJKSgogN39BqwQGtvhtygkfdJLKXGTWmvD99cj/5r0kTN9uwN&#x2B;JF0vnaFpmqZpCOmkGBGG/MLbpd7efwc36UMIIfRj4J8WCCGEEEI/K7Gxcffff39mZsZXq1f/9YMPDh8&#x2B;1NHRce2118pk/xKiVVRUDBs2LPzMzh072tvbX1m06GKs6vCRw/v27vV6vRXHjg3Lzn744QXXXz/75Zde3LRpU3t7&#x2B;6uLFhUXFw/Pze3r7ZOmuIKoqKjy8vKqysqsoUM3bFgvk8m&#x2B;W9WILkNSTCYNo8jOzg4EAl6vl&#x2B;d5jUYTFxfncDiioqLsdntERERcXBw5s7fd6dOnt23bFhUVdcMNNwQCAbVazTBMc3Pzhg0biouLBUEwmUxSzEfC5mZArAZPlDbCk8lk0pWXD6kuj2EYqPijKArbchFCCF0QGPYhhBBCCP0MjRkzNiUlteCaaz7&#x2B;6KPdu3cvrqm&#x2B;5557pAbDnu7u41VVA8K&#x2B;qdOm/ebXTzQ3N0dHR50&#x2B;fTo1Ne0Crueuu&#x2B;6W0TKWY2Euh0wmi4&#x2B;P//Pb72zbuvX1119rbW39&#x2B;4oVMbGxUwun&#x2B;gN&#x2B;2J6MELJv797U1DSj0bhixYpXFi3q7up&#x2B;&#x2B;aWXli1f/u9aHdFlKBQKQRWb3W6fPHnyjBkzOI4jhEC3bPh8W0JId3f37t27q6qq9uzZM27cuDFjxkRGRkK9W1dX16FDhzwez&#x2B;zZs4cNG2Y2myEvg87W8LCPoigoJ4SX4WV3lw&#x2B;KoqR/H2maxg34EEIIXUD4JwpCCCGE0M&#x2B;TxWK5&#x2B;eZb/vj6Gy///vdms7mvzyUIAvyovr6e/k78kZGR8etf/4bn&#x2B;f5&#x2B;zx//&#x2B;78v7GJGjx59/wMPPP74Ew6HQzrp9/uyhg79&#x2B;utv7rn3XjEUamtrUyqVrS2tJ04chwu2bdtGQuTe&#x2B;&#x2B;7bsmUzIWTkyJGnT9c6nc4LuzZ0MYiiyPM8OVO5BsdarRZ2spPL5bA5I8/z8CNRFFmWLSsrW7p0aU9Pz6xZs&#x2B;644w7ovfX5fISQzMzMu&#x2B;&#x2B;&#x2B;&#x2B;4knnrjttttyc3OlyrjwUlDpGPI&#x2B;GJt7aT/3TxCeWV&#x2B;GcSRCCKErF1b2IYQQQgj9nGVnZ6tVqmHZOaUlJYIgwJ5fPr//UHHR3Llzw6&#x2B;sq6sTRDExMbG3t3fTpo1r1q5JS0mlaCojI/OCrCQnJ2fAmb99&#x2B;mmIUIVTpjz//Aszps9YtOgVGSNTqVX33nPPww8v&#x2B;OWjjwoCX99Q9/TTz5w6eXLt2jVRUVHZ2dkCz1&#x2B;Q9aCLKrxOTalUQtAsimJ4Ry00rkq9twqFwmg0JicnT5s2bfjw4VFRUYFAQKVSqVQqeKM0p0UQBEjHoDhOepZUKwcnYdwt/OiyTdM4jpP27IPxIIO9IoQQQlc8rOxDCCGEEPqZe/fdv2RlZT4wf76UI8jlzNatW7/6arV0DcuyX3yx4vXX/njyxAmz2ZyennGoqNjpdL74u99dpNqovr6&#x2B;devWLf38s8WLP1Kr1RMmTlyx4gu7PXLixImNjY1vvfXmDbOvt1isPp9PqVQ&#x2B;/8Lv/v73LwLBwJw5N13YESLo4pGCNnJmsgRFUX6/PxgMwvBZ6NeGnAv&#x2B;mZWV9ctf/nLGjBlRUVHkzMZ/8E&#x2B;/38/zPMdxHMfJZLJQKAS/M6W4EPA8L&#x2B;3ZByHa5dnGK5XZyuVyaXmY9CGEELogMOxDCCGEEPqZs9sjX37ppfBppOnpGaIoLnrlleefe&#x2B;7UyZOEkJaWlr179pSXl3/yySeEkOuvn22z2bJzckRRLDp48GKsymQy5ebmTps&#x2B;3WK1wpkIi8VgMNx99z2FhYVer/fA/v1LPlsiCgIhJCMjw2g07dq5KzIyksKtza4ckPdJwZYoimq1WqlUymQyKMcTBIHjOJZlWZYNBoMqlSolJQXOw5javr4&#x2B;2NcPxnSER2OEEIqipKRP2rnviiCTyViWlfJQj8fj8XgGd0kIIYR&#x2B;Nq6YPw4RQgghhNC5efTRR60Wa/gZs9l8x7x5NdXVb7/952eeeXrp558rFAq/3z9z5sxDh4oJIbkjclNTUw0Gw0sv/15&#x2B;ZqzqBffEE7/&#x2B;1a8Wzp49O/ykSqX68KPFf3ztdb3B0NPdzZ/JiW6//fbDhw9HRUdfpMWgC45hGEjfpAyO4zie56WEi6ZpyO8UCoVcLocQkOO4YDAok8kYhuE4zmQywQgOQojf74dED2bXhhf0hd9T6guGDQEv5237YG1er7eqqqq8vLypqWmwV4QQQujnAPfsQwghhBD6mTNHRDz51FMDTj7yyC99Xt8HH7y/bevW48eP79q1C5IUQRB4jrNYLE2NTU2NjdnZ2RcvK0lLTyeEpKUNHPtrNBrvueeeadOmvf7aaxDcuFwuV5/baDRAdye6skhhX/iGfQNIyZ00eUM6ls6o1Wo4&#x2B;G5brvQI6YCiKOgdvmxBe3J3d3dJScmSJUsSExPvvPNOu90OWxzCZ/R6vRqNBuaNwEfzeDw6nS4YDIqiCFEp3E0QBJZl4SviOC78a0QIIXS1uaz//EMIIYQQQheEzW4fcMZsNj/51FOjRo9e8uknW7ZsWbXqS5vN3traGhcXx/G8JcJy4MDB0tISjuP&#x2B;88knTSbzJV5wT0&#x2B;PwWBYsGABrHznzp1bt27x&#x2B;Xzh28AhdEULhUJlZWV//OMf1Wq1TqfLycmJj4&#x2B;HgBJ2MySEqNVqiqL6&#x2B;voIIVDkqNPpWJZ99913p02bBkNvAoEAFEWq1WqWZaFMcnA/GkIIocGFYR9CCCGE0FXKYDDccMMNqamp4yZM&#x2B;PCvf3X29Kg1mu6uro0bNtwyd67H079q1aqmpsYQCb3yyquXeG3FRUVtbW2dnZ2/ffY5QsixY&#x2B;X//Of2MWPGtLe3OxyOS7wYhC4GqNfzeDyTJ08eNWpUenq6Xq&#x2B;XpovANTRNu1yuvXv3UhQ1a9YsCAHLy8uXLl06fPhwuEYURY7joE6QYRgYXXIFbV&#x2B;IEELogsOwDyGEEELoqpaRkZGSkpKbm7t82bLVq1ZxWu1rr/2xvLxcrdYUFk5dvXrV0qXLHpz/UNKQIZdyVSWlJWvWrKEJuemmmzKzsjiO6&#x2B;7urqys7OvtxbAP/QyEQiGKojIzM1988cXMzEyWZaHHGWI&#x2B;KOuD1t2urq4DBw40NTXFxMSMGDEiEAhs27ZNp9NFRETArVQqFUVRsI8hZHxS9ocQQujqhH/hgxBCCCF0tWMYZsqUwpde/v3bf3knIcFxvKrqnXfe3rhxfUxMjNVipSmqurr6Ei/pmoKC1NTUnNxcGcMQQqZMmcIwjFarO8umbwhdQaAhXaPRjBkzpri4&#x2B;K233lqzZo3T6YSfQuQH18DGfBUVFZs3byaEeL3eysrKefPmQeoNRXwQ9jU0NNTU1Ljdbkz6EELoKoeVfQghhBBCiBBCHA7H/ffPz8jIXL169YcffFBeXu50OlmWtdvtMEkDSIMCLqprpxSWVxxLSkiy2&#x2B;2EkEmTJv9zx84jR45Ex8Rc7EcjdAlAuy7Lsi6Xa8&#x2B;ePQcOHHC73WazecKECQqFQhRFaTBOTEzMhAkTqqurjx071tzczPO8TqebM2eOXq&#x2B;H&#x2B;wiCwDCM1&#x2B;vdvn37kSNHRo4cOXfuXJPJNJgfDyGE0KDCyj6EEEIIIfR/xo4t&#x2B;O1vn/1s6dJRo0Z1dnaKouhyudatXcuyLCHk2LFjb735Zmdn58VeBkVR0ZHRu3fvljKLzMzMu&#x2B;66CwIOhH4eGIYpKyszGAwjR45sb28vKSlxuVwQ89E0Dc28CoVizJgxt99&#x2B;u1arPXjwYFtb27Bhw&#x2B;Lj4weMJO7p6SkuLt6wYUNJSYnX6x2cz4MQQujygJV9CCGEEELoX1it1ltumZuSkrJzxw6lSvXB&#x2B;&#x2B;//&#x2B;c9/qqqqunHOjYeKD61YsUKj1Sxc&#x2B;NjFXgbLcbt37&#x2B;7p6bFYLHBGmlqA0JUOymNpmi4pKVGr1Q6Ho6ioqKury&#x2B;12m0wmaZxuIBBQqVQ6nW7SpEmVlZUnT56kKColJYUQwjAMz/MURcEAX7/fHwgENBqN3W632WyD&#x2B;NEQQggNOgz7EEIIIYTQ98jJGZ6enqFQKLwez/PPP79s6edHj5aFQqGbb77pwP4DlyDsmzRp0sEDBzDgQ&#x2B;cAJtKSM5maJBAIyGQyuVzu9Xq1Wm0gEJDL5YIgwCZ3UkssXAxb5n23ad3n8ymVSplM5vP5CCEajYbneXhXIBDw&#x2B;/1ms5kQ4vF4dDpdbW2t3W7X6/U8z8NlMpksGAwyDOPxeAwGg0KhWLt2rdvtFgTB7XYHAgF4Is/zNE3DJpWiKGq12smTJ7///vsMwyxYsADmezAMEwwGocRPr9dPmTIlLS0tLy9P&#x2B;ggIIYSuTvjHAEIIIYQQ&#x2B;n5KpZIQMv/BhxQK5V//&#x2B;kFDQ4NMD904PAAAIABJREFUJjt27JjfH/B4&#x2B;nW6i9tR63A4HnvsMZ1Od1Gfgi4THMdJ5WxnP/lj7kNRVHhMDNEYIQSyM4/H09jYmJ6eDtGbTCZjWTYUComiyDAMRH4ymUyabEsIgZewYaVGoxEEgZyJ&#x2B;QghPM&#x2B;zLCuKok6nU6lULMsqFIrGxsbFixeXl5fn5ubefPPN48ePlzI4lUpVV1f31VdfzZ8/3&#x2B;FwOByOlJSUxMTE/v5&#x2B;aeXwdFiJIAhyudxmsxmNxra2NqVSCdeEQiH4l5QQkpiYOG/evP7&#x2B;foVCcQl21UQIIXQ5w7APIYQQQgidjclkeuzxx7Nzcnbu3BEbE/v6669RFNXY0JQ1NOtiPzoz66I/Al0mpB3oIEeDlwO2pfsx5HK5KIocx8GYWijZc7vdR48e1Wq1WVlZra2tS5cuLSsrW7BgwaxZs2AUBsMw4QEZwzBSzgiDbuGYpulgMKhUKkOhEBzACuVyORz4/X61Wq1QKLZv3/7NN990d3fL5fITJ06UlpaOHz8eViUIglqtdjqdK1euTEtLy8/PV6lUoijyPN/V1SWKIkSKUthHzjSwx8TE5OTk1NfXazQa6buCZt5QKCSXy1UqFY6rRgghRDDsQwghhBBCP8akSZOys7MjIiIUCsXLL7/Y3&#x2B;8O/2lLS0tsbOxgrQ39DHxvMdq5VajRNF1bW7t582aO42644YaUlJTm5uYPP/wwIiLiscceMxgMKpWKpmmv1xsMBkOhkBSQhUIhjuM4jqMoSqooZBgmvCsWQj0oACSEiKIok8na2trkcrnJZFKr1d3d3evXry8tLU1OTr777rs7Ozs3btzY0dERCARCoZBarYb7RERExMXFvf/&#x2B;&#x2B;5mZmS6X69SpU21tbXl5eZMnTw5vJYZvgGEYv9&#x2B;v1WonTJiQmJhICOE4DsoS4aeEEEEQWJaFfBOb3xFC6CqHYR9CCCGEEPpRIiIiCCH33Htvd083x7PS&#x2B;ZaWlqKDB2fOmqlWawZvdeiKBw2zkLKFH/8kPp9Po9GwLFtUVNTZ2Tls2LDExESXy8XzfGlpaXV19ezZsxcuXHjbbbfFxMRIPbBQWKc4QzoJWR4U90EBIMMwsN&#x2B;fXC6Hzl&#x2B;O49avXy&#x2B;Xy&#x2B;&#x2B;9996urq6//OUvXV1dU6ZMyc7OViqVDQ0NHo/HZDJB&#x2B;R7cmef5pKSk&#x2B;&#x2B;&#x2B;//ze/&#x2B;U1RUVEwGIQFjB49WqVSyWQyqe9YAl/FkCFDYDoHIYSiKNiaEA5kMpmUJMJYj5/&#x2B;K4AQQuhnAsM&#x2B;hBBCCCH0E1AU9cgjv4StykBjYwOhKJnsf//D0u1yqTWaH4xpep1Ok9nc0d4eFR19EZeLrhzSYFlCiFwuD/899uNpNBq/3x8XF/fkk0&#x2B;6XK6cnBy1Wh0bG1tQUFBRUZGQkADXmM1m6H6FTI3jOAj&#x2B;eJ7v6OhQKpVWqxV6aaHxlpyp6evt7W1paUlJSVGpVBRFyWQyt9tdVFSkVqttNtu2bdu&#x2B;&#x2B;eabyZMnNzQ0bN261ePxVFdXu1wuh8MhimIwGISG31Ao5PV6W1tbeZ7Pzs42m81DhgyhKGro0KFmszm8kBDSRpjs4ff7GYaBiSJSNV/oDJqm4V86aTgJQgihqxaGfQghhBBC6KfRarXSMcdxp06dGjVylFQPtW/fvoiIiDFjx579Jhs2bHD3u7u6up5&#x2B;&#x2B;hmsQkJQN0cI8fv9hBC1Wg2tsufQkcpxnMFgyM7ObmxsDAQChJD4&#x2B;PjY2FiFQpGdne3xeNauXVtVVSWXy7OysmbPnq1WqyHp6&#x2B;vr27x58/79&#x2B;2Uy2cKFC&#x2B;Pj46ElVhRFyNECgUBZWZlCoQiFQrA9H0VROp0uMTFx7969GzZsoGnaYDB8&#x2B;&#x2B;23K1eu1Gg0wWCQpunIyEiLxeL3&#x2B;2maloK80tLSAwcOzJkz58Ybb4yOjk5OTqZpWqlUwoJhJ0EoKoQvB94FSZ9MJhNFkaIoaWs/wPO8KIoKhUIq8UMIIXR1wrAPIYQQQgidl7LSspkzZ0kv6&#x2B;vrampqxowdy7Jse3t7MBDgBSEzM3PAu2Qy2fLly7Uazd6Ca6ZOm3Zpl4wuO1CtFgwGGxsbCSGJiYlKpTJ897ofKRgMGgyG3t7eP/3pTytXrpwxY8Z//ud/xsbGxsbGdnV1lZSUbNu2bdmyZc3NzRaLZcKECePHj4cavVAo1NDQcPDgweLi4sjIyEOHDqlUqtjYWGiwhbCvp6eno6MDqgWh0VgQBKVSOWXKlHXr1vn9/mAwCGWDGRkZNptNEITIyEiz2Txq1CgpIvf5fCUlJS&#x2B;88EJvb&#x2B;/y5cuHDRsGmSbUD8KDoGRPmggM84LhRy6XKyIigmVZ2HkQ9hmETQbDRwlfyF8bhBBCVxoM&#x2B;xBCCCGE0Lmjabq5pfkf//hmwYJH4MzIUaPfevPN8ePH19XXFR08eOTIEZVK/fwLLxQUFIS/cdr0GcePV1ksVntk5GAs/HIHG8N99zxsJEfOjGUghMDOcWfJd6TkKLxMDAIsQRA4joPKSihVgwvC6&#x2B;kEQYCXNE3D/AqYBgttttJtBywP5sNC/6kgCIFAQKvVwpxZuD88Di6ApzidztWrVy9btmzu3LkPPPCAUqmUJtLKZDKO4&#x2B;BZfr9fo9FI29JJ2&#x2B;3BMdxt7dq1a9eu7enpqampOXr0qMPhMBgMSqXyyJEjpaWlEAgGg0GHwxEdHQ2DdysqKpYsWeL1eseNG1dSUlJRUTF16tRAIACFcoIg0DRdU1MjimJWVhY509VLURTP82q1Wq/Xz5o1S6vVmkymtLQ0s9lsNBpTU1OtVqtMJuvq6oKSQELIli1bli9f3tnZ&#x2B;fLLLyclJUnfNvwiSuN9w38FpbHC5MzWmVIxLEVR0o/gJSZ9CCGEMOxDCCGEEELnTiaTRUdFf/DBB&#x2B;PGjR86dCghJD8/v76&#x2B;7umnn5LL5YWFhbNmXb9ly5Z33nl7QNhnsUQ89vgTKpVKr9cP0tova1LSB72Z0v5xFEVJ2RAhBF6ePd&#x2B;BTeLgOLwh1OPx6HQ6qBqDSMvr9SoUivC96qCDFUI3iOfkcjkkelLaCLvRCYIgl8ulhA5AaZ5MJoP0CurRIGeEYNHn8xkMBkJIUVHRW2&#x2B;9dfz48VGjRk2bNg0iLbgVz/PSHQghMOlCpVJVVlZarVaz2QypJXwhcrm8ubm5vLzcYrEYjUZpMTabTaPRcBw3YcIEmqZ3797NMAzP8/v373e5XK2trcXFxUVFRR6Ph&#x2B;f51tbWuLi4vr4&#x2B;i8UC37YgCD6fr76&#x2B;vr29vbe312AwQHzp9/sPHDiwfPnycePG3XHHHcOGDQsGg9LcD8CyLM/zXV1de/fu3bdv3/Hjx51O5xtvvDFt2rTwPBc32kMIIXShYNiHEEIIIYTOy5yb5nz00YcvPP/cXXfdPfuG2U5nr1arLSkp0ev1I0eNfPF3L00pLHzmqac62tsjo6LC39jd3e1yucb&#x2B;0O5&#x2B;VzMoavt3u9dBTR9N0z&#x2B;4sd1380FyZmM4iqJYloXt5KQhD3CZlJRJaSO87O/vV6lUMJe2r6/PZrMN2CTuu9NgB1SfhX86QkhDQ8Prr7/udrt/85vfTJ8&#x2B;PSkpCS6A8ka32x0RESGTySBHo2kaZuCWlJSMHz8e8jipJo4Q4nK5enp64uLitFptV1dXR0dHUVGRKIodHR29vb1qtRrGWfA8v3nz5pUrVwqC0NHRYTAYCgoKDAZDTU2NQqEwm83SFwuRpdvtrq&#x2B;v37Jli8lkGjFihM/n6&#x2B;/vr6ur27FjR1FR0TPPPGOz2QghSqWS4ziGYTiO43leo9HIZDKTyZSVlSUIglarnThxotVqnTdvHgSaUjiIFXkIIYQuFAz7EEIIIYTQeZk0afI99967auXKmpra7du36XS6hISEEydO&#x2B;Hy&#x2B;L1Z80evsu3HOjbZIe0try4Cwb&#x2B;OGDbt27Vyzdt1grfwyB62jkDfBpnIwLEIK3SDkCoVCUjPs2UHIJQVYUFJHCNHpdFDHp1KpIEDkOC4UCsFmduRMPCflgEajkRDS3d1dVVX12WefXXfddTNmzIC7Qc8vwzCwToixgsEgTLqAyA9&#x2B;Cg2wUNpWU1NTUlIyZcqUOXPmxMbG8jwPVYRarba0tLSmpmb48OFpaWmCIEh536lTpxoaGmbPnh3&#x2B;wbu7u1mWPXHiRHV1dXNzM9Tu&#x2B;Xy&#x2B;vXv3lpSU9PT0wAReg8GQk5MTDAb37NkTFxen0WgyMjLGjx9///33W63Wo0ePtra2JiUlRZ357QpN0AqFQqFQQC6p1&#x2B;vb29u7u7sJIVFRUdddd93s2bNNJhNcD18UXA&#x2B;Bpkaj0Wg0UVFRhYWFJKzZlmVZ2KqPnCljRAghhM4fhn0IIYQQQui8MAzz2muvd3V2btu2raG&#x2B;zmAwPPqrhR99dOuyZUvXf/vtkr99WlJyhJHLWZaV3uJyuRQKRWdnR09Pz969e8ePHz&#x2B;I679sSaVe0hAGiMngDESBDMPA&#x2B;X93E6l6bkALsHRzqMKDjfDImV5d&#x2B;KmUIYZCIZ/Pp9VqpbsVFxevWbOmqampo6PD6XQGAgGDwSAIgiAI0AgcvgaphBDOS3klRIE&#x2B;n89oNCYnJ2/atKmnp&#x2B;e&#x2B;&#x2B;&#x2B;6bN28ewzA&#x2B;n0&#x2B;j0Rw7dqy4uJiiqLS0NI1GI0Vj9fX1FRUVRUVFVqu1v7&#x2B;/o6PD5XI1Nzc3Nzd3dHT4fD4pHt23b58oijqdLhAIxMTEEEJGjhz5wAMP9PX1JScnWywWrVYbGxubk5MzdOhQuVweFxdHCIHWZvi2gVarzc3Nzc/PLykp6ejooCgqKSkpOjo6KyvrzjvvTE5OZlkW1kwI4TiOZVm1Wu33&#x2B;3U6nfQ9QA4Iv5qEEIZhpJpH&#x2B;LbPYfowQgghNACGfQghhBBC6HxFRES8smhRXv7Ib77&#x2B;SqPRpKWnXz97dnpGxvgJEz786wdHjx6NjY2l6f/rUty3b19mZmZvb9/06TPWrVsbHvZJcQkCEG9JkVD4Tnk/Zlht&#x2B;G59UgYXDAbr6upaWloKCgogioKnFBcX7969e8KECWPGjIFn8TwP8ROU4PE8Dw2wlZWV1dXV0dHRDz74YFpamt1uhzuHx3ytra1yudxkMkGTLzS3QtcwNPl6vd7&#x2B;/v6Ghobs7Oynn37666&#x2B;/rqioWL16dWpqal5eHuRiDoejoqIiGAxCFkbTNBQPBgKBo0eP/u53v5PJZH6/v6OjAwaGhEIhp9Op1&#x2B;tFUTQYDA6HIyEhAWb79vX1ZWdnJyQk5Obm5uTkEEKmT58&#x2B;oAEZ9gcMhULwhUvxKAzxGDVqlMFgOHLkSHd3t8fjMZvNWVlZycnJubm55EwpH9xHLpfD5oZS0kfCSiOlA&#x2B;nrgi8Wkz6EEEIXBIZ9CCGEEELoAhg2LDs5OWXSpIm9Tuc148YTQlJSUlJSHsvOzvlixfKvv/46fP7AkSOH4&#x2B;Jia2trWY7t6e4O35DuxIkTqSmpesPVPrVDKn&#x2B;DWjk46fF4OI4zm82EEJh1Gz7f9nvv893mUOhsXb16dXt7u1KpLCgokMvler3e5XLt2bNn2bJlHMdFRkYmJiaGz/AFEH7J5fKxY8cmJSVlZGRYrVYIHKFDVgofW1tbV6xYEQqFZsyYAclac3OzWq2OjIyUy&#x2B;Usy1ZUVPT397Mse&#x2B;jQodTU1BtuuGHy5Mlbtmz54IMP3nnnndmzZ6ekpPj9/pMnT/r9fqmkESYLy&#x2B;Vym82WkpJSXFzc398P9XEWiyUqKspoNKrV6qSkpIiICJ1OFxUVZTabYZc9KW2EFUJzMSEENteTy&#x2B;UMw8DsYOiMlr522CUwFApZrVaj0Thy5EilUimVMcI14RWU0GssVTJClZ9CoYBPIZVkSoWT0NSMe/YhhBC6UDDsQwghhBBCF4ZarZ40abKUeoCJEyempCRPKSzUav&#x2B;vXs9ms7W0NE&#x2B;dOnXFFytMRmNfX6/ZHAE/amxsOHjgwK8WLrzUq79cSSFpV1dXdXV1X19famrqkCFDwkdSnMX3hn2BQECpVAaDwU2bNp04cWLevHl6vV6j0YwaNSoUCk2YMCEhIYGc6fwlZ4I8uVwuZVspKSlxcXGQUkHgKMV8oVAoFAoVFxd/&#x2B;umnHMdFRERkZGT4fL66ujqdTmexWORyudvt3rVrF8uyNpvtyJEjx44do2na5/PBOODy8vKamppgMHj69GlBEKxWa1ZWFtxciuri4&#x2B;PvuuuulJQUt9ttNBodDkdUVJTVarVYLElJSVqtFqr/NBoNhKFQMRoIBKA80O/3a7Va6IaGKrxgMCilltI4XSlbhGwOBpjAr0h4DAq9z5DoURSlUqkg0eN5HnZChFI&#x2B;OBn&#x2B;qyb1Vg9ocEYIIYTOB4Z9CCGEEELoQvpuAhUTE3vbbbe3trZIZ7Kysl599dWnn3o6MzNz3/79Xq9PCvv0Ov2XX/4dwr6WlhadTgfjIK420K8qk8mUSqXf7z916pTT6Vy2bJnNZktOTpbJZNC1CvkUx3Hh2V97e7tOp1u9evWsWbPsdjvsyifFdiqVCs7wPF9cXAxjdqFIcOTIkRzH6XS6urq6&#x2B;Ph4uVzu8Xh0Op2UgjEM4/f7FQqFXC7fu3fvRx99NHLkyJEjR06aNImE7XPHcdy6deuioqLq6&#x2B;vdbjfP8wcPHty3b5/dbtdoNMFgcN&#x2B;&#x2B;fVu2bHG5XBEREcFgcOHChU6n0&#x2B;12Mwyj1Wp5nof2YYqi9Hp9amqqyWSCRlqO46AFOCYm5pZbbrn55puljQvJd8IyqYWWoijoDZdmBENXcng9nRTwSQckrGk6/FjK&#x2B;KRnQS9w&#x2B;MRhuC3EiANO/pgbIoQQQucDwz6EEEIIIXQp1NbWxsTEwrFMxhwqPvSnP/3PzJmz8vLyOI6TLsvLz3O73XWnTycNGfLturVZQ4dOmDBxkJY8yKRsqKSk5I033tDpdPHx8YWFhbGxsbABn5QNQczk9Xrlcvnhw4cVCkUgEPjb3/7mcDimTJkCeRMM5RAEgef5hoaG/fv3W63We&#x2B;65JysrC8K76urqVatWrV&#x2B;/vq2tzWq1Pvzww/Pnz4e8DII2GNQrl8thm7yDBw/u3r375MmTBw4ckMvl11xzDSyY47iGhgafz/fwww8fPXr08OHDPp&#x2B;vurr66NGjFotl1apVTqezr69PLpcrlcq6ujqv16vRaBiGiYqKioiI0Gg0FEVFRETExcXp9Xq73R4XF5eXlwfxHGSUEPlJIziksAz3vEMIIYQIhn0IIYQQQujS0Gl177//3i23zG1pbl67Zo1er9u5Y0dZWdm1U6aMHj1ausxsjhhbMPZISYnNbjt48KA9MnIQ1zyIpBZav98PI2KHDRt2/fXXWywWjUYjbfcmNdiyLKvVajs6Onbt2jVmzBi9Xu/xeJqamqCIj5xpB4Y6QZlMds0116SkpMyYMQOK9crKyr788suTJ08mJCTY7XaHwxEdHR0IBHieNxgMkCpKoSEhxOPxREdH33fffa2trU1NTU1NTdIjFApFT08PTdMwNOP48eO7d&#x2B;82GAw6na6lpaW9vb2/v99ut&#x2B;fn58fExDQ1NXm9XofDoVAorFZrQkJCVFRUdHR0UlKSTqfr6&#x2B;vjOA5G6BJCYDQH7KxHvq&#x2B;GFMM&#x2B;hBBCiGDYhxBCCCGELo3cESM2btr41FNPevr76&#x2B;rq5s&#x2B;fX1dX9&#x2B;Xf/15WWiqT/Uv34rw7frFj547MzAyPx2O1WgdrwYPL5/NBLZtarR49erRSqYTRFtC9K5Gm5ULyVVJS0tXVxXGc1WrNz89XKBRS46rUNKpWq4cOHZqenq7X6&#x2B;G99fX1R44cOXHixF133TVp0iSbzUYIqaqq2rx5c2Rk5NChQ00mE7Towh04jmtqavL5fEOHDu3p6dHr9TDXAnJAmqajoqL6&#x2B;vqWLFnidrth47zJkyePHTu2s7OzvLzcZDIlJCTk5ORAPzJN01DQF/65BEHYtGnT8uXLExMT58yZM3LkSKlP&#x2B;SzTSBBCCCFEMOxDCCGEEEKXBkVRTzzx6wnjx7vdrqysrF/ceZdCoRg3bvyaNf8QxVD4lWMLCjZt2lRf35CampqamjpYCx5cWq0WpkNASJecnKzT6YqKikRRhBQPivugqZac2e4tIiLirrvugh5YuVzu9Xp5nocN/mia7u7upmnaZrNBhOp0OsvLy3t6eqqqqvr7&#x2B;wOBgNfr7e7uDoVCO3fu3Lx5c0dHx5NPPgl72MH9YT2iKFZWVr7//vtdXV1qtXrixInp6enQIxwMBmFq7ezZs/fv33/8&#x2B;HG73X799dcXFhZGRkZSFMXzPDydZVmYlQHDcGFWBvQaw&#x2B;wL6FP2&#x2B;/1Q0Cd9MzAVZMD2dtIYE8wBEUIIIQz7EEIIIYTQJaLT6d59772tW7aMnzA&#x2B;KSmRYeQPPfxwfn6&#x2B;yWQKv0ypVBqNxj5n7&#x2B;gxY6KiogdpsYMP4jPow4W98w4ePBgZGTls2DCFQgE76EHS5/P5IPUbM2ZMT0/PkSNHkpKSQqGQVAYIHbhtbW0ajQYK9wghR44cqa&#x2B;vVygUJ06c4Hm&#x2B;tbX1T3/6U1RUVH9/f2VlpUqlmjx5ckZGBkyfgMwRnkjTtFKppGk6EAhMmzbtlltuGTZsGFwDGZxKpbrlllsqKyvT09NvvfXWwsJCg8FACIEdA6VPJ3UHy&#x2B;XyQCCgUCik8kOapqdOnZqWlqbVaqOioqT3KpXK73bvwvxfggMuEEIIIUIIhn0IIYQQQuhSGjduXEZ6uiWsOXdEXt53L4uwRDh7e64Zd80lXNrlpbu722q1Sr2r/f395eXlW7ZsueOOO6RuWZjYW19fX1paOnXqVMhM165du2HDBphuIZPJpJCuo6Nj//79sbGxsBdeS0vL2rVre3t7MzIyent7vV6vTCbr6enp6uoSRXHEiBEjRoy46aabIGiTtgiUyWQw8XbUqFHPPfecUqlMTU0dMmQIIaS5udnn88XGxrIs63a7165du2PHjmnTpo0fPx6SPkJIKBSSZt3C54LBuyqVSmo3JoR4PB6GYVQqVXJyciAQCAaDkPFJMZ/P51Or1QOK&#x2B;LCmDyGEEAIY9iGEEEIIoUvK8iO24YuPd&#x2B;zevSshIeESrOfyBL2ufr8fUrCdO3d2dnZOmjQJumjJmSo2t9tdUlKydu3ahISEESNGBAIBpVJps9nq6&#x2B;t5nq&#x2B;pqWlsbBQEoaen59ChQ&#x2B;&#x2B;//35qauqJEydqa2tramo6OzsbGxv37NnjdDqVSqVer9fpdEOGDLFarffff390dHRaWhrLsjRNMwwj7ZQHYV9SUpLBYLBYLHBeFMXa2tpjx44pFIqOjo6qqqqjR4/m5ubee&#x2B;&#x2B;9UEgoiiLLsiqVCt4uCAI5U9wXHuERQjQaDZQxEkJg6i7LsvAujuPgLdLugQAWhmEfQgghBDDsQwghhBA6G5/PW1lZNWrUqMFeyNUlMTHx8OFD9L82bBYdPDhq1Cj6O12cVzRBEL7bl8rzvCAISqVSrVaHQqGqqqpNmzbl5&#x2B;d3dXXB1ntmsxlyQKPRKJPJlEplZ2cnzM3QaDQMw/h8PpVKtX///o6ODpqmT5482dTUpNPpKioq/vnPf8IufsnJyQUFBS6XS6VS2Wy2vLy8zMzMG2&#x2B;80WQywWwQWBssT4rSpE5bi8UinadpuqCgICIiYufOncePH29ubp49e/bcuXPz8vIIIVCap1KpOI6DhmLpI0N9IhwPmNFBznQfS9EevAxfgwSTPoQQQkiCYR9CCCGE0NnwPP/uX95ZtOjVuPj4wV7LVSQ5OTkrK3PAyR07dxyrqHjooYcGZUkXiUwmg9kUoVBIKnOTDrxer1ar3bRpU3V1dWlpaW9vb35&#x2B;fnp6emJiYiAQaGtr8/l83d3dCoVi3bp1JSUlx48fb2trU6vV8&#x2B;fP7&#x2B;/vf&#x2B;&#x2B;998rKytxuNyGkoKBgypQp/f39x44d4zhu5MiRSUlJcXFxFEUJgmA2mxMTEyMjI8m/hm4Qop1lAC7M1pDL5QqFIjs7OzY2dtasWRzHaTQau90OF0gX4556CCGE0CWAYR9CCCGE0NkwjNzn833&#x2B;&#x2B;eePPf64tPUYutgUCsXUqdMGnDxde/qbr7&#x2B;eM2eONGLiZ4OiKKlaDVI/OJbL5f39/V999VVtba1KpSooKNDr9Rs3bty/f39PT09DQ4PT6WxpafF4PDKZTKVSud3uYDCYn5&#x2B;v1WonTZo0ZcoUv9/PMIzD4Zg9e/bYsWPb2tpOnTqlVCqHDx8eERERvlPev1sYOWvdHCxbSgNNJpPZbJauh1nA0jXn&#x2B;zUhhBBC6EfAsA8hhBBC6GwUCvmECRObW5obGuqzs3NOHD&#x2B;ekTmw4gxdDEajacAZvV7v9/k6Ozt/fmGf1NYqCIIoinK5HHa1UygUp0&#x2B;fTklJ0el0EyZMmDt37pIlS1avXt3a2qrT6SiKgm3sYmJilEqlwWCw2&#x2B;16vR5G6MbFxb344ot&#x2B;vz86OtpqtcJGeEajMTExUaPRwC54A5bBsiz0zIqiCPndj2mPhWG4Ug1gKBSCOcIw1kM6H/4xEUIIIXTxYNiHEEIIIfT9fD4fy7Imk0mhUGRlZvX39xNCnL2927dvz87OJoRAlyK6ZO6YN6&#x2B;xsQFmzv5sQKhH0zRFUbBVH&#x2B;xMB5EfIUSr1b7wwgvd3d0pKSl2u72wsLCpqammpiYiIiIiIgIq6eLi4qKiokwmk8ViMZvNDocD7jB8&#x2B;HBBEKCwzu/3UxSlUqmgS5em6VAoBKGeTCaDSE6hUIiiKJ38MV230qgNeCkdUBQlDd5lWZaEbb2HEEIIoYsKwz6EEEIIoYGamhrj4x1lZWUajSY3N5fjORVR0RRNCGFkspycHJfLtXrVqt8&#x2B;&#x2B;ywhxNPf//bbbz//wguDveqfv9GjR//y0Uf1ev1gL&#x2B;RCgnQsFApBIiYFZNIwCrvdrlQq09LSCCGiKI4ZM0atVvv9fsj4LBZLX18fvDQajeF39vv9Wq1WJpNxHEfTtFqtJmcq7KTmXCmbk4I/qZtYSvpEUTxLiV94sZ4oilCZGAqFpAZhURSlKR/fW06IEEIIoQsLwz6EEEIIoYG2bt0WCPijoqLz8kYQQsxmc093j4xhCCGrVq0aW1CQn5&#x2B;/ffu2hx5&#x2B;2Gq1qlSq5ubmwV7yufP7/T09PXEHEljRAAAgAElEQVRxcYO9kB&#x2B;lsHDqYC/hooA0DQI&#x2B;QRA6OzsrKytZlp0&#x2B;fbpSqfR4PNCES9O0wWAYO3YsVMk5nc6DBw/u27fP7XY/&#x2B;&#x2B;yzhBBRFP1&#x2B;vyiKarVaSvekakFCSDAYpGlaoVBAoR/EcBDkhRflSdEeJHdnSejC08Pw0bowlyP8jCiKLMv&#x2B;4C6BCCGEEDpP&#x2B;BdrCCGEEEIDpSQnHzpU3NvrFMUQIUSv1yuVyp7u7mAw2NvXu2rlSo1GDZVWhJAep/PNt94SwkaOXkH6&#x2B;/sVcvknH3/s9XgGey1XKSjog&#x2B;o5ONPR0VFeXv74448/&#x2B;uijra2thBCtVitdDFGdIAjHjh3729/&#x2B;9tprr&#x2B;3fv3/IkCFqtRrq5rRarVwuZxiGpulAIACDfYPBIM/zPM&#x2B;rVCoICtVqtUqlksvlFEVJZX3wFEEQoDkXgsIf3LbvuxeIoggLkO7JcRwhBJM&#x2B;hBBC6BLAsA8hhBBCaKCJkyY988xvlUrl0s8/DwaD3V1d5gjzG2&#x2B;8XlJSwrKsyWxig6zD4YB&#x2B;0u7u7u3btsmYK6dhIhRyOp1wWFxcLGMYlmWPHDmMw1IHhUKh8Hq9NE0zDOP3&#x2B;wkhKpWqtra2vb3dYrFAWRxEb4IgQMxHCKEo6vTp00ePHh06dOizzz47Z84chUIh1dBJmRocyOVypVLJMAzzfb9LKYqCQFDK7BiGgSo/KDY8e&#x2B;Pt90aB8Ba4LZz5wfsghBBC6EK5cv6rFCGEEELoEsrIyJTJmDdef/3QoWKT2fzwwwt4QVjw0ENKlTIUIs3NzYFA4Ouvv46Jjo6Ni3vvvXdvnDOnpro6JTV1sBf&#x2B;wwLB4Lq16266&#x2B;Saj0QilW5lDszo6O4uKisaOHTvYq7saDdgmz2g0ZmdnP/vsswqFIioqSroMgjP4J03Tubm5KpUqKipq2LBhOOUWIYQQQhL86zWEEEIIoe&#x2B;Xmpr6&#x2B;BNPVFdXa9TqtLS01au/Gj4it7e3l2WD367/tqWl5c03Xn/mmafr6uqcTmdRUVFJSQnsszbYC/&#x2B;3/H4fIYTj2GAwsHLll21tbRUVx2QyGceyOp3u2LHywV7g1SgUCkkb6kl75w0fPvzxxx&#x2B;/&#x2B;&#x2B;67IQcckOXBdngJCQmTJ08ePny4TCbDqkyEEEIISTDsQwghhBD6tx588KHt/9zxyCO/jI6Ottlsixd//Mabb1mt1o0bNhYXF8&#x2B;f/2BGRsbWLZvnzLnpww8/NJlMq1etKjlyxHO57n934MCButOn//GPNT3Onq1bNvc6nXV1p0&#x2B;fPq1Wa&#x2B;RyOc9dkdsOXumk8Rc8z8tkMlEUCSEGg0GtVlutVkII7JoHcR78Ezp5CSFyuRyOg8HgYK0fIYQQQpcbDPsQQgghhP4tiqLi4uLyR46El2q1&#x2B;pZbbvnHmrU33HCDy&#x2B;VavPijuPj4xsbG3z77rEqpdPb28jx/4sSJrq6ui7GY1pYWl8t1PneIjIzcf&#x2B;BA3enTQ4Yki2Jo27atTmdvQ0OD2RzBczwWiA0iyOyggg&#x2B;KQ2H/PpiwQQgRRRFyQLhMmoELJ3HwBUIIIYQkGPYhhBBCCP00RqPx&#x2B;RdeWLp0mV6v//Lvf&#x2B;c4jqbpBY88snPHjunTpxsMBq/XezGee/r06bq6uvO5w9Chw2655ZYhQ4bceuutq1Z/5fV63W731i2bQyEhyAalGazhXH195/NE9IOkgFXajA8O4DxMy4VEj&#x2B;d56PNlGEYa0yG1ACOEEEIIAQz7EEIIIYR&#x2B;MrlcPn7ChPUbNs5/8EGVShUIBASBVyoUWVlZNru9vb09/OITJ06UlJSc/0M7Ojp0Ot153kStVusN&#x2B;mAgQFHUs889/9JLL9fW1u7buzfg98tkMlH8v7DP7XZvWL9h8&#x2B;bN5/lEdHZQuBc&#x2B;DBfCPo1GQ8Jq/cIvAFKhH8uyl/NOkQghhBC6xDDsQwghhBA6RwaD4emnn3n9jTedTue7f/lLv9dD07RGo2lpbg6/rL2t7ZOPPz7/xxmNxqNlZdJLv9/f0dERfgHHcb4fUVQYHR3T1tYGx3l5eV&#x2B;uXJU0JNloNEVERIji/1aZ8TxvMBgamxqtNttluwXhz4MU4YVCoWAwCAV9EOSxLMtxHDnT5AuxIOR6DMPASzhWKBSDsXaEEEIIXY4w7EMIIYQQOncymSw2Nlaj0RQVFR0/fry7p0etVsMEVUliUhJNU//uDj9Gd3d3IBCYOm3anj27Gxsa4CRN060tLeGXBYPBL7/88gfvlpWZOWCF8&#x2B;fPv3bKlOG5udAT2tvbW1ZWRgh5&#x2B;OGHMzLSz7&#x2B;cEP0YFEUplUrI/iDIUygU8Cui1WrJmSq/7&#x2B;Z6UuqHrkLhrfcwppngwBaEELrq4X8ZIIQQQgidr4iIiJd//4dJEyeazWaFQmGz2cJ/GhcXl5mZJb2U/of8x/P5fCuWLyeEFE6d&#x2B;tJLL5aWlvj9PqVSWd9QLwrCli1b4DKdTldaWtr3Q7vs6fT6hMTEASeVSmVqairESU2NjV6PhxCya9eupZ9/Ts4Mi0AIXW5kMhnP8z6fjxAihfhKpXJQF4UQQmiQYdiHEEIIIXQB3H777f/1yiKr1epwODKzMuFkUVFRMBhkGEYI2wuvpaVlz549P&#x2B;nmDodjxowZhJAbbrjxuedfePvPby9evLixoSEUCgWCgdraWkLI/v37CSE5w3MgsCOEFBcVndtn6e3rTUxMJIR0d3cdPnz4yOHDPd3dhw8dGnDZ9m3bzu3&#x2B;CKELJRQKwVAX6O8OhULn8NcJCCGEfmYw7EMIIYQQujCg41KhUMTHOwghPp&#x2B;vru600&#x2B;kkhFDkf9t4O9rbOY7dtWvnT715bFwcHKSmpj755JOWCMv/&#x2B;4/fVFZU&#x2B;nx&#x2B;h8PB83zJkSNer1er0RLyv/vuNTQ2fPvtt&#x2B;f2Wfo9/YSQUaNGB4PB0tJSrU5XWVkx4Jr9&#x2B;/d/d3ovQuhSgrBPqVTCbo8URUlxP0IIoasWhn0IIYQQQheF3&#x2B;/vc/aqVCpCSIQlQhCEYDD49tt/3r9/PyOTEULcbve5hWWHDh26buZ1f/vbEpfLtX379ra2Vo&#x2B;nPy4uzufzGY1GaOgjhNhstqrKypqa6p96/4SExK&#x2B;//poQkpSUdO999&#x2B;3evcvtchn0hgGXpaWnBQKBc1g/QuhCcblcMKhHqVRyHFdfX19ZWQlzXRBCCF21MOxDCCGEELooVErVyVOnoM6OIpQg8C6X6&#x2B;SpU&#x2B;u//Vaj1RJCNBrN66/9sb6&#x2B;HkpyfrwH5s/X6fQGg/HNt96yWa2HDx2GCj7IEHudvXCZ3W7Py8tbv359T0/PT7p/YmIix3GbNm3s7OyMj4tvbm5etWqlL2zbvsbGRkKInJHjEFiEBtc333zzzTffNDY2siy7fv36N99889tvv8VOXoQQusph2IcQQgghdFFoddpgMPj6a69VVVbW1tYGgyzPcyql0mQy&#x2B;X1&#x2B;QgjDML9a&#x2B;Fh3d/err776UytxYAP&#x2B;/v7&#x2B;lJTkR375y4b6hjVr1uzdu/fUqVNFxUVlpaWiIGi1Oq/P193V3dHe/lMX/&#x2B;ijv/r0k08&#x2B;/fST1V&#x2B;tfvjhBREWS4j8XyL5j2&#x2B;&#x2B;gQ/o8Xh&#x2B;6p0RQhfQoUOHGhoaWltbN23a9NVXX/X19UVGRuKAZoQQusrhHwMIIYQQQhfLrbfd9uWXX951150nTp7YseOfNputtbW1t7evqakJLti/f39eXt6cOXPObZiGp79/xYoVHR0dt9122/wHH1yyZMmu3bv6&#x2B;/vfeuut1atXmUymYDBgt9u9Pu9PvXNMTMzKVattNltMTKwgCGPHFlxzzTXST6E3Wa/X45RehAaXw&#x2B;FIT08PhUI7d&#x2B;7s6&#x2B;tbuHDhAw88gNN4EULoKodhH0IIIYTQxTJlypRFi1612mwTJ06sr6/3&#x2B;fzp6em9vb3Nzc1frFhBCNm7Z4/b7Y6OisofNeoc7h8dEzP31tsKCsYSQtpaW7/6&#x2B;uvZs2dv27r1rrvvXrdundFoDAQCdrtd4M9xjMaDDz70yCOPxMXHl5QcOVp2VMoo9Xp9cXFxb2/vkSNHTp06dW43R&#x2B;gyIYpi&#x2B;DG85Hk&#x2B;vL9eugb22QwEArA5Zn9/P5yHzlnpLRzHSb20ULcbfjeO4yAoDwaDcMblcoW/hOsH7OnJsizskgmL8fv9oijm5uYqlUqGYZxOZ1tb26lTp7xe70/dGQAhhNDPjOzll18e7DUghBBCCJ2Xvr4&#x2B;lmUjIyMHeyHfIzs7&#x2B;&#x2B;abb05PT09MTLh17ly1Wm212YYNG/b3L77Yum3rkKQhMbGxPp&#x2B;vo6MjKirqHO5vsVhUKpXFao2Ni1OpVHl5eZMmT/7k48Xt7e3Dh&#x2B;fU1tZGR8cIgjBkyBBCiCAINE03NjS63S6j0fhj7i&#x2B;XyxMTExUK5TUFBUfLjwaDwc7O9l07d&#x2B;7ft2/njh2CKFQcq7DZbXa7/RwWf5E4nU6apmmabmtrM5vNdrudoiiKogghoVAIDhCSUBTFcRz83qBpGlI2mUwm/VaRsjO4gBDCMAwcwzWiKML1FEWJogg/gpOEkGAwKJfLnU6nQqHgeb66ulqj0Wi1Wp/Pp1arW1tbN27cWFpaGhsbazAYKIpiWRbuJnXjCoIQCoXkcjlN0x6PR6lUwtRdmqYbGxtra2vT0tKysrLMZnNNTU17e3t6evoP7qdJUVRnZ2d/f7/VajWZTBfpu0UIITQosLIPIYQQQuji0uv1FoslKWlIRkZGQ0NDfn7&#x2B;rxYuvO2O24sOHlixYsWXf//CoDcUFxcTQqqrq5saG8/tKdL/rkdHR7/73vuPPPLLp558qrW11Wg0cixLCHG5XDt37AiFQhs2rn/7z39mWZYQ4vf7fszNMzIyZAwzYkTe8mXL/t//&#x2B;w8xFJr3izvVanVXZ5fD4Xj&#x2B;uefCL&#x2B;7s7Dy3j4DQYJHL5ZDfEUJompaOw0lnoFJPJpNxHKdQKILBIMMw0mVQ0AfBH5TmQZi4ffv2//qv/1q0aNGSJUvcbrd0h6&#x2B;&#x2B;&#x2B;urVV19dvHjx5s2bob5PLpeLotjQ0LBnz576&#x2B;npYEuSGcEBRVG9vLzwoMzNTEITa2lqO47RabUNDw8GDBysrKy/2N4YQQuhyhmEfQgghhNAl8u577y987LGbbrrZZDItXPjYho2b0tLTN6zfMG/e7c3NTf39/cuWLf2f/3nrgjzrhhtvXPvttw6HQ6/TaTQaQojH49Hp9RRFzZ59wx9eeSUUEgkhMMb3RzIYDDfdfNOYMWOnTCmcOHHi379cmZc3oqSkRAyJ7WEzQEpKSk6fPn1BPgVCF1v4vpOCIED77YD&#x2B;2fAiO0KIXC6Hk6FQiOf55cuX7927F94iVfORM8FcKBSCQLCmpmbx4sWfffZZX1&#x2B;fTqcLBAJKpbKtrY0QMmfOnJiYmPLy8t7eXo7jKIoKBAJbtmz5&#x2B;OOP4a8BIGeEpWo0mra2thMnTjidzkAgYDab6&#x2B;vrP/nkk6effvr555/fsGGDz&#x2B;fDNl6EELrKMT98CUIIIYQQuhBUKtUvfnEnHNM0nZ6e8emnn65ds&#x2B;app57s&#x2B;OILV19fX29ffUM9y7IKhaKnp8disZzP4xiGeeihh1mWtTidhBCFQtHS3EzGjImLi4MLPB5Pd1f3T&#x2B;pszcvLz8vLl14&#x2B;vOCR06dPf/rJx7CVGCGkqampsLCwuKgoweGQMQx8lvP5FAhdVGq1mhDCcRxkcxDVSWHZd//tYFmWYRjo9lUoFO3t7V9//fXEiRNHjx5NCAnPBOGN0G8rk8lGjBiRm5tL0/SDDz5oNBrhESdPnkxLS3vggQeWL1/u9XrVajXsx&#x2B;fz&#x2B;Xp7e3t7eyG5k0oO4c7l5eUURdlsNlgty7Iqleraa6&#x2B;dMWOGVqudOHFidnb2Rf/iEEIIXcYw7EMIIYQQGjQajWbeL34xbfr055797e49e9hg0Gw219bUZGZlbdy4MRQS77nn3vN8hEKhgN0AbTbb3r17R4eFfW//&#x2B;c9ZWVnhtUjnYMiQIa8sehUGC7hdru7urvj4&#x2B;IJrrtm3Z69cqWhoqM8bkZealnaenwKhi&#x2B;fUqVPt7e0WiyUlJQXm2ELVHuRx4WEfBHyEEFEUOY5TKpVardZsNickJMBlwWCwp6dHLpcbjcbwmFuhUIwePXrGjBn19fWjRo2C2/I8f/z48YMHD27dupVl2ZtvvtlqtTIMIwiCXC6fMGFCQkJCZmamtABpxu7p06fNZjPHcRzHLV&#x2B;&#x2B;PBgM3nTTTddff73Uy9/T06PVai/BV4cQQujyhGEfQgghhNAgs1gsb7/zlwMH9p88efLDv/61x&#x2B;n0&#x2B;/2nTp2sOHbsu2FfU1NTMBhMSUk5hwdNnz7j/ffefeLXv46KiiaEdHZ2JCYmnv/6yZkYovb0aaVCSQihafp0fV3FsXKNRltVWfnc8y9IOYWE5/nwnc4QGhStra2nTp1qbW0dMmSI3W43m80wDUOlUg24kud5nufhPOzrRwiRy&#x2B;WZmZlGoxEiuZMnT&#x2B;7evdtgMFx77bXx8fEwEge6gE0mU3p6&#x2B;vHjxyGkUyqVoVDIZrNVVVUdOHBg1qxZaWlpcE&#x2B;ZTGY0GvPz87Ozs3U6HTzd7/erVCqWZX0&#x2B;nyAImzZtqq&#x2B;vp2l6165d11133dy5c1UqVSAQEARBq9WeZ1EwQgihKx3&#x2B;BxZCCCGE0OBTqVTXXjvl2munBINBjmUZhunp6YmPj2eDQcW/xmQej2fx4o/&#x2B;53/&#x2B;dA5PuW7mdd09XY8//tijj/5q1KhR14wb19zUHBJFch6VfeECgQDLBuE4Jibmn9u3vfTyy263u6mpMSUldcDFu3btKiwsvCDPReic2Wy2mJgYjUaTnJxss9kIIdIc3gE1fTzPsyy7Y8cOnU43btw4mUwGLb3R0dG9vb2hUIjjuKqqqjVr1kRGRmZmZsbHx0MHLsznhU7effv28TyvUCjgKYWFhQqFwmg0ZmZmxsbGhkIhlmUhGadpWqoN5DgO2o2VSqVSqczIyHj77bc3btyo0&#x2B;nuvPPOCRMmQNIHQaR0gBBC6KqFYR9CCCGE0GVk4cLHvvhihVwupwhVW1vr8/kGhH1qtbr44MFTp06mpaWfw/3vvvue2bNn/9cf/rB71&#x2B;6UlORgMCiIIkNISUkJbCh2Pot3xMev/mr1mDFjCSE6na62trb6VPWM66773osPHz7EMLJJkyafzxPRZUIaOwsBWXhv&#x2B;HebYc9&#x2B;H3gjHPA8L0VvHMfJZDLYLA/abMPvCY3kSqUyGAxCWMZxHEzSgIbcYDAIeRlsjUfTtCiKUKBnMpk2b968ZcuWJ5980mq18jwP83PVavWxY8cqKyvT0tLy8vL6&#x2B;voWLVr0j3/8Iz09/b777ps5c6bVavX5fA6Ho7Kysr///7N33vFtVXf/P7rS1d7Tkm3Z8t5O7DhO4iQkwSbBmQRaoC20FMooo6xCeZ4u4Cn06au0jBbCKquQpISZkL1NnOnE8d6W5SHbkiXZmldX4/fHtz4vNQkhg/4eKOf9R17S1b3nnnPuDePz&#x2B;ny/H&#x2B;&#x2B;BAweOHj0KCp3T6YxGo&#x2B;DsoygqGo0Gg0GtVltQUAAt/xBCFEXp9fprr70Wr4LD4WAPbKLvFRaCKSwsfPHFF51OJ1T7GgyGeDyOz2FZloh9BAKB8C2HiH0EAoFAIBAIXyN4PJ5Gozl5smFWRcXJkw1nd9MzGo25eXlNTU3BYLC0dMYl3EKpVD3zpz/v2rXzT888M2fO3MHBQZVK9f4/No6Pjy9btuxybEHJKSneqal9&#x2B;/Zptdq21laxWPz&#x2B;&#x2B;&#x2B;8jDtJoNLNmVZxxsl5vaGluIWLfNx3Q8s54URO/gjB3gaPhC&#x2B;EDj8fD5d40TYfDYehnx&#x2B;PxwDEXjUbhs0AggCxdLJYlziESiYhEIpALcTM7UAMpijp69GhnZ&#x2B;fw8HB3d7dEIhGJRPF4nMfj1dXV/eEPf7DZbKtXr1YqlWKxuLCwkKbpAwcOvPnmm1NTU1dccYXP5zt06FBjY2NbW1soFPJ6vQ6HIxgMOp3OROWOy&#x2B;WKxWKKonJycs5Q7i4QkA5BSTQajRqNBnI/IBsnHo8Hg0GJRMLhcIjSRyAQCAQi9hEIBAKBQCD8uwgEAuvWrauoqFiwYMGFX7VgwcIbb7jeZEpONaee0equvr5&#x2B;3rx5ZrO5vHxWY&#x2B;OpSxP7gJqaq2pqrtq/b98Lzz83Z85c&#x2B;&#x2B;goRXEQQk6nc3h4CNx5l8CPbvnxz&#x2B;67t7CwyOl0/vnZ506cON7R0eFyucrKysHN5HJNiERikUhkNqdCgz/CNxrwxyUeOdvKl6j3fZHFLxaLhcNhEMgYhsFSHY/HCwQCXC5XIBCckezM4XAShTMulwv6HQ7MhTGFQiFcGAgEBAKBUCj0&#x2B;/08Hg/&#x2B;csVisT179hw8eFAsFre1tWVnZ4MsGAqFNBpNZWWlz&#x2B;c7ceKETqebOXOmWq1OS0vj8/mtra12u/2tt97yeDzDw8NcLjc9Pb2ysnLRokU8Hi8ej5eXl1MUxTAMn8&#x2B;Px&#x2B;Pg70MIXVq3TVgdl8uFbYQ9hy2CpVEUJRaL4Uyapi8qYptAIBAI/3kQsY9AIBAIBALh30UgEGCY0MYNG0pKShQKxQVeJZPJli5b9uabb15zzTVn1PA2nDih1Wopirt586dgUPJ6vX29vaUzLlH1W7R4sVqjufundyGEYrEY3L2pqUkkFOXm5Z2dqvGlpKSkfPDhRxs3bpSIxRaLpbCw0Ov1hsMM1oN6e/tEImFRUbFGo7GP2C9t2oSvDxBAAZ8h2uKMg5jz1/OCHAbSlc/nk8lkWNoTiURwFc678Pl8QqEQ3yUUCvH5fIqiIPUCX0hRlFAonJqaamlp&#x2B;eCDD5KTk5cuXVpYWMjn80ElPHjwYH5&#x2B;/ne&#x2B;850lS5aAWKbVar1eL9w9Ho9D&#x2B;W17e3t/f79YLLbZbBwOh8fjFRYW6vV6Pp&#x2B;v1WqTkpLS09M5HE5ubm5ubi6HwwmFQjKZDC8Z/8nhcBQKRaJH78KByxM7AEIbQYqiwuEwLD8ej4MOSJQ&#x2B;AoFA&#x2B;JZDxD4CgUAgEAiEfxcSiUQmk9VcddXp040UhyooLFSr1Rdy4d1335Oell5QWHjG8bS0tDfe&#x2B;FtPd7fb7XY4HDk5OQsWLIxEo5czyZKSkrvvuWfjhg3rXnpJrdakpaWZU9N27961Z8/uBx586Ozzz3Zync3111&#x2B;PvUUymQwhGf5pbGz0yiurEUJ6vb6tre1yZk74OoB1JRCLsYXt7NPOX8w7MDDA4/GSk5P7&#x2B;vo&#x2B;/PDDysrKgoICDocTDoe1Wi2Px4vFYtBuj6ZpqVQaiUTwffHg&#x2B;APDMBRF0TQdDAaPHTv25ptv9vf3m83mrKwsKMVFCE1OTu7bt6&#x2B;xsTEjIwMh1N3dDXof/Gq325955pnPPvtMq9WWl5frdDq1Wi2VStVqtVwuz8/Phw8GgwH8g9hYB5uAVw3CHHxOLEm&#x2B;2H0Oh8NQdIwbI2JjY3T6nwA434OIfQQCgfAth4h9BAKBQCAQCF896997Lzcvt6ys3O32BPyBrOzs7u7uvXv3VtfUlJWVfWlTLYqiVq5ahb9&#x2B;&#x2B;OGHK1as4PP5sXj8k08&#x2B;CTPMfff9zDPp2b1r14IFC5OSki5ztmlpabNmzTKZkjdu3KBSqdPS0h586OH77runrbWloLAInxaLRhsbGydcrpqami8d84vkBqdzAnISkpKSPB4PQggrIEA4HPb7fKoLU0UJXwfAUIZVLQCOnFHMe55Benp6VCqVyWQaGBj4&#x2B;OOPlUqlxWKZmJgwGAwwbCwWk8vlCCGv1xsKhSA5FyQ/sKDCi8ThcCYnJzs7Ow0GA8uye/bsGR4eNplMubm54&#x2B;Pjo6OjXq9XKpWCUiYWi//617/SNO1yueLx&#x2B;MMPPxwIBGCeIyMjer3&#x2B;Jz/5SWVlpV6vl0gkBoNBp9O5XC6fz6fVasFaiBCClA/w68GwXC43FotBi0AsjsdisXP2N7xAsM02EolAXTBCKBqN4upm2HDSsI9AIBAICKHLClwjEAgEAoFAIJyT4uLiDevXI4TuvPPOeDyenp6empKyf/&#x2B;&#x2B;/3nyybffeisYDF7UaLW1tfv27n3llZf37N69csXKeDz&#x2B;2muvcRCanJxECNXVHbzM2ZYUl0xMTHC53Gee&#x2B;VN&#x2B;Xt76997dunXr0qXLfvv4E4mnUVzuzp07XRMTLpfrku8VCPjD4TBCiKK4LMt6vd5t27YNDw/jEzo7Oz/6&#x2B;OPW1tZLvgXh/zMQd4u1vHg8HgqFsLaFOUP7OwOxWDw8PMzhcGbMmJGTk5OcnExR1ODg4PDw8OTkJFaEm5ub33777bfffhv&#x2B;EuFkW4/HMzo6CkOxLNva2vrJJ5&#x2B;8&#x2B;uqrL7744tGjRzUaTV9f3&#x2B;TkJPjjcGQwJOTOmTPnrrvueuKJJ6677josWfp8vszMzNWrV9fW1lZWVhYVFel0Or/f39XV5XA4EEJQNsuyLLzPXC4XamnD4TCIcQKBAAyJsA8QLYINiZcMTdN8Pp/H4&#x2B;G2gwihpqamd999d/fu3Q6HIxaLXf5dCAQCgfCNhjj7CAQCgUAgEL4y&#x2B;vv7x8fGmDBz8ODBEw0nmpqaSkpKbr/jdoVCkZWVtWnTpvsfeOCTjz/yTk2Bu&#x2B;0CEQqFNE3//Z13ymfNuuPOO398662P/eLR9957DyFUf&#x2B;jQxITrwiN0u7u6koxGaCiGkUily5ev6Ozs7OnpSUpK&#x2B;vu77z375z&#x2B;FQqGhQVvdwYMLFi7EZ/7isceikQiXd&#x2B;n/DTlrVsVf//LC93/wA4FAOGAd&#x2B;OyzLXt272lrbX3o4YdBzVGrVUlJSU6n45JvQfj/DIh9&#x2B;LPP5wPv2xki4PkZHh7esmWLUqlcsGBBRkZGOBw&#x2B;duzYZ5995nQ6r7322kWLFqWkpASDwYMHD&#x2B;7evTs5Odlms&#x2B;Xm5qLpZI/e3t5QKJSSkhIKhbRaLcuyb7755sjIiN/v93q9/f39BoOhuLg4KysL/qYEg8GRkZG2trabb7755ptvhr&#x2B;PbrcbPgSDwRkzZrhcLrDmxWIxUAAlEsmcOXMgBgQWiwtpoQ0fl8sFfx9CKBKJRCIR/BcTRgDV8gw364UAhj4ulwviJsuysVgMCntdLtdHH330t7/9raCg4N57712wYMEZf8EJBAKB8G2D&#x2B;46rrNwAACAASURBVNvf/vb/eg4EAoFAIBAIl4XH4wmHwwaD4f96IkgikZw4frynpycej2u1OofDMWfOHJFIxOFQAoGgru7gD266qbKyUqVWX2wpX7rFMmfO3JKSkvz8fK1Wu2LlSpVKtXfvnh07dkSikZUrV2LRwW63Q7XjOfnssy1erxealCWSkZFRMXt2a2trT0&#x2B;3z&#x2B;//0Y9uiaP4qVOnhoYGV6xYiRBqa2sVCAQCgbCxsdFoNF783vwTk8n03nvv9vX1HT161Grtdzid/f39KrUyJSV1aGjIaDTK5fK0tLTMzMxLvoXL5YLOcXa7XaVS6fV67Cn7BqWUQtjF2W44qNZE01rSOdMYoIA0FAqBs4zD4TAMA&#x2B;oSjBmJRL7IZxcOh/G1kFAxNTUlFAphzHA4zDAMvGxwJkLI7XZDYSzLsg6HY8OGDevWrYOaXFxhCicnzgTDMExfX99TTz1lt9tTU1PLysoaGhpcLldHR0ddXd3ExERJSUlVVRXLslu2bKmvrw&#x2B;FQizLZmZmWiwW0N28Xu&#x2B;&#x2B;fftWr17tcrnA9dbV1TUxMbFo0aI1a9bMmTPn&#x2B;uuvr62tXbVqlcFgmJycVCgUXV1dL7zwglqtvv/&#x2B;&#x2B;3EvPIFAANtF07RQKBwfH2cYxmAwiEQiXDkLAbs&#x2B;nw9Kd3E/Ph6PFw6HYT6wsVDeC2uMRCIQFsyyLJ/PDwQCfD5/cnJSKBSGQiE03fEQLoS9am5urq&#x2B;vhzdZJBLh&#x2B;F1sS&#x2B;Tz&#x2B;fBQBgYGBgYGFAoFCILFxcVSqfRLXzAOhzM&#x2B;Pu71erVarVKp/NLzCQQCgfANgjj7CAQCgUAgEL4y&#x2B;Hx&#x2B;dU3Ngf37k5KSMrOy/H5/4q85ObmhUEh/SaIkh8MpKCjAXyUSyY9uuWXlqlX/9dhjjY2n4rHY9Glo86eflJfPqpg9OxgMCATCxLSEeDyenpau0Wq&#x2B;6C4LFizIzMwwmZIRQmNjY9t37Hz9tdfGx8b0BsOO7Tvso/b//f3/7tixPTU1RafTX8IqYCEv/OWv77zzdltb2w9vuYXLoTo6Ow7X13d1dv7mN79&#x2B;5k9/rq6u7u/vpygqOzv70m7xn8EZ/e9Ax0EJ2Q6JkhlIVBDOgH1n4CmDFwBGA9udRCIBAxpUmELhKr4dn893u924PpTH4ymVSp/PB0NBjq3X66UoCvKgQ6GQRqNBCLEsy&#x2B;FwNm/evHv37vT09IyMDDgBXGwCgSASiUCPuf7&#x2B;fi6Xq9Vqo9GoTCaLRCK9vb0SiYRhGK/X6/F4YJ7xeDwtLQ1Uv9dff31qaqqtrW1wcBD0Mr/fz&#x2B;FwQHezWq1ut5tlWbVaHY1G9&#x2B;7da7Vaa2tra2pqkpKSIKwWluPxeJqamjZv3tzZ2SmTya6//vpzBmug6RaBPB4PW/MikUgoFAIdTSKRcDgciqJAqgMx9IyAXXhqkUhELBb7fD6RSBSJRA4fPmyxWLKysmCr8WNKBFbX0NAQDoeTk5PhjvBYWZYdGxtLTU2laZphGIFA4PF4enp6amtrly9fvnnz5uTkZIVCEQwGL8o7TCAQCIT/MIjYRyAQCAQCgfBVolAoCouKrFarRqMBEQSTkZkJ0sBXhUajee755w8fPkxxuQihrq4um23g1ttu87g9k5OTBw4c2L5t6x133lVaWgrnczicAdvA&#x2B;ccEpQ8hdNVVVyGEbr3tNoZhEEI8mkfz6BG7XSqRjY6O6nT60dHRS84Guemmm30&#x2B;H6gYixYvdk246urqtFrtB5ver66u5vF4O3ft/JaLfYkmRFDZ4DPLsmAoS1SmoH8c9uLRNO33&#x2B;yUSCRZ9otEohFdAXzn0r1ohANofl8tVqVQIIb/fD94xHo8HT8rr9fL5fIFAgKtEw&#x2B;EwTBLscocOHXrrrbdycnJ&#x2B;97vf4cTbhoYGlUpVWloKTrexsbHjx4/n5eWZzWYYZHJysqmpqbOzk2GYpqamrVu3Wq1WaLHHMMzk5OSGDRtCoZDJZJo3b951110nEok8Hg/WvgUCQSAQ2LFjR0dHR05OzvDw8MmTJ3Nzc5cuXQrvJ946r9erVCorKyspikpOTs7MzCwqKkrsLQj&#x2B;Pqg&#x2B;pigqLy9PIBDA3sKuwj6AORHEPpD50LQIG41GI5FILBbj8XjQXA8se3K5PBaLdXV1vfHGGzU1NVlZWZFIBOtxsWmxnmEYLpfL4/Ha2tr27Nkjk8mqq6ulUine58bGxnXr1t18880LFixgWVYgECiVyp07d/r9frlcHgqFZsyYQWQ&#x2B;AoFAIBCxj0AgEAgEAuErJikp6ciRI2cf1&#x2B;l0Esk/bUSxaLS3r&#x2B;/y9SyhULh48WL43N7eZjIl0zRfpVJt275t3769133nO88/9&#x2B;yvfv2b9PR0OOeGG268QMHRaDTBh67OzuKSkoULF951550ZGRkisYjL5SGEbLYBoVB4yQWAuNKQoqhf/upXBw8e1Ol1toGB7u6u7Owc4UHBJfQ1&#x2B;08CK30gHuHiTfDcQZEviFAg/OFkCXCKwWlCoRD8X3hY&#x2B;BwKhaAcFcQshBAuU4UUi97eXqfTWVNTIxKJQMyCa0E4YxgmHo9DHC2Px2NZFp6mz&#x2B;eD1IvOzs7i4mK4xOFwBAKBgoKCaDQqFotdLtfAwIDH4/F4PFardWJiwuVyHThwwO12u93u9evXb968maIolUo1a9asyspKqE7lcDgajSY7Ozs7Oxt7G0Ejo2k6IyNDp9Nt3759//79ycnJSUlJV199dUlJSTweDwaDoMdBXAZMqbKyEmtzZxfUY70P66SJwitcAhXNCCGwOsJB6NaHdxv2TSgUgrWQoqhIJOLz&#x2B;SBHGCZjt9s1Gg12VtI0zePxfD5fZ2fn8PAwGBuNRiPUESOEBgYG1q9fbzabKysrsSdRrVbv2LFDpVL9&#x2B;Mc/njlzJrZ2EggEAuFby7f3v58IBAKBQCAQ/k1IJJLsrKyzjxcUFOCSvWAo9MYbf/vVr379FdpwOjs7k5NTEEJhlj1x/Hg4HJbJZC/85a9TU1P4nImJCb1Od1HDmpKT9&#x2B;7d63Q6rlq69Nixo5OTU1VVVQghx7ijrKz8q5r8woULFy5c&#x2B;Oqrr7z55ptlZWUSsbivvz81JQVkjm9Ko72vHNCzsDcNe9Bw&#x2B;zaojeVwOGDig0pe8PGhad0KISQQCOLxeGya0dHRSCSiUqkSzWVgVVMoFPX19R0dHcFgsKmpKSMjAwyq0WjU5XI5HA6lUpmamoqm3YLxeHxqasputweDQYvFcv/992/duvXVV1998MEHJRKJy&#x2B;Xq6elJSUnBDewmJycHBgbq6uo8Ho/b7RYKhWazWSaT1dTUGI1GpVIpEonMZrNEIklKSkpPTxcIBFi6giWA&#x2B;okHDIVCRqPxySefPHr0qMfjsVgsGRkZOTk58M6AIgYCHLxLDMPAvlEUhcU&#x2B;2CWsqMJx2FUQ4BBCkOSbKPMxDAOSNJfLxaJqNBoF7TVRlAQfq1arzc3NlcvlcHJra&#x2B;vWrVvLy8vLy8sVCgWaVgDFYnFqauqSJUuysrJyc3MT/xFRWFi4YsWKnJwcOMgwTCgU&#x2B;ulPf1pYWCiRSJYuXcrlcmHO/4aXkUAgEAjfGIjYRyAQCAQCgfDVUzF79tkHEyMyJRKJ0&#x2B;H87LMt1133na/qphKx5P1//GPWrFlisVgul9fV1d3/s5&#x2B;98Je/&#x2B;nw&#x2B;XG/b0NCQlZmZm5d34cNqNJrWlpaTJxsUCuXvnnrq1MlToI&#x2B;AWKOblg77enszLiNVA/jJT27v6uz8n/95Uq3WjDucycmmOXPmuF3utPT0vr7eoqLib5vqB/kM&#x2B;CvsuUqlgkpbhBCfzwcbGla1wImGEAoEAlBJihAKBoPgCgQbWjweHxoaAr8bmPKwLBiNRgsLC1UqVTwex6Wyfr8/Go2uW7fuyJEjP/zhD2&#x2B;88UabzWaz2WbNmiUUCg8cONDd3S0QCOBCuVw&#x2B;MDDwzDPP0DTtdrttNtvVV18dDoehhV9WVtZVV10lk8lCoZBer9fpdCaTKTk5WSAQpKamQmAFnImVONDUYC34CC59BYEsMzMTQl3wVcFgEIptIcsCxFAcjwvmRD6fD8pdYtfCxD3HQltvby/Lsnl5ebFY7NixY6Ojo6tWrYJAD7hjYp01aJHj4&#x2B;P9/f0WiwUKlmOxmE6nS01NdTqdIAvu37//o48&#x2B;8vv9&#x2B;fn5MpksEAhIpVLw5anV6mAw2NDQYDAY5s6dKxQKORxONBotKCh48skn1Wo13ALSSBQKxcqVK0FzJN36CAQCgYCI2EcgEAgEAoHw7&#x2B;BCNKkbv/c9&#x2B;8jIV3jTa9Zes7y2Vi6X//Tuu/3&#x2B;wMCANRgMPfaLX2RnZ&#x2B;Xm5kJaMY/L7e3ruyixDyF07333HTr0uclo0mp1NVddBQdLSkvXvfTSI48&#x2B;IhAIEUIdHR2eycmysrLLXEVObu7b7/z9vffe3bVz57Gj0Xg8rtFowyw7PDQUDofLy2dd5vjfOMDI5vf7&#x2B;/v7&#x2B;/v7tVotl8uVyWTgqoNQ3Xg8HolEOjo6srKy&#x2B;vv78/Pz0bSpDSHU2dl5&#x2B;vRpvV4/c&#x2B;ZMhULh9XqHh4ePHz9uNBqnpqbS09PVajX2gkG16XvvvdfV1XXLLbcsXbrU5/PJZLK&#x2B;vr6xsTHwrJ0&#x2B;ffrAgQNer5em6QMHDpw4cWJqakqhUBw8eHBkZGR4eDgQCOTk5MhkMj6fX1paOnfuXNDFwuGwVqtdtGjRvHnzpFJpYvYFZHcghCQSCawLFgXhHvBTOByORCL4K0IIOhXGYjGPx8Pj8eRyOZfLhctxES7IcNgKBwogy7IgKSamasTjcUjUBX0Qpsey7MDAwKZNm3w&#x2B;39q1a9PS0lpaWg4ePFhVVWU0GkEWhLLozs5OlmVLSkpkMllra&#x2B;vGjRsPHz48d&#x2B;7cVatWlZSUgMyqVqvBaXvixIne3t54PG6328PhMETuomnt0ul0trS09PT0yOXyoqKixBCPvLw8hBCIelC7DR39uFxuLBaDQYjkRyAQCN9yuL/97W//r&#x2B;dAIBAIBAKBcFl4PJ5wOGy4pJTb/0MsFktmZib9rwmeO3ZsFwoFcrniEgaUyeRer/eVV17e9P77AoHg3vt&#x2B;lpuTa0hKys3NnVVRAWqOx&#x2B;Ox2&#x2B;1FRUUXO7jZbMZuMsBgMLz33rt2&#x2B;6jZbJZKpR6Pp7u7Czq1XT7FxSULFixsa2vr7emx2QZMpuTMzMye3p68C5ApXS4XmLPsdrtKpdLr9aCIoX9NvfiaA43qoLSWy&#x2B;UKBILJyUmn06nX600mEwh5LMuCH41l2bfffnvTpk3xeLyurg4nS8BQW7duXb9&#x2B;vd/vT0tL4/F4HR0ddXV1SUlJKpVKo9GoVCow98ViMYZhIGy3ubl5YGBgamoqJycH/mbV19fb7fZ4PD46Onro0KH29vaTJ0&#x2B;uW7fu2LFjixcvpijK7XabzWaNRjNz5szvf//7a9asmTdvXklJydKlSysqKiiKAgUNIcTlcqVSKY/HYxgG1EPwGCKEwuEwl8uNRCKwLvwrpMRAgzyQIxFCYHaDmUskEoFA4PP5&#x2B;Hx&#x2B;IBCAG4VCIVDBQqEQFOHy&#x2B;Xyo4QWvHJwPGt/ExITVau3s7Gxvb&#x2B;/o6CgtLY3H46FQCGTKbdu27d692&#x2B;VylZaWjo6OWq3WNWvWgKcSIjXa29sff/zxd955JykpqbCw0Gq1NjU1IYTq6uqsVqtQKKRpuru7u6Wlpbm52Wazvf/&#x2B;&#x2B;1arlcfj&#x2B;f3&#x2B;4uLitLQ0iqJAtqMoSiAQpKSkzJ07d9myZSkpKXghsD9oOg8EipFBAEXTjRe9Xi/omOeHw&#x2B;GMj497vV6tVnvJnTcJBAKB8PWEOPsIBAKBQCAQ/s8Q/&#x2B;v/kw8MWCsqZre0NKekpF7agA8&#x2B;&#x2B;FBqqvnpp34nlUqvueYahFCYYcLhMLb5iMXiqclJhNDJkyfN5lSt9uL6953Byy&#x2B;/8vrrrz366CO33nqrVCKlaRpn7F4&#x2B;Go3md797as&#x2B;e3X97/fU9u3ddvexquUz&#x2B;lYx8TuLxOGhnIKZArSuPxztnTsg5gx2&#x2B;FAhqQNMhtjRNQxQs6DsIIRytAHGuHo8HVBi/3y8QCPLy8vLz861WKz4TRvP7/QghmUy2atUqiqLGxsY8Ho9er0cIweTLy8uzs7Ph7mNjY5999lllZWVNTc3o6OiuXbs&#x2B;//zztWvXGo3GaDQKDrKDBw9yudyUlBQwzSGEAoGAUCgcGBg4deqUQqHQ6/V5eXlVVVXj4&#x2B;Nz586FYt7h4WGRSGQ0GsViMYito6Oj4&#x2B;PjUqkUh1ok9tpD06304AOuS0UIQe0t7AlcC3Y8eEzwXAKBgFgshq2DMyORCGigfD4fl9bipocURcF&#x2B;QqtBKLCFMTkcztDQUGtrq8/ns1gs27dvnzlzpsfjkclk0AYxGo1WVFT09/c3NTW999578Xj8jjvuwNsF73woFMrJyRkcHNy5c6fRaBQIBBaLRaVStbW11dfX22w2jUYzPDwcDAbj8fjGjRvnzZt3xRVXBIPB5ORki8VyRi2wyWQymUz4zcHOPpqmcd9GDoeDI0fgK7yTie0CCAQCgfDthIh9BAKBQCAQCF8LnE7n0OBQ1fz5M2bMPHbs2Oxzdf37Urhc7g033HDVVVeNjY3BEb5AwE8IY5XL5ZDGax8Z2bdv70MPPXyZ0/7ud6&#x2B;vnF358svrJBJpUlLSnt27V69ZEwqFJpzO5JSUyxwcIXTlldVXXln9v7///cZ//GPZ1csuf8AvgsPhgDYE8hBFURAHgf1x0WgUUiwS&#x2B;7tdFCAdglwFsg6IeiAniUQiSHSFW6PpVA2YGMg6R44caWlpqa6uVigUYPLicrmgcK1du7a/v18oFJ4&#x2B;fZqm6VAoJBQKg8FgIBAoLCyEa0&#x2B;ePEnT9MjIyJYtWw4fPux0OhFCK1asMBqNCKGpqSnI4nA4HC&#x2B;&#x2B;&#x2B;CJFUf/93/&#x2B;t1WqDwaBYLF6wYMGePXu8Xm9VVdWcOXNyc3NTUlIQQl6vF9QljUaT2F4QIaRQKHg8nlgshu3CmcLnBHxtsVhMKBTCYlmWBataYg8&#x2B;EEMZhoFVYwERPsP4iSXJ8BMchxAMDoczPDzc39&#x2B;vUqmUSiUogCKRqKCgANx/M2bMALscBA0fOnQoGAzOnDkzPT3dZrN1dXXZ7XaapsHoCqnEaFqgpGnaZrO98cYboVDIarWOjIz4/X4Oh6NSqXQ6XX5&#x2B;flpamtlsjkaj8&#x2B;fPz87OdjgcCCHY/2g0iouOzwZiWBJ3GJTiS3sVCQQCgfCfDRH7CAQCgUAgEL4WWPv7FUoFQkgul58&#x2B;fbqgoOCSLXJqtVqtVp/zJ5FIJJVJEUJJRuNzzz370EMPBwJ&#x2B;sfjLi/6&#x2B;CJFItG3bthf&#x2B;8tetW7c&#x2B;88c/5ubmZGVnMwzT091dWFjIFwiys7MveXDMAw8&#x2B;uHfvXrn832hZwg47nKaKlSn4CZQ1qBu9BFiWRdMd2fDI8BVrf1DrihACAUskEoGnDw6GQqHjx483NzenpKTodDqJRBKNRnt7e6PRaE5Ojtfr3bVrV3p6eigUgnZ4Xq93x44dBQUF0E5u3759NptNp9P19/fbbDaVSjVjxozFixfjNotQ&#x2B;&#x2B;l2u&#x2B;fOnXvXXXclJSVde&#x2B;21Xq&#x2B;3sbERqnSHh4dzcnKWLVtWUlICxbAsy4LSB6ocfICoWQ6HIxQKsaUUOyXPs0VYAIXRQLPDRjaczgHbleiCxM4&#x2B;kOewtgh3hKn6/X6wSVIUJZfLLRYL3E6pVNpsNoPBYDQaW1paOjs7fT5fcnIySI3QaK&#x2B;/vz8tLW327NnZ2dmTk5MdHR1QVgyPFfySL7/88s6dOwOBQH5&#x2B;/tjYmEwmq6qqksvlGRkZcrlcrVZLJBKZTGYwGEBzDIfDPB4PZD7g/CIyvJNnHMGbQyAQCARCIkTsIxAIBAKBQPhaEAgGhaJ/FusZjcauzk6lUrlp0/sP//yRMwxTlwPF4aSmpj7zzB9Likvkcnk8Hj906BCXy5s3b15iCADQ19eXkpLyRVYjgMfjPfDggwih2tra2tra3/3Pky88/1xefoFMKuVyuQ8/9OBdd/102dVXn7nYQGBiYiI19UKrlQ8fPjwyMrxgwQ0XvNCLBjQ&#x2B;7CMDQOaDzmhwHPIfLmF8bDcLhUIej2d8fNxgMBgMBpDG4CeWZUGcomkajoMAB53d9u/f39raCjITHB8aGjp48KBIJDKbzR6Pp6enB8Y/ceJEUlJSU1PTpk2bMjIyKIqC6tGmpqbBwUGpVJqVlbVs2bKamhpQ&#x2B;qDCVygUMgwDUb8WiwWksampqVgs9tFHH23ZsiUjI&#x2B;OWW27Jy8vDa0EJtcnBYBD0OBgH9ipR3Tu/Bw2PA9eCSpi41bDzgUAAbkHTNOh9IIGB8Q1ckIm3i0ajkUiEz&#x2B;crlcpgMDg4OJiTkyORSHp7e0dGRsrKyoLB4NNPP/3zn/88IyNjYmJiYGBgaGgIIaTVavv6&#x2B;oRCoc1mYxgGElGsVmtDQ8Pk5CT0N8SNEQcHB30&#x2B;3zXXXDNr1qz8/HyRSCQSicBZGY/H09LShEIhrgeHhoMgHGN9&#x2B;TyePgArfSA3w&#x2B;q&#x2B;KQ0oCQQCgfD/GSL2EQgEAoFAIHwtsFgsn3zycVFRMUJIIOAfO3bM6506evRoc3NzaWnp2ecP2mxyhQJcQheOSq2eVT7ryOHD99xzt0qlGhgYcDicu3fv&#x2B;vnDD/3tb2&#x2B;UzpiReHIkEnnssV/85je/lcvP1ywvUdD571/&#x2B;6sTx40899Tuz2ZxqTl338iuP/PzhJVdeeYaQEY1GX3rpxd/&#x2B;9vHzCxyJt8jJybFarVCR&#x2B;u8A&#x2B;tPhBA8odgYBlMvlgs8LAnDBZ3ex5ZMMw8C1J0&#x2B;edDqd8Xhcq9UihCBWAnx8HA4HglljsVh9fX12dnZKSgp0c2ttbX3xxRe9Xq/X6120aFEwGBQIBC6Xy&#x2B;fzud3uuro6iKOVSCSxWOypp57i8/mhUMjn8x05ciQtLW3&#x2B;/Plr1qypqKjo6urKzMy84oorsrKyEk1z8AGkq1gsBkWyoVBIp9PV1NT4fL7i4uLCwsL58&#x2B;cLBAKWZaFjHX70HA5HIBDgVoY8Hg&#x2B;78HDt8/n3B3xqOEUXiMfj0WgUtMXR0dHR0VGpVJoyXR7u9XrVajXk9qLp9xD2GT&#x2B;7kZGRiYkJhUJhsVgaGhpOnTqlVCp5PF5jYyPDMFVVVSKRyO12d3R0OByOI0eOcLlcvV5/8uTJhoaGvr4&#x2B;p9M5PDw8Z86cVatW2e32jz76aOvWrQsXLkxOTobXAFo9xuPx7OzsW2&#x2B;9NTMzE0t4brfbZrOp1eozhDlcXIzNieDag736oo0CrRC/fnDJORtKEggEAoFA/t1AIBAIBAKB8LUgNTW1paXl1KlTubm5sVh8584dWp0uJye3r6/vnGLfxMTEofpDN9xw48XeSKVW/&#x2B;Kx/xoaHt69a9fqVSuv&#x2B;853LOnpu3ftXLdu3Uvr1iWemZOTc999P2tqOj1//oILH39WRcWHH328bt1Lr7322qOPPpqRmblly5a1a9cmniOTycZGR3t7e/Pz8y9kzKqqqgufwOUA6Q0oIRIBIQTpqOFwGHq6XVqXNGzfS09P1&#x2B;l0FEWZTKZ4PP7JJ590dXVJpdLq6uqcnBzcru7IkSPxeNxkMgWDQalUCn632bNnx2Kxtra2P/zhDxKJxOFwnDhxwmq10jQ9NjZWVFSUmZk5Y8YMl8ul1Wpzc3MhOlYqlWo0mpKSkoULF8ZiMVxQzDBMMBgEcQ10Opqm3W63UqkE&#x2B;U8oFMLxG264gWXZWCwGqzjD/8gwDKh7EF&#x2B;L623RWdYzLG&#x2B;dDYitcH5/f39vb6/BYCguLsYjQDzIzJkzs7KyWJbt6upqamqqra0FvRvu2NrampqaKhKJ8F28Xi&#x2B;E4VosFoj1OH36NJfLHRoaGh4efvPNN91ut9Vqfemll/x&#x2B;f09PT3V19dq1a5uamqxWq1qtrq2tNZlM5eXlWVlZvb29XC531apVtbW1GRkZ8ETAYCiVSjMzM6HgOhAIQGmzSqWqqqry&#x2B;/0wGQj2BYUOujEGAgGpVIpzh9F5FWTQ&#x2B;MD1ecZBAoFAIBDOgIh9BAKBQCAQCF8XHnrooeeff16r0Q4PD/3wR7colcrnnn02yZh0zpMtFsuOHdsv7UY0TT///Auf19X94hePfvrJJ6mpqWZzusfjCQaDXC7X5/Phln86rdZgMFzCLe68867a2tonn3hCqVS&#x2B;9uorq1atAhlramoKfIJp6ZavKrf3KwG70rAgxTDMwMCATCbT6/WQlMqy7CUXTnZ3d58&#x2B;fXrWrFmg3x07dszj8bhcrk8//bStrY3L5TocjjVr1kBMxPDw8OjoKMuyFEXBLpWUlDzwwAO5ublNTU0vvfRSfX290WiEiVVWVkK1dXl5eVVVlV6vr66ujsfjKpUq0SUHOpRUKoUHAQkeCKF4PB6JRLDMBLkTDMOAhsXlciHCArKDYXPwRjEMA9PDNc64X97k5KRCoQBZEDc6PE9BejgcRghxOByn09ne3j48PIyTeUOhEIfDYVnW4XB4PB54WMeOHTtw4EBeXt6MGTPgoUxMTOzbt2/VqlVQRxwMBoPB4NDQUHd3dyQS6e7u9nq9x48fr6uri8Vidru9v79/3bp1kHvL5/NNJlNFRcXChQuXL1&#x2B;elJQUDAbh7gzDKJXKeDyekpLyyCOPMAyjVqsTM4VpmtZoNDqdbmxsTCqVQvkzwzDhcFgqlUqmE7eFQiHeJRgZ23Jh/udRQlFCGThotfD1POcTCAQC4dsMEfsIBAKBQCAQvi5kZ&#x2B;f89Kc/PVx/WKFQLF&#x2B;&#x2B;nMfjJSUZjh8/fs6TpTJZUkJ3f6Curm7Bggty4QkEgiurqzds/McHmzZ9&#x2B;umngYDf6/WC7Wj//v3YiFd/&#x2B;HC6JT0rM&#x2B;sSlmM2p7362usffvjh559//umnn8KYzU1NVfPnI4S4XC7WQb4OgOBFUVQoFILGeT09Pbt3787LyysuLjaZTGg6cRVyYy&#x2B;wABmzfv36TZs23XTTTffdd59MJhsaGmJZVq/XL1u2LCkp6ciRIx9&#x2B;&#x2B;GFHR0dVVVU8Hj916tT4&#x2B;LjH44HKVoZhFApFdXU1Qkij0bAsu2zZMolEwuFw9Hp9QUGBPGxmygAAIABJREFUWq0GCTUUCnm9XqPRCPNMdH5RFAUbDnorKH0QZwGaEfgWYRCRSIStiHAVVIxSFMWybCQSga55NE2DTw0hFI/H/X4/aH9Wq9XtdpvNZp1OhxKSZM8fQIE9lSUlJXPmzAF/HEKor69PIpGIxWKapj0eD8MwsVhMoVB4vV6fzxcMBmEtfr&#x2B;/v79//fr1FovF5/NZrVafz9ff39/a2urz&#x2B;Xw&#x2B;n1wup2k6IyPDaDSaTKbvfve7GRkZCCGlUqnVanU6ndlshnFmzZoFq9iwYcORI0dWrFiRm5sL9ctarZZhGMgPiUQisBV6vV4ulysUClD6IKFYIBBAvgoUgOO1Q3dIsDFCO0VIGT6/jgy/BoNBkDshQZj07CMQCATCOSFiH4FAIBAIBMLXiPz8gvR0C8X5p/CRm5uXnPzPDmXYigVQFEXT/6I3jY2OdnZ2FBUWqr4givdsGhtPWSyW115/fevWzz7YtOmHN9989z33jI&#x2B;Nwa/1hw5t&#x2B;fTT2hXLL03sA9auXbt8&#x2B;fJXX3kFITQ1NRUIBuG4Vqv1&#x2B;bxflBr87wMLTwihWCwGohhFUSBageAFGgqkl7AsW1NTY7PZIKo1Pz9/2bJlWOmD2l4wbeES4M7Ozs7OTqVSOXfuXJZlxWIxwzATExO5ubnQHm5iYsJms42NjYE219fXNzo6arfbOzo6Nm/ebDKZkpOTs7KycnJyoHg28bmLxeI1a9aEw&#x2B;H29nabzQaN8yBrBQJw4WRYYGKmMJoWjBI7MELxLGwLKH3QNQ96AoKsCVfxeDyo&#x2B;YVLYOEymQwLoInhGPv27Tt&#x2B;/PhDDz0EIh0chxcYRMNAIABtAdG0o43H473//vvBYPC73/2uUqlsbGzs7e2tqqqC&#x2B;OBgMGg0GuVyOdzX7/dLJJKMjIz&#x2B;/v6Kigr8NCUSybvvvjs8PMwwjMlk0uv1Eolk/vz5WVlZ2dnZDodDp9NlZ2er1WqtVsuybGdnZ0dHh8lkKi4uhsng14DP5xuNxquvvnrhwoWZmZkooZWhQCAIBoMwZyynVlZWYjkPZEp4cLCxsEvQkg8eCiQOQ&#x2B;tD2OHEJzU4OBgKhRiGOXny5KJFi5KTk7lcrtPpFIvFzz33XHt7&#x2B;2233bZ8&#x2B;XLc&#x2B;w9Gw70RsU2VQCAQCN9OiNhHIBAIBAKB8PUisfQSIYRrXdvb2wx6gyk5Gb5yOJwwE/Z4PHa7HTrfiUQilmVl5w3TOIPa2uX79&#x2B;/T6XQPPPCgJd3yxBNP3HH7T6697jqEkM/n3bBxPc2jx8fHL3NFAoHgnnvvRQhFo9HQtNiXlJQ0OTl5zvNDoaBQKDrnT5cPTkKgpsGThA88Hg8XqJaVlfH5/NHR0W3btvX09EilUpFI5PP54ByZTMbn87HCBWJNJBJ5&#x2B;eWXd&#x2B;7cuXTp0tmzZ4M8BFkNGo2mr6/v4YcfBksaQigcDiuVSolEUlhYWFNTk5KSotFooGBWKBQWFxcnxi9AFS2fzwdNB4pJJRKJRqPBd0&#x2B;Mrz1D6TsDhmESBUqsDZ2RkpEoa&#x2B;LRYK/4fD4od1BuDGvn8/l&#x2B;vz8UCk1NTTEMgz13IHKh6RgNsLbBCZFIhKbpnp6e1157jaKokpKSGTNmeDyeqampiYkJsVjs8/kCgYBOp4M4jrq6um3btjU2Nkaj0aysLDxzk8l0xRVXCIVCkUjE5/MlEonZbM7MzJRKpcFgsKWlRSQSZWRkZGVlgfrm8XhisVhKSopIJAIhEix4eH8EAkF&#x2B;fn44HIaHCPsJMiXeHxwKjI/g9BLchg8nBfN4PBAiMzIyeDwejtfARlF4M8fGxj7&#x2B;&#x2B;OPdu3fTNJ2enj579mx4rCqVavv27YcOHfJ4PG&#x2B;88YbRaAQHIkVR&#x2B;/fv7&#x2B;3tLS8vLykpSXQREggEAuHbCRH7CAQCgUAgEL4BgAspP78gEok0NDRUVlYihNgI&#x2B;&#x2B;GHH7S0tJhTzfc/8IBcoYCcVlz/&#x2B;KWIRKKrrloK0sA1a9cuWLjwwQfudzqdCCEej&#x2B;7q6urr7UueDj89J7FYzD4ycv5zMFKpdHBoED6rVSqfz&#x2B;/zeuvq6q6urcXnNJ0&#x2B;3dbW9t3rrz9Pf7fLAVJfE0UxNF2jihACNQ0KVLlcrk6nC4VCDQ0NLpfr4YcfNhgMvb29R48eLSsrw73twNEWiURAHtq&#x2B;fbtIJLrttttAeHK73VKpNBqNSiSS9vb2SCQChbcmk0koFCoUCpPJpNPpDAaDUqkUi8WhUKi7uxuMgaFQSCwWgzUM1EmBQABT5XK5Wq1Wo9FgUQnASzu/0ocQgjSJM7Jcw&#x2B;EwlDDjofDgWPULBoN8Ph&#x2B;788LhMKh1aFrI4/P5ZrO5vb0devZFIhGv15uUlIQQCgQCoCSGQqGenh6Hw5Gdna1UKiORyMDAgEAgMJlMPT09brf7888/93q9g4ODIyMjTqezuLjYbDbLZLJIJDI&#x2B;Pt7b25uWlpacnDxjxgyapkGg5PP5c&#x2B;bMueKKK3g8HojgoPdBA0FYGgTawkKUSuXs2bNBoIQjUMYOo8EmYDEX9h9NJ7fEYjGv16tQKMCyB0fgQnh5YrFYNBqNx&#x2B;N8Ph9aJUYikUAgsGnTJpZl7777bgjogERmmAO25oFRFMe2mM1mHo8XDoeDwWA4HH7ssce8Xu&#x2B;GDRs8Hg/ojNFo9Pjx4/v375dIJAUFBYj08iMQCIRvPUTsIxAIBAKBQPhmcOTIkRtuuLGp6XRPT8///v7ph3/&#x2B;CEVxenp75s2rYpiQzWYzm82Tk1P5&#x2B;Req9AGJJiCtVnv7HXeAq04oFP7mN48//9yz0CMsEomMjY6eLepFI5Hnnn/&#x2B;gQfuNxpNX3ovmqYZhunv77NYMmKxWEtzc1dn5&#x2B;HD9Tq9HjxKCKHe3l6lStXX25uVnX1RC7lwQMqBpmlYEfP5fBKJBHe1g454CoXi8OHDPT09TqeztbV1165dO3bsMJlMixcvxkOBtW1sbMzj8QgEApfL5XQ6lUolpFJAXXBycvKcOXOGhoaqq6tvvvlmjUYjkUhAkUmsuISsDB6Pp1AoCgsLpVIp1uOw2ITVt0QHKB7kohRShmFgEKx1grAFEhKHw4HucqCOgfbH5XJBkTx27Njw8LDRaJw9ezZWDCORSHt7e3FxcWFh4bFjx2iaDofDp06d6urqqqyslMvlDQ0NM2fOZBimoaHhwIEDfr//Bz/4QUpKCkKopaWFZdmJiYk33nijq6vL7/drNBqfz5eWlqZUKi0WS1FREYfDEQgENE0XFxerVCqZTAY9ASE4haZpeHx&#x2B;v9/r9fJ4PFzRnJGRkZGRAWIcQigYDIIMx7LsGUZaUAOx3Ik/YOsiPG6apnHpNN75YDAIgix8jUajONQYphePx/v7&#x2B;8EZCjuJpquDE2NSFApFVVXVqVOnKIqaP3&#x2B;&#x2B;WCyOxWJ8Pr&#x2B;lpeXEiRNLlixxu93p6el5eXmQgMzhcLRarclkUiqVOHSFtPMjEAiEbzNE7CMQCAQCgUD4BkDTtEgobG5upml629bPHv75I5s3fzo2NmbQ61OSk2eWlQUCAYTQ1q2fVVZWXs7/57td7gUL/9m/bO7cuRaL5cknHgcV49NPP73rpz89c2J8vk6rtVqtFyL2IYSuumrpo48&#x2B;8sMf/qi5qfngwYNJSUksG&#x2B;7oaOfz&#x2B;RkZGVKp9Jq1a6Ej2yUv4fxg1QzqeXFtqVgsBimHw&#x2B;HgrnZarTYcDrvd7qNHj544ccLr9S5fvnzNmjUURYGvDdQcp9M5OjoqlUqzs7M9Hs/mzZsPHz6cmpqq0&#x2B;kOHjyIEPL5fAcOHMjNzf3e976XmZkZCARw4K9AIIhGo&#x2B;AohOzd/Px8qMtGCeIdaG246jYRXJV89nM/j&#x2B;gTjUYjkQjeE/gKQlVirAdsFG506Pf7&#x2B;Xw&#x2B;wzB&#x2B;vx/ibh0Ox8DAAEKouLg4Eol8/PHHYrFYIpEEAoHJyUlIBHY4HHV1dRwOp6mpqbOzEyHU0dHR09ND07TNZsvLyxOJROXl5Rs3buzq6qqurs7KykpPT09OTpbL5RwOx&#x2B;/3FxUVGQwGmBhFUXl5eTjcFlvzsBVRIpHgX6PRKM4CBsUNJeiksJlwApx/xo5FIhFc640lv1AohBs7JgYZQyFwNBoFlx82DOJnrVQqc3Jyent7QfhDCG3fvp3D4Vx55ZV4bqDbZmZmlpeXOxwOcOlit2ZdXd2&#x2B;ffsoirr11ltBJI3FYjRNL1myJD8/32w2w6xAyD7ncycQCATCtwEi9hEIBAKBQCB8M7jp5psffeTRBx96qLJyTnt72x133HG68fSzz/45jpDRZDQYkhBCbDg8OelRKlVWq9Vut9M0jR1zF8iyZct4CTWASUlJQqHwzjvvuP9n97tcLrfbrVKp6g8dmldVBSeMjtpXrV6t1&#x2B;sucPzCwsJnnvnz759&#x2B;Wi6X//JXvxoaHNy7d09vT6/T4XzhhedffPFFmuY3NjZWTY//lZMo9mFBBBQWyKOYmpoaHBzs6enp7Ozs6&#x2B;s7ffp0MBiMRCIVFRWzZ89euXJlRkaGy&#x2B;XC0SKhUGh0dPT06dOhUKi/v7&#x2B;/v5/L5er1&#x2B;sLCwrS0tMzMzLfffvvvf/97UVHRd77znaysrEAggL1yIK6BPRA8dFDoKhaLA4EAFG&#x2B;KxWI84USlDzQ&#x2B;9M&#x2B;oFvqMwuQvZXh4mMvlgpYEspTP54P5gHrldrudTmdmZiaoXbBXdrs9Fovl5OTU1NTAOFNTUw6HIxqNzps3D76ePHkSDHd1dXWHDx&#x2B;enJw8dOiQy&#x2B;ViWdbr9XZ3d2dmZpaWli5ZsgQMaz6fTyQSVVRUZGZmajSan/zkJxaLRSaTTUxMUBRVX1/PMEwoFILyYZibRCIJhULga0vcEJAjRSIRFuC4XC6Xy4VwDFxyCyeDxofHRGdpZLDh0FAvGAwGAgGo3UYIHTt2TKvVWiwW3HQPhsKFwHw&#x2B;H7rvRaNRnU4nEAjgzPT09NHRUZiA3W7fsGFDLBZLSkoqKCiAacCfYrE4MzOTZdlwOAwvp8/ny8zMnDNnjtPpLCkpueGGG2AJIMWCdZFlWby6i3oZCAQCgfAfBhH7CAQCgUAgEL4ZFBQU/vo3v9786ac0zWcjkfR0i9mclpWdtWH9&#x2B;tdee02n0917731arc7n9SmVKoNB/&#x2B;7f31l4xaKLvQvN559x5Pobbrzv3ntuvvmmqvnz/X6/SqX66KOPGhoa7r3vvqGhITYcfuutt5566qkLv0VqaupfX3yxvb0d/GtZ2dm/&#x2B;fUva2uXH/r80IEDB6urqwcGrBqNJi8v72InfyEkKjsgogUCAYfDwePxkpOTPR7PO&#x2B;&#x2B;8s2XLFpvNFo1GVSqV0WhUq9WLFi1as2aNXq8PhULxeByUPpBaIADXarVu377d5/N5vd7vfe9711xzDQS8lpaW3nvvvUuWLNFqtUuWLEEI4RRaiKcA0Qon4WJLI5zG/9fHgett4WRcxYkSgkewC&#x2B;ycXj/MyMiIQqFQqVQ8Hg/u0tPTk5SUZDQaYagdO3b09vauXbs2Pz8f7HXRaLS3t1cgEGRlZVEUFQqFXC5Xc3Pz4cOHp6ampqamWJY9ffp0Y2OjTCZrb2/fuXPn6OioQqHg8/mFhYVlZWUWi8Vut6enp5eVlaWlpbW2tjqdzi1btvT19UEcx9VXX52XlwehNElJSRMTEwUFBTRNZ2Rk4JmDOAj1qriKFlyKFEWJRCKcURuNRgUCASwH7xsueYY/cZtCiMrFj8bn82k0GqwJ2my25uZmiUSyZMkSLpe7bds2gUBwzz334PwcPp8/NTXldrtFIpFer0cItbS07N27NxaLzZ8/v6ioCB6oXq8Hr6hYLD516tTk5OTU1FRXV1dBQQH0&#x2B;IvH4zRNRyKR1NRUl8sFWl48Hocb/eAHP&#x2B;DxeNCYDwyweIZoOlsGd10kEAgEwrcWIvYRCAQCgUAgfGOoqJitVms6OjoggJWiqMLCovt&#x2B;dr/VavV4PNFoNCUlJRgKIYREIvGq1Wtyc3Mv/6azZ8/e9MGHDz34QF9fH65n/GzrZ/fed1/DiRNsJHLgwP6mpqZgMJiXl6dQKC5wWFypWlZWtnnL1j/96ZnZs2cHA/5wOFxcXNLT0/1vEvtw9SUYweLxuMvlstls2dnZwWBwz549b775Jk3Tt912W0FBgVgslslk2dnZKpUKehcmdtADIxhFURqNJjc3F2pyy8rKFi1ahFNoIWk3Ly8Ptg5XKEMVMKTuwsTAlgWqXyQSARkLlCmWZUHCO7slH6hU0E0P&#x2B;r7holRcanpOCgsLJRIJRVEMwyCEGhsb//a3v4lEoieeeILH442Pj&#x2B;/YseP06dO5ubkQXyuRSKxW64kTJ0KhkN1ud7vdIyMjgUBgaGiovb3dbrf/4x//CIfDpaWlsEurV68uKiqChnQURWVmZprNZojThUwPhFBubm5hYaHD4dizZ4/f7587d&#x2B;6NN94olUoZhgmHwzKZTKFQaLVaODkUCkHPPminGI/HQ6EQbCCXy4VwWzDuQWktBGXAw&#x2B;JyuTjxFr8AULYMTxD2BGp&#x2B;x8bGBgcHI5HIjBkz&#x2B;Hw&#x2B;1Py6XK4tW7ZMTEywLLt06VKv1&#x2B;t0OkEchCRfhNC2bduOHj1aUlJSU1Pj8/k2bdr0wQcfcDgcu93udDoXLlwolUqlUunY2NixY8fcbvdHH33k8XgYhrHZbNg&#x2B;CUvg8XhJSUlOp1OtVmPBNxKJlJSUwJvg9XplMhlIvWA/xNkgibEqBAKBQPh2QsQ&#x2B;AoFAIBAIhG8SmZmZEDWAj&#x2B;h0OqiaRAjJpFIel4sQisViQ0ODoVCooqICn8kwzMDAQE5OzsXeVCQS3Xffz3r7&#x2B;uLxGEJoeGQ4OzPL6/UGg8GDBw9a0i2vv/7a6lWr3v3731euXJlqNl/Cuh588CGr1XrvPXePjY&#x2B;Xlpb6/X7I8biEoc4PyGc4WIOm6a6uruTk5KSkJLfbHQwGMzIyLBbL9ddfn5GRAZIcXAhuPhD7QDCiaRoUOo1G873vfW/x4sXj4&#x2B;MjIyNWq7W0tDQej4NOFAqFIEUXJDNw5&#x2B;EWgXhiiQmqcByfACXGMHmI7ABhEY5g2xqY1Jqaml5//fXbb78ddDeU0Ifuvffe02q1eXl5ZrO5p6ent7e3vLzcYrEwDGO1WoeHhzMzM4eHh7Ozs5977rlgMJiVldXV1QW7BKtWKBTbt2//05/&#x2B;RFFUSkqKRqMxGAylpaXXXHONxWIRCoUikchgMGg0GovFAkHGIyMjpaWl&#x2B;fn5icG&#x2B;PB4P654rVqzIzs6G0AmlUgnLhztyp19mlmVBUIMsDh6PF41GYXunpqagxyLeTCxJ4wwWUAZBNYMefzweLxgMCoVCmqZhJpOTk5s3b6YoKjc399ChQyKRKD09PWU6kSYWi2VlZW3duhXmbzQai4uLYcBwOAyxyy0tLcePH&#x2B;/r60tPTy8qKlq0aBFCqKmpqa6urrW19cSJExKJ5OTJk11dXb/85S99Pt&#x2B;MGTPi8TjLsmq1GlYaDAZhURRFKZXK&#x2B;fPnJ766ie8e1F9jMTfRAUpsfQQCgUAgYh&#x2B;BQCAQCATCN4zEZnNncMXixWCDmpiY8Hg8zU3NiWIfGw4fOvS5xWJJ1JUuBI1GM2Ab8Pt9x44eu2ZtikAgaO9o379//5y5c3fs2HHTTTf98pf/fd111&#x2B;3YsV0qk1177bWXFq&#x2B;Rnp6&#x2B;ectnr736yp&#x2B;eeSY3L8/hcNxzz71&#x2B;v7&#x2B;h4cSCBQu7u7svQaY8G7B94fQGLpfrdrtZlpXL5aOjo4FAwGAw6PV62Eas9H0RFEXhhFaQ4aB6FNxVOP0Dxy&#x2B;gBC0G&#x2B;ruBbsUwDMwKlDt8IUIoFouBtAe9&#x2B;eBaUPrcbjePx5PJZCzLhkIhmUwWi8V27NjxwQcfjI2N/fGPf0xPT4/FYpFIRCQSHTx48P3339fr9XfffbfZbEYI2Ww2i8VisVgoinK5XDCHjRs3Tk5Otre3BwKBrq6utLQ0vEadTnfFFVdotVqHwyEWiyFTODU11WQy0TTd3Nzc0dGh1&#x2B;tnzJghEom8Xi&#x2B;Hw1GpVGDuYxgGehQyDANeP4lEAvsvFApLS0t9Ph8uicXltGC9hD/BTYl3gMfjTUxMQHIxmu5SxzAMdD/EXQ6xwohDV0AXczgcvb29PB6vvLwcFFgul2symaRSaXJysslkgtQUeEmGh4dHR0crKyuffvrptra2nTt3crncG2&#x2B;8kWVZLpcrl8thUcnJyTKZ7PTp0y&#x2B;//HJpaWk4HB4YGOjv7x8ZGWlsbDx69KhMJhOLxSaTyWw2l5WVVVVVCYVCj8eTnp4OczsjGphAIBAIhEuDiH0EAoFAIBAI/zlglY3L5Z46dSo1NRX74yA0wOFwBIPBixX7EEJr117b3dV17Pix9evX5&#x2B;fn9/b07Ni&#x2B;7e233ioqKqqYPfvBhx7ev29ffn7B5KTHarUWFhYihCYmJiZcEznZF6fQ3faT26&#x2B;uXf7E4493dXaWFJdEIpHDh&#x2B;srKma//fbbjz/&#x2B;OJaBLhmQyUA&#x2B;EwqFDMO0t7e3trZKJJKJiYlIJFJQULBw4UIQFrGB7mxAqMLzEQgERqNRp9MVFBSAcoQrK&#x2B;EE0KHwtSihZxxKUBVBm6NpGheHRiIRiHnFtwYnWiwW27NnD8Mwy5cvh9TaAwcOGI1GlUpVW1tbX1&#x2B;/e/fu22&#x2B;/HTcE7O/v1&#x2B;l0oVCoubl5cHCwsbERJCqEkM1mm5ycHB8f37lzJ6xr7dq1ubm53d3dV155pVAoxLEhxcXFWVlZYFoERRLMaGAeFAqFMpkMimHBepafnx8MBrEeB4OghAQJKM6laRorfSCVomlVFEp08XGw6fn9/oaGhsbGRpPJtGTJEolEAlnGsFG4iSHIqdBaESHk8/lkMhnshkAg0Gg0crkcDg4ODlosliVLlkAKDfTsCwQCoBV2dXWNjIyUl5cvWLDAbrc/&#x2B;&#x2B;yz4XDYaDSCSisQCOLxeFNTU2Nj4&#x2B;DgoN1u37lz5969e5VKpUKhKCsrW758udFolMlkMplMr9drtVqRSKRUKsHGiF&#x2B;PaDT6peIygUAgEAgXAhH7CAQCgUAgEP4DUavVUom0taWlsnIOiH29vb0qlYrP54dCIexyunCEQmFxSUlySsrqVSu5XG5JSenChVc8&#x2B;OADwVAwHo&#x2B;vXLnyxz&#x2B;&#x2B;5bbbfuLxePr7&#x2B;kDsC4WCLzz33At/&#x2B;evF3is5OfnlV17ZsmXLU0/9rry8PBKN8ng8uUxmt9txWeVlglNZ&#x2B;Xw&#x2B;OOP6&#x2B;/vNZvOcOXOqqqqysrJQQlruOWFZlqIo8H/RNM2bBk2reLiyErx7iUPF4/FwOIx9fKAo4cBZUGxxLz/ONHCVQCCAbFkIx4BUjSuvvNJmsx06dKiqqqqpqUmtVs&#x2B;YMaOjo&#x2B;P48eN5eXlyudxut/f09HA4HEgZ5nA4vb29y5YtAwNjZmbmggULTpw40draetddd6WkpMybN08ul0ciEbFYHAwGoegY5pPoPguHwyKRCNS0ioqKWbNmneE55fP5eB9YloXP0FuQpulEiyU8FGg&#x2B;mDhCIBCAVnTQwTAajfJ4PKlUyuPxNBqNWCyGUIvEMmc0HdwBBb88Hg9cgWq1GlryGQwGqVRqtVojkYjBYPB4PJ988sn3v/99jUbT2dnZ0dHh8XhSUlLgEQwPD3d0dLAsq1QqhUIhLHBycnJsbCwpKQleAKFQuHXr1pGRkcrKyrVr16alpfF4PK1Wq9FoIGMEvHvw0KPRaCAQUCqVcC30DYQk3wt8ewkEAoFAOD9E7CMQCAQCgUD4z&#x2B;Tue&#x2B;5pbmrCMReDg7ahoSGhUAhWsktDrVb/&#x2B;Me3fvDBphUrV1RX1xQVF7/22qvRaLS5uclgMBiNRj6f7u3phZNpmm5qampuboZc2otlxYoVS5cufep3/9PZ0tJ0&#x2B;nRBQUEwGLzkmWNA9wEzGohEq1evnjdvns/nM5lMGRkZ2IuXGM96NmAiAzdZOByOxWI0TcdiMdC/EELRaDQcDlMUJRAIuFxue3s7BK1aLBYejwfan9/vB0dbZ2dnQ0MDQqi0tNRsNrMsK5PJuFxuV1eX3&#x2B;8vLy9H06pfT0&#x2B;PQqGQyWRarXbp0qUymSwQCExMTPT09IyPj9fV1W3btk0qlRoMBqVSyefzwSxmNBqzsrLq6&#x2B;tHRkZyc3Pz8/OXLVtmMpnGxsb8fj&#x2B;fzz969GgkErn22mvvuusubNkTi8VQlYwSOuLhRnhYMMX&#x2B;Rw6Hg8OFwZ2H9xDKnNF0I0LYZOzC&#x2B;6L4EfSvldQOh8NqtapUqtzc3KqqKgi78Hq9Wq0WTWeeJKYtw&#x2B;AMw0xOTkYiEZPJdOrUqebm5tWrV6vV6vb29r6&#x2B;vvz8/EAgMDw8PDIyEo1G&#x2B;/v73W53SkpKfX39rl27lErl2NjYxMTErFmzPB6P0&#x2B;n89a9/bbVac3Jy4G3k8/lgABSLxcuXL6&#x2B;urpbJZHK5HITCgYEBcCZCiTRFUaBv8vl8SNGF0xJtmwQCgUAgXD5E7CMQCAQCgUD4z0Sj0SxavBiUGoTQrFmztm/fTvNoSF&#x2B;9ZG758Y&#x2B;ra2pMySYuxS0oKHj66d9HI5F33n67r6/X6XAolEqvzwtnSqXS8vJyx/h4a2sreP0uFpqmf/Pbx48ePfpf//XYokWLc76KcOFERQnEoPT09LS0NFCvGIaJxWIgXSVGuJ6T/8fenUfJddd33v/&#x2B;7r21V1fvm9RSS21Zakkta7MWZMm2bGzjEGxjG7BZEjvATM4EwmSBBCfkSWZCgOfhecIMSYAwycwzQ9hsiBeMbZAjWd6t3dpa1t7qVa3eu7a7/eaPn1RpDPHYlqy2S&#x2B;8X5zTVVbdu/e6tPnD0Od/v73vq1KnKysrKyspS1V42mz1z5ozZw85Eiub58fHxXbt2VVdXNzc3m9TMBGSRSGRsbMzUdsXj8XQ6bWrBdu7cefvtt09OTh44cGB4eHjx4sVmEG00Gn3sscdWr17d29s7ODh48ODBvXv37t69&#x2B;6mnnjp27Ni&#x2B;ffuCIJgxY0Yqlerr62tvb58xY8bY2FihUJgxY8bKlSu///3vX3XVVb/927&#x2B;9ePHi6upqrfXu3bt/9rOf7dy58&#x2B;DBg/PmzbvzzjvNlI9CoWAKDLXW6XR66iyR0g20LMvSaAoAAAAgAElEQVTcnFJLr2lVnjpHohS9lWbjmldNcZ8pvpNze/OZ6kXP80rVjuYuTUxMmJG7XV1dL730UktLy5w5cyYmJjZt2nTw4MF169bNnTvXbJgoIocOHWpoaKiqqjJnyOfznZ2de/fu7ejomDFjhpnLMTk5mUgkhoeHBwcHN23aNDEx0dnZ&#x2B;Q//8A9KqcOHDzc3N6dSKTMzNx6P19fXL1y4sL29XSk1MDAwPDw8a9as2267be7cuSawS6VSk5OTtbW1NTU1pqav9BdinjRjQMwzZtCwiMTj8dKRhULBFIeWercBADgfhH0AAADl7MSJE/X19ZlMpui62Vw2U1npe955nnPWrFmlx7FYTGKxQqHQ3d3jeW48Ho/FzqYVyUSyqbn5snnzTnWdMivZs2f3rbfe9kY/bs2aNU/87Odf&#x2B;9rXXqOp9g0xGU0patFaj46OptPpSCRSmp9renhfI&#x2B;nbunXrrl27Ojo6rr/&#x2B;etNeKiLHjx9/8sknb7jhhgULFpQmyVqWlc1m16xZY7o1zdtNQ&#x2B;7p06fPnDmzaNGi&#x2B;fPnm5zItu2dO3fu2bPnpptuMtHh&#x2B;Ph4LBYz58/n87FYrKenZ8&#x2B;ePVu3bj1y5Mj4&#x2B;LgZx2yaeWfOnLl69eq6urqxsbG6urqGhobNmzdv27atUCgEQZBOpzdu3Lh06VLHccbGxioqKtrb28fGxpRSy5YtW7t27cKFC0XE9/3S5o&#x2B;m99YUpsmU6SKlblmllGnjNXGkeTUIAtPjbI4PgiASiZQGkvi&#x2B;b4oczXlK85HNCU3FpYiMjY11d3fv27cvHo8vWrRo9uzZJr&#x2B;LxWKxWGzHjh1btmwZHBxsbGw0ZYOxWKxQKOzbt2/58uXV1dVmJabxdnJycvv27aOjo0ePHn322WcPHjwYiUR27tzpuu7DDz&#x2B;cTCb3799fVVXV2NjY1tZ27bXXXn/99ddcc405LJ/PZzKZBQsWmC/oj/7oj6LR6Lp168yXaJbkOM6cOXMGBweHhoYaGxt93x8eHq6srDRliabteurip/4pmkDZ3F6SPgDABUHYBwAAUM5mzZr1xOOPL1q0aMfOnb7nz5w50zpXbJXL5Y4eObLkiivO/1O&#x2B;/jd/&#x2B;w//7duLFi3O5rJm0quIjI6N6VA/9OCDFRUV6zesb2lp2bVr59DQUG1t7Rs6eRiGe/fubWxomBoyng&#x2B;zU56I&#x2B;L5fLBZTqZTJhsyOb47jvJ7M5eDBgzt27DCjJ0ob6g0MDIyPj6fT6Wg0evz48eeffz4Mw40bN86cOVNEDhw4sG/fPhFpaWkx8yuOHj3a29tbXV09Z86cIAgGBwfHxsb279/f29v71a9&#x2B;NZlMbtu2rba2tlS2Ztv2zJkzx8fHLctau3btjTfeaCIqs9XdjBkzli1bZlmWOXhsbExEli9f/sorr9x///3Dw8Mf&#x2B;tCHrr/&#x2B;evPRiUTCDPq49tprlyxZUlFREY1Gzf6DJngyr0YiEVO89qobaNKrUkJXSjZN3675ObXGbWqWV3q&#x2B;s7Nz165dZtjFxo0bI5GI53nj4&#x2B;Om7u&#x2B;VV17ZuXOnqaTr6OgwIzVKczz6&#x2B;vpMoGbbdrFYNNHhkSNHDhw44DhOf3//wMDA6Oio7/uHDx/evn17Pp83GVxXV1cmk5k7d25FRcWcOXOuv/765ubmysrKpqYmc5mXX355bW1tU1NTa2trLpd78MEHX375Zdd1W1tbZ86cab5KEXFd19Rvikg8Hq&#x2B;uri7NYHEcp6GhQUTMwszNKYWY5oGZu1JKSM1gltcIlwEAeP0I&#x2B;wAAAMpZNBptamq699575i9YcOutt65du9ZkQCISj8c3b9585OhR27ZuueXW8/mUVCr16U//rrIsEamsrBKRo0eP3n//Dw91Hjpx4ng2m6usqpw/f8GJE8ff//7b3&#x2B;jJLct65pmnGxubCvl88hdTpzen1Iha6jk1pk7Xnaq0tVw&#x2B;n4/H46bIrqampqWl5fLLLxcR13V/8pOf9PT0LFiwoL29vaenp6am5tvf/vY//uM/hmH4la985cMf/rCpO9u9e/eaNWtMLZvWuq&#x2B;v74knnti3b191dXV/f/&#x2B;RI0cmJiZMRdvo6Gh7e/vMmTNvvvnmUlNtPp9/5pln1q1bd88996TT6erqasuyhoaGXnzxxfHx8Uwm47puOp2enJxMp9PpdDoMw8rKyn//7//90qVLx8bGVq9eXV1dbdavtTZjN5RSJn41SZ&#x2B;ImI5mc2dMAjj1GXOAKdCzLKvUeToxMZFIJMwxkUiktJHf1DHE5r25XC4ej5s258rKyjAMS4WQkUjkiSee2Lt3b0NDg2VZS5YsWbdunVLqzJkzL7/88uTkZCqVMh/97ne/u7Gx8dChQ2Y/vmg0ajZAPHXq1NatW/P5/MTExLFjx2zbbm1tjcViLS0t8&#x2B;bNmzt3bjqdTiQSZnpGPB4/dOiQ67pz585dtmyZqVIsRXLpdHpkZKS6ujqRSMybN&#x2B;9VfxuvCuaam5tbW1vNn0cp3Sv1I5euvfR46j2RKT3RAACcP8I&#x2B;AACAMnflqlVf&#x2B;tKXT3Z1rV37LjMvwjxvWVZFRcXqVav&#x2B;4j/9xfz5C0qjPLLZ7A&#x2B;&#x2B;//0wDD/xyU&#x2B;&#x2B;/k9R50KNpqYmEXEc53vf/W4ul7vzzg8kU8kf/uAH77vllm9961t33PGBUunf6/c7v/OpN/qWCyWfz5cGSpgmXxPTXHnllT09PSJi6sU6OzuPHj0ahmE6nU4mk5WVlc3NzXV1dYVCwfO8wcHBU6dOPffccwMDA6bj1fd913UXL17805/&#x2B;9Lvf/e7IyMiiRYtmzZpVWVl55ZVXtra2zpgxY3x8PB6Pt7W1TUxMpFKprq6uv//7v8/n8&#x2B;l0urW11SzP1NC1tbVlMpna2lqzNrPO0mSMSCRiRnyYqyhFUSazMz3IZqqGaao1BWul7Mm865VXXnEcp6qqymyHZybnmj7WbDarlDIFgyIyPj6eSqVisZjZ/i8Wi/m&#x2B;bxp4bds2QaSIFAqF1tbWQqFw4MCBfD5vQrHx8fGhoaFDhw6dPn3a5JWe55m6vJtuumnOnDl79&#x2B;7dtm3b8PCw67qdnZ29vb2xWGxwcLCtrc1MI1mzZo0pPGxvb6&#x2B;oqEgmk42NjWbrvaNHjxaLxfb29vb2dsdxzB04fPiwmZBrkkRz&#x2B;XJuaMasWbPq6&#x2B;tNhPra03Lr6urM/I3SM6WCRwAALjLCPgAAgDKnlLpq/frV5&#x2B;q2XNft7e2dN2&#x2B;e67pdXV3ZXO7uu&#x2B;7&#x2B;8pf&#x2B;6n/8///THJ9KpWLx2GVt887nQ1tbW3/nU5/&#x2B;8pf&#x2B;6uGHH7rhhhsKhcLQmaGFCxft2bMnlUq90U7eaRSLxaYOi/A8T0RKQ3hHR0fDMDTjLwqFQqFQEJGXXnppbGzszJkzs2bN6u7ufuSRRzZv3tzd3T04ONje3j45OVldXW0CtSVLlvzu7/7uzTffHIbhZZddVl9fH4lEzDjXrq6u48ePFwoF3/fPnDmzbdu2rVu3DgwM3HPPPYsWLTJrM720mUzGfLPRaNQEUmYkrsnvTB&#x2B;uOaBQKESj0dJuemaIcGnDODNcuBRpmbSrtOnewMBAPB6vq6szeaK5J/39/S&#x2B;&#x2B;&#x2B;GIul1u4cOHixYvNeFnTuGrOLCKnTp3q6&#x2B;traWmZMWNGNps1QaTWOh6P5/P5f/7nf37&#x2B;&#x2B;ec3bNgQhuGiRYsymcx73vOegYGBAwcO7NixY8eOHYODg/X19dddd93MmTOrq6vz&#x2B;fzmzZt/8pOfDA8PJxKJ&#x2B;fPnr1ixwjTziojneR/5yEeuv/76YrFoZn00NDQ0NjaKyMmTJ82Fl67O9/1IJHLTTTcVCoVEIlHafc9s6ViaQRyPx&#x2B;PxuJmzrJQqjdp4ldLzpXbdUufyhfxzBADgdSDsAwAAuCSUwoiqqqqnnnpqdGRk&#x2B;/btw0Nnvvr//N/Ll6&#x2B;IxeI7d&#x2B;5YsWKlOeb22&#x2B;84efLEeX7iJz/5yfe&#x2B;97333ff5xx57zHXdhoaGM4ODx44eOX369JHDr3zpy185z/NfHKWwxtzAwcHBTCZjWmjnzJkTj8d37dqVy&#x2B;X2798/MTEhImNjY4899lihUHAcxxTo&#x2B;b4/MjKyYMGCFStWrFu3bsaMGSZXMtnTkiVLVq1aJSJBEORyuVJ9XDweTyQSNTU1M2fOjMfj3d3dTU1NH/zgB83BJnsyXaKWZSWTyamNxqUt9vL5fCKRMIV7JogsBZfJZNLs7mdiMjNSQ35xBIfZV878WllZaeaWyLk5ISLS398/Ojrqum5jY6MpEhSRRCJRmkfx/PPP//3f//2RI0c2btx41113LVq0qNQkG4bhwMDAjBkzWltbN2/efMMNN3R2dj7zzDPZbPbgwYMDAwNmSbfddttNN920ceNGs84bb7yxqanJjCWpqqqaOXNmMpk0G&#x2B;SZSj3LsubMmSMiXV1dPT098XjclCK2tLQ0NzfLlGbtUp1j6XaVlm3Gs5ibbEaLmIkuU3tyf5m5KBP2mZWQ9AEApgVhHwAAwCVn7dq19933&#x2B;WKhcPXV16xaterFF1/ctm3byOjID394v4horScnJ5/a8lR7&#x2B;8Lz&#x2B;RSl1MyZM7/5zW/99KePfuFP/3Tz5s2&#x2B;7/cPDCysrvnRjx647f23r1mz5gJd0FvIdLaagjjXdfft29fS0jJ37lzTNDowMPDjH//4mWee6enpWbp06Xvf&#x2B;94FCxaYuKelpWXp0qVmxkUmk6mpqXEcp7T1XiKRMM2tZpc3U1VnhrcaM2bMiEQi9fX1Zg3vec97brjhBtP/a9u2KS2cOsrWtOuaoG1q/ZqZ3WEq6cyp8vm8WYZpX/V9PwgC89GmetFkXo7jlLIq13WPHDnS2dnZ399/3XXXlQZTLFu27PLLL3/55Zfr6urMXTJjPTzP27dvX2Nj48TERCaTSSaTW7ZsGRkZuf3225cvX27SNxHp7e3du3fvyMhIRUVFU1PTo48&#x2B;et999yUSCTN&#x2B;99prr120aNEdd9xRui2u686ePdts8GeG2IqIqbU0t9Tkd57nOY4ze/bs2bNnl/ZbNPdBRMwlmwq&#x2B;sbGxWCxm6vVMuFkqPJRf3Efv3yrom4q&#x2B;XQDA2wRhHwAAwCWnsbHx937v97u7T61evaampqbtsstWrFz513/9/&#x2B;3atXP58hWdnQcffvjhHdu2f/wTn3jVGIE3IZFI3HHHndddd/2Xv/RXP/7xj&#x2B;&#x2B;///7Pfvazd9/94S/91RcffOjhC3I5bymTK5nHw8PDp0&#x2B;fXrBggYmEcrmc7/sdHR0LFizwPK&#x2B;9vX3jxo3ZbHb58uUm2ivN/NVamzipdNqp82pNm&#x2B;3UKrBcLpdMJk3S53meCaFs2/Y8r9ReKucmaZSyORNsmWI0Mx3CcZzSeFylVG9v76ZNm2bMmPHud7/79OnTTzzxhOu611xzzbx580oXazpYTchlluS67okTJ3bu3PnCCy/k8/l169ZlMpmJiQkzneOLX/zi3r17b7755rvvvru5uTkWi2mt&#x2B;/v7n3zyyRUrVjiOs3DhQqXUCy&#x2B;88LOf/ayrq&#x2B;tzn/ucmblhbsLTTz8dj8f/4A/&#x2B;oLGx8eqrr77vvvsuu&#x2B;yy2trampqa2tpacwdKLbfRaNQsTGv9qhjOdFUXi8WKigoTy1qWZe6q67qe55nRt6bgzrxRKVVVVTX1iy69ZAJQU8pnbp1lWWaPwtKWl/9HJml97WJAAADeCoR9AAAAl6KOjo6Ojg7zuLKycvXq1V/96v9riqRc1/0f//2/X3XV&#x2B;mw2a3Z5q66uPs&#x2B;Pq66u/s9/&#x2B;cVbb73tvvs&#x2B;/1//y39paGg4ffr0008/vWHDBhEpDW14e/J93zwYGxtzXdd02j722GN79uy54oor1q9f39bWJiKm1qxUhpbNZoMgMOFXJBIxG&#x2B;SZYrFEImGCuVLZoIh4npfNZjOZjCnxM/ek1BhrNu9Lp9Mm2yoVA5rULwxDz/OefPLJ7u7uxsbGG264IZlMBkEwNDRkWlyLxWIikdi5c&#x2B;eWLVve9a53meTu2WefbWtru&#x2B;mmm8yCTbw19XrNlFuzNeFzzz3X1dU1d&#x2B;7cvr6&#x2B;&#x2B;vr6iooKrfXQ0NDSpUvDMOzu7p6YmGhsbJycnKyqqjLTMPbs2dPX19fV1TU4OBiNRpubm7PZ7PDwsFLKzC1ZtmzZ1772tYqKisWLF&#x2B;fz&#x2B;Xnz5n3qU58qXZHJWM1NM1dtKvJEZHx8vLKyshTJmdpGEwWaUkfbtnO5XBiGsVisFBGWBEGQz&#x2B;fN857nme0FlVKmoE9ETLmfeTw1HHyjSV/phAAAXEyEfQAAABARmTlzpnnQ0bHk//rzP3/onx/s6&#x2B;ubM2fO7//ef/yN37hn7bvWnuf5o9HouquueviRn3zrW9/8xt/9ne/7X/&#x2B;v/9WEfUcOH7YdZ8mSJed7DW8NEzBls9nOzs7NmzdPTk52d3cfO3asvr5&#x2B;yZIlc&#x2B;fOFRGTGZnjTd5U2gnONNiavCkIAu/cpBQ5l8GZlDASiVRVVZm8VUTS6bSpaDNxodY6nU5ns1kzc8O0i5qyvtID0xRcW1ubSCRMW2tDQ4P5uFJiVVtbW1tb&#x2B;8ILLzzyyCOrV6&#x2B;&#x2B;9957W1pafN/3PG9qBFnadc6spL6&#x2B;/lOf&#x2B;tTExER9fb3jOGNjY1VVVUEQHDp0aMuWLabzt6KiwvM8UytnWdbSpUsfffTRTCZz7733xmKxioqK&#x2B;fPnV1RUmGA0FouZtuIlS5akUilzH8ytzmaz8Xjctu14PG4CzWKxaBI9sy2gbduVlZUiUiqN9H3fbJBnCgBd1y01Jpd2QjQb6pkyPcdxTLhsjjfjSqZ&#x2B;d&#x2B;an53mlDf48zzNvfJ1/M6aK8M39vQEAcJ4I&#x2B;wAAAPALbNu&#x2B;6667G&#x2B;obHnzwn//4jz9/223v/9a3vnn&#x2B;YZ&#x2B;RyWR&#x2B;//f/4Lbb3v9nX/jCrl07Dx06tGDBgs7OzsvnX35Bzv9WMDMuUqnU4sWLn3jiiS9/&#x2B;cvpdHrDhg133nmnGYxr8inTPPvLG7dN3YmvFB6ZJMgkXCYHNLHd1KGuJl0y5WzxeDyXy5UCRKM0TcLEXrfccsuTTz7Z29trZnfIuQ5iObcJXUdHR09PT7FY7O3tDcMwHo&#x2B;XRtCGYWi22ysUCsViUSllEreuri4ROXLkSDweP3DgwNGjR5ubm02il8vlJicnX3zxxXQ6/Yd/&#x2B;IfNzc2lpPLw4cMvvPDCpz/96SuvvDIajWYyGTmXo5kDSkGYuaKpFXNTr9EcNvXVqfe2dJJSBleaSjz1eFOJab6XV3015o2lJ0vnMQ&#x2B;mnuf17NkHAMDbBGEfAAAAfoXrrr/&#x2B;0KHOT3zi45/97Ofmz5&#x2B;/Zcvma6/deEHObNv25Zdf/g//&#x2B;I8PPfRgsVgQkUKhcODAwZUrrzQH9Pb2zpgx44J81vkrtYWKyGWXXfbRj3501apV1dXV7e3tLS0tImJ2x5sa4b0hpQkSr9rcrVAoFAoF00A9Pj6eTqeTyWQ2m00mk1MrzsyH&#x2B;r4/Pj7e3d29d&#x2B;/enTt3BkFw9913m5Wb3Ko0VDefzyeTyY6ODtd1h4aGNm3adMMNN8yaNatUe7h58&#x2B;ba2trVq1f7vv/AAw8888wzfX19g4OD&#x2B;/bti8fjV1111eTkpNlSMJPJrFu37utf/3pTU1NbW5vneblcLhaL7d&#x2B;//3vf&#x2B;966devmzZtXWVlZKng0uwe&#x2B;ya8BAAC8boR9AAAA&#x2B;NU&#x2B;8tGPLVy46B/&#x2B;27dd1/3mN75ZCvvMNmrnefJkMnn33R82j5ctX3b7&#x2B;9&#x2B;fSiVvv/0OrfUjDz9894c/nM1mm5ubz/NTzp&#x2B;ZfivnrnrdunWmWs28aqI6U3pmGkXfaJ71b&#x2B;WDiUTC1P2JSDKZNI2upurNsizzKblcTimVSCQcx6mpqfn5z3/&#x2B;4IMPep536tQpc5g5&#x2B;cjISFVVlVKqsbFx3rx5WuvGxsZcLvf000///Oc/b2lpaWhoMJdw4sQJ13VNN/GmTZuefPLJPXv2zJ49e8WKFbfccksmk7niiivWrl0r5zYorKmpWbFiRVVV1eTkZFdX18DAwMGDB/fs2XP69Ol/9&#x2B;/&#x2B;XVtbmxlwYa5i6nwSAADw1iHsAwAAwK&#x2B;WyWSu3bhRlHR1df3R5z63adPP3/3uG0RkcHCwt6dn&#x2B;YoVBw4cMH2s52np0mULFy36k/vue&#x2B;ihh/78z/&#x2B;iv79/87/8y9/93d/8yZ9&#x2B;4eqrrzn/858PE6sFQeC6rknfTEenmYlRmh0h51G5ZnpsTTBnJm&#x2B;Yx7ZtF4vFYrGYyWQcxykWi0EQbN&#x2B;&#x2B;XWu9ZMmSmpqaUoOw67rHjh0zS5o/f77neWa&#x2B;h&#x2B;nM7erqGh4erq2traqqqqysfPTRR/v6&#x2B;nK5XGdnZywWGxsb8zzPhH27d&#x2B;/etWvXrbfeKiJz587dsGGD7/v33nvvhg0blFJT&#x2B;3BLTcem9rCiomLBggXV1dUjIyMVFRXLli2bO3duqcvYvIW5tAAAXByEfQAAAHgt0Wisqan5sccff/HFF03Yl06nH3jggeUrVux9&#x2B;eVMJmO6Wc&#x2B;HUur&#x2B;&#x2B;x/4yle&#x2B;/E/f&#x2B;c77b7t18eLFGzZsSCRTX/va16Y97DNtsGYPO/NMqdbPBGRmou4bmt7wKlPDPsOyLNd1bds2w2RN/NfX1/e9731v06ZNtm1/6EMfuuuuuxKJRLFYHB4e3rVrl&#x2B;M4a9eujcfjk5OTPT09JoJMpVJBEPT09LS0tMyePVtExsfHDx48ePLkyblz565atWrevHnLly830ypyudzRo0eff/75b3zjG5OTk/l83nXdysrKlpYWz/Oi0Wg2mzXThM30jNLiSylndXX1DTfcEI1GS7fCjM4oXdSbuz8AAOANIewDAADAa1myZMmpU6cWLVrU3Hx2H71UKpXL5cbGxlavWfOzJ574rY9//Pw/JZlMfu6zn3vfr7/vz/7sCy&#x2B;99NKpU6c&#x2B;9enf/du/&#x2B;fpTWzZfc4H2CjxPpTDuVbMazJ595lUzTOONnjkIglIQZtv21NbgwcFBEamvrz9&#x2B;/Pjjjz8&#x2B;ODh4zTXXvPLKK2ZgrmVZiUTC1NZt2bLlpz/9qdb61KlTDQ0Nvu/7vp9IJPbt2zcwMLBo0aJIJHLq1Kl9&#x2B;/Z1dHR87GMfmz179qxZs2pqasy0XzN7d86cOaOjo5/5zGeqqqqam5uvuuqqj370o2Z&#x2B;roiYORslhULBzAUuhX1aa1NsaJp8fd8vjfQ1l3ZBGsABAMBrI&#x2B;wDAADAa6moqDC9uo2NjYdfeeXy&#x2B;fNd140n4keOHF658spnp0wsPU&#x2B;pdPrRR3/yP//Xd/75xz/&#x2B;y7/8z1/6qy8qpb7&#x2B;N39zzbUbXdf9znf&#x2B;12/91gVIFd8EE6uJiOd5pVwvDMMwDKfO3tVav7mwbyrP84IgiEajplpw69atfX19S5YsefHFF5977rkNGzZUVFScPHlSRHzfLxQK8Xg8Ho8nk8n9&#x2B;/cfOHCgpaUlHo&#x2B;vXLkylUqZZC2bzfb39z/99NMvvPDC7t27e3t777jjjve9732l0M3M4U0mk/F4/LrrrovFYidPnpw9e3Y8Hl&#x2B;4cKEp2xwZGTEtzPF4vFAomPq&#x2B;0lgSU9xnWZbjOLlcznGc0pTb0r0i4wMA4KIh7AMAAMDr1d3dHYlGX3jh&#x2B;RPHT/zogQe2vbRt0eJFZmO4C3L&#x2B;j3/8E4lE/BOf/OQtt976x3/8R09v3fr88889cP8P3/vr73vwwQfvuefei58ZeZ5XKuUr7aZnQj2llNm6LgxD03Vbam59QyzLMp28YRjm83nP81zXraioUEpprZ944okf/vCHZ86cGRoa6u7uHhkZGR0dnTt3bkVFxdScsa2t7c4777zqqqtc121tbTX5Wj6fb25uPnny5A9&#x2B;8IMzZ87U1NTcdtttGzduNLfRZIWWZVVUVJiLqq6uvvHGG6PR6KZNm0ZGRlpaWsIwLBaL1dXVpWs31XxyLvoUERNNFovFWCyWTCZL0V6pFtJ13VgsNrXKDwAAvHVUacdcAACAd6gTJ05MTEwsWbJkuhdS/sbHxv7iP/3F0Jkzs2bNuvMDH3ju2ee2bd/&#x2B;1a9&#x2B;taam5pcP/ta3vnnPPfeadtQ3obu7e/u2bX/2Z1/wff9d71pXV1/32c9&#x2B;rq6u7v/4xiNHjpiisx07drS1tXV0dCil3uYlZqWF7dixI5fLvetd73IcZ2hoKBaLrVy5Mh6PNzY21tfXz5gxI5PJLFmypL29ffbs2clkMpvNPvLII5s2bbr33nvb29tra2tlSgWi67qO4zz55JPPPvtsLBZbu3btypUrM5nM1FEbv6yvr6&#x2B;/vz8SicyaNauyslLOxYIX7W7grWai23379vX29i5YsKC1tXW6VwQAuJCo7AMAAMDrlams/PhvffzgwYNXrb&#x2B;qqal57ty2q6&#x2B;5Ohb/FXFeGIbXXnutqfZ6c5/lOE4QBE9tfforX/7yD37wvVkts/zf889v&#x2B;W9HuVwumUyaWbfDw8O9vb2mQ9Z13dra2scff3zDhg233HJLY2NjR0dHJBJxHMf3/Xw&#x2B;f&#x2B;bMmcOHD7/00kunT5&#x2B;eNWtWKekTkVK4GY1GRWT9&#x2B;vVr1qxxHCcajZpI8bWnBtfV1VVXVyuloud6tEn6AAB4ByHsAwAAwBuwaPHi&#x2B;QsWmP7NTCazeHGHef748eMtLTMjkbPx0JHDh7/7T//0H/7D77xqqsPr19TUtHzFiurq6j/50z9573t/7W//9m/fnkV55ymZTBaLxRdeeKFQKFRXVw8NDY2MjNTU1HR3dw8MDPzgBz/42Mc&#x2B;dsstt5jSv8HBwfr6ejP7IhKJWJaVyWQuv/zy6667bmpx5dQbZcZ0mB33RMT0204N8l7FnLnUuWz2JZw6KRgAALzNEfYBAADgjfmVMygGBgaSyWRjY6OZxKos1dff9&#x2B;xzz91&#x2B;&#x2B;&#x2B;1v&#x2B;oPMHNiKiszTzzzzhS/8WVVV1Ztf9NuV7/tbt279/ve/r5S68sorX3nllS1btjzwwANjY2Nm9u573vMeOdfnW19fPzk5mUwmk8lkLBbLZDIdHR3pdNpkeWYDQcuyzCaA5ldTIGmmasTjcdu2zcDff2s9juOY95qMr3SqskxaAQAoS4R9AAAAOF9hGPb3919xxRVjY2NPPP54oVj4jd/4zSAIX3j&#x2B;&#x2B;fMJ&#x2B;4U3hPUAACAASURBVEruuuvuLZs3L&#x2B;7oOP9Tvd3Ytr1gwYJbbrkllUrNnz&#x2B;/paUlCIIwDGfPnh2Lxe66666GhoZisSgipoE3nU6bN4ZhmEqlUqmUKdYzIV0ph506Jti27VdNUPk/VuqZsM&#x2B;cjco&#x2B;AADeWQj7AAAAcL4sy&#x2B;rr7e3r6/Nc9&#x2B;iRI1XVVR/9yEfe9773dR7qLB3juu7Ro0cXLlz4Js7f1tbW2Nh44db7NqKUmj17dnNzs&#x2B;mcbWxsbG9vT6VSsVissrJSKTUxMWGm5cqUkM5U6pnHYRhGo9GpeVwYhmEYmqjOFFqa54MgKI39fY02XsdxaOMFAOCdi2p8AAAAXACr16z5xjf&#x2B;bkF7&#x2B;/GTJxLJ5Mc/8Ymdu3ZmJ7PZbFZEfN&#x2B;PRqPbtm0bHBx8c&#x2B;d/VW1a2dDnuK4rIrFYbN68ec3NzZWVlbZtW5aVTCZFZGhoaHJy0rZt3/dFJB6Pl9K6V4Vxnuf5vq&#x2B;UMqc1h3meVywWLctyHGdqlvcr1/PLy3sLrhsAALxVCPsAAABwAaxcubK6uuY3f/M33v3udw/092/cuPETn/jkddddZ5pJ&#x2B;/p6&#x2B;/v7f/3Xf318fLz0liAIpm&#x2B;9bxcmqotGo9Fo1PM88&#x2B;TExIRt2yYn1Vpns9na2tp0Op3L5UrHFAoF89hU8JUiOTN117ZtpZTneeYYM3OjVNn3Gnc&#x2B;EolorYvFonmjCRzfussHAAAXHP/PDQAAgAvj4x//&#x2B;NannvqXf/mXxR1LwjC8/PLLb7jxxng8LiInT570fb&#x2B;mpsZx7Icffsgc/8Lzzx07enRal/z2Uiq4M327ppjRcZxSVWMymSzN1Y3H41ML9ErFfVOr/KLRaOkYU9ZnXv2VI1amnioWi71G9R8AAHg7I&#x2B;wDAADAhdHU1PTTxx5/19p3rVmzxpSDlWZEdHV11dXViUgmU7ljxw7z5BVLlwVhKCL5fH6algwAAFBuGNABAACAC2bRokULFiwoZXwlvb29xWIxHo9nKioa6hsmJyfT6XQ6nR4dHRWRY8eOdXV13XzzzdOxZAAAgLJCZR8AAAAupF9O&#x2B;kRkxYqVWzZvFhE/CKqqqnzPExGt9VNbtpweGDhz5kxdXe3FXigAAEA5orIPAAAAb7mNGzf&#x2B;x898pru7u6amemhoyOwcZ1lWdXX16NjYk5t&#x2B;vrijY9Wq1a96l&#x2B;d57BwHAADwhlDZBwAAgLecUup3P/MZUeqBBx7IZDL9A/3m&#x2B;fqGhoH&#x2B;/g9&#x2B;6K7/9u1vFwoFEcnn82EYmld/8sgj3d3d07ZoAACAdyDCPgAAAFwMl1122cc&#x2B;9rEv/tWX3nPzzZ7n5fO5PXt2v/zyy1/84l&#x2B;eOHH8Ax/44I9&#x2B;9CMRGRsdfeihB81b5ra1ffe7/yRM8AAAAHjdaOMFAADARZLJZDKZjIhUVFR8/vOfD4KgkC/89m//9v79&#x2B;/e&#x2B;vPf06dN33XVXprJy61NPvf/9t4vIsmXLdu/e5XneM08/vXTZsoaGhum&#x2B;AgAAgLc7KvsAAABwsaVSqXvvvXfmjBkf&#x2B;OAHb3v/7b/5m/d8&#x2B;CMf8X3va3/918lksrKyqnTkHbffsfWpp0ZHR&#x2B;//4Q&#x2B;nccEAAADvFFT2AQAAYBosXbqsdXarKfRramr6tV/7tfb29p888shtt926ZMmS0mEVmczefXtbWloqKiqmb7EAAADvGFT2AQAAYHpUVVdbtl36ta2t7Z577/2DP/hD9YuHXXHF0j27dy9duvQiLw8AAOCdiLAPAAAAbxe&#x2B;78&#x2B;a1XLTe94z9clVq1b1DwzMbWubrlUBAAC8gxD2AQAA4O0i4jjf&#x2B;V/fmZiYmPrkmTNn6uvrTcMvAAAAXht79gEAAODtoiKT&#x2B;ejHPpZKJUvP7D&#x2B;w//vf&#x2B;146lZrGVQEAALyDUNkHAACAt5E5c&#x2B;bU1zeUfp05Y&#x2B;bOnTtHx0ancUkAAADvIFT2AQAA4O2rqqrqr//6a3v27J7uhQAAALwzEPYBAADgbW3&#x2B;/Pmtra3TvQoAAIB3Btp4AQAA8HYXi8WmewkAAADvDIR9AAAAAAAAQJkg7AMAAAAAAADKBGEfAAAAAAAAUCYI&#x2B;wAAAAAAAIAyQdgHAAAAAAAAlAnCPgAAAAAAAKBMEPYBAAAAAAAAZYKwDwAAAAAAACgThH0AAAAAAABAmSDsAwAAAAAAAMoEYR8AAAAAAABQJgj7AAAAAAAAgDJB2AcAAAAAAACUCcI&#x2B;AAAAAAAAoEwQ9gEAAAAAAABlgrAPAAAAAAAAKBOEfQAAAAAAAECZIOwDAAAAAAAAygRhHwAAAAAAAFAmCPsAAAAAAACAMkHYBwAAAAAAAJQJwj4AAAAAAACgTBD2AQAAAAAAAGWCsA8AAAAAAAAoE4R9AAAAAAAAQJkg7AMAAAAAAADKBGEfAAAAAAAAUCYI&#x2B;wAAAAAAAIAyQdgHAAAAAAAAlAnCPgAAAAAAAKBMEPYBAAAAAAAAZYKwDwAAAAAAACgThH0AAAAAAABAmSDsAwAAAAAAAMoEYR8AAAAAAABQJgj7AAAAAAAAgDJB2AcAAAAAAACUCcI&#x2B;AAAAAAAAoEwQ9gEAAAAAAABlgrAPAAAAAAAAKBOEfQAAAAAAAECZIOwDAAAAAAAAygRhHwAAAAAAAFAmCPsAAAAAAACAMkHYBwAAAAAAAJQJwj4AAAAAAACgTBD2AQAAAAAAAGWCsA8AAAAAAAAoE4R9AAAAAAAAQJkg7AMAAAAAAADKBGEfAAAAAAAAUCYI&#x2B;wAAAAAAAIAyQdgHAAAAAAAAlAnCPgAAAAAAAKBMEPYBAAAAAAAAZYKwDwAAAAAAACgThH0AAAAAAABAmSDsAwAAAAAAAMoEYR8AAAAAAABQJgj7AAAAAAAAgDJB2AcAAAAAAACUCcI&#x2B;AAAAAAAAoEwQ9gEAAAAAAABlgrAPAAAAAAAAKBOEfQAAAAAAAECZIOwDAAAAAAAAygRhHwAAAAAAAFAmCPsAAAAAAACAMkHYBwAAAAAAAJQJwj4AAAAAAACgTBD2AQAAAAAAAGWCsA8AAAAAAAAoE4R9AAAAAAAAQJkg7AMAAAAAAADKBGEfAAAAAAAAUCYI&#x2B;wAAAAAAAIAyQdgHAAAAAAAAlAnCPgAAAAAAAKBMEPYBAAAAAAAAZYKwDwAAAAAAACgThH0AAAAAAABAmSDsAwAAAAAAAMoEYR8AAAAAAABQJgj7AAAAAAAAgDJB2AcAAAAAAACUCcI&#x2B;AAAAAAAAoEwQ9gEAAAAAAABlgrAPAAAAAAAAKBOEfQAAAAAAAECZIOwDAAAAAAAAygRhHwAAAAAAAFAmCPsAAAAAAACAMkHYBwAAAAAAAJQJwj4AAAAAAACgTBD2AQAAAEB50lprrad7FQCAi4qwDwAAAADKkIn5lFLTvRAAwEXlTPcCAAAAAAAXUqmaj6QPAC5BVPYBAAAAQFmhexcALmWEfQAAAABQhijrA4BLE2EfAAAAAJSbVyV9WuswDKdrMQCAi4mwDwAAAADKimVZrwr7wjAk7AOASwRhHwAAAACUM33OdC8EAHAxMI0XAAAAAM6P74qI2CIivlIi4okSESW2iERFiYjlmSNFRMTKiWWJrURELEtEXLFFxAtD27LPHh&#x2B;IiEggIhJEzygRJbYWrcUWEVvHRCkJIyIioSWlHE&#x2B;LhCIDIjmRAdG9Iz09XQP9Aye9nmKxeNsffTjRlFEJJVpEx9yilfAq3/KbAwC4uAj7AAAAAODisiwRkSAQrQPHVkqFSolIxDr7DzTfF8fVopSlRCxxw6Jt2RGxlSjLZIqmS1fr0HXdvO&#x2B;6rlfwxscnRoaHx8fHU9ucQqGQPzMxNDQ0PDw4OTFx2hnRoX6v98GEiNailFjKspQI1X4AUHYI&#x2B;wAAAADgPEVFREKRc//EclQocrY8zxctIm5ERCSIaBFJ6LiI&#x2B;CJKJFClt4ongSWWL744EjqmtM/3dZD2ZoqIBCK&#x2B;SEHEFRkXcUWKEvSNndl/5OTJk7m&#x2B;M&#x2B;PjY8XRiXy&#x2B;0LMg8DwvnHTz&#x2B;ZxXLOpQ52OBE7XdyJg4aV8FtrItx1O2F1o5kaqLdpsAABcBYR8AAAAATANryggN031rkr4gLIhIxBJHHFusqLJCX8JQVFFyWZnsGT527Gjvy4d7e3tyJwY8z0tMeqHW6cBSSjleGITB8ROnHNtOqWgkEklWVsbjcb/SikYisVhMLOtsb7AIu/gBQFki7AMAAACA8zLoiIjEREQkJSIidmCJiPihiDiWLyLO2Sq/QESyKmqJOCJaxC5KqCUVijgioRKJnN2JT4sU/Pzg4NjoWGx7tK&#x2B;v7/DRV7q6ukbGh/zA15ZvWSrvZyNOxI8rpdS4drXWYoltWS1rM8lksq6iqqqyMpOqSCTikog7juPU&#x2B;OKMaXFCsUIpBFII7eLFv10AgLcUYR8AAAAAXFT63F55SiQSFZFzgzu0iCeSL7iT2aHBwePHj79y6FBPT09sR9T3fNcvaK3F1pFIJFSita7MZOKJRCIdi8Vi0YRTUVFRW19TWVnVM&#x2B;tYIp6oTlYkk8mYHVFKCkq01vFY7NzHmP&#x2B;isg8AyhBhHwAAAACclwoREbGmPmWLiIh2/vUVHcq5vfwyYVFExLdFRPKOBFr6i5KdlBOjvd3dJ/afOHmya2w4WygUikVfe16QGBStxfEc23ardCKZLNaraDQaacvU1CRjbdU11TVulW1b1nBMjVmTjW6V7Ti2FRZlsuCFnuf5bjQMw4LlRkSHErHEtlRUxPGVAADKDGEfAAAoB8PDw9O9BAB43ZSI1hJqsZQU3PypUz3bjhw/cbxvX/fY6Ojk6ZzrFqN2KhqLOpGIsqxIJJJMJlMNFfX19ck5mYaGRmtWIpVKjVW6tmWPV3hKqfGoq7VYUW0p5edyfhD4YRCGoQSh1qLEsWzLC/yIHQnDUCxRtqWUYtc&#x2B;ACg/hH0AAOAdLxKJDA0Nbdq0af369fF4fLqXA&#x2B;CSE8&#x2B;OSRCIExHbkkhMwjCnIhFbmUm7VmgpkYjZxS8QCUUmRLpHzxw6cuLEid4jx0&#x2B;ePJkfnVBKeb4XhrqQCHQsdFOqpiZR19JUU1Mzsvqy6urqqtpULBaTSD4XiViJYtH2Qyc/6Raz7pjv&#x2B;6EObMuKhEpE8olqJaKtoojoUGsd2sWYDkPbTnmiYlaVEnELTkRVBBKZzhsHAHgLEPYBAIB3vOrq6kWLFu3fv//RRx9tb29fvHjxdK8IwKXHtsXzxFdiR8SyIpYSETcQy5K46e8NJCzK5OD4&#x2B;Ph49xMv9vb2DpzsHh4Zdkcm8vl8wnKSydTY2Fgmk5nR1NzY2Fg5s7GxoaGqsb4iU3Hksu5EIhGJSxiGxTDUWvu&#x2B;53luUY/7vl8Mi1prcbRSSsJQi0QtJaKUbYuIqND3tdY6DMPpvD8AgIuFsA8AALzjJZPJ9vb2lpaWgwcPdnZ2HjlyZMOGDTU1NdO9LgCXihFrvCKR1pIQES3RUAJVlDCQjNkRLyeSFTk20n/w4NFtu0&#x2B;cPHF6zMlms1l/wrbtIB2LpzPSJJHKyqUrl1ZWVtpzozXVNV5dmHOskVi/UgNhWFOwbaWLvuepIFBK7CD0fb8wOqlFYqGybTvmR2zLsrTSWo8mtLJUYPlKqdDxQydUodKhpcRRYtm&#x2B;iBIVOiqM&#x2B;Rab9gFAuSHsAwAAZSKdTq9ataq&#x2B;vv7AgQObN2&#x2B;eNWvW6tWrp3tRAC4J6URKiRWKLvpFpeyoHY1ERCISDEh3d&#x2B;/pHYdeOfxK4XD3mTNnvNMjuWw209BuWVYikUgkEvHG6KxZLTOWN7W2znHr3Wg0mqsrOo4zlpj0fd9Vvg51IV8QJSosaK1jTuhYjtba9/0gCGzbdhwnEolElaOUqEDCMAyCQIWhb/mWZYmtbduOxWKKWA8ALg2EfQAAoKzMmTOnrq7u5MmTnZ2dp06dWr169axZs6Z7UQDK3LDUiEhMi9jJqqKIJ9IlwydPHX92Z29fb2/nob6&#x2B;Pr84HovGkqlIZXXF3vSBuXPndlzZMX/&#x2B;/EhTTCkrl86NRiZzyayI5GOTWuuildMRrW1fWWrmeEREAu1qrZX44nsThaw7OWlFIrbj&#x2B;NG4OI6nYlqHQWCFOox7rg61H7hhIIHyHMuxLM&#x2B;ybUe0Ei2hiBKRQFQQWsXpvXUAgAuOsA8AAJSbdDq9ePHi1tbWrVu3vvTSS0ePHt2wYYNt9q4CgLdAIGKLRJQEIgMnRvbv39/77IHjx4/bA2P5fMGanFRK1dfV19fX19VlUqn0tTctrqysTDVUJBKJyVguDEIrbUcjkTAaaK2DiBuEgaesIAj8INC&#x2B;tiyz7Z&#x2B;ttdaWH/ih53mFQiEdT9u2bVuWEgnCIAjDINCiteM4QRgqJUEQBr6vtS56rm3xP4MAcEkg7AMAAOUpnU5fffXVpsTvwQcf7OjoWLBgwXQvCkB5mtErMiaTr/QeOnCg7/n9x44dk9GJKtsuRr2o6IE6K1NZOXRFZc3ll&#x2B;eWz6pobPBrtw8pNSDK9/2CFxaLxcJ44LpubbLGsqxMmIg5TlOQVkqingpDPZDsUcrSlidaQtsNJHAjo15swk/Y2rY9R4uI60dCCUMVESUVOVFa23ZgSRiIqwMJvGwgYolvickNxVKeUkVt56f1zgEALjzCPgAAULZKJX7bt2/ft2&#x2B;fGdyRyWSme10Ays1AZ//OnTs7t2zr7empGde2bVcmktFIpGlmpqmxKXFlc1vb3OzCZCKZHKryRGS4UMxms6PZbBgE0VRFOp2uiqWDMLSLljq3tZ5SYinLUkos7TiOUiqQIAxDHeowDEOtRcSyLMuyQlH6HFFiWVaxmFdK6WioLGXbdmjeoJnGCwCXBMI&#x2B;AABQ5tLp9LXXXrt///7Ozs6f//znbW1ty5cvn&#x2B;5FAbi4/EBExLJFxLdERDwRMTvXicQkFBEV5kVEQldECrpaKYmZ9&#x2B;q8iBanKCK&#x2B;iKMcCSpERMZEJqXn0Vc2b9481nlCRArOYNIt9tQOVFRUZC9P19XXNa6/LFpXm26tG43pnPTlYzFt5UdGR3qOjqUrKloqZ6aSSaUiYRiGoRIRK26HYRjYvhuGp5WnlLLiopQKg4zWOtQFLdpyHEuFESk62otpR3wR8UVJVKtQ6zBwwzD000UtOtA12tOhHtBahToron1JWmJFbREloT0i9mjEbb9Y3wEA4CIh7AMAAJcEU&#x2B;JnunqPHTt21VVXNTU1TfeiALxN2Y6EoYgnYplEUInv&#x2B;YWiF4s5UUdEjr9y5OjjR/bt2&#x2B;u9ks3lcjWhcl2vGHXT6XTTorqFCxfWr5rZ3NQ8mvQTyYRURcMwdMOI73vjudHTpwerqquTiUQymYhEo6LtIAiUUkpUGGp1joj5qX9hZfrsf5RSyrJ837ctS9m2Ukpr87I&#x2B;WxuoS2/VpXcCAC4FhH0AAOBSYbp66&#x2B;vrt2/f/uyzzzY2Nq5fv366FwXgojAjerSIiBOIlP4hZImIaKVExLeiIhJatohEfU9E3Hgk0EFWJRyRtCQkIolRKR6cGNj6zIG9L/fsOzQxcFokTCeThzL5pqameR1LFi5cWNteVVNT7WVELBVzfK2UF0wEQWhbk2Hg&#x2B;bn&#x2B;IHe6tnVhJBKNRGKWpQJfRIsSSylRKtQSKqUspbQSEVFKKyU6DEVElIjp1RVRyrIt2/N8iUQcc3Fah1qLaEsp07GrRWsJtWhdyvv&#x2B;9aeh3sJ7DgCYJoR9AADg0tLQ0FAa3PGjH/1o2bJll1122XQvCsDbjOdJJCIitrKdc0&#x2B;MjXldP31x&#x2B;/btQ8/tc12vzolXVVValorFYjdev761tbW1Y2ZVY2OQGvc8rxjmbWUXCkXLsvI6J6KduA6CIAjDeDweTyQsZYmI7weBr8MwFDk7cleZgj5lnU0iz23hJ0qdK&#x2B;vTIkpZlm07QeDblqUdrURpbV6acuTUXM9khACASwBhHwAAuORMHdyxe/fuo0ePrl&#x2B;/PplMTve6ALxVfCVS&#x2B;sePqZIz0yq0EhHl2CJSlEjpZywxaIsdkxoRqTojwz2Tx3929OWX9/Q987Jt243ptFhyxDqeSCTabl507bXXTjbZmYoKv8o6owfH3DHP8lQ8Eo8nvIJEIrbl6jAMHDuX8ybEO1ORsCyJ61CHoQSBhIHWopSydKi0BKbOUCtRZyvygnMBnsnwtA7N7A7bcSKuH4RagiDUlmhtnQ34dCg6MJeqRYsOtdbnsj/9S9V8FPcBQLkh7AMAAJeodDp95ZVXmhK/xx57bP78&#x2B;UuWLJnuRQF4W4hIRES01t093T3PDe7csWPs6Z6&#x2B;/v7VdXMGBgayQ8MLFixY&#x2B;&#x2B;tXLbliSXBZxIlE&#x2B;lM50eIWXcu24vF4NBrN&#x2B;97kxITlOLZtBUpppZSyfN/3fT&#x2B;dTouI1meL7UzLrlJKlOjw7MZ7Z9ehX73TnhbRWisllmXZtm1rW2vxfd&#x2B;yLKUcZaK&#x2B;UJvuZK2nFvRR2gcAlwrCPgAAcOkqlfiZyO/IkSMbNmyoq6ub7nUBuMBMzBUoERHbCc1vIiLaLj1MhSIiqbOJWNVk/&#x2B;nRbTuP7Ns/suVo4eSJpGcvy2Q6i/sXrGmvuWlle3u7vTgyXBnLWWPFsJC2krkgl81nAzewJR6JRsSKK8cq5Dzl6KIbKCUJx9ZKhSpworYObZP2KbGUUqZg72wFnohWJvILtWitAy2ixVZqaoKnlNi2FYk4oR8Evh9YKrQjlm1ZWodhGFhWoEWLCkS0SCD/WtY3tbdXTfkJACgfhH0AAOBSZyK/VCp14MCBp556qqWlZc2aNdO9KADTafD4ia1PbT380It9ff2zR9OO41QkKlKp1Ptvvmbx4sX22irbcXqcXs91g7jv&#x2B;8GQOxSNRNLptBLlhqHn&#x2B;X5QFC3RWMyJRNyCWMqKWBHbtk2iF4ZhqbJPRER0GIZhGCplenbPhn6m/XZqRV5pJz6lRFnKVnYQBGEQaMuytRalTNeuTH3Hv74RAHBJIOwDAAAQEZkzZ05dXZ0p8evu7l61atXs2bOne1EALgxbxHX9ghXEnFhBLBEJJFSiIn4YjUQtT6QgYgr&#x2B;Dk3ufPbZvT96NpfL2W6uyU8OVY82NTWnf61l5YoV7pLUmbSXk1MTesIfGRJXqseVJaJ1IrS9oOA4jhOxoxHteDqmQx0GThDoqFMZhuFoNmdFKhOVzQMj43OawnPpmxIRpZTtWJZWYRjqEgnCUGsJRbSoQOvQlPO5vvi&#x2B;p2xtWY7WYSQStx0nDMNQh9pzRSnHVqH2tNaheOY8vzis4xen8ZIBAkDZIewDAAA4q9TVu3Xr1m3bth05cmT9&#x2B;vXRaHS61wXgfIWhRKOOJU4oYSHM25YTEUdEohFbi5ZQSVykJ&#x2B;x8aduOTc8fOnSoYTI&#x2B;MTER2m5ra&#x2B;vc9XM6OpaoFelMVdWp9Pjp06ePThx3XbfKUtFY1PaVEtFWaFmW5diRSMSKJBzHETtmO3bglqrzzm7PZztOJBrN5/ORSCQSiSqlgiAMgkBEK0v9YhJ3tsNWl35qrbVWUzpvXzVyV4soLVqJY9ta61BsrbWyba3Ftm1yPQC4RBD2AQAA/IJ0On311VebEr9HHnlk0aJFCxcunO5FATg/ylNiW2JZYqWtlBKxRcJQvCE/VumIK6MHu/Y89tSOHTvyPYORMDxZTDW3zqi8qm7&#x2B;kivS1yT1jBk56R&#x2B;Wrrx7aqI4UJfPVVZV1VbPsmw75zlhGKbzyTAMfe1qT4eBrywtTkFZliMxpXWglApVqOKW6IhTE4slcoXRpEo6UbEsSwdBqH0RsbSl5ewU3bMRnhLRokSJhOeae7WIGcyrtFaiLdGm&#x2B;k&#x2B;Z6b3nCgYDUSI6VKLPlSxqUa&#x2B;axmvJ2c8AAJQVwj4AAIBXK5X4bd&#x2B;&#x2B;/cCBA0ePHl2/fn1VVdV0rwvAm2Qr2wu8UNmO5SiRQMQKxbIkUum4Y37nv7zw9NPPDO4&#x2B;NDE5mXK1aFm6dOny5ctn3Dinuql5qKnH8/xhezg7me09eSiRSMxsaKytrYnaFYEOdCQqWqpjVX7gF4O853rF0Ndh6Pu&#x2B;UkqciBVa2jpb3mcpFYlE4loXXdcPfNd1HdvW&#x2B;myop/UvDd8VEWUCP6X/N3v39i1ZdZ0J/ptzrbV3XM8l85yETNKQQoCQMKJkQAiRYCz5UiW3Xerhh&#x2B;5&#x2B;6Bqjx6iHHv3SD/3e3X9Fv3Y/dPcojxKUSq2SbckWEpZMYSXGEgalJEBkcsvLuV8iYu&#x2B;91pz9sHbEicNFMiWkA4f5kxQZZ8eOHevETj3kHN&#x2B;aU1VVpg38aBb0mx2ZvkGhiDECiBqhmhAV4Bh/Q9&#x2B;1McaYo2bFPmOMMcaYdzYYDB599NHnn3/&#x2B;4sWLf/M3f3Pu3Ll77733qBdljPkvUaMiRx31SIJdhgcqAMCLo&#x2B;9/61vf&#x2B;9u/2dzcrHRXvS5&#x2B;fOXOT9x57r97sLuyuncq7elrDa8xc7eqx3u7K&#x2B;PyphOnVwdn415zNYr3YTRYBIEagbIQNHhCDVWvNVRFhJidMologmNmdB156jUqVVXX0TnvS&#x2B;dYhETaQN/85lwC5b25gKiKqgBEBAWrqEh7Sh7pi1wQhEIioKKNKkRifgRweBovcGhPsDHGmGPCin3GGGOMMb9IjvjlXb2vvPLKgw8&#x2B;eObMmaNelDHmvamlLrkEIClxYABYxwsXnvnGv/&#x2B;PV958c2fnelGUS6tLt3781vO/98AnPv/5jRXx3u/xZlVVyQuA2MS6rldWVk6ePNnv9Pb29gouer1ecuV&#x2B;tZ8SiIiY2BGTV5EkUFVNAmUQ0NbhBAQQdTudqqrqOqrCsYAdEVSV2srbtNLXTucFEUSQh3eA8n7cPHX38LQNtP0BmaBKbVUwZwPx1oaAxhhjjisr9hljjDHG/BLzgzueeuqp1dXVhx9&#x2B;mMjiMMZ8aCSWMSZF5dkF7AGXt3/y&#x2B;H/&#x2B;3pNPhp3906nsDVZOnz599g9u/9znPte7c3nMzV74SeHDENzviMZmMp68upd297G7urLj&#x2B;l0MZdBfnPQa9afWeX8/7d6oIBBVUCWtRRKlRkU1MZz3WiZKnBIrqwollX4KuQOfJkWTRABHJJpzdgc7c5VypRBAW&#x2B;vTXC6E0mzsB&#x2B;ZLhLlxC2vfFwAAIABJREFUHynl0t80ykc03e9rjDHmuLNinzHGGGPMP8v84I7HH3/805/&#x2B;9O23337UizLG/LMEhAo1nAdQPffqY48/9tp3fxabyIpup/vbv33XF77whZMP30ydzp7uOcd935/oeHe075zrFaEoCzf2RFhcXg4h5MZ6TWyqquqm7nA4XKuvA2CqAPIcAThmYqqrvOu2rcaJiEJFRFWdc2XhkyRJSCkREROp4Bfl7w6X69rSH80O0mwXsKi0m3rbBKCKqCX7jDHmI8KKfcYYY4wx/1zzgzt&#x2B;9KMf5cEdg8HgqNdlzEdPSgAaxwAqEIAOAMCPE5yDCoCqmDDxFlSgN0wG/UbwZnP1n/7pb//Pv/jxj37ke8OF5YXXl6pHHv78HX/2L4ozZ66U10SkKEaN9009ZB2or5VpQk2ttUtbLoXh9rjf56KoUkqJagq072OMaUgVoKpeFZCFtsqm6gtVRQ1RZslRPC0QQjV2xERgVW1n7xJApFSDAGoAVTSqqtqoai2VqAgJCMSqCqFGWJJEIhCUiACBCkgIymlRAXJjqAIeouqvAApZAhG4BhGkB&#x2B;mBJ0d4G40xxvw6WLHPGGOMMea9GQwG9913X474/dVf/dVtt912zz33HPWijDEAAOdQ16gn6PY8eUATkgOjTiC6&#x2B;OSTjz32WOf1tLS4uDNpqqr6N//9v/nYrR9ztwyLUNQcVNX5WlVpujc2F&#x2B;0AOHbBT//1lFvmiRARQZlJDlYwTd/pwbmHZ&#x2B;wqgBCCqKgoEYhYVUVSoymP2QDlgJ&#x2B;IqEK0bc/XTuFISURSSk0SYZ5&#x2B;qCogcmg&#x2B;7/wHHn5ijDHmWLNinzHGGGPMezaL&#x2B;OWS34svvvjwww&#x2B;fOnXqqNdlzEdF7RjTf8wMIEAeLAsUBB/QLUBwDSC4UUsAeA5/8ed//r3vf7Np4jW/1ev27vlvPvOlL30p3LZQlrJfrG&#x2B;lKkp0zmlTNHVDhU6nXYiogsiH0Ol0RTQlUZ&#x2B;LeyoiTJ6ZBHMVtvapKkCan8x657Wlv6RjSUlEiYjYARCNMUafh4eoqKog1wNFVZUERCBIkhibGKNIVICJFKQQAnTW1E/bT8zpQqW3LMD6jRpjzDFnxT5jjDHGmP9CueTX7/dfeOGFv/3bvz19&#x2B;vTnP//5o16UMR9p1XhSdjsQIAkSwwG79euvvPLE//HXL7zwQlVXw&#x2B;HwxInuAw888Lk/fbB79mwq95KkUT1KMXFwjp2mmFKa/TNJFSJCQAih2&#x2B;02ddP4JvjEzMwsIiAQkUqu6k374h3U&#x2B;97SZQ/5PyklAJyDeQpAmTmEoEhQKE2LgrOkHhMAEYkxxhhFhJgcO&#x2B;JD16d2Uu90dsf8uF6bz2GMMR8ZVuwzxhhjjPmVnDt3bmVlJUf8HnvssXvvvffcuXNHvShjjrncp6/Imb5GAMArAOqWNdQlSsLFGADGX/vZf/7GNy5/79Xbbjjz88VmsDj8nf/xM4/87u9uLV7dxcUJtgXKKcChhxsYBBoWoWxkwpS3yObNtuRdUXZ0sl3VdeN9LMvCOQdgLkaH6cyMXGITKEDT7n2qqpILeABcmDh2RC6lFBsREWLvvGuaCAIw3RZMIGVAmSmlFGMdYyOSmDkE772PqdY2QZiTjSAQGCKS16DTx4OyIx2uQKoF/Ywx5rixYp8xxhhjzK9qtqv3ySeffOaZZ/Ku3rIsj3pdxnwUJUhwznngGn72g3/4p7/89rPP/sPphdu2trbOfPzMl7/85dNfuDHGuLG/MegPrm5eIyCkLhFNJBRFUbJ3zqUY4TxxTtgpETnnihBCCKJa17Vz7Ngj1/ok5/qmK9BZgG&#x2B;6bRdzCbu2IqgxxpSapmmaRlSE2TM75920VSCQa32Us4MkIrGJKQkzee&#x2B;9d&#x2B;wcCR2cjbxDl4jaQ7P6Y/ujZfuMMeajwYp9xhhjjDHvj8Fg8Mgjj&#x2B;SI39e//vU777zzrrvuOupFGXM8ddo/CWgzfe3TJhXeYwzdqF7&#x2B;2j888e1vj5&#x2B;7skonNxdfue222x74n/7g9D23/7D&#x2B;&#x2B;7X19b3O9Ws/ufap02eIqFM5YmrSJI3r/aIMIQRfE8O1kT2alvtoOFiYTCZN0zBxUTgAqkJg0LRHHoBpv7y5Gt/sVVUIgCh71WQyHtci4rh0zknyEqVD3bZaB0zzfaRQVUkpJkmAOu&#x2B;ddwppmqi5ox9ERRVCBCKoEiipAkhtxrB9zNdsh3pA87dmyT5jjDlurNhnjDHGGPO&#x2B;mUX8Lly4cPHixZdeeun8&#x2B;fMnTpw46nUZ81HRhtcmuHDhwg&#x2B;/892f/OTijXV3YWHhzvvv&#x2B;KM//VP89sntVy&#x2B;/IW&#x2B;mlAYrg7t&#x2B;6y7CNoEW6qGKVuNBNan2U0qSmNWLqJuG5EiJiIj6/X6Mqa7HdVMTeWYmOLAeyvVhFuh7VwTUTTMej5m57Pe73a4K13WTUsqDgImIaDrIV6EiKqKaNxQ7Zo6xaerGB84bhEUVEFXK9b53&#x2B;GZmD8YYY447K/YZY4wxxrzPBoPBo48&#x2B;&#x2B;sorr7zwwgtPPPHEzTfffP/99x/1oow5VkIDTCYyLAm0LbHjOh2l0f5&#x2B;T/uY4GePP/Htxx7fvbLHKcWzg7sefujj/3MnrqxdTq9cdpdkEG666ewpPkmgpXhCFd3aq&#x2B;peyYMwcAUrtN7ZmtTJC3vniVkVklRF4bjXGzgX6rqu64qYvfMMx/5gzC3lPnhKgDrnYkqSkoi0&#x2B;3pVVHVrew3AiZML/V5f1U/GYxXf7RUptiN4ARATAaKkKj44jkwNAFUVqBABpMyUB/fm3oBExEzE5NjHGGuNSZJQBNoJv9OWggSAyYEs2WeMMceQFfuMMcYYY34t5gd3XL58&#x2B;YEHHjh79uxRL8qY46Ku0ek0sSGg4zsKHY1GvX4fe/j2nz/2/F88PZ6M67peWVn5o3/5r/7Fo49Olp4Zj8drO2sieuLEiUVeUuhYx4va03ZqhubhFjlXF0IAANWYImsuooGcy5NwmTn4INz2wFORJsb89C2PkhN50x2zeVaHiKSUQgjeeYWKCIiI80jfQ6W36UhfqAi103vbK6gqM8/G9Yoe1PxIiNkfhPlyF8C3jQY2xhhzXFmxzxhjjDHm12V&#x2B;cMfTTz&#x2B;dB3e0EzyNMb&#x2B;SBEjpQ103AQSQm/RB&#x2B;Nm/e&#x2B;KHX/&#x2B;7S89fLIpQ3rLy4B88dMef3YflcK2zeaW8&#x2B;ubmTrlcfqy/0kfH1YWrCy8LANrMm6uU1FMNBQovIilFSSKizjlidsRVHYnA5DiwqIqISFKRvOV2atZ0DzE1mqN3AEghqppEpGlSp9PzoVBBikLEBE4iBM7FPQDTQp0CklIEwXlWEVVJooAwEzFYczqPVPN4DoCgaESTIoFkOpNXD4b8zlj1zxhjjiP&#x2B;5acYY4wxxphfQR7cceedd66vr3/1q1/96U9/etQrMubDr2inXTvn9vcjABT4hyf&#x2B;/itf&#x2B;crW9lZRFEuLS48&#x2B;&#x2B;nuPfPGLvaVlGY8jYtM03vvFxcUC5Rijuq56vd4sGTeteuVoH7FjZibmXLfL2TkR1dwVkECUX2dmx8w0lctzB4G7JDmFl6&#x2B;umObwRJxjxyyqSRK1yb72zDaFp&#x2B;0oXQApJQCOHTO3YUCAiFJKkmRaTDyQP3T6m7WjeG0YrzHGfERYss8YY4wx5tdufnDHc8899&#x2B;KLL54/f35hYeGo12XMh1UVYiXVQjN0zAsTRo297176wf/z15ONejyuws0nHvjCFz755d&#x2B;pV3Wzf7m/OABOUh0X6no5rZ5Ab1SNmqgl&#x2B;&#x2B;0yAkgsAJwKgF4NAGOXQOqYiJwqAxCBijA5AHleRp6rywwwNzIrqGnO70FFAc2pOlUlnd&#x2B;gy1wSgqrTlCt7DuAc5dN2qC8pCUBAytN4QUQMUsoVQFUldk1dAwCEiECaZ3OQqkgSTUopjwluxwHr25J9No3XGGOOI0v2GWOMMcb8huTBHXfeeed4PP7Wt7717LPPHvWKjPkQK7mMVQ0ADmvPX37sscd&#x2B;/vOfN00D4P777//iH/3RqRtOEVHXdyc69gjMnFJqmppAnbLD7CaTam52rc4H8nKfPSJyzK7N96mo5BBfO/52GsQjIGf7chawDfvlN&#x2B;YNttBpJhBExMxlWapq0zSiQu3IXyUiPZjjO9f&#x2B;b/a0DRXSLG/ovffehxDyY/Dee&#x2B;&#x2B;8F5Hcxg/TKx7KLxpjjDnWLNlnjDHGGPMblSN&#x2B;eXDHyy&#x2B;//NBDD914441HvShjPmSuo2HwmaKLBPw0/vjxJ68/9bNTrrzeo/MPP3LPlx/Gx1Y2&#x2B;q8GVzTYXWvWzoSPxfFgMrnW3eiEAh3f2S92KjRbJSvQAApdalhVhyMCaNzLVTZqU3YAwAepO&#x2B;SKX66gCYA65oQdiCjP&#x2B;ciDPoiJcs5P2423xMTgTtmXJLUk7z1TEBGAmF1KCdN6H03LdICAqP0s1VzrU0AkeZ//QScAFAkKFVFANM3WOkv2AToN&#x2B;rWL/Q3dLWOMMb9ZVuwzxhhjjPlNy7t6V1dXL1y48P3vf//GG2986KGHjnpRxnyYCCQiAl1U6Yf/6RtP/d3fkaqIfOzcuf/qT/6E71hNo3FnoVOj2Ygbp4pT49G4KArf7yeR0WjUKTtUkHcOUDqYg9Gm71RBxO1mWWkLZsTEoDwogwgghopKOxh3Z2eXqE3t5XAfMQhUFF7pUE2NiZQphDAej0XUOU9M&#x2B;WOZKSXMVqA6Sx3m4qLMsoHIUUDVGCMA1aSqolGkbRHoKZf6lOYqepbsM8aYjwgr9hljjDHGHI1Tp0498sgjOeL32GOPfeYzn7n11luPelHmQ&#x2B;sdu7H9giPvUvbJjeXe/iK//fq/omlnupyCq10EUICgioamkTRI6VUlEQOo44SZehxSSksuVFphHZvfufD8177VXd9&#x2B;/Sbp93t/8L8/vHZ6e3E4kqHwKHWJTvlbpJJub380Hm2XO5PJJFJvZbhaAnvV9jJ5VUCdAhCvwG6Pp93taDrdVgAINQAijUIIu6N1H7wvpWmautl/88qVgpeLogghiKJuGgWKwhdFMYkTACAFQeZ35mJQdnoppZhSEyMREYvEJklNxOyJiUAsIhBSpiY1AJQEqrm0p0ggFWkAKCIUiqgEdQJFo1CCOKiKUAKUWYhJKSkAyrczEiVCfL9vrTHGmCNmxT5jjDHGmCMzP7jj2WefffHFFx9&#x2B;&#x2B;OFut3vU6zLm12ZW4JvrlncIEZjbJ4Cq1HVNZcmg0hf5FOecoOlSV569&#x2B;MR3nqiqam9vd3Hx9Je&#x2B;9Mc3nTmzsLDgUTdoKATHnNjXdZ00Oe86nU6MsWma8WRUdoL3PsY43S8LgIGDOmO72PxkekburOe8Y&#x2B;LxeH93d4c4OeeWFpedc8yURFzDSYSIRDT348OsfqrT5wRo/g5ouvcXBDjncowPQI7ppRT1LeuYLXCuKKuHKon6llqvvu18Y4wxx5gV&#x2B;4wxxhhjjthgMLjvvvtyxO8b3/jGHXfccffddx/1osyHzbu1X3u34/rO55C&#x2B;y5veY3s3fZfzkwgR89vKfO3PSQHN42fzAdcJZSgkv560aRoPFtUl7iHi23/z98/&#x2B;4CeuqWW5f/fD993z5T8cn9xX5lrHddU4LTmEKL6O0bMGX/Z7w9hI1Yz29ycgCj5QuxJWbRetB&#x2B;W0&#x2B;VpaO7VWEomQ4&#x2B;Ccq/fjzvZ&#x2B;f1AuLCz3B0OoigonYWZJ0u66zd370P5Gqm3tD6S52tl&#x2B;PrX/ZcqFTtVc6EsppSgi8Dod1dG2CpyN2T10vP0gnVYFBVC0Q3jfqUY4990bY4w5NqzYZ4wxxhhz9GYRv1zye&#x2B;mll86fP7&#x2B;ysnLU6zLmfcbMmA&#x2B;ozYJuuejFBACOgFmyT6uq4k7hyDFzKALBOQANvvvN7168eDHGRmP67Gfv/8K/&#x2B;pdY7IjuppgkVk3TAJ45icshOyGioiw73a5ok1Kq61pVi6KEqiqrqiRWzdUxKM2ieDpXJFOFxhRFpCgKZlbVoihOnjgRK00piaT8OzKzpJQkte9rLzV3vbbClufq0sHl2/Z9IgejgWff09xs3fbH2fHp5&#x2B;j0c&#x2B;ZX3A77PcgnGmOMOd6s2GeMMcYY80GRS379fv&#x2B;FF1747ne/e/bs2QceeOCoF2U&#x2B;HN4tSfeuqS16j3Wf9xj/iu8eNdRZBg3ERAQGgNSAAGEwz/8yBOp2uu3FamK4tmD11Pji//33b7yxydR3d/c//d/&#x2B;4eB3zu7t7VRuQuAenCOoBAUpe1eyRCdCTK4seqqaUkpRJSbOyTud/YZMxKBZZa5dhrahPGLykhAjtHSOS&#x2B;&#x2B;63neD79WjlJKmJETkyeXdu6rKhDZtpwrIbECualIFcvKOcjc/UUBSyuN3VVUkAUIMUqR8JkTbvF77CJ0eV805vvZ4WwKcvWt23BhjzPFnxT5jjDHGmA&#x2B;Wc&#x2B;fOrays5Ijfa6&#x2B;9dv/99998881HvShj3h/TcNmhPawAvHP5OFQhApF2u2oniCSFG08m1eauiNCo2djYeO0vf37p0qW9nZ3lpaWHzp8/d9/dTawB5Pqa856YY00ppciRiYhIUlKGc67T6cYYm6ZKKY7HI4CYHDMzeWJmAhElOUjBtVk6UuRZuoCopJhUQUySZDwZM3ecKuDyRF9VFREVgWuTjHnQb/sHIDLbbNtm7lQUUNEEhSJhGgKkPP33cN8&#x2B;PYjwzbbxzp7joKR4OMpnw3iNMeYjwop9xhhjjDEfOLNdvU8&#x2B;&#x2B;eQPfvCDPLgjhHDU6zIfXPOprV88hjdLb0v20due/yq93MK7vFuE5ot8kjSJiAgVAQBi0rqRqm6apkpRRF69esWxC1TElAbRd7rd8dXtyz958ZVvXjg14tECf&#x2B;zuj53740/iJrzBb/hBYOxGUCmk0MSdpCkpCaggp6qaQMyOCOzg2bE0TU1EChIBSAiaN/DmclvOIeZ9sLlylgTeOceFKqswwYu4apyKQEScc3y5W58q2okf7Vch0&#x2B;IeKVTaGbjtZ2mesXuQwkuqChU9OEcOioN5Jm8uCB6k/BSHzsmFvtz&#x2B;8ODM2V7ft91tY4wxx4cV&#x2B;4wxxhhjPqAGg8EjjzySI35f&#x2B;9rX7rrrrjvvvPOoF2XMr2q&#x2B;0jepqslk3NTN2tUrquqiiiREkSQRoqrJMTPXElOMJfdDkTY3N1968cX1a9cWFxdXVlY&#x2B;&#x2B;9nPnjt3LlZV2S0jIoMTUkzKzM45Zg4ulxEPGtflhJtzLoTA3HYGzOU5TaIQqHIAZhU&#x2B;5OcAEJsmhOC9Z2YQHDvHnI9j1kFPp5uUmXD4/QdBvnbn8HSaxvRdeT1QmmvYNy0b4m3TeOfoW57Oh/qsX58xxnzEWLHPGGOMMeaDaxbxu3DhwvPPP58jfouLi0e9LvOB026OnTuSn8emcc4R88FJAIAJwbUFpNl4CFEoqRKxA2FuTiwA/qUN32Z7R7N0eDVRUdcpxuvXr9V1Mx6Px5NxUzeiwsTEFJkAeFUi8gRmdo6JqVOUzJT2JDY09KVsNls/u7p28Y3eoGrk&#x2B;h2P3H/z505v9a&#x2B;XKBts7GFvEaqQSp1GVYrOOabGwaXpN5Rn5KoSwCkhhDKlJBKdc8wQFZWkIHBUVREVFRUCAcxM7EOITQOmpm6cKxYWlps4qepJv&#x2B;uZiJiICWCZygNJkAODehC&#x2B;I5pu480HSQEhIEmcbeMFyaxAqUjTAR2qiDrb6tseT4Cqpmnnvnw3kdOCirw1WKaxvsN/Wd6t3aMxxpgPLSv2GWOMMcZ80A0Gg0cfffT555&#x2B;/ePHiX//1X587d&#x2B;7ee&#x2B;896kWZD4d297cipaiiBDh2YHbEAARSxxqqwYdAHtMKn0JTalSUCEx5uOz0im2Rqh0X69piFoEITGh/xPj6Zl3Vo9H&#x2B;3t7e/v5oUk1i04hIp9MVFUkiklRBBGImIu6U77j&#x2B;pmmIKHDo9ftU0/W1tddee&#x2B;3a9Wu3h06v1/vEJz4xuP32MV69tH5pVG6K6NbWFoj6UjrvfRgWRcFlcs55KWgaKSQiIlKVPESDACJS1ZRkGspDNZkQEZFjZninqlFSTJF4OjmYiImdY1EHQESQNyhPR3McjPFtLzkN5c0n7GZ5u0MNAg&#x2B;9cvhtb2m7N3fW4cvObhU0DyCZ6&#x2B;xnjDHmuLNinzHGGGPMh0OO&#x2B;OVdva&#x2B;88sqDDz545syZo16U&#x2B;aA4lMKbOy5NZGYQO/bT3nGCJopD8D6AS9/Jh1Odmqbp9Tq5r1xAQJ6ZkeNoVQIxHE0/yfE0EIi6qfZ2t7a2t7a2dna29/f367pZLnoxphibGBOgzjnvQ3BuvLuVN9gW3jvHRExKAFJiEJwKERHnvnkgwCk1dTNA2e903Xpcf&#x2B;mNrZeu8kazfvPe2XvuWX1gGcOrL2/98PUrb6wudIloyQ0BRN9RooZiFVNZ7xNRr3cDETE7Zm7n/xJDNUkiAlNuHVgpQCRE1OmySBJRIuL8PSRKpEmEQO2wDibnnMIzs0ojINK2IWFO2OVpI9o&#x2B;CiBKqsizP9L069Npf0CZPs4CgG&#x2B;d1Ts7rtNzgKRor6ZIs4Z9qtNefqRz18Thgt98S0FjjDHHhxX7jDHGGGM&#x2B;NPKu3tXV1QsXLjz11FOnTp06f/48kf1b3bwr9h54S4WHwVy4g8P5L1AoXChcaoSZD/5OJUjTxJSKsgOB7u1vbW1vbm5sbm7t7u5W1URkOl92ejEiIsLu7l4u6pVlycyzv6UhBGb23jnnZ8dVNb3L&#x2B;kMITVPn4babW5uXX311a2ur3&#x2B;svLJSPPPJIb3n5lZ/99NLo0nA4XFlZiTGeHd6k0BohxlSl2DSNq6qUUmwiM6sDgOmvpwpISs67dtytgpjyxltmrpt6Mq5jisyF957YAxAVIgIkf225gEhEUdLsO1BSUPuyiORfcDZ0d/pH1j6d9uKbhgDbC83eNj949yC4N4sMHo7tqR409pteAocbEBpjjDnWrNhnjDHGGPMhc&#x2B;rUqdngjscff/yee&#x2B;657bbbjnpR5oi5&#x2B;R/08KMqqjql5EDwPhf7fKI27JWjXQpEIKkrGAAaoGrS3v7O7s7&#x2B;7l5VVS&#x2B;99BKmFTtta0gH23jbOhIRQYkAIvbsyHn2zjkCJUkpJRHpdrsASEmSqGhbGgScMhQMJRC1beSUAFZ4coX4NGp23thYv3wV23Glt4T74vLvn3vZX3322rPLZwa33HLmHJ8EQHERwJrvklfvxyjTIu&#x2B;KyG7TQBmigCjLNKAI0ehAREmRiKNzDpRSimtrV5umruukIuxK7z1zQURlt0t5rgZROzMXAoCdImcUp7k/guTra87lqSpESacFPsl99GYZvTwYBHMd92bn5JWibdinepD7wyy1d3Bc2&#x2B;Nz6T/Rg2m8&#x2B;QZawz5jjDnOrNhnjDHGGPPhMz&#x2B;444c//GEe3NHv9496XeaDJ6e&#x2B;ytLhrd3iQNMaoSDtjrfWN3d3d1&#x2B;7dCnG2EyqyaRqJlXTNJKSqna6HSJi4txib5bUYxEiyiE&#x2B;7733Ps/AHY32Y4qiwomdcznil1vj6TRtlt&#x2B;YB3S8W7Kvrmtm58DbOztvvvnm&#x2B;tp6kWKv1735zpu4KK5cudrtdu/82Cc8fFVX3aI7qSoiarzPJTcHDt6rqhNBDhGKpLbGSG1tDpSjcHk9TazH4/Huzo73viw7wQfmQvMWXFEVUSKI5orl9AvWg0EcioOoo0JlNlVD27G7b8vZtYfmWvwdXGkW3aNpXk8x9wEHz9trTo&#x2B;/dQCv6uFTjTHGHGdW7DPGGGOM&#x2B;bAaDAb33Xdfjvj95V/&#x2B;5e233/7pT3/6qBdljpS&#x2B;7TEmqAIEZihQVZO9vdFovPHK&#x2B;u7u7sb6xu7OTqwbVSVRVfWg/JyICnb9UBQheOf2WfK&#x2B;1LaS1JbstNfvtc8blSY2iA0RgP4NiyKSUkopNSpNFJZERCEEzEptRGBW5lw5Qzvmg9qsYe5F18ROt4sxNq6uXbn8erU7OtU5edPK6eX7z12m9Tfr9ZWbVxYx3MZ2d7/vJuhiGUBCF4pEewqlZkKKohBVESFV0bzLlhyI2BGRCpJIZJdEtar3d3a3Ol3f6Xb7vYWiCCIcY4qJAK3qBqBpDW7WBU&#x2B;JRRWqeWyJtFtvVbXtqaezObnTsOV0ey8O/jut7qniLcen9cDDBw/qhG0fQJmeM7v9cnDNd6j0WazPGGOOJyv2GWOMMcZ8iM0ifrnklyN&#x2B;q6urR70u80Gxtba2ubl59Y0319bW9nf36rqOTZNSWsRiXddNXUO18MF7Px0rAWIOjtk5DyKiFGOMMXqidi4v5157ufaXUkLbqI85n0BERFtbW0SUM32ztwAQEZqjqiklVfWueMf1M7P3PjbN2vr69etrKablU8s3nbnpxptvqevaO7&#x2B;wsFCjrpvaD2/U0agNsIlqu0WVmFhJQ/BJBFGTtNWwPITXERNRW6NTFZG6qvf390&#x2B;sDsqy9N6JaF03TWwA75ybRhoJUKW8nxfTqlmu80n7cLBtdi7E99bfT2evv&#x2B;sZhzvyvfX1ueZ/Bz/PmvbN/&#x2B;8dr26MMeY4smKfMcYYY8yHXi759fv9F1544cknnzxz5syDDz541Is6YnOzDkC5RZuCEx9qbpd3XhIAxHe4Qn58e8lGAXhRohwQo4PeaapMHgdzVSVn6ggomzGYQe7gI8nNXbl91Gk7tZo2GMTwCoV6IgraPVhomnsUIAFjYHeyvba&#x2B;dn1te21zc3NztLU3Ho87FFTVNYgpdaJ0QJ56zrkYYg8e7JmZPIgYXglEBUGhLCQQTioQCIBahg5cwkFJYwCoHrzMTBM6o6ouLBER8z&#x2B;WZTmo7ptMJr1ip/12lEiYNH8NIGYCIAQATMRtxq8TAWC7J0S0XIMZlAoiGg2W1kfjT43KyU/X3ZUrNwE/vPGNz/3Zn/SC39m&#x2B;foZWzmAFqddpinFvuOFjWUwAXZCxQiEJiv1AAEmcIPcSdFBmhQoEKkkbElISBCcsTdOMU5OIQjgN5bpmIlKI41zCg3euze6pqogCrApQjQhAlZRYIWAFEqCiETnf107IVYWAIFrNJmlM&#x2B;x/mYihDVeGg0&#x2B;MAFE6cAkBUhaLKjRgBdRwBAudMXyOqoo2q7pQAlLCrqi5CVWV8ToGGrjCIcCuBIhCh&#x2B;jCxAAAgAElEQVQZjnd&#x2B;2f&#x2B;ZjDHGfMhYsc8YY4wx5pg4d&#x2B;7cyspKjvg99thj995777lz5456UcdWSjH3sGPHBAbAIBAaTZRHVLRbZ6cVRzdXZZzlqwgptae2G2QVMUIF0kmMAIBAbQExqYh4cqnC3nrc3Nzcvr63vrG&#x2B;vb47Go1o&#x2B;42maVIdk4gXAuASiQi4ZGZSx8zOOyJ4cszsO6HdH6qaNKmm1CQoJAkzkSfnPTtyzpEjIriyT8xBoaoSWURERJU6/TKlJDmjJ1LVtZtMmrr27xzUe8/YOVW9fn1tb29PVcpO98yZM0tLS4QaQIxRUiqKouGmRu29f0uI7ZfPn1WADpJ11M7X5bdmD0WIwMwi73CBaXpu7unslbf&#x2B;gcPn4PDm2tni5w7PJ/MO/awKOOZ227CIQPL7iCjGhgiOFSDn2BEVZWm7do0x5iPCin3GGGOMMcfHbFfvk08&#x2B;&#x2B;cwzz7z00kvnz58vy/Ko13UE2u5v2qb32n2WrDlfln&#x2B;cL8l4efv&#x2B;yfY97/IJvm2elkCzRmqA4/noYM4XCoCdTiEqpOKcCyAADhEA&#x2B;6gQlYpAjggO3gkAbKwCQA3sYbK9u7G&#x2B;vrV5ZX9//&#x2B;WXXkgpxWavaZrYjOumbqpxE5ulYqAKEHnnKBQ&#x2B;BHLeO0xEHbvoA7MDMQBiZqIRbxMRsXPM5Ap2DhyIiFxJIGnziU5VJUEVm&#x2B;n73vue5xBCKMl7r4s/9s5NissAwM45V5Q/UFXsveyhuP5H7&#x2B;l&#x2B;5W&#x2B;fBcTTpnRERBSEuJHXL1/e2dyskYb98qY7bl0&#x2B;dWKEa84VKjoeV0tdF0KoYxO8l7YV3lsrZABD892chicPHvPUX4UQwI69d6VKBHsQVEWkERHnmJgg6aBxHsm0yqdCLnfN04PWe6yATD9l7u8IlCBS5pSfQhUJgFIDQLgGoGhUVRGhyK82GgEoErR9FRRVVVErVLQWCBDBRKRENCg4dw5MKUrNKaW0N1IVBjGYQQSwBk6BUuc93SljjDEffFbsM8YYY4w5bgaDwSOPPJIjfl//&#x2B;tc/&#x2B;clPfupTnzrqRR1f9AvmHLSFJACBAGozgFktzWQyHnQCM3sOACRNrl&#x2B;//vprr15fux7/aWUynuzvbY/Go7rar&#x2B;u6qXab2HQKJebgUgi&#x2B;CDTo93nYI1ApbjaCQcFA24YuhIKZ2TkAkl8XEeZerwdVUVKVlCdpaFQFB2Fmch3vnfPOOZdnWHSXzjjnSlbHzFBiSoMBM&#x2B;808D74oijLstNd2N3dHY1GILxPwT6klGJsrly5ur&#x2B;/D9VOp3PLLbf44VBwpdftFkW5u7uzvDQpXFFHISJth2ZMZ1kodDbs4520lb88PwMKgnM&#x2B;FKGuawAhF0Dp4B4fRO4I7aV1Wt&#x2B;bbR4/aJk3e34wc6M9fmhNszkb04&#x2B;g2e8wPR2Y&#x2B;4iDlcg0asjMlDeGkwA0Ho9BcJQAeOe890G6NpHDGGM&#x2B;IqzYZ4wxxhhzDM0ifhcuXPjxj3&#x2B;cB3csLy8f9bp&#x2B;c5yQEyIlKCsrESlBoERvz3wBgLIAoPnMl74t/jf3uBHyn6IQQlKoRwLQASuU0RDI54oQUhLpbpwEDnfZG3V7Vbj2wx9dX1u7cuny9WvXmtGIiAI7Zp7s/1PTNE1smHihLLvdTigH3HXjybidWDuB5HZvUACxKJkJjolJPTGzBBBRUwCg2iVVbVgof4DjSjtERKFi9gi7zIxig4ios0bE3Nny3nG575wjXxFRKgvvPWNBvS/SGeec63aZ&#x2B;TO/9V&#x2B;XZceljxdFcPLSyy&#x2B;/fOX1U6oKrL2n&#x2B;yWsALwqCQlNx2cQ8X6tO&#x2B;P9rS2ZVKlEWO4t3LCEEgLqdobD4XhjY2N7e&#x2B;eG5RvYRZ0ruh0eUkFQf3AH882laf2NALBKAhPBOVcUQap6TCzOg12ulCpIRRo96O6oIM39&#x2B;KY/tJ&#x2B;glEuHogTNW2spKVQ1KSlUlJCUMasRkihUqYZCaARAaaIKoNLp9SPkUH8/RU6MKjsiEHkghxAlJVGRAXVUlbRWVReDqrqqr4BHwWCnIAInzxpYLNlnjDHHjRX7jDHGGGOOrcFg8Oijjz7//POXLl369re/ffPNN99///1HvahjQtvYHgPswAAcEgBCmrbgo&#x2B;k2YGbmjefe2N7evn716rWrV7fX1re3t6ud3aqquuxUJIgyc8kMYNLEGONCb0BF4YMHiJhjjE2KqvBlcOzI5e2aAEDExFQlIWIQEShXg4jYOTeqxkRovAIQD&#x2B;&#x2B;9dz4EP64aZnbMIRSh1yuKwnWF2fk&#x2B;O8fcKUMIvrvvvafQMFH35IkQwoI/0el2&#x2B;3xLBx3CCMAmBl10NfQc2HFZV9Xm5gZA/e778z03TbO1tbW/v9/E2Ot2b7jhhoXFBYjkb3hxYWF3d3d/f79ermfd9A5V&#x2B;vKRX9S4T1VJqU3kEbFzvghFik0SiTF6eBAxs2hKkpviEZECeRZvfp8qzaYZz/fum24oni9CHmrip9OTDroLHiT36PCx2eZknT&#x2B;rzWuqqkhKSVJKquLJA2BEACTt1nLL9RljzEeEFfuMMcYYY465HPHLu3ovX778wAMPnD179qgX9WvHwpw4J/VyWSQhCQvPhmkA&#x2B;XkenTviHAAjtCU8uHZgLAC4t41lOLkG8HSfrjAEaBgKNAGbafTa&#x2B;utvvH799StXrl5dv3Z9b3eXT67HJtZVjDGSeOd8yf2ucwGFEqv4mFQ0ELEjz44kveac88EzUSJW1USOgLGII6cIUESBqio7Vk7lbxGRuImK1G6TSTVseO90ecs5Rm/LOcedvRCC74j3/uypa0RE6DIzY4mZoSsE6pYfDyF0ipv6/X6ve7rX65XFomc/0ZIJOQPmEgRQd42AEouAY7ACARuhs1n0NjqdDsYn3tP9SqQAfAKTJkfKlJN93UqrK5v17h4mFZ0anLztpnCi24TGobM/2e92hyeWV0f7493dPSbX7XalnYQ82/k63ROrbq76156TR3PQNOKnSuTYcVBPZaeBaky1aHS5tKopJQGEpmOYVQUQRVJVUAMoDnrw6XRwcg0AaBRQxHwOAOXcfU/avo85CQioOqgqCqhCXXtcNeQpvUoKVWFAVRygIqyqKqyqjnzJ7NgzU9xsvPed0vV6vUFnodfr9vgm771Dn8Es&#x2B;W95IhH&#x2B;haVQY4wxH0ZW7DPGGGOMOf7mB3c8/fTTeXCHm58Pa96rAkjABtauXr1y&#x2B;bVXX3tt441ru7u7463dqqrSfpUkBThmpqRJ0mRjwznnufDekwQASZKqpjhxzgUumNlpQURMnolnNaskGlVARMF77&#x2B;smAciDgJUIADnvnNtNyTlmIg7Bl91QFH7RlUWBQeG9p0EvBI/OvnOOy4bZ1Z2dEEK3szwcDof9mwaDQdedDQgepwEoTgBQLABQFAD8XCqMCDQtmDEcgEYbJopo6rqKqd34&#x2B;r4gYHdvbzIZN7Hpdjqrq6vdbpeIPNx4PBp0BktLS1VVj0Yj50Kv1wPmE30HybhfGmtT1WlSkpi50&#x2B;k0dd00jSSBOnasqqpC025689c71FmvzdnNv/q253r46FzDvoPA3/Qqh1r0Tc&#x2B;dXb8IhaioMBGF0Ol2Op1urwjF2U/exGAPcXAFSgcfsPqWxRhjjDmurNhnjDHGGPNRMT&#x2B;446tf/erdd999xx13HPWifn0IIM0d&#x2B;kimtRllIMboxcF5NADaPnq9XJ/Sts0ecBD/ggJjYKR761uvv/765VcuX79&#x2B;3f3kx1VVTfaruq4RSVUpOhHxjfNA0MI5F8gzMykrdFx/ggA4ZmZ4R0QNVEQbUk4uekdCEyYGgeEc6s4dBAhHAMlNQIh&#x2B;RFBdqCfVTu9E6Ha7W6NrRDxc6ik0nfvfTpw4maIbDIekw8XFxfFuWXZKpysppZXl2/b29ob9O8/dcm48St1ut/B3LvQXxtUkFIWj0MSm2o9Ff6hgBRiQ6eDivb1mMAgeGwAcAgDHAwAOFYA8x7YkLwnerbjxcIgF3nvPxb7ESoReJGKaMCuREAAsT0TWdn2UDjguhu5Nyzrg7ckeSVpaXK1FVNyJ5ZW6ruumunbt6omTJ4gIlHfVEkRERFSZiMBAElHRqFBiZWYgSYpCQgwAKUW0u27Fec/MqqoQEc39/IgwPSKqqiIAmJiwT&#x2B;2mWoUmqKpGBZjbgp2oYNZwT5Wn3x6Atp8gOgAkkqqKcEqiCSKSJ60sUC&#x2B;fz8TOld577zvMvHLytA&#x2B;hDP2yKAM6eV85oA6LAAgRIIYSiJGHwBSOGQRN6A6cYgyu3&#x2B;vNMsYY8wFnxT5jjDHGmI&#x2B;Q&#x2B;cEdzz33XI74DYfDo17Xbw6Bgg9IDEkQB5nus&#x2B;zPnTSWrWvX3nj1zbW1tZcuvry3t7e9vrO7txsnMaUkUUTklr3dlJIkJSBQwexcUlUddPtQOAlE5NSBiISggIoCuTYEISJSIhD6/T4RJWZVbTQXkFREYtMQEVziKfKBCMs3LMYYXT/1B/2zgxsWFoadfkhJdm94ajgc7O/FoigggxtO3eB5ZeXkiqfV0pcpDYduIaFz&#x2B;c3Lw/7KysJKTu2NJ&#x2B;Onn356&#x2B;cTKp3/708F3BTIeV71uF8BkUne7BYBuLzQNEH7jtwoAsLu7O5lMVKQoin6/3ylLAqnmb5KIQEzOuRA8SMW5/f0REbn8jXG7j5uI2iwc5T24UEFKKaVETCBiyvE8msXqYnzn9Ugu2GFaESYihZJSjvwRu4OUHwHYH&#x2B;0CAJIqFLOtu/ClV1VJmlKKMaWUJOV9wYGJmEvvnS9L55xznohPFovOsfdlURRl0Q1ceHQYnMAMdugwGMg11rxRnTHdkD6fafTOiQgSJMlob6Q6XbkxxphjxIp9xhhjjDEfObPBHRcvXvzmN7956623fuYznznqRb3PlFRJhVRIclmGQVAab&#x2B;70FpcwAdShAgS4CmztvPGDH1xfW3vj9TfW19cno0lsYlPFpqkd&#x2B;bqqaVL3kwTnQyi880R&#x2B;4vqkcETsHDtPxNGRqm4oiKBeqJ3TkcfK4nTTAUioIVCkETM35YiINqoX2LnUnTjmVFTsHBVKzNtnXvbeF92i1&#x2B;t1B91evxe6wXsfOS4uLlBASkIFjVO6urczGU8&#x2B;c&#x2B;rfd7vdzulydXGJgUmSye7&#x2B;MAxz&#x2B;ecbX/tPO9uXqtF4e2vrX//ru1c&#x2B;eRsl/H//8en/8B8e&#x2B;/GPX/ji7//euf/lvqWTYOFh4ZHQNNKB8woAnhROIk4A8DntmGcKhwJAgCiUQEQCrDted27smJHOvKf7JSwABVFS7BOIkIiIqLq6SVsjauKwKMtTC1jqTBAnoQ6JmRisROQcETE7VpX9/T0iUnWszOqZKN/56ayLBMqPIlqryMHgjNzD72AHLh/suZ3bVCuScPBTntABKKU6zXbzavvAUAzLVVVVURFJOacnoqqpGhHBwwdmRkGByXeIqAgLjtn7QVEUZRgUReF96ZwbRM/sPAcCTYt6&#x2B;dHPPbbzo1XRpLb9JOW&#x2B;k3NlPyIGi/OcUPkuudK28xtjzHFjxT5jjDHGmI&#x2B;o&#x2B;cEdL7/88vnz52&#x2B;44YajXtSvXW9xCcClf/zxN7/5zd2XNpq6nlzb29nZvW1xcTwej/b266ZhsGNHSiJa&#x2B;IKIut1uCCG4ACA2KaU47XjIlEspUAKBqAwFiECsaJvAETMRj3bGRKQuElHSyjufQvLOF0VRFIVb7PT7vbDI/V6vHISiKDZvWSVm9uS9dwV77xFAzK7DZ06fcR3nvFtwC9u69Y8/&#x2B;setzc3xeHz7LedyRmu/rvtF0VsaCuAAUTzzzDNf&#x2B;cpXBp3u73/xi8PhAoD1a7h06dJwOFxdPbW1tfXSyy9/orh1MMTOdvWd73zn47fdfNdvfxJAapqYmrLzPs3Wfe/29vYm1SSlVBTF4tJip9up8l5rhSI32QMRmAnEqtTt5qXmshe1KTuFcySqKtLOYWFyykIkGqcd8NotuPmq7xZ3c45VoSp5/i3abd9aFMXcJt0WgNFoNF1j&#x2B;8DMIHQ6fefY&#x2B;05ZFGUxKIoy&#x2B;AGDPQYEYnQdHKHInwmg9O7g98rTZpKoaBH8wbhfdbm6RwQ/V8GjQ38gJfWO81eo0JTSr3SHjDHGfPBYsc8YY4wx5qMr7&#x2B;pdXV29cOHC9773vRtvvPGhhx466kW9P4Q0zxnVaY2DwZQ37Vbp6nOvvvCdf8SlamFh2J&#x2B;UHR3svbZeFMVqueBDICDlnZUiQQpRERFoBCUiKogAGlafApAoAtr4mplTWTPzbr3FRE0xUtXaTQCioM65Fz//Pee9LziEwB0qy8L3XRHC6Y/dwE61SER7tU&#x2B;Rt8mD2a3I50MIve5wMBgOB6uD4aDLJwEoegAEHQAE8Mbez77/2BNPxM/&#x2B;ryM0&#x2B;2XoAGCXCqQmNYULVT3pFJ1Hfve&#x2B;C8882e12//CPf/fMzScSmtev/6iSl5dWR8ujcW9he7i8N1gcgfmpp7/&#x2B;//67/&#x2B;vf/tv/4a5P/xY0uoLjaB/UkCwC00xfm&#x2B;xbBCDqc3c/UWZ0EzoJhZIr3vv9AuBFifIuZ8qPvF&#x2B;HSaqa2HHOL3Wl58aoap&#x2B;KFAgETaqklDfJqqoWRQAgAlVRYVVRMKDU9utrVJVcYmYiYdWUC3Y5nqekijaYJ67t4KhtbXG6x1dnob5c9csHdNzNlV3KQ0sIlEtvIszO&#x2B;6IIRSjKIhTeB2Yehi4xMXlH/z97d/Ik2Xne&#x2B;/153vc95&#x2B;RUc1d1o7uAHtDdaBAzCEIUCfAybEv/gq8Xd&#x2B;HtDcdde6GtI7xzhMI773zXDFmhkCxdK2QK4qUVFEQQvARI8GIQ2QAB9FRDDifP8L6PFyerutCcBBJgA8nvJzqKVVknM0&#x2B;dLERk/fgM3i9CvfBzH70c1Rves2DEi3gv4u9&#x2B;&#x2B;55D3NEiEbPuaiyKEPNCnDPRVkSi2LSclTVhHwAsG8I&#x2B;AACA33c7OzvHizu&#x2B;8Y1vPPPMM5cuXbrfJ/WpMZHMZ1meZVk2cHmeW5liTKe3t0Ustqmu6qZtvHO9Xr/XK6qq9tLNYRPtluCqU9VqnqQrsEqpipWIRKu9821os5CFLMtCNuj3irzIR3mR5&#x2B;uP3MyLojfIe71eGPh&#x2B;v5evZEVR3JndKoqiWM1WRiuD9d5osDKQXiHFQJ4WEVu8XS9ksSnEGqu9hphi5ryJzKuq1&#x2B;tvbGwOh8Ne1hORNjUHB4ebm5snZ7G98MILr7766t6dO2fPnWvaxjkXY/zOP33n&#x2B;6&#x2B;&#x2B;&#x2B;uCDD7744levXLkiTlNsL168&#x2B;NxzX&#x2B;w2t0wnk&#x2B;HKajEYiKXf9ct0pD0aaOd9GA6HIQtRau3q40S6urquTXaxHONog0b3oQsMRUQknijsExExs5hS3VRy3MDbrctYNLz&#x2B;4tK&#x2B;qqpMRCR1pYXHHcDOdb3EwTvnfea9dy5T1Y31U6rOSfDivXRNuCoimRyf/0eko57h7qN&#x2B;9JiuYFBVf&#x2B;2gvbYVVXEqquI/UhQozjmTdn9/f21tzf/MF0Xxqx8KAPC5Q9gHAACAu4s7XnrppVdeeaVb3HHUEfm5lNSSmh2NahMRSaK2SFHSXl1&#x2B;OMluhyL59XYwGAx&#x2B;Vn7ovPc&#x2B;SBFSnuoYp22UybRq6hB8yIL3QZ2ZJbPWkt3e/b&#x2B;C99qLzvumN3HeNaPDEMLapTwvclufFUVuK1Wv3&#x2B;&#x2B;tZf1&#x2B;b7T3b4qi6PdWi6IIbiXP815&#x2B;Ks/zZ9evOFGRkYkkEbNFG6akRYuodDP/jgrLMpW2qr3VoSjE5PTAPXJ25WB3rb5&#x2B;M3vw6s3r1//0T//0YDz5kz/5k52HHqwOy&#x2B;FoKElGvdUrl576Yfvjqsrb1M&#x2B;DbO6sffVrX/7C49e&#x2B;/OUvP/vs8&#x2B;pzEW8Sr1794r//908M&#x2B;rlE8TaSeHTFwi0R8a4QEfHdRpc9EWn1gaSmoslLkKxxea19rx97DJypiJizu8uQTdVEUllrHaVNuffZqKdFaCQmSbqYWJfseDZdd5EWO0663txu&#x2B;YaKaEqVWVzUC7qUUqzaWV3XZTVTVV0s9Mi8c6pBVVXyoyK&#x2B;j8zsCyHXbuqdO8p9naroqf5DqurUO&#x2B;e95F68LnaadH9wZUnMxJmlZCpmRbq39rGbGpj5nw8ARUTSIhvUpF3R4uJ8vA8/9xgmYiGbiEi34VekSCmlFMXk9v6Hbdu2sbl58&#x2B;aNDw73DyZ1w8w&#x2B;AFg2hH0AAABYGI1GxyV&#x2B;f/VXf/XII488/vjj9/ukPmlJRKToFevr6&#x2B;ttURR5M2lms1lv0O82KKhqCCHLsq57tz/oJ7NkMcWUzLz3RVGEEPz2dn8wGG4Wq6ur2WYaDoeyWeZ5Ps5vhCzUowNVrfJD730YalEUV688X4SikJEXb9JTUZUVkbtZpErXbrqIeo4q1&#x2B;71X773yj//8z9X8/kXn/vic889N1xd297ejm17587em9///rf&#x2B;839&#x2B;9Xvfq9r4Ty//03&#x2B;7udUbDUSkbcznurt77mA8GY1GeS5tK&#x2B;cfPP8f/qf/IKIiGqPNq3mvGDrnppNqOCzqUvJcekOZHtpwRS3et78b6qaOMdrRlZfQddd2BXyL/znaguIWHbdmliSldJTUmYjEFLu6P&#x2B;ecqLapraqqLMs2Nc6p80FVnahz3fZbTb9kG&#x2B;/6&#x2B;oZz6pwLzgfxXrwXr6KZDFVEFvV6d&#x2B;Ozo9fXdJFIeq/3bsjt6M/f56jIz0TMLX41nKioPz46ddtRTjxGVwwYJdZ1PZ1MDg8PD/bmBwcHs9m0rmsNrYiG4O/s3ekX6xcvXdrY2Ph4LwkA4DOPsA8AAAB3HZf4/fCHP3zjjTfefPPNF198cWtr636f18dWB6uCDWoLrYkzUS2dJCfDvoiIzSahqfI6ajNvenl07azaGwwGq7e2LCXZsPm8&#x2B;sFD/3Dq1Kn/eurlPM8Hq7K2trq53husrYXNOs/zfNOJ3mkl7HXrIVSda0U0tfMsy5qp5Xmu8zVpTMdrf/zlPx7KH8lHI56jSWytiKiUJz5PIjKVta7GazKb/e9/&#x2B;r99&#x2B;9v/3//47/6Hr37lq2/9y4/e&#x2B;&#x2B;CdV7/7T3//93/53/03/&#x2B;app556/Qc/&#x2B;N53/98fvfLjd997t2nbyWTSH/Rv3djrFX2JImJBrC3bJ69d/cLVh733rk79zC1KxdREzDvzuRcpVWW4kkTafLiY4zbcEBOzkCo5JSJVN8euu6ucEhEv81rqnmgmOqtOebskw59WbePqoZioqpouOldt8cOpiugiolITdaIiWhaW7L2VyjnVdpwXxZn5&#x2B;nw&#x2B;fyXfGOfrHw7rlcH6hWgSpSd7IiZhYhK7ltaUpG1bJyHLsvm8FREx163hsOOsTJs6Ns6Jz/KmieP9w7IsnXObqw&#x2B;oqEquzjkpNDlNmaoO046qeu&#x2B;99yGEEIJzrktgF9s3Ypc56i&#x2B;LZU8ysy5HPj7YnB234p5szjW7e7ue&#x2B;Jb7aDzYBaAhhO72pmnKsjw8PNzb29vf35/NZm3b1nWtqnmet217cHDwwAMP9Hr9tbW11dXVLMtCCLu7u//a/5wAAJ8rhH0AAAC412g0&#x2B;tKXvrS9vf36669/85vf3N3d/YM/&#x2B;IP7fVKfrqJXdIFOTBZj7KKQxx5/7LGnd1XV5aX3IQ&#x2B;N96EZHqjqHTkQFZO7ZVVmdqJQ77flRaJIJtLvD8pZeefOnb/6q//71Vdf3VgZ/OAHr/34jTdms9l/&#x2B;d53TcyJZVme2ez0zs5Tzzxz6tRWyLKnnnpKgkoUCSqiIXPBspRMxJx33eneu3G2KyRb3NZlUscT7u7mWUeLH8QkmZgXMbPJfBpjPLx16/DwMMZ2sd7248iyLMZoznVRV0rWNPV8Xo7Hh3VdqapzPqUkTROldeLrtk6L3ReLGC5Fq&#x2B;smC5mJWFIzS0kspW4xRead6qJsskvxsixzzq&#x2B;MVlTFac8557TvnHOaq&#x2B;owbSy6p39uOt5xKidHKV5XeHh0Fe34WyLS3d494/EB3S/Y8ZcnZ/Ad311EnHPH30opdXGhqs7n84ODg/F43DTNW2&#x2B;91a3TDSHkea6qbds2TRNC2NjYeOSRRz744INLly6tra193FcEAPD5RdgHAACAX&#x2B;zChQunTp3qunrffffd559//sEHH7zfJ/VpmWnbimqYJ5fm7kDEsp3moSdPvbv7gVkyjcmaJjV1slIPTcy5u5tSbdE5GkVENKXun4viWhHR1EZpc3lXRI7efuciItYXEUndxyByPKxORKSXJWtqzfK//&#x2B;u//k9/9hfv/Mu/7P/s1ubmZhItyzLG9bWt3a3tnd3d3StXHzn/0Plzu9nu7oMXz18UkXlTee&#x2B;TK6OPycQ71024M6&#x2B;y6GOWFAt14k5uiVARkWSLz7uvosW6rdqmXRu8LCJR9iuZT9NPp9PJbP5hXTcHtw/atnXzdRHRcqdtmpV83Tkvpf2SLRd2osDx7ueFaJMstck5p&#x2B;ZCUmnatpyrxCzooJcNitD3mZjrpSw470NRVVVTtVabqqTkUlRVUe9ExJLr9nOIue5Fauuexcx7F0IvDxJWNmyUspAN&#x2B;6sqolKoqEq3qsLLL2&#x2B;jjjGezOBOhnTHt/zq7RlmdvzgKd3dfBJjjDGeXJdhZl29XlmW4/F4PB4fHh7Wdd0Ff865LrJcX19X1UuXLr377ruXL18OIZyM9h544IFfcTIAgKVE2AcAAIBf6uTiju985ztdV&#x2B;9xUdIyaZqmS2jyPK&#x2B;9K2dlU9eqWpaliIibi4iTKCLJTEWOdrzq0S6IxWy4X7Mk9ePQLC8nk//4f/7Hvf39P/zyl8&#x2B;c3R2NRo898eTZs2evXfvC&#x2B;YfOu0zmZXTe93ridHp8xyJbbO/16r0eddCKiFhrsesAzSXvyvMWqV6SZGImIVsc2qbYxqqp66qeN237vdf/XkSS248xtfJ&#x2B;0zRN3EsxWmM&#x2B;hKwJKaWsHjrnXNvGWPU&#x2B;5g&#x2B;bUooxphi7jcfeO1HtKuZSSlVVVXUd2yhmMcaU0jD0m6Y5PBzHGJ0Lzjnv8&#x2B;C7gkh16tU5p8E5p90WDXEppRBcr9cL6gaFOHEqejRf7zjas8V63RPFiSfDO3dUe3jvi3Xixu5n6a5zt&#x2B;Umxnh8QJf0NU3TTYc8vlcIoa7r99577&#x2B;Dg4Pbt213h3tE5mapOp9Otra2U0hNPPOCON/UAACAASURBVNE1F6&#x2B;vr6&#x2B;srBw/wrlz5z7mVQcALKclfKMGAACAT9bJxR1//ud//thjj127du1&#x2B;n9QnzIqi8b7Jkys0DcrKxtPsZ/vuert2W8RMGhFx0ZtZnVdi0o&#x2B;5iERRFes6YJMkEVEXk3PRx&#x2B;ic&#x2B;NbM1DetNG27K7JI1uxEJZ11WZMX&#x2B;WgPcFHflpSknkp963/9X/7n//7f/lvJByKSJPu7b/7d3/zD//PFL37x6aef8SPfipQiToYiMq0aVRnm2fHjxMVqCOl2OjgVF7onvy4iSbo4adb4ppX9KOn6u681TVM1t&#x2B;u6btvDpm3aWMYY1/YeFzFJK84ki&#x2B;czEUlrKtqULssyb9o2jU&#x2B;N815TXdeNFSd&#x2B;Gj1RPHj0z7RbPLzoHVaLTqIm8Um8qEsqmkxTymLtqnma1TIPLkjeW3OryWzv5nwyqabTqCp5Flye&#x2B;aznLYSQq6pzwXvvXea9d86raj8bdn3HTpyImSSRrq23i/mCiKWki1ZsEwmLkXz3/J4c39KV1x1ngscj&#x2B;bz3XVtxlt19FY4jwi4E7I7Z29t7//33b9&#x2B;&#x2B;XZZllwymlNp20QTdtu2pU6eKonj44Ydv3ry5vr5&#x2B;/vz5f&#x2B;1vMwDg9xthHwAAAH694xK/l19&#x2B;&#x2B;bXXXnvrrbdeeOGFZRoE5r03kaZpzKzNW6fOedeNVxMx61ZdRBGxFKN0wdzdTbqLnbC/way6XyoESSnLss2tzUuXLon344P9fn&#x2B;guX/2mWeeef4rK4NBFGlM2iTF0fbXYbEImFqTtm2KLAuiJhItxpT0aN6eiV3/4M0YY91Mq6qq6r2qqpp2L8bU69dN09TtnaZpTKZmIlKbmZ&#x2B;MU0pNU8fYxqZOZtLORaTwq845bypmhZder1fkeVEUsf54P673LiVv3quqRUsxdeVs83kpIkWvl&#x2B;V5jFHK2UxnzrnxeNy2sd/vDwaDfn8QfOgCvizrqYqKV1VV70T1qGpPxendTmn9uR5jPdm5&#x2B;/MdyPfU&#x2B;h3v6/hluijQOVeW5Xw&#x2B;r6pqf3//ww8/PDg46PK&#x2B;rjpPVeu6XllZ&#x2B;fDDD59&#x2B;&#x2B;umyLJ966qn333//5PaMs2fPfryrCQD4/UbYBwAAgH&#x2B;t0Wj09a9//bXXXvvRj370t3/7txcvXnz22Wfv90l9MlKVe&#x2B;8lujZaEyvnk8vrFGYpTERVxVTFx4GqZqFQFSlPDNgTU5Vuv6ypmVo3tk80mopqSpJCmMvdGX/dR3fPx5PqckNVXG/r0qN/fDBbiWl1uLYqItOqXl3bSiJNaupYFVmRea1TpUmykIXFPt/DoOKyPRExuTGX&#x2B;bS&#x2B;PplMZuX708lkVt6pqnqzdybGWM&#x2B;1qqqmLNq2TfWaWdqfjmJ0qb4mZs5WVZ1aoSZpZupcL1gI3uXmg3eFU9XMD2OMUg9F1LdrMjFnIx9CM3hDukTNLWI2OZoPqEeVfU5F1bpFs6U20UcXnKpakuS07mmKWbY7OjN8KPSz3d3dfG1lWs4Oq7rX622NzjnniqI3GA6Cy7qrqh&#x2B;pIZSTe0XatlXVo5F6wR2X7P2yePb4&#x2B;0eOP/fen6z4a9v2eNbefD6fzWbdfL3pdFrX9cHBQVVVIpLnuZnN5/OU0pUrV0RkZWWli/wuXLhwz5OzJxcA8Nsg7AMAAMDH05X4dV2977zzzle&#x2B;8pUlWAIQUyqKoigyM2tCELEQgop21VvdztXYtmZWp0bEvC3m4onIibW2n9jIvvxo6N2ZM2fef/9958REyjL2&#x2B;3mX9GUuC4slIalwhXMaJU7r6XQ6PRy/O5/PZ&#x2B;VPb926lRcHMaakN8VMdZxSbOOkbdo7k0mMsa19jNGaoYj4bsNF68VM28Y5t&#x2B;hQTsmS&#x2B;ZA751xIzrlkTaxjTNHM8mAxxlzyfr8XJDRN3bTtb1Dg2DSNWVLTbhiicy7L815Kf/RHf2Rmq1tr/fUNuZiJyFkvvdATGYrI8QXvdqSo&#x2B;m7i3tELc3ez7cntt0fJnaSUwtGS3O6Wro3XRPzR30m/bOHG8faMw8PD&#x2B;Xx&#x2B;/fr1k5tzu3bdlNLq6urq6urFixd/9rOfXbx4cWdn52NfGgAAPibCPgAAAHxsXVfv9vb2yy&#x2B;//O1vf/v06dMvvPDC/T6p38pKWkvj2GsHbdv6OohIPakzy7V1ctTUmaVCRMQWQ&#x2B;9E5GRhWHdMNa9zn&#x2B;e&#x2B;KCez9f7OfD7PXZ5LIfPeoqjt5F3NRFtRFW1ErFsuIV5FZOr7IlLZ&#x2B;NEXL6V454Pqv54apNBPQfZNLHM3GmnadHMymYwPb8xms&#x2B;nhxJKlNouxTdUgxmj1ei&#x2B;l5sOVlFKcXZ1XVT3N27a1lKvISrPqxfIkIrLoSdWg6rqmV6fBOXXqVZ1TJ6qmM&#x2B;e8SvTeJY1mJlqbpLyoU4wWb81bzfQg64egfVWdSPTe&#x2B;&#x2B;CcOhNJuqjvq5rGOVXngxMfgg/eOafOWc/led4f9kbD4epw1O/3g&#x2B;uJF6lE3NEWjcxEzLn1WiRPR1trux24cqJm8vhlMVE7vuLt4mjtKjWTqnfeW4xN2&#x2B;Z5LqqWonNOnMamEcm6TLDL76qqmk6ns9lsb29vMpkcHByUZdl16XZxcFmW29vbN2/evHbtWr/f7/V6qnpye/USb7IGAHzWEPYBAADgN7Szs3O8uOMb3/jGU089dfny5ft9UvdZnufOOy8hpZ73PsZYp6aS&#x2B;S&#x2B;o&#x2B;VukiK7bTyHykRRwnuqey3taXHjwQptGIrJXvnd4eHjjg&#x2B;/HmFRumSW1g7Zt6/qgaZp6VqUU29rXddOURVPXcb6aYrR6U1V93DIzjStOXXC58z5V6eg8VI930IqF4FVVxTunToM6depE1Gc9EUm&#x2B;q4lLi6ZZdU1de&#x2B;&#x2B;zLHPOaevqui7rNqVUnB10pXNtrJOZcy5kQULo9XohhF6/PxwOh6PhcDjs9ftZFmS1d7cHt4vqooic&#x2B;HsliVgSda5rztUTfbaLRRmqoho&#x2B;Mnjv&#x2B;LLXVdXtUFbnul29i0O8z08U93Vrc&#x2B;um3rt1czwe37lzZzweV1XVlemllLz3dV2XZbm5ufnkk09mWXb9&#x2B;vUnnnhiOBz&#x2B;Br8tAAB8Ggj7AAAA8Js7ubjj1Vdf7RZ3fB6DjyxZihKik&#x2B;h8zEVE48ClvsS&#x2B;iKhGEXEpiIhPSUSiSyJiJxbrqjkR8Sm0s&#x2B;hb75J30Yc6G/jhUFb2i6PjRFQqExM5FJEgUxFRGZuYyDRKrGVSS30w&#x2B;U9t287HNpmM47iXUnKz9aZphulcXddx/1RZlu34VFVV7UzbtvW2vpgtlywlUzOfzJuoOu&#x2B;cd0G7mjbnvPPeufWiPD5/WywD9mJiTaMiJkFUk3hVTepEpPZRRFIaOFVL2yF4dQPnXJQ6mTa2n5ok7pYvQm&#x2B;j6ef5nZmGEIpeMeiPBoPBcDgcjEZFUWxub4uKqIrTk2Fc602OqiNVJCUTSWYSXXLO&#x2B;eBUtDvPZHlKaT6ZZiHkRaFO1flFSBh/0Qw&#x2B;EzHJi3D8SomoiImlGOP&#x2B;/v54PC7L6Xg82du7WTeNqtV1rdrvVug2TbOxsZFl2YULF27evHnhwoXNzc2TD3/u3Lnf9pcPAIBPFGEfAAAAfluj0ei5557rSvz&#x2B;&#x2B;q//&#x2B;sqVK08&#x2B;&#x2B;eT9Pqn7YzQczedzTa5bB5vn&#x2B;bA3zCSLJ47RrgZNvIi8u3&#x2B;9qqp5fbOpm5gO67qelfvz&#x2B;bw/fHNeVW3pUkpSDspZ2e7fbtsm7t9IKfnZRozR16si4mNPRNr5gXaNqYstr8GrV6di6pzz6kXEkplZN4BwXpbS7at1TtR0sUpDnHarZn0I3vnce&#x2B;9cUHVTPzYzSxpTatpqXllrjYgMVwsfQuieMh8OBoP1DTccjR7feaTI87zflyL7SFXjPZ8fZXNJksii69aL817VexEJ0s0lvMurFyejlaGIWJJ5WVlKIYSsyNTLL3AUKc7n5eHhZDKZzKbzyXRyeDCZzWbdLL/BoOecK&#x2B;fztbW1g4O9p59&#x2B;ejqNw&#x2B;HQe3/&#x2B;/PnjR6IVFwDwuUDYBwAAgE/AcYlfF/l1JX7b29v3&#x2B;7z&#x2B;tcxPTFKyIlnbOhORxoVGs8blIuKkFhHnk4i0vhaR7o10t0W3i6i6yj6tXZpbHjMxc9G7KrRz2ysPBv3/o5a6lOpwPJ7sVePxeD62pq4fOHWpLGfz/VTOy1j5pmmqsq3ruvejfzebTZtqrqrOYtM0EmvnXDOfeOe8lyKE3IsPIfPOOddYraYi6sw0NdrGLlNMlpz33jt1rtsarM451Vg/KaLioxOnWe2cs2yuqtarzKzVcbLUyiyllFJjZrl/NIQQhm2vVwxGh1mWWe&#x2B;Oqjuze3o4zFdXrwz6fa/rok40ExExW9TuiYhIqtu6bVJMvUGvu2CL77nFyL0gJiKui&#x2B;u6LRkqItJIY2J1rFNKhfWyLPjkvPhk5pyql97gaHjfCU1TTyfT8Xh8eHh4OD4sy3JajZumaZskIt4XKtI0affcuel0cvnK1evX37l48eJDZHkAgKVA2AcAAIBPTBf5DYfD119//aWXXjp79uwf/uEf3u&#x2B;T&#x2B;p2az8u2bQfBO&#x2B;fyWDjn4rR99913P6heSymlVtu2tTrEGLUpTOTvv/nNqqrqidR1bW1mySy6lNKV6TNlWc5ns5RiUAtZNizyoihcP3POBU0mJm0TU6zaRkSyIjuumeuWzYqImKjrRvKZpGRd2CcizuVZlpJFadu2iXEuoinMVDXOJ85516uzLOv3&#x2B;3me&#x2B;0ycc6vDi0VRDNZ1bW1tsJWGw6GMavGhKg/zPNewJiKSMrG0mLXnPzKk0OWhl59cbCJ3PzexRbS3aETW5Mwsumi2&#x2B;Hul8IV4yaSLESU1ovndJHFezvf29u7cuTOdTt9977qYqGoIIcsydRrb2MY2WrO5tfnoI4&#x2B;997P3rly&#x2B;lmV5r8iOT&#x2B;TSRWI&#x2B;AMDyIOwDAADAJ&#x2B;zChQunTp06Xtzx3HPPneyF/GxqwyS51MggStv4KCKN09pr47s9Gt1EuUZEmlCJSIhHNWgiXWrlzIlIPys0&#x2B;lyKel63VSui873q3el7D7z6xaZp5tN6Mp2Uh/VsNotTa2N8qP&#x2B;MpaRNllLyKVN1QTNV/aD&#x2B;9uZgMBgMs15m6mKcVeNY36593vfeu5Crqonzos4VzvtYedXj/RNdc65TVXVOVZOJJUuWTNR5Z87dHv6DmKTu21kvz3NXDIMPRW&#x2B;nKIrB6ubGxsb6qdMbGxujlcwVIjIWVZFu9GC2&#x2B;KFNQn8niZhISpLMVEPIk4h4cyKSTNq2iTGKaPDeez&#x2B;bz7vuYe&#x2B;c897pYnKfT0lUJS3SSFV1LohIJdPuGjtx2vqmqpo7aTabvX3wTlVVs9msLMsYo/c&#x2B;z/MsywbD/sbmxvvvf/DwlUvqVFW891cuXzt&#x2B;oU/vnPn0f5sAALifCPsAAADwyTvu6n3ppZdefvnlN99888UXX8zz/H6f16duOp0dHh7eGR9&#x2B;eOPDuD8U0cMPrWmaq&#x2B;88I2YSnYn5lDvVzHrB&#x2B;/F47JzLTZxzZqJioqKqq2trRZ6buul0GpPkRVEUvV6vZxqcc6ohmcUkouK8D953EwBNVUxSjCmlrg1WvVfVRUWfarc5N4Rgg2EIoegPVlZX1zZ3Tp3aWtncGfQHfntL5BdN1lusrzVJi8W90YmK1FFURb34IE66dR8WU9KkzqtzkueZyN0ausGgf/x5l&#x2B;J1W4G9pW4/8UKSmJpkdnt65&#x2B;Dg4NatW4eHB27qxaxXD02sHMxTSlVVra&#x2B;v53l&#x2B;/vz569evP/nkk6urq5/8iwoAwOcKYR8AAAA&#x2B;LaPR6Gtf&#x2B;1pX4vcXf/EXjz766Be&#x2B;8IXfzVNXLq9c3ngn6kRqEcukTpIk9kSkH&#x2B;t&#x2B;rHutOpeiZc5ZVq/E2N5Zfae32ruz9lpVVZtZPkyTiwfbZlb76FRd6scYY&#x2B;nqur56&#x2B;GJVVfVhmk1n7R09HI/rW1KWZXm7cU6DZWfMUmyT2Rk1VS2OquHMzNS8874IWciavDGzVkydts6ck0orMytsNVYiKpkrQlARaaKKSCsxz70vvKqmFM0seUvexjr23ot3llKVooq4Xp5lmWXmvdciy/O8Nxpsbm5unz69tra2&#x2B;fCp4&#x2B;Dv&#x2B;KJZFzeapZRU1bkT6Zt8ZMOymXlVEenfzfEkpWRmIpKpF2eienywmamqqrqjI0XEOyfSbQKWJvluMe7e3t7NmzfrulbVuq7NLIQQQqjruLo6DCE8/PDDt2/f3tra2tzcPLn3&#x2B;bNfPQoAwO8GYR8AAAA&#x2B;Rcclfi&#x2B;//PIPf/jDbnHHxsbG/T6vexVF3rZOVWOMqloUhXM6n89jjHVdHzbT&#x2B;bysp1rOy2YidV3/4Ds327bVeZZSyquRWQqzYYxxqGsqEi2JiKq4LuFybl7OQwhZnuVZbk7MUtu0dVWLFxUVr159V09nXd1cbFVVnDt&#x2B;BPXaBXwxxbosY1xM6/N5lmdZkzUpJWchy7L11dH62vra9tbq6ur2uQdGo9Foc90P&#x2B;4sCOxVRscJU9RdeClX1frHXNqXUNE2McTAY3HPMyS&#x2B;7OE9Eju94z8Hd8V3k17ZtWZbj8fjg4GBvb29/f382m6WUnHMrKyshhNlstr6&#x2B;vre39/jjj7dtu7Ky4r0/d&#x2B;7c8QOyFRcAgF&#x2B;BsA8AAACfutFo9PWvf/211177yU9&#x2B;8nd/93fnz59/7rnnPtVn7Lep36a8NUkmXkWlFhdF8syJyDTz08wXmXfqonnnXJhdFRHX7CSVjeaMqq5&#x2B;N8WDh2fTD6u6lkllZVlMvGtbV/qY0u3NDzR5bbyI71nhvS/SSEQH2Uo6Sr7UiaqaJEkW1rOULFmqbW5JRKTVaGpFv6eq5lVUosTWLFoyMxmKiSVpzSyKmVmMYma90TDLgivyEHw/hDzPil4vz4uLjz&#x2B;8urZ6ant7dWNDBoX4o6bYViQ/ass9EdA1TbPIED8a293zpXOuKAoRmU6nXSVgF&#x2B;ellNq2TSn1ej05EefJUX1fd9h8Pi/LcjabTSaT8XhcluXt27e7i3N8cNu2u7u7KaVLly69/fbbu7u7Fy9e/CR/FQAA&#x2B;D1D2AcAAIDfka7Er&#x2B;vq/clPfvLlL3/5ZLnW/TWfz4uicN6ZmPc&#x2B;xvjhjRuH43Hd7qWYXCNmqd8MvXM9G6pqr9dLZhoyMcnaXFTUnKrM53MzE1HnvFdV1WhtSmkeGzMzMR98yLMsy4LPRGQ6L51zGtQ5r16d94UPzvv9et8554LPstzlIQtBsuCcrm1trq6ubp3ZOXP6zObOdrGxLiuZOJG6leAlqBzN1lvIRUwkSmpTk6JzLuRevfzq&#x2B;YlmFmOMMXaxnXPuuGG2K8FzznWPUNe1c857b2ZVVR0eHh4cHEyn0xs3bnRpYBcpxhirqprP56urqxsbG1evXr1&#x2B;/frly5f7/X4XJnY&#x2B;O78PAAB8fhH2AQAA4Hfn5OKOf/zHfzx16tSLL7740dlwn4xem/pN8iYSRYKKaC0uiTZORGTuw9yH2gXnnKXgnNuyGz3t1amylKTqxRjvjNdTSsPVC6ra&#x2B;lxUY9FLqo0rVLV47wfOOa&#x2B;Fc6rSExGRTESjiXdqmYYQJDdVNTExl/rRqYpT51yrVsVyHus2Rs29U41ORCSJeQlZyLIsi6dXisFgY2vrgTNnzuyePXPmgY1TmzLoiRPxH63U637Glbtv7JOJmKiKOmlNXLdLWJwXJyJRRI7&#x2B;DDhuv5Wjmr6qqrryvW5SXvetGGPbtu5Id9hkMinL8vDwcDabHRwczGaztm27O3rvy7Lc3Ny8efPmtWvX8jwPIWRZtru7e3ySp0&#x2B;f/sRfdAAAIIR9AAAA&#x2B;N07ubjjz/7sz5588skrV67c31Pqgq22bWMbXeFUJcsydVrG6J03LyoWY0wpRUuiOujiMJ975yRlJiKWiaoXdc4ln7pKN0uWXFTVNjQpWZvaGKM5yfO8GPZXe0WVmkF/sLK5trm5ubmztbOzc2pne7S6KpdOiYg4ET1qyD3ur01Hn&#x2B;jRAUGqsgpZ5oOTo8W5lqSpozkV5/REmmoiyUxTN1VQT3bgikjXltv9pHrC/v7&#x2B;/v7&#x2B;jRs39vb25vO5yGKcYFe&#x2B;1zTN9vb2YDA4f/78W2&#x2B;99eijj&#x2B;7s7Hx6LxYAAPgVCPsAAABwH5xc3PH973//zTfffPHFF0ej0Sf3DGnxT22xk0K8ySL1yqLPoi9ap041inPyzpnXvPNx3pqlkR&#x2B;ZmW9c0etJGYN6lxoRbWVqauKdOhUbiXOt&#x2B;iZZndqUUusbp65yrXOuCW3btnMpfe7zYdbr9eca8zzP&#x2B;6OVfn&#x2B;wOtrePrV99szGxsbDj14NeSa9XIIXr&#x2B;Ld4h36yffpeu/HKJKSmcpxUKehiCKNxLpuVKXICnUquV8M7ksxpSii3nuvzp1YwSEiKaUu3Uspee8PDw9v3759cHBQlmVd1/P5vNuK25X1mdnOzk6v11PV4XD40EMP7e/vnz179vjRTpbvAQCA3z3CPgAAANw3x4s7fvSjH/3N3/zNww8//PTTT9&#x2B;fUzFTp3meO6eF5vOqSimZiIglM0nJTGKXGjrn1DWxMbOkllJqzERUfHDO5Vme5VmvJ845K2x1dWXrzNbm5sZD185vbm6unDkta8PFVtzunXgUyU7U7iWRePTlLzzNJKKiKt7pcYXf8SdefD9fpHgmliwF9SbmnPPOnygNTF5c0zSz2Ww8Hh8P2qvr&#x2B;nhUX5frbW5u7u/vP/XUU2bW7/dF5KGHHrrnlO5Z1AsAAO4vwj4AAADcZycXd7z11lsvvPDCbz/QrQppnqXoRJyJqahmIk7UtyIi6yHvtSlv66IoZvNpnheb7elYtVKLmWnKR37oJchEgxNN2rgkllpXmVkrpSbdH8UQgsuDcy7lviiKfG3Q6/cfunZhfX1j&#x2B;6Htc&#x2B;fOjXZWpZ&#x2B;LE&#x2B;nSwGMn23KdiEhUU5EkKkerNbI2yWLThy7qEVXMrEltFrLumCRJRU0sxujUvPMqevzAlpKkGIKKSGzb6WRalrPZdLa/v39wcHA4nYUQur0Zzrksy&#x2B;q63tjYMLPHHnvsnXfeOX/&#x2B;/Ml6PQAA8HlB2AcAAID7r&#x2B;vqHQ6Hr7/&#x2B;&#x2B;re&#x2B;9a0HHnjgK1/5yqfyTK1Ykrrp&#x2B;KLoZVkeQhjPx977PCucc771McamaWKMVdsEH6yv2RHpuRD86fObGxsbZ3bPnj17duvc6f7Ojuw4cSK1iBPpiXiR405Z1Xvr9UwkWkrJ9Xz3ZbIUu3I8MTHJXNbdT5KJmajK0Yg9WzyAOXEioqLOOz0q74sp1lVVlmU5m9VV/doPfqBO1URVMx988G3TzMt51h9Mp9NHH300xnj16tVbt249&#x2B;OCDx2d35syZT&#x2B;XiAwCATx9hHwAAAD4rLly4cOrUqa7E7xvf&#x2B;Mazzz578eLF3&#x2B;yhai&#x2B;1l9gN6zORpFm3jNaLOglD7/o6zmcxyMRSSmmUr0aVsVqKzTyrQi/EUZbn/flIVlZW&#x2B;uc3zp3b3bx8&#x2B;ty5c&#x2B;vntlZW&#x2B;lkj4o/yu26Xrpml5Da8iCRJJhatMTFVUVFxveMSvaO0TkV8I0e3qDM5UQAYkyQzM1UVf/wEFu5246qZNU1zOBlPxpODvTuz6Ww8Hs/n85SimaU2xhhP75weT8ZZll948CGz1G3LvXjtkXsu18mkDwAAfK4R9gEAAOAz5Hhxx0svvfTd7363W9zRrYj9xNSSYhTRlFIIYaVXiEg9bgbDwanNja2trbWzO7vndjcvnV3Z3JKrA3Ei3VS6QkQk5eKcyFzEjt5Nq4iKCyri2xRV1FxSUa9daZ&#x2B;JiFsU8EmMFi2JinpRcVWsvfPdmo0kybpKPXGiTvxR8qciInVdzefV4WQ8nU5v3bq1v7/ftm0IQVTb2A7yoqqq2Wy6tbU5Gq5cevjS22&#x2B;9fe3atbXNzU/y0gEAgM88wj4AAAB85oxGo6997Wtdid9f/uVfPvLII48//vjHegRTZ&#x2B;qcqXT/VNSLE5Og87q&#x2B;2Z/Pd4JbWbvw6LWdL1zdPrU9eP78YDBcWR0UwcmiSTbORbxUIhIkSZe5mbkue1vrS7dOI8XGWlFV55w4E1ExJ2oivuvjTcnM5qkVUefUOZepl6MSPu9zXSzmkKO&#x2B;XxOxlOLh4eGNGzdu3749nk5ijN0zNE2jqmY2n883tjZv3rx1&#x2B;fKlXtEvfDYcDh/YvTtlb/s0rbgAAPw&#x2B;UjO73&#x2B;cAAAAA/GKTyeSHP/zhT3/60xDCCy&#x2B;8sLW19Wvv8uabb4YQqp5/&#x2B;Z//&#x2B;UtnLl594vFuf22TaZJk06Y3KOSwq7ITEZFcZCbjbcmcHL8zjhJNajPx1jrnim4Nbzc7rztIF2GfiERJIpLETLr31tZ193aVed5URBrx7sSKjk4b28yHJGk6nYzH48PDg8ODg8PDw3JepnnMs7zX64UQ6rY5ODgYjUabm5srKysHBweXL1/e3t7&#x2B;ra4sAABYUlT2AQAA4LNrNBp96Utf2t7efv3117/5zW8&#x2B;&#x2B;OCDzz///L/mjs7EmfikYnczNhOJQz&#x2B;TOMhUxCTz4mTfi6zIenk8Sy/FvPE&#x2B;tM6LSlInIkmCiKj5lMRHEZXSVU5VnHPiupgvWowxDsJAjt9ktyIiEkVM8kLEpGliWZaT8fjw8HAyPqjm1cH&#x2B;ftu21rbOuRCcmNR1dfbMmfFQvvDoYitur9/bWl/7JC8rAABYXoR9AAAA&#x2B;Kw7ubjj&#x2B;vXrzz///G&#x2B;8UCJ0b4CDiBNRkVZaf/SeWLt3x86HTERMUmvR6903zKpyvB0j890xR98SDZqFkB0fbCaxbCbjcXkwnc/n7&#x2B;z9LLaxaZq2bS1FVQ1OndOVldGd23uPPvponuf9XhFC2No9d/wgD5ymfA8AAHw8tPECAADgc2Mymbz00ktlWW5tbb3wwgsh/IL/67pr4zWz73//&#x2B;7u7u0888USe5/ccY2Yxxu6dsKqqqvf&#x2B;5LdSSnrEObdYoJHS8fGLPbknlGU5mUxu3rw5Ho8PDg7Kskwpee&#x2B;dc929yrIcjUa9Xu&#x2B;RRx557733HnzwwdOnT38KFwkAAPxeI&#x2B;wDAADA58lkMulK/ETkscceu3bt2j0HdGFfnuevvvrqzs7OU0891YVuTdP0er3xeBxC6PV690R1MUaRozUbP6d7z2xmx5/cvn17Op3evn37zp07TivWSgAAGPJJREFU8/nczNq2bZpmOBzGGKuq2t7eHg6H58&#x2B;ff&#x2B;utt65du5ZS2tnZ&#x2B;ZSuCQAAwDHCPgAAAHz&#x2B;TCaTl19&#x2B;&#x2B;fbt271e78UXX1xdXe1uTym9/fbbIYS6rt94441z5849&#x2B;&#x2B;yzx3cZDAZdltdtszUz732WZd2NKaWuXs8514V3bdv2&#x2B;/3jUG88HpdlWVVV0zQppTzPQwgxxp2dnVu3bl2&#x2B;fLnX63nvh8PhxsbG/boyAADg9xxhHwAAAD6vXnvtta7E7&#x2B;LFi12odxz29Xq9V155ZWVl5atf/WpZloPBoG3bEEJVVaoaQvj5Cr6U0mQymc1m0&#x2B;l0PB7v7&#x2B;9Pp9P9/X3vfZ7nRVGo6nQ6XVlZ2djYOHXq1O3bty9cuEC9HgAA&#x2B;Ewh7AMAAMDn2Mmu3q985SsPPPBA18arqq&#x2B;99trp06e/&#x2B;MUvdkeWZSki/X5fRNq2ret6Npvt7&#x2B;/fvn378PBwPp&#x2B;3bRtj7Cr7UkpVVZ05c2Z1dfXKlSs//vGPH3rooeFwOBqN7uMPCwAA8GsR9gEAAOBz78aNGy&#x2B;//HJZlqdPn15dXV1dXZ3P52&#x2B;88cbly5evXr2aZdl8Pt/f39/f379582ZVVXVdd4P8VDWl1LbtaDQ6PDz8whe&#x2B;EEIIIXjvz5079&#x2B;ufGAAA4DOGsA8AAADL4LjEzzn3zDPPDAaDb33rW865bjPveDxeWVmZTqej0Wg6na6uro5Go8uXL7/99tu7u7vnz5&#x2B;/36cPAADwySDsAwAAwPKYTCavvPLK&#x2B;fPnVfXHP/7x3t7eysrK2tra&#x2B;vp627YXLlwws5WVlft9mgAAAJ8Wwj4AAAAsldls1i3Vret6fX39fp8OAADA7xRhHwAAAAAAALAk3P0&#x2B;AQAAAAAAAACfDMI&#x2B;AAAAAAAAYEkQ9gEAAAAAAABLgrAPAAAAAAAAWBKEfQAAAAAAAMCSIOwDAAAAAAAAlgRhHwAAAAAAALAkCPsAAAAAAACAJUHYBwAAAAAAACwJwj4AAAAAAABgSRD2AQAAAAAAAEuCsA8AAAAAAABYEoR9AAAAAAAAwJIg7AMAAAAAAACWBGEfAAAAAAAAsCQI&#x2B;wAAAAAAAIAlQdgHAAAAAAAALAnCPgAAAAAAAGBJEPYBAAAAAAAAS4KwDwAAAAAAAFgShH0AAAAAAADAkiDsAwAAAAAAAJYEYR8AAAAAAACwJAj7AAAAAAAAgCVB2AcAAAAAAAAsCcI&#x2B;AAAAAAAAYEkQ9gEAAAAAAABLgrAPAAAAAAAAWBKEfQAAAAAAAMCSIOwDAAAAAAAAlgRhHwAAAAAAALAkCPsAAAAAAACAJUHYBwAAAAAAACwJwj4AAAAAAABgSRD2AQAAAAAAAEuCsA8AAAAAAABYEoR9AAAAAAAAwJIg7AMAAAAAAACWBGEfAAAAAAAAsCQI&#x2B;wAAAAAAAIAlQdgHAAAAAAAALAnCPgAAAAAAAGBJEPYBAAAAAAAAS4KwDwAAAAAAAFgShH0AAAAAAADAkiDsAwAAAAAAAJYEYR8AAAAAAACwJAj7AAAAAAAAgCVB2AcAAAAAAAAsCcI&#x2B;AAAAAAAAYEkQ9gEAAAAAAABLgrAPAAAAAAAAWBKEfQAAAAAAAMCSIOwDAAAAAAAAlgRhHwAAAAAAALAkCPsAAAAAAACAJUHYBwAAAAAAACwJwj4AAAAAAABgSRD2AQAAAAAAAEuCsA8AAAAAAABYEoR9AAAAAAAAwJIg7AMAAAAAAACWBGEfAAAAAAAAsCQI&#x2B;wAAAAAAAIAlQdgHAAAAAAAALAnCPgAAAAAAAGBJEPYBAAAAAAAAS4KwDwAAAAAAAFgShH0AAAAAAADAkiDsAwAAAAAAAJYEYR8AAAAAAACwJAj7AAAAAAAAgCVB2AcAAAAAAAAsCcI&#x2B;AAAAAAAAYEkQ9gEAAAAAAABLgrAPAAAAAAAAWBKEfQAAAAAAAMCSIOwDAAAAAAAAlgRhHwAAAAAAALAkCPsAAAAAAACAJUHYBwAAAAAAACwJwj4AAAAAAABgSRD2AQAAAAAAAEuCsA8AAAAAAABYEoR9AAAAAAAAwJIg7AMAAAAAAACWBGEfAAAAAAAAsCQI&#x2B;wAAAAAAAIAlQdgHAAAAAAAALAnCPgAAAAAAAGBJEPYBAAAAAAAAS4KwDwAAAAAAAFgShH0AAAAAAADAkiDsAwAAAAAAAJYEYR8AAAAAAACwJAj7AAAAAAAAgCVB2AcAAAAAAAAsCcI&#x2B;AAAAAAAAYEkQ9gEAAAAAAABLgrAPAAAAAAAAWBKEfQAAAAAAAMCSIOwDAAAAAAAAlgRhHwAAAAAAALAkCPsAAAAAAACAJUHYBwAAAAAAACwJwj4AAAAAAABgSRD2AQAAAAAAAEuCsA8AAAAAAABYEoR9AAAAAAAAwJIg7AMAAAAAAACWBGEfAAAAAAAAsCQI&#x2B;wAAAAAAAIAlQdgHAAAAAAAALAnCPgAAAAAAAGBJEPYBAAAAAAAAS4KwDwAAAAAAAFgShH0AAAAAAADAkiDsAwAAAAAAAJYEYR8AAAAAAACwJAj7AAAAAAAAgCVB2AcAAAAAAAAsCcI&#x2B;AAAAAAAAYEkQ9gEAAAAAAABLgrAPAAAAAAAAWBKEfQAAAAAAAMCSIOwDAAAAAAAAlgRhHwAAAADg/2/HDmQAAAAABvlb3&#x2B;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" />
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>